



US 20150099707A1

(19) **United States**(12) **Patent Application Publication**
Pastan et al.(10) **Pub. No.: US 2015/0099707 A1**(43) **Pub. Date: Apr. 9, 2015**(54) **MODIFIED PSEUDOMONAS EXOTOXIN A**

filed on Apr. 21, 2014, provisional application No. 61/908,464, filed on Nov. 25, 2013, provisional application No. 61/887,418, filed on Oct. 6, 2013.

(71) Applicants: **The United States of America, as represented by the Secretary, Department of Health and Human Serv, Bethesda, MD (US); Hoffmann-La Roche Inc., Little Falls, NJ (US)**(72) Inventors: **Ira H. Pastan, Potomac, MD (US); Ronit Mazor, Rockville, MD (US); Masanori Onda, Rockville, MD (US); Byungkook Lee, Potomac, MD (US); Gerhard Niederfellner, Oberhausen (DE); Sabine Imhof-Jung, Planegg (DE); Ulrich Brinkmann, Weilheim (DE); Werner Scheuer, Penzberg (DE); Guy Georges, Habach (DE)**(21) Appl. No.: **14/505,590**(22) Filed: **Oct. 3, 2014****Related U.S. Application Data**

(60) Provisional application No. 62/052,665, filed on Sep. 19, 2014, provisional application No. 61/982,051,

Publication Classification(51) **Int. Cl.**
C07K 14/21 (2006.01)
A61K 47/48 (2006.01)
(52) **U.S. Cl.**
CPC **C07K 14/21** (2013.01); **A61K 47/48484** (2013.01); **A61K 47/48376** (2013.01)(57) **ABSTRACT**

The invention provides a *Pseudomonas* exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.




Fig. 1A-1B




Fig. 2A-2C




Fig. 2D




Fig. 3A-3C




Fig. 4A-4B




Fig. 5A-5D




Fig. 6A-6C




Fig. 7A-7C




Fig. 8




Fig. 9A-9D




Fig. 10A-10E





Fig. 11A-11B




Fig. 12




Fig. 13




Fig. 14




Fig. 15




Fig. 16




Fig. 17




Fig. 18A-18B




Fig. 19




Fig. 20




Fig. 21




Fig. 22A-22L




Fig. 23




Fig. 24




Fig. 25




Fig. 26




Fig. 27A-27F

MODIFIED PSEUDOMONAS EXOTOXIN A**CROSS-REFERENCE TO RELATED APPLICATIONS**

[0001] This patent application claims the benefit of U.S. Provisional Patent Application Nos. 61/887,418, filed Oct. 6, 2013; 61/908,464, filed Nov. 25, 2013; 61/982,051, filed Apr. 21, 2014; and 62/052,665, filed Sep. 19, 2014, each of which is incorporated herein by reference in its entirety.

INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

[0002] Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: one 144,473 Byte ASCII (Text) file named "718352_ST25.txt," dated Oct. 1, 2014.

BACKGROUND OF THE INVENTION

[0003] *Pseudomonas* exotoxin A (PE) is a bacterial toxin with cytotoxic activity that may be effective for destroying or inhibiting the growth of undesirable cells, e.g., cancer cells. Accordingly, PE may be useful for treating or preventing diseases such as, e.g., cancer. However, PE may be highly immunogenic. Accordingly, PE administration may stimulate an anti-PE immune response including, for example, the production of anti-PE antibodies and/or T-cells, that undesirably neutralizes the cytotoxic activity of PE. Such immunogenicity may reduce the amount of PE that can be given to the patient which may, in turn, reduce the effectiveness of the PE for treating the disease, e.g., cancer. Thus, there is a need for improved PE.

[0004] Several deimmunized *Pseudomonas* exotoxins (PE) are known in art. The domain II deleted versions (for example, PE24) may be less immunogenic and may cause fewer side effects (such as, for example, capillary leak syndrome and hepatotoxicity) as compared to PE38, which contains domain II. Without being bound to a particular theory, it is believed that the reduced immunogenicity and fewer side effects of PE24 could, at least in part, be due to the reduced size of PE24, which disadvantageously results in a shorter serum half life. Different furin cleavable linkers may be employed in PE24 variants. PE immunoconjugates have mostly used dsFv fragments as targeting moieties. Such deimmunized *Pseudomonas* exotoxins (PE) are described in, for example, International Patent Application Publications WO2005052006, WO2007016150, WO2007014743, WO2007031741, WO200932954, WO201132022, WO2012/154530, and WO 2012/170617.

[0005] Previous immunotoxins have many disadvantages. For example, deimmunization of previous immunotoxins has been incomplete with respect to the human B-cell epitopes because immunogenic reactions still occurred. In addition, the deimmunization of previous immunotoxins was accompanied by a reduced cytotoxic potency. For example, a LO10 deimmunized PE variant described in WO 2012/170617 provided a loss of potency of at least 40% compared to wild type (WT) PE and other PE variants. In International Patent Application Publication WO2013/040141, *Pseudomonas* exotoxins with less immunogenic B-cell epitopes have been described. In the PE variant LRO10, all B-cell epitopes were removed. This, however, also led to a reduction of cytotoxicity towards tumor cells.

[0006] In addition, fusion of a dsFv with domain II deleted versions of PE (PE24) have a shorter serum half life due to their reduced overall size as compared to dsFv fusions with PE38. The linkers of previous immunotoxins also contained T-cell epitopes and poor developability such as, for example, a poor stability at 37° C. In addition, previous anti-mesothelin (MSLN) immunotoxins have only used mouse-derived dsFv fragments fused to PE, which may further contribute to immunogenicity. International Patent Application Publication WO 2012/154530 refers to *Pseudomonas* exotoxin variant chimeric molecules with short flexible linkers which improve the cytotoxicity towards tumor cells.

BRIEF SUMMARY OF THE INVENTION

[0007] The invention relates to deimmunized *Pseudomonas* exotoxins and Fab fusions thereof (e.g., humanized anti-MSLN), methods for the treatment of cancer, stabilized pharmaceutical formulations, methods for the reduction of side effects and methods for enhancing the serum half life and optimizing treatment schedule.

[0008] An embodiment of the invention provides a *Pseudomonas* exotoxin A (PE) comprising a PE amino acid sequence, wherein one or more of amino acid residues F443, R456, L477, R494, and L552 as defined by reference to SEQ ID NO: 1 are, independently, substituted, wherein the PE optionally has:


[0009] (i) a further substitution of one or more amino acid residues within one or more B cell epitopes, and the further substitution for an amino acid within one or more B-cell epitopes is a substitution of, independently, one or more of amino acid residues D403, D406, R412, R427, E431, R432, D461, R463, R467, R490, R505, R513, E522, R538, E548, R551, R576, Q592, and L597 as defined by reference to SEQ ID NO: 1,

[0010] (ii) a further substitution of one or more amino acid residues within one or more T-cell epitopes,

[0011] (iii) a deletion of one or more continuous amino acid residues of residues 1-273 and 285-394 as defined by SEQ ID NO: 1, or

[0012] (iv) a combination of any one, two, or three of (i)-(iii).

[0013] Another embodiment of the invention provides an isolated, mutated *Pseudomonas* exotoxin A (PE), comprising a sequence of the following formula:



[0014] wherein:

[0015] $n=0$ or 1 independently for each of R^1 , R^2 and R^3 ,

[0016] $R^1=1$ to 10 amino acid residues

[0017] FCS=a furin cleavage sequence of amino acid residues, which sequence is cleavable by furin and has an amino end and a carboxyl end,

[0018] $R^2=1$ to 10 amino acid residues;

[0019] $R^3=1$ or more contiguous residues of residues 365-394 of SEQ ID NO:1; and,

[0020] PE functional domain III=residues 395-613 of SEQ ID NO:1, wherein one or more of amino acid residues F443, R456, L477, R494, and L552 as defined by reference to SEQ ID NO: 1 are, independently, substituted, wherein the PE optionally has:

[0021] (i) a further substitution of one or more amino acid residues within one or more B cell epitopes, and the further substitution for an amino acid within one or more B-cell epitopes is a substitution of, independently, one or more of

amino acid residues D403, D406, R412, R427, E431, R432, D461, R463, R467, R490, R505, R513, E522, R538, E548, R551, R576, Q592, and L597 as defined by reference to SEQ ID NO: 1,

[0022] (ii) a further substitution of one or more amino acid residues within one or more T-cell epitopes, or

[0023] (iii) both (i) and (ii).

[0024] Another embodiment of the invention provides an isolated, mutated *Pseudomonas* exotoxin A (PE), comprising a sequence of the following formula:



[0025] wherein:

[0026] $n=0$ or 1 independently for each of R^1 , R^2 and R^3 ,

[0027] $R^1=1$ to 10 amino acid residues

[0028] FCS=a furin cleavage sequence of amino acid residues, which sequence is cleavable by furin and has an amino end and a carboxyl end,

[0029] $R^2=1$ to 10 amino acid residues;

[0030] $R^3=1$ or more contiguous residues of residues 365-394 of SEQ ID NO:1; and,

[0031] PE functional domain III=residues 395-613 of SEQ ID NO:1, wherein the PE includes an arginine at position 458, as defined by reference to SEQ ID NO: 1, and

[0032] wherein the PE has:

[0033] (a) a substitution of alanine for amino acid residue R427;

[0034] (b) a substitution of alanine for amino acid residue R463;

[0035] (c) a substitution of alanine for amino acid residue R467;

[0036] (d) a substitution of alanine for amino acid residue R490;

[0037] (e) a substitution of alanine for amino acid residue R505; and

[0038] (f) a substitution of alanine for amino acid residue R538.

[0039] Additional embodiments of the invention provide related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions.

[0040] Still another embodiment of the invention provides a method of treating or preventing cancer in a mammal comprising administering to the mammal the inventive PE, chimeric molecule, nucleic acid, recombinant expression vector, host cell, population of cells, or pharmaceutical composition, in an amount effective to treat or prevent cancer in the mammal.

[0041] Another embodiment of the invention provides a method of inhibiting the growth of a target cell comprising contacting the cell with the inventive PE, chimeric molecule, nucleic acid, recombinant expression vector, host cell, population of cells, or pharmaceutical composition, in an amount effective to inhibit growth of the target cell.

[0042] Additional embodiments of the invention provide methods of producing the inventive PE and methods of producing the inventive chimeric molecule.

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS

[0043] FIGS. 1A and 1B are T cell epitope heat maps showing the strongest (>20%, black squares), medium (10-20%, dark grey squares), weak (3%-10%, light grey squares) and negative (absence of response; <3%, white squares)

responses for naïve donors ($n=50$) (A) and previously treated patients ($n=16$) (B). The responses are shown as a percentage of responsive spots for each donor. Responses were clustered using automatic sorting based on the responsiveness of the pools.

[0044] FIGS. 2A-2D are graphs showing the response of three donor samples (A-C) and one HCL patient sample (D) to one of 22 peptide pools, control pool (CEFT), or no peptide after stimulation with HA22 (shaded bars) or LR-R494A (unshaded bars) as measured in spot-forming cells (SFCs) per 10×10^6 cells. * indicates statistical significance between HA22 and LR-R494A ($p<0.01$).

[0045] FIGS. 3A-3C are graphs showing the response of two donor samples (A-B) and one HCL patient sample (C) to one of 22 peptide pools, CEFT, or no peptide after stimulation with HA22 (shaded bars) or LR-R505A (unshaded bars) as measured in SFCs per 10×10^6 cells. * indicates statistical significance ($p<0.01$).

[0046] FIGS. 4A-4B are graphs showing the response of two donor samples (A-B) to one of 22 peptide pools, CEFT, or no peptide after stimulation with HA22 (shaded bars) or LR-R551A (unshaded bars) as measured in SFCs per 10×10^6 cells. * indicates statistical significance in student T test ($p<0.01$).

[0047] FIGS. 5A-5D are graphs showing the response of two donor samples (C-D) and two mesothelioma patient samples (A-B) after stimulation with recombinant immunotoxin (RIT) and restimulation with peptide 93 or 94 with either the wild-type (WT) amino acid sequence (black bars), L552N (dark grey bars), or L552E (unshaded bars), or treatment with no peptide (light grey bars). * indicates statistical significance in student T test ($p<0.05$).

[0048] FIGS. 6A-6C are graphs showing the response of three donor samples to 22 peptide pools after stimulation with either HA22-LR (WT) (shaded bars) or LR-R427A (unshaded bars) and restimulation with the appropriate peptides as measured in SFCs per 10×10^6 cells. * indicates statistical significance ($p<0.05$).

[0049] FIGS. 7A-7C are graphs showing the response of two patient samples (A-B) and one donor (C) to one of pools 8-22 after stimulation with either HA22-LR (WT) (shaded bars) or LR-F443A (unshaded bars) and restimulation with the appropriate peptides as measured in SFCs per 10×10^6 cells. * indicates statistical significance ($p<0.05$).

[0050] FIG. 8 is a graph showing the fold change in EC50 of HA22-LR-GGS (circles), HA22 (vertical dashes), or HA22-LR-T18 (triangles) at various temperatures.

[0051] FIGS. 9A-9D are graphs showing the response of four donor samples after stimulation with RIT and restimulation with no peptide, WT peptide 67, or peptide 67 with either a valine or alanine substitution at position 471 as measured in SFCs per 10×10^6 cells.

[0052] FIGS. 10A-10E are graphs showing the response of three donor samples (A-C), an HCL patient sample (D), and a mesothelioma patient sample (E) after stimulation with peptide 67 or 68 that contains an alanine mutation (white bars) or histidine mutation (grey bars) at position 477 or no mutation (WT) (black bars).

[0053] FIGS. 11A and 11B are graphs showing the response of samples from a mesothelioma patient (A) and a hairy cell leukemia (HCL) patient (B) after stimulation with RIT and restimulation with no peptide, peptide 93, 94 or 95 with either the WT amino acid sequence (shaded bars) or L556V (unshaded bars).

[0054] FIG. 12 is a graph showing the aggregation (% Area) of HMW cFP-0170 (Fab-LO10R-456A short linker; diagonally striped bars) or HMW cFP-0171 (Fab-LO10R-456A elongated linker; horizontally striped bars) as measured by size exclusion chromatograph (SEC) after incubation at 33° C.

[0055] FIG. 13 is a graph showing the aggregation (% Area) of HMW cFP-0170 (Fab-LO10R-456A short linker; diamonds) or HMW cFP-0171 (Fab-LO10R-456A elongated linker; squares) as measured by size exclusion chromatograph (SEC) after incubation at 33° C.

[0056] FIG. 14 is a graph showing the aggregation (radius in nm) of cFP-0166 (Fab-LO10R short linker; diamonds) or cFP-0174 (Fab-LO10R elongated linker; circles) as measured by dynamic light scattering (DLS) at various temperatures in a range from 25° C. to 50° C.

[0057] FIG. 15 is a graph showing the aggregation (radius in nm) of cFP-0170 (Fab-LO10R-456A short linker; diamonds) or cFP-0171 (Fab-LO10R-456A elongated linker; circles) as measured by DLS at various temperatures in a range from 25° C. to 50° C.

[0058] FIG. 16 is a graph showing the aggregation (radius in nm) of cFP-0172 (Fab-LO10R-456A-551A short linker; diamonds) or cFP-0173 (Fab-LO10R-456A-551A elongated linker; circles) as measured by DLS at various temperatures in a range from 25° C. to 50° C.

[0059] FIG. 17 is a graph showing the response of patient sera clone 9H3 to (10⁷) or (10⁸) phages/well or (10⁷) or (10⁸) phages/well with antigen pre-incubation incubated with huSS1Fab-PE24LRO10 (with 458A mutation) (left diagonally striped bars), huSS1Fab-PE24LRO10R (with 458R backmutation) (horizontally striped bars), or huSS1Fab-PE24LRO10R-456A (with 458R backmutation and 456A mutation) (right diagonally striped bars) as measured in optical density at 450 nm.

[0060] FIGS. 18A and 18B are graphs showing the antigenicity of the chimeric molecules SS1P (T1), SS1-dsFv-LR-LO10R (T2), SS1-dsFv-LR-LO10R456A (T3), SS1-FABLO10R (Roche 116, T4), SS1-FABLO10R456ALongLinker (Roche 171, T5), and SS1-FABLO10RLongLinker (Roche 174, T6) with respect to 20 patient sera. Two representative examples (A and B) are shown. The Y axis is relative IC50 (%).

[0061] FIG. 19 is a graph showing plasma concentration (ng/ml) of chimeric molecules SS1P38 (0.4 mg/kg (diamonds)), SS1P38 (0.2 mg/kg (squares)), Fab-PE24 (0.231 mg/kg (triangles)), (dsFv-PE24 (0.16 mg/kg (x)) administered to mice over a period of time (hours (h)).

[0062] FIG. 20 is a graph showing the serum half life cFP (ng/ml) of 0.3 mg/kg cFP_0205 (squares), 0.3 mg/kg SS1P (circles), or 0.3 mg/kg cFP_0205 (dashed lines) over time (hours) in cyno monkeys.

[0063] FIG. 21 is a graph showing the body weight change of mice treated with control (vehicle; circles); cFP 0205 3 mg/kg i.v. 3q7d (squares on solid line); cFP 0205 2 mg/kg i.v. 3q7d (squares on larger dashed line); cFP 0205 1 mg/kg i.v. 3q7d (squares on short dashed line); cFP 0205 0.5 mg/kg i.v. 3q7d (squares on dotted line) over time (days after cell inoculation).

[0064] FIGS. 22A-F are fluorescence images of sections of lung (A-B), spleen (C-D) or liver (E-F) of mice treated with labeled cFP0205 at 10× (A, C, E) or 40× (B, D, F) magnification.

[0065] FIGS. 22G-L are fluorescence images of sections of lung (G-H), spleen (I-J) or liver (K-L) of mice treated with labeled SS1P at 10× (G, I, K) or 40× (H, J, L) magnification.

[0066] FIG. 23 is a graph showing the tumor size of mice that were untreated (open diamonds) or treated with paclitaxel alone, (grey diamonds) RG7787 (also referred to as R205 or cFP 0205) alone (black diamonds), or a combination of RG7787 and paclitaxel (black and white diamonds) over time measured in days.

[0067] FIG. 24 is a graph showing the tumor size of mice that were untreated (vehicle) (circles) or treated with RG7787 (squares) over time measured in days. Each data point represents the average of mean tumor volume for n=9 animals treated with RG7787 and n 8 control animals. Error bars show standard deviations.

[0068] FIG. 25 is a graph showing the tumor size of mice that were treated with vehicle (control) (circles), RG7787 alone (squares), paclitaxel alone (triangles), or a combination of RG7787 and paclitaxel (diamonds) over time measured in days. Error bars show standard deviations.

[0069] FIG. 26 is a graph showing the tumor size of untreated (UT) (x) mice or mice treated with R205 alone (diamonds), a combination of R205 and taxol (squares), or taxol alone (triangles) over time measured in days.

[0070] FIG. 27A is a graph showing cell viability (%) of CD22-expressing cell lines treated with various concentrations of T18 or MP RIT (ng/ml).

[0071] FIG. 27B is a graph showing the relative cytotoxic activity (%) of T18 or MP RIT that had been heated to one of various temperatures (° C.).

[0072] FIGS. 27C-D are graphs showing the cytotoxic activity (IC50 (ng/ml)) of MP or T18 RIT on cells from hairy cell leukemia (HCL) (C) or chronic lymphocytic leukemia (CLL) (D) patients.

[0073] FIG. 27E is a graph showing the effect of LMB-T18 on tumor size in a xenograft mouse model after four injections of 5 mg/kg (squares) of LMB-T18, three injections of 7.5 mg/kg (triangles) OF LMB-T18, or PBS-0.2% human serum albumin (circles). Arrows represent days of injection for all dose groups. Broken arrow indicates additional injection of 5 mg/ml group. (*) P>0.01 in one-way ANOVA. Error bars indicate SD.

[0074] FIG. 27F is a graph showing the % binding of MP, HA22-LR, and LMB-T18 to serum from patients with neutralizing antibodies to MP.

DETAILED DESCRIPTION OF THE INVENTION

[0075] *Pseudomonas* exotoxin A ("PE") is a bacterial toxin (molecular weight 66 kD) secreted by *Pseudomonas aeruginosa*. The native, wild-type PE sequence (SEQ ID NO: 1) is set forth in U.S. Pat. No. 5,602,095, which is incorporated herein by reference. Native, wild-type PE includes three structural domains that contribute to cytotoxicity. Domain Ia (amino acids 1-252) mediates cell binding, domain II (amino acids 253-364) mediates translocation into the cytosol, and domain III (amino acids 400-613) mediates ADP ribosylation of elongation factor 2. While the structural boundary of domain III of PE is considered to start at residue 400, it is contemplated that domain III may require a segment of domain Ib to retain ADP-ribosylating activity. Accordingly, functional domain III is defined as residues 395-613 of PE. The function of domain Ib (amino acids 365-399) remains undefined. Without being bound by a particular theory or mechanism, it is believed that the cytotoxic activity of PE

occurs through the inhibition of protein synthesis in eukaryotic cells, e.g., by the inactivation of the ADP-ribosylation of elongation factor 2 (EF-2).

[0076] Substitutions of PE are defined herein by reference to the amino acid sequence of PE. Thus, substitutions of PE are described herein by reference to the amino acid residue present at a particular position, followed by the amino acid with which that residue has been replaced in the particular substitution under discussion. In this regard, the positions of the amino acid sequence of a particular embodiment of a PE are referred to herein as the positions of the amino acid sequence of the particular embodiment or as the positions as defined by SEQ ID NO: 1. When the positions are as defined by SEQ ID NO: 1, then the actual positions of the amino acid sequence of a particular embodiment of a PE are defined relative to the corresponding positions of SEQ ID NO: 1 and may represent different residue position numbers than the residue position numbers of SEQ ID NO: 1. Thus, for example, substitutions refer to a replacement of an amino acid residue in the amino acid sequence of a particular embodiment of a PE corresponding to the indicated position of the 613-amino acid sequence of SEQ ID NO: 1 with the understanding that the actual positions in the respective amino acid sequences may be different. For example, when the positions are as defined by SEQ ID NO: 1, the term "R490" refers to the arginine normally present at position 490 of SEQ ID NO: 1, "R490A" indicates that the arginine normally present at position 490 of SEQ ID NO: 1 is replaced by an alanine, while "K590Q" indicates that the lysine normally present at position 590 of SEQ ID NO: 1 has been replaced with a glutamine. In the event of multiple substitutions at two or more positions, the two or more substitutions may be the same or different, i.e., each amino acid residue of the two or more amino acid residues being substituted can be substituted with the same or different amino acid residue unless explicitly indicated otherwise.

[0077] The terms "*Pseudomonas* exotoxin" and "PE" as used herein include PE that has been modified from the native protein to reduce or to eliminate immunogenicity. Such modifications may include, but are not limited to, elimination of domain Ia, various amino acid deletions in domains Ib, II, and III, single amino acid substitutions and the addition of one or more sequences at the carboxyl terminus such as DEL and REDL (SEQ ID NO: 7). See Siegall et al., *J. Biol. Chem.*, 264: 14256-14261 (1989). Such modified PEs may be further modified to include any of the inventive substitution(s) for one or more amino acid residues within one or more T-cell and/or B-cell epitopes described herein. In an embodiment, the modified PE may be a cytotoxic fragment of native, wild-type PE. Cytotoxic fragments of PE may include those which are cytotoxic with or without subsequent proteolytic or other processing in the target cell (e.g., as a protein or pre-protein). In a preferred embodiment, the cytotoxic fragment of PE retains at least about 20%, preferably at least about 40%, more preferably at least about 50%, even more preferably at least about 75%, more preferably at least about 90%, and still more preferably at least about 95% of the cytotoxicity of native PE. In particularly preferred embodiments, the cytotoxic fragment has at least the cytotoxicity of native PE, and preferably has increased cytotoxicity as compared to native PE.

[0078] Modified PE that reduces or eliminates immunogenicity includes, for example, PE4E, PE40, PE38, PE25, PE38QQR, PE38KDEL, and PE35. In an embodiment, the

PE may be any of PE4E, PE40, PE38, PE25, PE38QQR (in which PE38 has the sequence QQR added at the C-terminus), PE38KDEL (in which PE38 has the sequence KDEL (SEQ ID NO: 5) added at the C-terminus), PE-LR (resistance to lysosomal degradation)(also referred to as PE24), PE24-LO10, and PE35.

[0079] In an embodiment, the PE has been modified to reduce immunogenicity by deleting domain Ia as described in U.S. Pat. No. 4,892,827, which is incorporated herein by reference. The PE may also be modified by substituting certain residues of domain Ia. In an embodiment, the PE may be PE4E, which is a substituted PE in which domain Ia is present but in which the basic residues of domain Ia at positions 57, 246, 247, and 249 are replaced with acidic residues (e.g., glutamic acid), as disclosed in U.S. Pat. No. 5,512,658, which is incorporated herein by reference.

[0080] PE40 is a truncated derivative of PE (Pai et al., *Proc. Nat'l. Acad. Sci. USA*, 88: 3358-62 (1991) and Kondo et al., *Biol. Chem.*, 263: 9470-9475 (1988)). PE35 is a 35 kD carboxyl-terminal fragment of PE in which amino acid residues 1-279 have been deleted and the molecule commences with a Met at position 280 followed by amino acids 281-364 and 381-613 of native PE. PE35 and PE40 are disclosed, for example, in U.S. Pat. Nos. 5,602,095 and 4,892,827, each of which is incorporated herein by reference. PE25 contains the 11-residue fragment from domain II and all of domain III. In some embodiments, the PE contains only domain III.

[0081] In a preferred embodiment, the PE is PE38. PE38 contains the translocating and ADP ribosylating domains of PE but not the cell-binding portion (Hwang J. et al., *Cell*, 48: 129-136 (1987)). PE38 is a truncated PE pro-protein composed of amino acids 253-364 and 381-613 which is activated to its cytotoxic form upon processing within a cell (see e.g., U.S. Pat. No. 5,608,039, which is incorporated herein by reference, and Pastan et al., *Biochim. Biophys. Acta*, 1333: C1-C6 (1997)).

[0082] In another preferred embodiment, the PE is PE-LR. PE-LR contains a deletion of domain II except for a furin cleavage sequence (FCS) corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGWEL (SEQ ID NO: 8)) and a deletion of amino acid residues 365-394 of domain Ib. Thus, PE-LR contains amino acid residues 274-284 and 395-613 of SEQ ID NO: 1. PE-LR is described in International Patent Application Publication WO 2009/032954, which is incorporated herein by reference. The PE-LR may, optionally, additionally comprise a GGS (SEQ ID NO: 283) linking peptide between the FCS and amino acid residues 395-613 of SEQ ID NO: 1.

[0083] As noted above, alternatively or additionally, some or all of domain Ib may be deleted with the remaining portions joined by a bridge or directly by a peptide bond. Alternatively or additionally, some of the amino portion of domain II may be deleted. Alternatively or additionally, the C-terminal end may contain the native sequence of residues 609-613 (REDLK) (SEQ ID NO: 6), or may contain a variation that may maintain the ability of the PE to translocate into the cytosol, such as KDEL (SEQ ID NO: 5) or REDL (SEQ ID NO: 7), and repeats of these sequences. See, e.g., U.S. Pat. Nos. 5,854,044; 5,821,238; and 5,602,095 and International Patent Application Publication WO 1999/051643, which are incorporated herein by reference. Any form of PE in which immunogenicity has been eliminated or reduced can be used in combination with any of the inventive substitution(s) for one or more amino acid residues within one or more T-cell

and/or B-cell epitopes described herein so long as it remains capable of cytotoxicity to targeted cells, e.g., by translocation and EF-2 ribosylation in a targeted cell.

[0084] An embodiment of the invention provides a *Pseudomonas* exotoxin A (PE) comprising a PE amino acid sequence wherein one or more of amino acid residues F443, R456, L477, R494, and L552 as defined by reference to SEQ ID NO: 1 are, independently, substituted, wherein the PE optionally has:

[0085] (i) a further substitution of one or more amino acid residues within one or more B cell epitopes, and the further substitution for an amino acid within one or more B-cell epitopes is a substitution of, independently, one or more of amino acid residues D403, D406, R412, R427, E431, R432, D461, R463, R467, R490, R505, R513, E522, R538, E548, R551, R576, Q592, and L597 as defined by reference to SEQ ID NO: 1,


[0086] (ii) a further substitution of one or more amino acid residues within one or more T-cell epitopes,

[0087] (iii) a deletion of one or more continuous amino acid residues of residues 1-273 and 285-394 as defined by SEQ ID NO: 1, or

[0088] (iv) a combination of any one, two, or three of (i)-(iii).

[0089] It has been discovered that amino acid residues F443, L477, R494, and L552 are located within one or more T-cell epitopes of PE. Thus, a substitution of one or more of amino acid residues F443, L477, R494, and L552 may, advantageously, remove one or more T cell epitope(s). Accordingly, the inventive PEs may, advantageously, be less immunogenic than an unsubstituted (e.g., wild-type) PE.

[0090] A preferred embodiment of the invention provides an isolated, mutated *Pseudomonas* exotoxin A (PE), comprising a sequence of the following formula:



[0091] wherein:

[0092] $n=0$ or 1 independently for each of R^1 , R^2 and R^3

[0093] $R^1=1$ to 10 amino acid residues

[0094] FCS=a furin cleavage sequence of amino acid residues, which sequence is cleavable by furin and has an amino end and a carboxyl end,

[0095] $R^2=1$ to 10 amino acid residues;

[0096] $R^3=1$ or more contiguous residues of residues 365-394 of SEQ ID NO: 1; and,

[0097] PE functional domain III=residues 395-613 of SEQ ID NO: 1,

[0098] wherein one or more of amino acid residues F443, L477, R494, and L552 as defined by reference to SEQ ID NO: 1 are, independently substituted;

[0099] and the PE comprises optionally a further substitution of an amino acid within one or more B-cell epitopes.

[0100] The substitution of one or more of amino acid residues F443, L477, R494, and L552 may be a substitution of any amino acid residue for one or more of amino acid residues F443, L477, R494, and L552. In an embodiment of the invention, the substitution of one or more of amino acid residues F443, L477, R494, and L552 is a substitution of, independently, alanine, glutamic acid, histidine, or asparagine in place of one or more of amino acid residues F443, L477, R494, and L552. In an embodiment of the invention, the substitution of L552 is a substitution of glutamic acid or asparagine in place of L552 and the substitution of L477 is a substitution of histidine in place of L477.

[0101] In an embodiment of the invention, the substitution of one or more of amino acid residues F443, L477, R494, and L552 is a substitution of alanine in place of amino acid residue F443; a substitution of histidine in place of amino acid residue L477; a substitution of alanine in place of amino acid residue R494; and a substitution of glutamic acid or asparagine in place of amino acid residue L552.

[0102] In addition to the substitution(s) for one or more amino acid residues within one or more PE T-cell epitopes described herein, the inventive PE may, optionally, also include additional substitution(s) for one or more amino acid residues within one or more B-cell epitopes of SEQ ID NO: 1. In this regard, in an embodiment of the invention, the PE has a substitution of one or more amino acids within one or more B-cell epitopes of SEQ ID NO: 1. In a preferred embodiment of the invention, the substitution of one or more amino acid residues within one or more B-cell epitopes of SEQ ID NO: 1 includes a substitution of alanine, glycine, serine, or glutamine for one or more amino acids within one or more B-cell epitopes of SEQ ID NO: 1. The substitution(s) within one or more B-cell epitopes may, advantageously, further reduce immunogenicity by the removal of one or more B-cell epitopes. The substitution(s) may be located within any suitable PE B-cell epitope. Exemplary B-cell epitopes are disclosed in, for example, International Patent Application Publications WO 2007/016150, WO 2009/032954, and WO 2011/032022, each of which is incorporated herein by reference. In a preferred embodiment, the substitution of one or more amino acids within one or more B-cell epitopes of SEQ ID NO: 1 is a substitution of alanine, glycine, serine, or glutamine, independently, in place of one or more of amino acid residues E282, E285, P290, R313, N314, P319, D324, E327, E331, Q332, D403, D406, R412, R427, E431, R432, D461, D463, R467, Y481, R490, R505, R513, L516, E522, R538, E548, R551, R576, K590, Q592, and L597, wherein the amino acid residues E282, E285, P290, R313, N314, P319, D324, E327, E331, Q332, D403, D406, R412, R427, E431, R432, D461, D463, R467, Y481, R490, R505, R513, L516, E522, R538, E548, R551, R576, K590, Q592, and L597 are defined by reference to SEQ ID NO: 1.

[0103] In an embodiment of the invention, the further substitution of an amino acid within one or more B-cell epitopes is a substitution of, independently, alanine, glycine, serine, or glutamine in place of one or more of amino acid residues E282, E285, P290, R313, N314, P319, D324, E327, E331, Q332, D403, D406, R412, R427, E431, R432, D461, R463, R467, R490, R505, R513, E522, R538, E548, R551, R576, K590, Q592, and L597, as defined by reference to SEQ ID NO: 1. Preferably, the further substitution of an amino acid within one or more B-cell epitopes is a substitution of, independently, alanine, glycine, or serine in place of one or more of amino acid residues R427, R505, and R551. In an especially preferred embodiment, the substitution of one or more of amino acid residues F443, R456, L477, R494, and L552 is a substitution of alanine in place of amino acid residue F443, a substitution of histidine in place of L477, a substitution of alanine in place of R494, and a substitution of glutamic acid in place of L552, and the further substitution of an amino acid within one or more B-cell epitopes is: (a) a substitution of alanine for amino acid residue R427; and (b) a substitution of alanine for amino acid residue R505, as defined by reference to SEQ ID NO: 1.

[0104] In an embodiment of the invention, any of the PEs described herein may have an arginine at position 458, with

tion of alanine for amino acid residue R467; (d) a substitution of alanine for amino acid residue R490; (e) a substitution of alanine for amino acid residue R505; and (f) a substitution of alanine for amino acid residue R538; as defined by reference to SEQ ID NO: 1. A preferred embodiment is a PE comprising SEQ ID NO: 288 (T15-L010R).

[0113] In a preferred embodiment, the FCS is a furin cleavage sequence (FCS) corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGWEQL (SEQ ID NO: 8)).

[0114] In a preferred embodiment,

[0115] $n=1$ for R^1 and R^2 ,

[0116] R^1 =a linker of the amino acid sequence of SEQ ID NO: 282 (DKTHKASGG),

[0117] R^2 =a linker of the amino acid sequence of SEQ ID NO: 284 (GGGGGS), and

[0118] FCS=furin cleavage sequence (FCS) corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGWEQL (SEQ ID NO: 8)). In an especially preferred embodiment, n is 0 for R^3 .


[0119] In an embodiment of the invention, the PE has the further substitution of an amino acid within one or more T-cell epitopes. In this regard, the PE may comprise an amino acid sequence having a further substitution of any amino acid in place of one or more amino acid residues at positions R421, L422, L423, A425, R427, L429, Y439, H440, F443, L444, A446, A447, I450, 463-519, R551, L552, T554, I555, L556, and W558 as defined by reference to SEQ ID NO: 1. In an embodiment of the invention, the further substitution of any amino acid in place of one or more amino acid residues at positions R421, L422, L423, A425, R427, L429, Y439, H440, F443, L444, A446, A447, I450, 463-519, R551, L552, T554, I555, L556, and W558 is a substitution of one or more amino acid residues at positions R421, L422, L423, A425, R427, L429, Y439, H440, F443, L444, A446, A447, I450, Y470, L471, A472, P475, A476, L477, I493, R494, N495, L498, L499, R500, V501, Y502, V503, R505, L508, P509, R551, L552, T554, I555, L556, and W558.

[0120] The substitution of one or more amino acid residues at positions R421, L422, L423, A425, R427, L429, Y439, H440, F443, L444, A446, A447, I450, 463-519, R551, L552, T554, I555, L556, and W558 of SEQ ID NO: 1 may be a substitution of any amino acid residue in place of an amino acid residue at any one or more of positions R421, L422, L423, A425, R427, L429, Y439, H440, F443, L444, A446, A447, I450, 463-519, R551, L552, T554, I555, L556, and W558 of SEQ ID NO: 1. The substitution of one or more amino acid residues at positions R421, L422, L423, A425, R427, L429, Y439, H440, F443, L444, A446, A447, I450, 463-519, R551, L552, T554, I555, L556, and W558 of SEQ ID NO: 1 may include, e.g., a substitution of alanine, glycine, serine, or glutamine in place of one or more amino acid residues at position 421, 422, 423, 425, 427, 429, 439, 440, 443, 444, 446, 447, 450, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 551, 552, 554, 555, 556, and 558 of SEQ ID NO: 1. In a preferred embodiment, the substitution of one or more amino acid residues at positions R421, L422, L423, A425, R427, L429, Y439, H440, F443, L444, A446, A447, I450, 463-519, R551, L552, T554, I555, L556, and W558 of SEQ ID NO: 1 is a substitution of alanine, glycine, serine, or

glutamine in place of one or more of amino acid residues R421, L422, L423, A425, R427, L429, Y439, H440, F443, L444, A446, A447, I450, Y470, I471, A472, P475, A476, L477, I493, R494, N495, L498, L499, R500, V501, Y502, V503, R505, L508, P509, R551, L552, T554, I555, L556, and W558. One or more substitutions in one or more T cell epitopes located at positions R421, L422, L423, A425, R427, L429, Y439, H440, F443, L444, A446, A447, I450, 463-519, R551, L552, T554, I555, L556, and W558 of PE as defined by reference to SEQ ID NO: 1 may further reduce immunogenicity of PE. In an embodiment, the amino acid sequence does not have a substitution of one or more amino acid residues at positions 427, 467, 485, 490, 505, 513, 516, and 551.

[0121] Preferably, the PE comprises one or more substitutions that increase cytotoxicity as disclosed, for example, in International Patent Application Publication WO 2007/016150, which is incorporated herein by reference. In this regard, an embodiment of the invention provides PE with a substitution of an amino acid within one or more B-cell epitopes of SEQ ID NO: 1 and the substitution of an amino acid within one or more B-cell epitopes of SEQ ID NO: 1 is a substitution of valine, leucine, or isoleucine in place of amino acid residue R490, wherein the amino acid residue R490 is defined by reference to SEQ ID NO: 1. In an embodiment of the invention, substitution of one or more amino acid residues at positions 313, 327, 331, 332, 431, 432, 505, 516, 538, and 590 defined by reference to SEQ ID NO: 1 with alanine or glutamine may provide a PE with an increased cytotoxicity as disclosed, for example, in International Patent Application Publication WO 2007/016150, which is incorporated herein by reference. Increased cytotoxic activity and decreased immunogenicity can occur simultaneously, and are not mutually exclusive. Substitutions that both increase cytotoxic activity and decrease immunogenicity, such as substitutions of R490 to glycine or, more preferably, alanine, are especially preferred.

[0122] In an embodiment of the invention, another embodiment of the invention provides an isolated, mutated *Pseudomonas* exotoxin A (PE), comprising a sequence of the following formula:



[0123] wherein:

[0124] $n=0$ or 1 independently for each of R^1 , R^2 and R^3 ,

[0125] $R^1=1$ to 10 amino acid residues

[0126] FCS=a furin cleavage sequence of amino acid residues, which sequence is cleavable by furin and has an amino end and a carboxyl end,

[0127] $R^2=1$ to 10 amino acid residues;

[0128] $R^3=1$ or more contiguous residues of residues 365-394 of SEQ ID NO: 1; and, PE functional domain III=residues 395-613 of SEQ ID NO: 1, wherein one or more of amino acid residues F443, R456, L477, R494, and L552 as defined by reference to SEQ ID NO: 1 are, independently, substituted, wherein the PE optionally has:

[0129] (i) a further substitution of one or more amino acid residues within one or more B cell epitopes, and the further substitution for an amino acid within one or more B-cell epitopes is a substitution of, independently, one or more of amino acid residues D403, D406, R412, R427, E431, R432, D461, R463, R467, R490, R505, R513, E522, R538, E548, R551, R576, Q592, and L597 as defined by reference to SEQ ID NO: 1,

[0130] (ii) a further substitution of one or more amino acid residues within one or more T-cell epitopes, or

[0131] (iii) both (i) and (ii).

[0132] Another embodiment of the invention provides an isolated, mutated *Pseudomonas* exotoxin A (PE), comprising a sequence of the following formula:



[0133] wherein:

[0134] $n=0$ or 1 independently for each of R^1 , R^2 and R^3 ,

[0135] $R^1=1$ to 10 amino acid residues

[0136] FCS=a furin cleavage sequence of amino acid residues, which sequence is cleavable by furin and has an amino end and a carboxyl end,

[0137] $R^2=1$ to 10 amino acid residues;

[0138] $R^3=1$ or more contiguous residues of residues 365-394 of SEQ ID NO: 1; and,

[0139] PE functional domain III=residues 395-613 of SEQ ID NO:1, wherein the PE includes an arginine residue at position 458, as defined by reference to SEQ ID NO: 1, and

[0140] wherein the PE has:

[0141] (a) a substitution of alanine for amino acid residue R427;

[0142] (b) a substitution of alanine for amino acid residue R463;

[0143] (c) a substitution of alanine for amino acid residue R467;

[0144] (d) a substitution of alanine for amino acid residue R490;

[0145] (e) a substitution of alanine for amino acid residue R505; and

[0146] (f) a substitution of alanine for amino acid residue R538.

[0147] In an embodiment of the invention, n is 0 for R^1 and R^2 of Formula I. In another embodiment of the invention, n is 1 for R^1 and R^2 . In an embodiment of the invention, when n is 0 for R^1 and R^2 , the PE of Formula I may further comprise a GGS (SEQ ID NO: 283) linking peptide between the furin cleavage sequence (FCS) and PE functional domain III.

[0148] Without being bound by a particular theory or mechanism, it is believed that PEs containing the FCS undergo proteolytic processing inside target cells, thereby activating the cytotoxic activity of the toxin. The FCS of the inventive PEs may comprise any suitable furin cleavage sequence of amino acid residues, which sequence is cleavable by furin. Exemplary furin cleavage sequences are described in Duckert et al., *Protein Engineering, Design & Selection*, 17(1): 107-112 (2004) and International Patent Application Publication WO 2009/032954, each of which is incorporated herein by reference. In an embodiment of the invention, FCS comprises residues 274-284 of SEQ ID NO: 1 (i.e., RHRQPRGWEQL (SEQ ID NO: 8)), wherein the substitution of an amino acid within one or more B-cell epitopes of SEQ ID NO: 1 is a substitution of alanine, glycine, serine, or glutamine for amino acid residue E282 of SEQ ID NO: 1. Other suitable FCS amino acid sequences include, but are not limited to: R-X₁-X₂-R, wherein X₁ is any naturally occurring amino acid and X₂ is any naturally occurring amino acid (SEQ ID NO: 9), RKKR (SEQ ID NO: 10), RRRR (SEQ ID NO: 11), RKAR (SEQ ID NO: 12), SRVARS (SEQ ID NO: 13), TSSRKRRFW (SEQ ID NO: 14), ASRRKARSW (SEQ ID NO: 15), RRVKKRFW (SEQ ID NO: 16), RNVVRRDW (SEQ ID NO: 17), TRAVRRRSW (SEQ ID NO: 18), RQPR (SEQ ID NO: 19), RHRQPRGW (SEQ ID NO: 20),

RHRQPRGWE (SEQ ID NO: 21), HRQPRGWEQ (SEQ ID NO: 22), RQPRGWE (SEQ ID NO: 23), RHRSKRGWEQL (SEQ ID NO: 24), RSKR (SEQ ID NO: 25), RHRSKRGW (SEQ ID NO: 26), HRSKRGWE (SEQ ID NO: 27), RSKRGWEQL (SEQ ID NO: 28), HRSKRGWEQL (SEQ ID NO: 29), RHRSKR (SEQ ID NO: 30), and R-X₁-X₂-R, wherein X₁ is any naturally occurring amino acid and X₂ is arginine or lysine (SEQ ID NO: 4).

[0149] In still another embodiment of the invention, PE functional domain III comprises residues 395-613 of SEQ ID NO: 1, wherein one or more of amino acid residues F443, R456, L477, R494, and L552 as defined by reference to SEQ ID NO: 1 are, independently, substituted. Amino acid residues F443, R456, L477, R494, and L552 may be substituted as described herein with respect to other aspects of the invention.

[0150] In an embodiment of the invention, the FCS is represented by the formula P4-P3-P2-P1, wherein P4 is an amino acid residue at the amino end, P1 is an amino acid residue at the carboxyl end, P1 is an arginine or a lysine residue, and the sequence is cleavable at the carboxyl end of P1 by furin.

[0151] In another embodiment of the invention, the FCS (i) further comprises amino acid residues represented by P6-P5 at the amino end, (ii) further comprises amino acid residues represented by P1'-P2' at the carboxyl end, (iii) wherein if P1 is an arginine or a lysine residue, P2' is tryptophan, and P4 is arginine, valine or lysine, provided that if P4 is not arginine, then P6 and P2 are basic residues, and (iv) the sequence is cleavable at the carboxyl end of P1 by furin.

[0152] In still another embodiment of the invention, the PE functional domain III consists of the sequence of residues 395 to 613 of SEQ ID NO: 1.

[0153] In still another embodiment of the invention, the mutated PE comprises one or more contiguous residues of residues 365-394 of SEQ ID NO: 1 between the FCS and the PE domain III.

[0154] Aspects for the development of *Pseudomonas* exotoxin chimeric molecules as anti-cancer agents include their cytotoxicity towards tumor cells, their immunogenicity towards human B-cells and human T-cells, and their thermal stability. Thermal stability may be useful for the development of pharmaceutical formulations or compositions.

[0155] Therefore, in one aspect of the invention, it has been discovered that by introducing the mutation R456A instead of R458A, it may be possible to remove all B-cell epitopes from a PE without substantially reducing their cytotoxicity towards tumor cells (in case no further T-cell epitopes are removed by further substitutions). Thus, for the first time, a PE is provided in which all B-cell epitopes have been fully removed and which retains its cytotoxic activity.

[0156] An embodiment of the invention provides an isolated, mutated *Pseudomonas* exotoxin A (PE), comprising a sequence of the following formula:



wherein:

[0157] $n=0$ or 1 independently for each of R^1 , R^2 and R^3

[0158] $R^1=1$ to 10 amino acid residues

[0159] FCS=a furin cleavage sequence of amino acid residues, which sequence is cleavable by furin and has an amino end and a carboxyl end,

[0160] $R^2=1$ to 10 amino acid residues;

[0161] $R^3=1$ or more contiguous residues of residues 365-394 of SEQ ID NO: 1; and,

[0162] PE functional domain III=residues 395-613 of SEQ ID NO: 1, wherein the PE includes an arginine at position 458, as defined by reference to SEQ ID NO: 1, and wherein the PE has:

[0163] (a) a substitution of alanine for amino acid residue R427;

[0164] (b) a substitution of alanine for amino acid residue R463;

[0165] (c) a substitution of alanine for amino acid residue R467;

[0166] (d) a substitution of alanine for amino acid residue R490;

[0167] (e) a substitution of alanine for amino acid residue R505;

[0168] (f) a substitution of alanine for amino acid residue R538; and

[0169] (g) a substitution of alanine for amino acid residue R456.

[0170] In a preferred embodiment, the FCS=a furin cleavage sequence (FCS) corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGWEQL (SEQ ID NO: 8)).

[0171] In a preferred embodiment,

[0172] $n=1$ for R^1 and R^2 ,


[0173] R^1 =a linker of the amino acid sequence of SEQ ID NO: 282 (DKTHKASGG),

[0174] R^2 =a linker of the amino acid sequence of SEQ ID NO: 284 (GGGGGS), and

[0175] FCS=furin cleavage sequence (FCS) corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGWEQL (SEQ ID NO: 8)). In an especially preferred embodiment, n is 0 for R^3 .

[0176] In a preferred embodiment, PE functional domain III comprises the amino acid sequence of SEQ ID NO: 37.

[0177] An embodiment of the invention provides an isolated, mutated *Pseudomonas* exotoxin A (PE), comprising a sequence of the following formula:



wherein:

[0178] $n=0$ or 1 independently for each of R^1 , R^2 and R^3

[0179] $R^1=1$ to 10 amino acid residues

[0180] FCS=a furin cleavage sequence of amino acid residues, which sequence is cleavable by furin and has an amino end and a carboxyl end,

[0181] $R^2=1$ to 10 amino acid residues;

[0182] $R^3=1$ or more contiguous residues of residues 365-394 of SEQ ID NO: 1; and,

[0183] PE functional domain III=residues 395-613 of SEQ ID NO: 1, wherein the PE includes an arginine at position 458, as defined by reference to SEQ ID NO: 1.

[0184] The inventive PE may be less immunogenic than an unsubstituted PE in accordance with the invention if the immune response to the inventive PE is diminished, quantitatively or qualitatively, as compared to the immune response to an unsubstituted PE. A quantitative decrease in immunogenicity encompasses a decrease in the magnitude or degree of the immune response. The magnitude or degree of immunogenicity can be measured on the basis of any number of known parameters, such as a decrease in the level of cytokine (e.g., antigen-specific cytokine) production (cytokine concentration), a decrease in the number of lymphocytes activated (e.g., proliferation of lymphocytes (e.g., antigen-specific lymphocytes)) or recruited, and/or a decrease in the

production of antibodies (antigen-specific antibodies), etc. A qualitative decrease in immunogenicity encompasses any change in the nature of the immune response that renders the immune response less effective at mediating the reduction of the cytotoxic activity of the PE. Methods of measuring immunogenicity are known in the art. For example, measuring the types and levels of cytokines produced can measure immunogenicity. Alternatively or additionally, measuring the binding of PE to antibodies (e.g., antibodies previously exposed to PE) and/or measuring the ability of the PE to induce antibodies when administered to a mammal (e.g., humans, mice, and/or mice in which the mouse immune system is replaced with a human immune system) can measure immunogenicity. A less immunogenic PE may be characterized by a decrease in the production of cytokines such as any one or more of IFN- γ , TNF- α , and granzyme B, and/or a reduced stimulation of a cell-mediated immune response, such as a decrease in the proliferation and activation of T-cells and/or macrophages specific for PE as compared to that obtained with an unsubstituted PE. Alternatively or additionally, less immunogenic PE may be characterized by an increase in the production of TGF-beta and/or IL-10 as compared to that obtained with an unsubstituted PE. In a preferred embodiment, reduced immunogenicity is characterized by any one or more of a decrease in T cell stimulation, a decrease in T cell proliferation, and a decrease in T cell IFN γ and/or granzyme B secretion. Alternatively or additionally, a less immunogenic PE may be characterized by a decrease in the stimulation and/or activation of B-cells specific for PE as compared to that obtained with an unsubstituted PE. For example, less immunogenic PE may be characterized by a decrease in the differentiation of B cells into antibody-secreting plasma cells and/or memory cells as compared to that obtained with an unsubstituted PE. Reduced immunogenicity may be characterized by any one or more of a decrease in B cell stimulation, a decrease in B cell proliferation, and a decrease in anti-PE antibody secretion. Qualitative and quantitative diminishment of immunogenicity can occur simultaneously and are not mutually exclusive.

[0185] One of ordinary skill in the art will readily appreciate that the inventive PEs can be modified in any number of ways, such that the therapeutic or prophylactic efficacy of the inventive PEs is increased through the modification. For instance, the inventive PEs can be conjugated or fused either directly or indirectly through a linker to a targeting moiety. In this regard, an embodiment of the invention provides a chimeric molecule comprising (a) a targeting moiety conjugated or fused to (b) any of the inventive PEs described herein. The practice of conjugating compounds, e.g., inventive PEs, to targeting moieties is known in the art. See, for instance, Wadwa et al., *J. Drug Targeting*, 3: 111 (1995), and U.S. Pat. No. 5,087,616. In an embodiment, any of the inventive PEs described herein may lack a targeting moiety. In an embodiment, any of the inventive PEs described herein may have any of the targeting moieties having any of the sequences described herein.

[0186] The term "targeting moiety" as used herein, refers to any molecule or agent that specifically recognizes and binds to a cell-surface marker, such that the targeting moiety directs the delivery of the inventive PE to a population of cells on which surface the receptor is expressed. Targeting moieties include, but are not limited to, antibodies (e.g., monoclonal antibodies), or fragments thereof, peptides, hormones, growth factors, cytokines, and any other natural or non-natural ligands such as, e.g., scaffold antigen binding proteins.

[0187] Scaffold antigen binding proteins are known in the art. For example, fibronectin and designed ankyrin-repeat proteins (DARPin) have been used as alternative scaffolds for antigen-binding domains, see, e.g., Gebauer and Skerra, *Curr. Opin. Chem. Biol.*, 13:245-255 (2009) and Stumpp et al., *Drug Discov. Today*, 13:695-701 (2008), both of which are incorporated herein by reference in their entirety.

[0188] In an embodiment, a scaffold antigen binding protein is selected from the group consisting of CTLA-4 (Evi-body); lipocalin; Protein A-derived molecules such as the Z-domain of Protein A (Affibody, SpA), A-domain (Avimer/Maxibody); heat shock proteins such as GroEI and GroES; transferrin (trans-body); ankyrin repeat protein (DARPin); peptide aptamer; C-type lectin domain (Tetranectin); human γ -crystallin and human ubiquitin (affilins); PDZ domains; scorpion toxin/kunitz-type domains of human protease inhibitors; and fibronectin (adnectin), which has been subjected to protein engineering in order to obtain binding to a ligand other than the natural ligand.

[0189] CTLA-4 (Cytotoxic T Lymphocyte-associated Antigen 4) is a CD28-family receptor expressed mainly by CD4⁺ T-cells. Its extracellular domain has a variable domain-like Ig fold. Loops corresponding to CDRs of antibodies can be substituted with a heterologous sequence to confer different binding properties. CTLA-4 molecules engineered to have different binding specificities are also referred to as Evi-bodies. For further details, see *J. Immunol. Methods*, 248 (1-2): 31-45 (2001).

[0190] Lipocalins are a family of extracellular proteins which transport small hydrophobic molecules such as steroids, bilins, retinoids and lipids. They have a rigid beta-sheet secondary structure with a number of loops at the open end of the conical structure which can be engineered to bind to different target antigens. Anticalins are between 160-180 amino acids in size, and are derived from lipocalins. For further details, see *Biochim. Biophys. Acta.*, 1482: 337-350 (2000), US7250297B1 and US20070224633.

[0191] An affibody is a scaffold derived from Protein A of *Staphylococcus aureus* which can be engineered to bind to an antigen. The domain includes a three-helical bundle of approximately 58 amino acids. Libraries have been generated by the randomization of surface residues. For further details, see *Protein Eng. Des. Sel.*, 17: 455-462 (2004) and EP1641818A1. Avimers are multidomain proteins derived from the A-domain scaffold family. The native domains of approximately 35 amino acids adopt a defined disulphide bonded structure. Diversity is generated by shuffling the natural variation exhibited by the family of A-domains. For further details, see *Nature Biotechnology*, 23(12): 1556-1561 (2005) and *Expert Opinion on Investigational Drugs*, 16(6): 909-917 (2007).

[0192] A transferrin is a monomeric serum transport glycoprotein. Transferrins can be engineered to bind to different target antigens by the insertion of peptide sequences in a permissive surface loop. Examples of engineered transferrin scaffolds include the Trans-body. For further details, see *J. Biol. Chem.*, 274: 24066-24073 (1999).

[0193] Designed Ankyrin Repeat Proteins (DARPin) are derived from Ankyrin which is a family of proteins that mediate attachment of integral membrane proteins to the cytoskeleton. A single ankyrin repeat is a 33 residue motif consisting of two alpha-helices and a beta-turn. They can be engineered to bind to different target antigens by randomizing residues in the first alpha-helix and a beta-turn of each repeat. Their

binding interface can be increased by increasing the number of modules (a method of affinity maturation). For further details, see *J. Mol. Biol.*, 332: 489-503 (2003); PNAS, 100(4): 1700-1705 (2003); *J. Mol. Biol.*, 369, 1015-1028 (2007); and U.S. Patent Application Publication 20040132028A1.

[0194] Fibronectin is a scaffold which can be engineered to bind to antigen. Adnectins contain a backbone of the natural amino acid sequence of the 10th domain of the 15 repeating units of human fibronectin type III (FN3). Three loops at one end of the beta-sandwich can be engineered to enable an Adnectin to specifically recognize a therapeutic target of interest. For further details see *Protein Eng. Des. Sel.*, 18: 435-444 (2005), U.S. Patent Application Publication 20080139791, International Patent Application Publication WO 2005056764 and U.S. Pat. No. 6,818,418B1.

[0195] Peptide aptamers are combinatorial recognition molecules that include a constant scaffold protein, typically thioredoxin (TrxA), which contains a constrained variable peptide loop inserted at the active site. For further details, see *Expert Opin. Biol. Ther.*, 5: 783-797 (2005).

[0196] Microbodies are derived from naturally occurring microproteins of 25-50 amino acids in length which contain 3-4 cysteine bridges. Examples of microproteins include Kal-ataB1, conotoxin, and knottins. The microproteins have a loop which can be engineered to include up to 25 amino acids without affecting the overall fold of the microprotein. For further details of engineered knottin domains, see International Patent Application Publication WO 2008098796.

[0197] Other antigen binding proteins include proteins which have been used as a scaffold to engineer different target antigen binding properties, including human gamma-crystallin and human ubiquitin (affilins), kunitz type domains of human protease inhibitors, PDZ-domains of the Ras-binding protein AF-6, scorpion toxins (charybdotoxin), and C-type lectin domain (tetranectins). See Chapter 7—Non-Antibody Scaffolds from *Handbook of Therapeutic Antibodies* (2007, edited by Stefan Dubel) and *Protein Science*, 15:14-27 (2006). Epitope binding domains of the present invention could be derived from any of these alternative protein domains.

[0198] The term “antibody,” as used herein, refers to whole (also known as “intact”) antibodies or antigen binding portions thereof that retain antigen recognition and binding capability. The antibody or antigen binding portions thereof can be a naturally-occurring antibody or antigen binding portion thereof, e.g., an antibody or antigen binding portion thereof isolated and/or purified from a mammal, e.g., mouse, rabbit, goat, horse, chicken, hamster, human, etc. The antibody or antigen binding portion thereof can be in monomeric or polymeric form. Also, the antibody or antigen binding portion thereof can have any level of affinity or avidity for the cell surface marker. Desirably, the antibody or antigen binding portion thereof is specific for the cell surface marker, such that there is minimal cross-reaction with other peptides or proteins.

[0199] The antibody may be monoclonal or polyclonal and of any isotype, e.g., IgM, IgG (e.g. IgG, IgG2, IgG3 or IgG4), IgD, IgA or IgE. Complementarity determining regions (CDRs) of an antibody or single chain variable fragments (Fvs) of an antibody against a target cell surface marker can be grafted or engineered into an antibody of choice to confer specificity for the target cell surface marker upon that antibody. For example, the CDRs of an antibody against a target cell surface marker can be grafted onto a human antibody

framework of a known three dimensional structure (see, e.g., International Patent Application Publications WO 1998/045322 and WO 1987/002671; U.S. Pat. Nos. 5,859,205; 5,585,089; and 4,816,567; European Patent Application Publication 0173494; Jones et al., *Nature*, 321:522 (1986); Verhoeyen et al., *Science*, 239: 1534 (1988), Riechmann et al., *Nature*, 332:323 (1988); and Winter & Milstein, *Nature*, 349: 293 (1991)) to form an antibody that may raise little or no immunogenic response when administered to a human. In a preferred embodiment, the targeting moiety is a monoclonal antibody or an antigen binding portion of the monoclonal antibody.

[0200] The antigen binding portion can be any portion that has at least one antigen binding site, such as, e.g., the variable regions or CDRs of the intact antibody. Examples of antigen binding portions of antibodies include, but are not limited to, a heavy chain, a light chain, a variable or constant region of a heavy or light chain, a single chain variable fragment (scFv), or an Fc, Fab, Fab', Fv, or F(ab)₂' fragment; single domain antibodies (see, e.g., Wesolowski, *Med Microbiol Immunol.*, 198(3): 157-74 (2009); Saerens et al., *Curr. Opin. Pharmacol.*, 8(5):600-8 (2008); Harmsen and de Haard, *Appl. Microbiol. Biotechnol.*, 77(1): 13-22 (2007), helix-stabilized antibodies (see, e.g., Arndt et al., *J. Mol. Biol.*, 312: 221-228 (2001); triabodies; diabodies (European Patent Application Publication 0404097; International Patent Application Publication WO 1993/011161; and Hollinger et al., *Proc. Natl. Acad. Sci. USA*, 90: 6444-6448 (1993)); single-chain antibody molecules ("scFvs," see, e.g., U.S. Pat. No. 5,888,773); disulfide stabilized antibodies ("dsFvs," see, e.g., U.S. Pat. Nos. 5,747,654 and 6,558,672), and domain antibodies ("dAbs," see, e.g., Holt et al., *Trends Biotech.*, 21(11):484-490 (2003); Ghahroudi et al., *FEBS Lett.*, 414:521-526 (1997), Lauwereys et al., *EMBO J* 17:3512-3520 (1998), Reiter et al., *J. Mol. Biol.* 290:685-698 (1999); and Davies and Riechmann, *Biotechnology*, 13:475-479 (2001)).

[0201] Methods of testing antibodies or antigen binding portions thereof for the ability to bind to any cell surface marker are known in the art and include any antibody-antigen binding assay, such as, for example, radioimmunoassay (RIA), ELISA, Western blot, immunoprecipitation, and competitive inhibition assays (see, e.g., Janeway et al., *infra*, and U.S. Patent Application Publication 2002/0197266 A1).

[0202] Suitable methods of making antibodies are known in the art. For instance, standard hybridoma methods are described in, e.g., Köhler and Milstein, *Eur. J. Immunol.*, 5, 511-519 (1976), Harlow and Lane (eds.), *Antibodies: A Laboratory Manual*, CSH Press (1988), and C. A. Janeway et al. (eds.), *Immunobiology*, 5th Ed., Garland Publishing, New York, N.Y. (2001)). Alternatively, other methods, such as EBV-hybridoma methods (Haskard and Archer, *J. Immunol. Methods*, 74(2), 361-67 (1984), and Roder et al., *Methods Enzymol.*, 121, 140-67 (1986)), and bacteriophage vector expression systems (see, e.g., Huse et al., *Science*, 246, 1275-81 (1989)) are known in the art. Further, methods of producing antibodies in non-human animals are described in, e.g., U.S. Pat. Nos. 5,545,806, 5,569,825, and 5,714,352, and U.S. Patent Application Publication 2002/0197266 A1.

[0203] Phage display also can be used to generate the antibody that may be used in the chimeric molecules of the invention. In this regard, phage libraries encoding antigen-binding variable (V) domains of antibodies can be generated using standard molecular biology and recombinant DNA techniques (see, e.g., Sambrook et al. (eds.), *Molecular Clon-*

ing, A Laboratory Manual, 3rd Edition, Cold Spring Harbor Laboratory Press, New York (2001)). Phage encoding a variable region with the desired specificity are selected for specific binding to the desired antigen, and a complete or partial antibody is reconstituted comprising the selected variable domain. Nucleic acid sequences encoding the reconstituted antibody are introduced into a suitable cell line, such as a myeloma cell used for hybridoma production, such that antibodies having the characteristics of monoclonal antibodies are secreted by the cell (see, e.g., Janeway et al., *supra*, Huse et al., *supra*, and U.S. Pat. No. 6,265,150).

[0204] Alternatively, antibodies can be produced by transgenic mice that are transgenic for specific heavy and light chain immunoglobulin genes. Such methods are known in the art and described in, for example U.S. Pat. Nos. 5,545,806 and 5,569,825, and Janeway et al., *supra*.

[0205] Alternatively, the antibody can be a genetically-engineered antibody, e.g., a humanized antibody or a chimeric antibody. Humanized antibodies advantageously provide a lower risk of side effects and can remain in the circulation longer. Methods for generating humanized antibodies are known in the art and are described in detail in, for example, Janeway et al., *supra*, U.S. Pat. Nos. 5,225,539, 5,585,089 and 5,693,761, European Patent 0239400 B1, and United Kingdom Patent 2188638. Humanized antibodies can also be generated using the antibody resurfacing technology described in, for example, U.S. Pat. No. 5,639,641 and Pedersen et al., *J. Mol. Biol.*, 235, 959-973 (1994).

[0206] The targeting moiety may specifically bind to any suitable cell surface marker. The choice of a particular targeting moiety and/or cell surface marker may be chosen depending on the particular cell population to be targeted. Cell surface markers are known in the art (see, e.g., Mufson et al., *Front. Biosci.*, 11:337-43 (2006); Frankel et al., *Clin. Cancer Res.*, 6:326-334 (2000); and Kreitman et al., *AAPS Journal*, 8(3): E532-E551 (2006)) and may be, for example, a protein or a carbohydrate. In an embodiment of the invention, the targeting moiety is a ligand that specifically binds to a receptor on a cell surface. Exemplary ligands include, but are not limited to, vascular endothelial growth factor (VEGF), Fas, TNF-related apoptosis-inducing ligand (TRAIL), a cytokine (e.g., IL-2, IL-15, IL-4, IL-13), a lymphokine, a hormone, and a growth factor (e.g., transforming growth factor (TGF α), neuronal growth factor, epidermal growth factor).

[0207] The cell surface marker can be, for example, a cancer antigen. The term "cancer antigen" as used herein refers to any molecule (e.g., protein, peptide, lipid, carbohydrate, etc.) solely or predominantly expressed or over-expressed by a tumor cell or cancer cell, such that the antigen is associated with the tumor or cancer. The cancer antigen can additionally be expressed by normal, non-tumor, or non-cancerous cells. However, in such cases, the expression of the cancer antigen by normal, non-tumor, or non-cancerous cells is not as robust as the expression by tumor or cancer cells. In this regard, the tumor or cancer cells can over-express the antigen or express the antigen at a significantly higher level, as compared to the expression of the antigen by normal, non-tumor, or non-cancerous cells. Also, the cancer antigen can additionally be expressed by cells of a different state of development or maturation. For instance, the cancer antigen can be additionally expressed by cells of the embryonic or fetal stage, which cells are not normally found in an adult host. Alternatively, the

cancer antigen can be additionally expressed by stem cells or precursor cells, which cells are not normally found in an adult host.

[0208] The cancer antigen can be an antigen expressed by any cell of any cancer or tumor, including the cancers and tumors described herein. The cancer antigen may be a cancer antigen of only one type of cancer or tumor, such that the cancer antigen is associated with or characteristic of only one type of cancer or tumor. Alternatively, the cancer antigen may be a cancer antigen (e.g., may be characteristic) of more than one type of cancer or tumor. For example, the cancer antigen may be expressed by both breast and prostate cancer cells and not expressed at all by normal, non-tumor, or non-cancer cells.

[0209] Exemplary cancer antigens to which the targeting moiety may specifically bind include, but are not limited to mucin 1 (MUC1; tumor-associated epithelial mucin), melanoma associated antigen (MAGE), preferentially expressed antigen of melanoma (PRAME), carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), prostate specific membrane antigen (PSMA), granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR), CD56, human epidermal growth factor receptor 2 (HER2/neu) (also known as erbB-2), CD5, CD7, tyrosinase tumor antigen, tyrosinase related protein (TRP)1, TRP2, NY-ESO-1, telomerase, and p53. In a preferred embodiment, the cell surface marker, to which the targeting moiety specifically binds, is selected from the group consisting of cluster of differentiation (CD) 19, CD21, CD22, CD25, CD30, CD33 (sialic acid binding Ig-like lectin 3, myeloid cell surface antigen), CD79b, CD123 (interleukin 3 receptor alpha), transferrin receptor, EGF receptor, mesothelin, cadherin, Lewis Y, Glypican-3, FAP (fibroblast activation protein alpha), PSMA (prostate specific membrane antigen), CA9=CAIX (carbonic anhydrase IX), L1CAM (neural cell adhesion molecule L1), Endosialin, HER3 (activated conformation of epidermal growth factor receptor family member 3), Alk1/BMP9 complex (anaplastic lymphoma kinase 1/bone morphogenetic protein 9), TPBG=5T4 (trophoblast glycoprotein), ROR1 (receptor tyrosine kinase-like surface antigen), HER1 (activated conformation of epidermal growth factor receptor), and CLL1 (C-type lectin domain family 12, member A). Mesothelin is expressed in, e.g., ovarian cancer, mesothelioma, non-small cell lung cancer, lung adenocarcinoma, fallopian tube cancer, head and neck cancer, cervical cancer, and pancreatic cancer. CD22 is expressed in, e.g., hairy cell leukemia, chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), non-Hodgkin's lymphoma, small lymphocytic lymphoma (SLL), and acute lymphatic leukemia (ALL). CD25 is expressed in, e.g., leukemias and lymphomas, including hairy cell leukemia and Hodgkin's lymphoma. Lewis Y antigen is expressed in, e.g., bladder cancer, breast cancer, ovarian cancer, colorectal cancer, esophageal cancer, gastric cancer, lung cancer, and pancreatic cancer. CD33 is expressed in, e.g., acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CML), and myeloproliferative disorders.

[0210] In an embodiment of the invention, the targeting moiety is an antibody that specifically binds to a cancer antigen. Exemplary antibodies that specifically bind to cancer antigens include, but are not limited to, antibodies against the transferrin receptor (e.g., HB21 and variants thereof), antibodies against CD22 (e.g., RFB4 and variants thereof), antibodies against CD25 (e.g., anti-Tac and variants thereof), antibodies against mesothelin (e.g., SS1, MORAb-009, SS,

HN1, HN2, MN, MB, and variants thereof) and antibodies against Lewis Y antigen (e.g., B3 and variants thereof). In this regard, the targeting moiety may be an antibody selected from the group consisting of B3, RFB4, SS, SS1, MN, MB, HN1, HN2, HB21, and MORAb-009, and antigen binding portions thereof. Further exemplary targeting moieties suitable for use in the inventive chimeric molecules are disclosed e.g., in U.S. Pat. No. 5,242,824 (anti-transferrin receptor); U.S. Pat. No. 5,846,535 (anti-CD25); U.S. Pat. No. 5,889,157 (anti-Lewis Y); U.S. Pat. No. 5,981,726 (anti-Lewis Y); U.S. Pat. No. 5,990,296 (anti-Lewis Y); U.S. Pat. No. 7,081,518 (anti-mesothelin); U.S. Pat. No. 7,355,012 (anti-CD22 and anti-CD25); U.S. Pat. No. 7,368,110 (anti-mesothelin); U.S. Pat. No. 7,470,775 (anti-CD30); U.S. Pat. No. 7,521,054 (anti-CD25); and U.S. Pat. No. 7,541,034 (anti-CD22); U.S. Patent Application Publication 2007/0189962 (anti-CD22); Frankel et al., *Clin. Cancer Res.*, 6: 326-334 (2000), and Kreitman et al., *AAPS Journal*, 8(3): E532-E551 (2006), each of which is incorporated herein by reference. In another embodiment, the targeting moiety may include the targeting moiety of immunotoxins known in the art. Exemplary immunotoxins include, but are not limited to, LMB-2 (Anti-Tac(Fv)-PE38), BL22 and HA22 (RFB4(dsFv)-PE38), SS1P (SS1 (dsFv)-PE38), HB21-PE40, and variants thereof. In a preferred embodiment, the targeting moiety is the antigen binding portion of HA22. HA22 comprises a disulfide-linked Fv anti-CD22 antibody fragment conjugated to PE38. HA22 and variants thereof are disclosed in International Patent Application Publications WO 2003/027135 and WO 2009/032954, which are incorporated herein by reference.

[0211] The antigen binding portion of the targeting moiety may comprise a light chain variable region and/or a heavy chain variable region. In an embodiment of the invention, the heavy chain variable region comprises a heavy chain CDR1 region, a heavy chain CDR2 region, and a heavy chain CDR3 region. In this regard, the antigen binding domain may comprise one or more of a heavy chain CDR1 region comprising SEQ ID NO: 49, 65, 81, 97, 113, 129, 145, 161, or 177; a heavy chain CDR2 region comprising SEQ ID NO: 53, 69, 85, 101, 117, 133, 149, 165, or 181; and a heavy chain CDR3 region comprising SEQ ID NO: 57, 73, 89, 105, 121, 137, 153, 169, or 185. Preferably, the heavy chain comprises all of SEQ ID NOs: (a) 49, 53, and 57 (anti-mesothelin heavy chain CDR1-CDR3, respectively); (b) SEQ ID NOs: 65, 69, and 73 (anti-glypican-3 gc33 heavy chain CDR1-CDR3, respectively); (c) SEQ ID NOs: 81, 85, and 89 (anti-glypican 3 ab acidic heavy chain CDR1-CDR3, respectively); (d) SEQ ID NOs: 97, 101, and 105 (anti-Fap heavy chain CDR1-CDR3, respectively); (e) SEQ ID NOs: 113, 117, 121 (anti-PSMA heavy chain CDR1-CDR3, respectively); (f) SEQ ID NOs: 129, 133, and 137 (anti-CAIX heavy chain CDR1-CDR3, respectively); (g) SEQ ID NOs: 145, 149, and 153 (anti-L1CAM-(1) heavy chain CDR1-CDR3, respectively); (h) SEQ ID NOs: 161, 165, 169 (anti-L1CAM (2) heavy chain CDR1-CDR3, respectively); or (i) SEQ ID NOs: 177, 181, and 185 (anti-L1CAM(3) heavy chain CDR1-CDR3, respectively).

[0212] In an embodiment of the invention, the light chain variable region may comprise a light chain CDR1 region, a light chain CDR2 region, and a light chain CDR3 region. In this regard, the antigen binding domain may comprise one or more of a light chain CDR1 region comprising SEQ ID NO: 50, 66, 82, 98, 114, 130, 146, 162, or 178; a light chain CDR2 region comprising SEQ ID NO: 54, 70, 86, 102, 118, 134,

150, 166, or 182; and a light chain CDR3 region comprising SEQ ID NO: 58, 74, 90, 106, 122, 138, 154, 170, or 186. Preferably, the light chain comprises all of (a) SEQ ID NOs: 50, 54, and 58 (anti-mesothelin light chain CDR1-CDR3, respectively); (b) SEQ ID NOs: 66, 70, and 74 (anti-glypican-3 ab gc33 light chain CDR1-CDR3, respectively); (c) SEQ ID NOs: 82, 86, and 90 (anti-glypican 3 ab acidic light chain CDR1-CDR3, respectively); (d) SEQ ID NOs: 98, 102, and 106 (anti-FAP light chain CDR1-CDR3, respectively); (e) SEQ ID NOs: 114, 118, and 122 (anti-PSMA light chain CDR1-3, respectively); (f) SEQ ID NOs: 130, 134, and 138 (anti-CAIX light chain CDR1-CDR3, respectively); (g) SEQ ID NOs: 146, 150, and 154 (anti-L1CAM(1) light chain CDR1-CDR3, respectively); (h) SEQ ID NOs: 162, 166, and 170 (anti-L1CAM(2) light chain CDR1-CDR3, respectively); or (i) SEQ ID NOs: 178, 182, and 186 (anti-L1CAM(3) light chain CDR1-CDR3, respectively).

[0213] In an especially preferred embodiment, the antigen binding portion comprises the CDR1, CDR2, CDR3 regions of the light chain and the CDR1, CDR2, CDR3 regions of the heavy chain. In this regard, the antigen binding portion comprises (a) SEQ ID NOs: 49, 50, 53, 54, 57, and 58; (b) SEQ ID NOs: 65, 66, 69, 70, 73, and 74; (c) SEQ ID NOs: 81, 82, 85, 86, 89, and 90; (d) SEQ ID NOs: 97, 98, 101, 102, 105, and 106; (e) SEQ ID NOs: 113, 114, 117, 118, 121, and 122; (f) SEQ ID NOs: 129, 130, 133, 134, 137, and 138; (g) SEQ ID NOs: 145, 146, 149, 150, 153, and 154; (h) SEQ ID NOs: 161, 162, 165, 166, 169, and 170; or (i) SEQ ID NOs: 177, 178, 181, 182, 185, and 186.

[0214] In an embodiment, the antigen binding portion comprises framework regions FR1, FR2, FR3, FR4 of the heavy chain and FR1, FR2, FR3, FR4 of the light chain in addition to the CDR regions described above. In this regard, the antigen binding portion may comprise a heavy chain FR1 region comprising SEQ ID NO: 47, 63, 79, 95, 111, 127, 143, 159, or 175; a heavy chain FR2 region comprising SEQ ID NO: 51, 67, 83, 99, 115, 131, 147, 163, or 179; a heavy chain FR3 region comprising SEQ ID NO: 55, 71, 87, 103, 119, 135, 151, 167, 183; and a heavy chain FR4 region comprising SEQ ID NO: 59, 75, 91, 107, 123, 139, 155, 171, or 187. The antigen binding portion may comprise a light chain FR1 region comprising SEQ ID NO: 48, 64, 80, 96, 112, 128, 144, 160, 176; a light chain FR2 region comprising SEQ ID NO: 52, 68, 84, 100, 116, 132, 148, 164, or 180; a FR3 region comprising SEQ ID NO: 56, 72, 88, 104, 120, 136, 152, 168, or 184; and a FR4 region comprising SEQ ID NO: 60, 76, 92, 108, 124, 140, 156, 172, or 188. Preferably, the antigen binding portion comprises the FR1, FR2, FR3, F4, CDR1, CDR2, and CDR3 regions of the light chain and the FR1, FR2, FR3, F4, CDR1, CDR2, and CDR3 regions of the heavy chain. In this regard, the antigen binding portion comprises (a) SEQ ID NOs: 47-60 (anti-mesothelin); (b) SEQ ID NOs: 63-76 (anti-glypican-3 ab gc33); (c) SEQ ID NOs: 79-92 (anti-glypican 3 ab acidic); (d) SEQ ID NOs: 95-108 (anti-FAP); (e) SEQ ID NOs: 111-124 (anti-PSMA); (f) SEQ ID NOs: 127-140 (anti-CAIX); (g) SEQ ID NOs: 143-156 (anti-L1CAM(1)); (h) SEQ ID NOs: 159-172 (anti-L1CAM(2)); or (i) SEQ ID NOs: 175-188 (anti-L1CAM(3)).

[0215] In an embodiment, the light chain variable region of the antigen binding domain may comprise SEQ ID NO: 46, 62, 78, 94, 110, 126, 142, 158, or 174. In an embodiment, the heavy chain variable region of the antigen binding domain may comprise SEQ ID NO: 45, 61, 77, 93, 109, 125, 141, 157, or 173. In a preferred embodiment, the antigen binding

domain comprises both (a) SEQ ID NOs: 45 and 46 (anti-mesothelin); (b) SEQ ID NOs: 61 and 62 (anti-glypican-3 ab gc33); (c) SEQ ID NOs: 77 and 78 (anti-gc33 acidic); (d) SEQ ID NOs: 93 and 94 (anti-FAP); (e) SEQ ID NOs: 109 and 110 (anti-PSMA); (f) SEQ ID NOs: 125 and 126 (anti-CAIX); (g) SEQ ID NOs: 141 and 142 (anti-L1CAM(1)); (h) SEQ ID NOs: 157 and 158 (anti-L1CAM(2)); (i) SEQ ID NOs: 173 and 174 (anti-L1CAM(3)); or (j) SEQ ID NOs: 93 and 290 (anti-FAP).

[0216] Another aspect of the invention is a humanized anti-mesothelin antibody comprising the comprising the variable heavy chain domain VH of SEQ ID NO: 45 and the variable light chain domain of SEQ ID NO: 46. The humanized antibody was generated by using mouse anti-mesothelin antibody SS1 as a starting material and generating specific combinations of certain framework regions with the CDR regions of mouse SS1 antibody. The humanized antibody advantageously provides good binding properties, stability, and developability.

[0217] In an embodiment of the invention, the targeting moiety may be humanized. In an embodiment of the invention, the targeting moiety is a humanized SS1 or an antigen binding portion of the humanized SS1. In this regard, the targeting moiety may comprise a light chain comprising SEQ ID NO: 33 (cFp-0199) and a heavy chain comprising SEQ ID NO: 38 (cFp-0200). In another embodiment, the targeting moiety may comprise a light chain comprising SEQ ID NOs: 31 (cFp-0199 humanized variable light chain domain VL) and SEQ ID NO: 32 (cFp-0199 kappa constant light chain domain). In an embodiment, the targeting moiety may comprise a heavy chain comprising SEQ ID NOs: 34 (cFp-0200 humanized variable heavy chain domain VH) and SEQ ID NO: 35 (cFp-0200 constant heavy chain domain CH1). In an embodiment, the targeting moiety comprises all of SEQ ID NOs: 31, 32, 34, and 35.

[0218] In an embodiment of the invention, the chimeric molecule comprises a linker. The term "linker" as used herein, refers to any agent or molecule that connects the inventive PE to the targeting moiety. One of ordinary skill in the art recognizes that sites on the inventive PE, which are not necessary for the function of the inventive PE, are ideal sites for attaching a linker and/or a targeting moiety, provided that the linker and/or targeting moiety, once attached to the inventive PE, do(es) not interfere with the function of the inventive PE, i.e., cytotoxic activity, inhibit growth of a target cell, or to treat or prevent cancer. The linker may be capable of forming covalent bonds to both the PE and the targeting moiety. Suitable linkers are known in the art and include, but are not limited to, straight or branched-chain carbon linkers, heterocyclic carbon linkers, and peptide linkers. Where the PE and the targeting moiety are polypeptides, the linker may be joined to the amino acids through side groups (e.g., through a disulfide linkage to cysteine). Preferably, the linkers will be joined to the alpha carbon of the amino and carboxyl groups of the terminal amino acids.


[0219] In another aspect of the invention, it has been discovered that by introducing specific amino acids at both sides of the furin cleavage sequence (FCS), a more stable chimeric molecule of the *Pseudomonas* exotoxin with a targeting moiety has been provided. In addition, further potential T-cell epitopes in the linker region have been removed, which may be particularly advantageous when using Fab fragments of an antibody as a targeting moiety. These chimeric molecules provide improved thermodynamic stability compared to chi-

meric molecules without these elongated linkers and retain their cytotoxicity towards tumor cells. Accordingly, in an embodiment of the invention, the linker is an elongated linker. The elongated linker may comprise SEQ ID NO: 36.

[0220] In a preferred embodiment, R^1_n -FCS- R^2_n =a linker of the amino acid sequence of SEQ ID NO: 36. The furin cleavage site is located between amino acid residues 15 and 16 of SEQ ID NO: 36.

[0221] An embodiment of the invention provides a chimeric molecule comprising (a) a targeting moiety conjugated or fused to (b) any of the PEs described herein.

[0222] An embodiment of the invention provides an isolated chimeric molecule comprising (a) a targeting moiety conjugated or fused to (b) a mutated *Pseudomonas* exotoxin A (PE), comprising a sequence of the following formula:



[0223] wherein:

[0224] $n=0$ or 1 independently for each of R^1 , R^2 and R^3

[0225] $R^1=1$ to 10 amino acid residues

[0226] FCS=a furin cleavage sequence of amino acid residues, which sequence is cleavable by furin and has an amino end and a carboxyl end,

[0227] $R^2=1$ to 10 amino acid residues;

[0228] $R^3=1$ or more contiguous residues of residues 365-394 of SEQ ID NO: 1; and,

[0229] PE functional domain III=residues 395-613 of SEQ ID NO: 1, wherein the PE includes an arginine at position 458, as defined by reference to SEQ ID NO: 1, and wherein the PE has:

[0230] (a) a substitution of alanine for amino acid residue R427;

[0231] (b) a substitution of alanine for amino acid residue R463;

[0232] (c) a substitution of alanine for amino acid residue R467;

[0233] (d) a substitution of alanine for amino acid residue R490;

[0234] (e) a substitution of alanine for amino acid residue R505;

[0235] (f) a substitution of alanine for amino acid residue R538; and

[0236] (g) a substitution of alanine for amino acid residue R456.

[0237] In a preferred embodiment of the chimeric molecule, the FCS=furin cleavage sequence (FCS) corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGWEQL (SEQ ID NO: 8)).

[0238] In a preferred embodiment of the chimeric molecule,

[0239] $n=1$ for R^1 and R^2 ,

[0240] R^1 =a linker of the amino acid sequence of SEQ ID NO: 282 (DKTHKASGG),

[0241] R^2 =a linker of the amino acid sequence of SEQ ID NO: 284 (GGGGGS), and

[0242] FCS=furin cleavage sequence (FCS) corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGWEQL (SEQ ID NO: 8)). In an especially preferred embodiment, n is 0 for R^3 .

[0243] In a preferred embodiment of the chimeric molecule, R^1_n -FCS- R^2_n =a linker of the amino acid sequence of SEQ ID NO: 36 and the targeting moiety comprises the Fab fragment of an antibody.

[0244] In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-mesothelin antibody, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 37 (L010R-456A). In one preferred embodiment, the antigen binding portion is the Fab fragment of an anti-mesothelin antibody comprising the variable heavy chain domain VH of SEQ ID NO: 45 and the variable light chain domain of SEQ ID NO: 46. In this regard, the chimeric molecule may comprise (a) SEQ ID NOs: 39 and 40; (b) SEQ ID NOs: 41 and 42; or (c) SEQ ID NOs: 43 and 44.

[0245] In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-glypican-3 antibody, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 37 (L010R-456A). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-glypican-3 antibody comprising the variable heavy chain domain VH of SEQ ID NO: 61 and the variable light chain domain of SEQ ID NO: 62.

[0246] In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-glypican-3 antibody, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 37 (L010R-456A). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-glypican-3 antibody comprising the variable heavy chain domain VH of SEQ ID NO: 77 and the variable light chain domain of SEQ ID NO: 78.

[0247] In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-FAP antibody, a FCS corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGWEQL (SEQ ID NO: 8)) and a PE comprising SEQ ID NO: 37 (L010R-456A). In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-FAP antibody, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 37 (L010R-456A). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-FAP antibody comprising the CDR1, CDR2 and CDR3 of the variable heavy chain domain VH of SEQ ID NO: 93 (SEQ ID NOs: 97, 101, and 105, respectively) and the CDR1, CDR2 and CDR3 of the variable light chain domain of SEQ ID NO: 94 (SEQ ID NOs: 98, 102, and 106, respectively). In one preferred embodiment, the antigen binding portion is the Fab fragment of an anti-FAP antibody comprising the variable heavy chain domain VH of SEQ ID NO: 93 and the variable light chain domain of SEQ ID NO: 94. In another preferred embodiment, the antigen binding portion is the Fab fragment of an anti-FAP antibody comprising the variable heavy chain domain VH of SEQ ID NO: 93 and the variable light chain domain VL of SEQ ID NO: 290. In this regard, the chimeric molecule may comprise (a) SEQ ID NOs: 291 and 293; (b) SEQ ID NOs: 291 and 294; or (c) SEQ ID NOs: 292 and 294.


[0248] In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-PSMA antibody, a FCS corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGWEQL (SEQ ID NO: 8)) and a PE comprising SEQ ID NO: 37 (L010R-456A). In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-PSMA antibody, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 37 (L010R-456A). In a preferred

embodiment, the antigen binding portion is the Fab fragment of an anti-PSMA antibody comprising the CDR1, CDR2 and CDR3 of the variable heavy chain domain VH of SEQ ID NO: 109 (SEQ ID NOs: 113, 117, and 121, respectively) and the CDR1, CDR2 and CDR3 of the variable light chain domain of SEQ ID NO: 110 (SEQ ID NOs: 114, 118, and 122, respectively).

[0249] In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-CAIX antibody, a FCS corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGWEQL (SEQ ID NO: 8)) and a PE comprising SEQ ID NO: 37 (L010R-456A). In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-CAIX antibody, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 37 (L010R-456A). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-CAIX antibody comprising the CDR1, CDR2 and CDR3 of the variable heavy chain domain VH of SEQ ID NO: 125 (SEQ ID NOs: 129, 133, and 137, respectively) and the CDR1, CDR2 and CDR3 of the variable light chain domain of SEQ ID NO: 126 (SEQ ID NOs: 130, 134, and 138, respectively). In this regard, the chimeric molecule may comprise (a) SEQ ID NOs: 295 and 297 or (b) SEQ ID NOs: 296 and 297.

[0250] In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-L1CAM antibody, a FCS corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGWEQL (SEQ ID NO: 8)) and a PE comprising SEQ ID NO: 37 (L010R-456A). In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-L1CAM antibody, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 37 (L010R-456A). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-L1CAM antibody comprising the CDR1, CDR2 and CDR3 of the variable heavy chain domain VH of SEQ ID NO: 141 (SEQ ID NOs: 145, 149, and 153, respectively) and the CDR1, CDR2 and CDR3 of the variable light chain domain of SEQ ID NO: 142 (SEQ ID NOs: 146, 150, and 154, respectively). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-L1CAM antibody comprising the variable heavy chain domain VH of SEQ ID NO: 157 and the variable light chain domain of SEQ ID NO: 158. In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-L1CAM antibody comprising the variable heavy chain domain VH of SEQ ID NO: 173 and the variable light chain domain of SEQ ID NO: 174.

[0251] In a preferred embodiment, the invention provides an isolated chimeric molecule comprising (a) a targeting moiety conjugated or fused to (b) a mutated *Pseudomonas* exotoxin A (PE), comprising a sequence of the following formula:



[0252] wherein:

[0253] $n=0$ or 1 independently for each of R^1 , R^2 and R^3

[0254] $R^1=1$ to 10 amino acid residues

[0255] FCS=a furin cleavage sequence of amino acid residues, which sequence is cleavable by furin and has an amino end and a carboxyl end,

[0256] $R^2=1$ to 10 amino acid residues;

[0257] $R^3=1$ or more contiguous residues of residues 365-394 of SEQ ID NO: 1; and,

[0258] PE functional domain III=residues 395-613 of SEQ ID NO: 1,

[0259] wherein one or more of amino acid residues F443, L477, R494, and L552 as defined by reference to SEQ ID NO: 1 are, independently substituted;

[0260] and the PE comprises optionally a further substitution of an amino acid within one or more B-cell epitopes.

[0261] It has been discovered that a substitution of histidine in place of amino acid residue L477 leads to a strong reduction of T cell responses compared to substitutions with other amino acids (see, for example, Example 4) while at the same time improving the cytotoxic efficacy of the PE compared to substitutions with other amino acids (see, for example, Examples 3, 5 and 6). Therefore, in a preferred embodiment of the invention with respect to the chimeric molecule, the substitution of one or more of amino acid residues F443, L477, R494, and L552 is a substitution of histidine in place of amino acid residue L477. The substitution of glutamic acid or asparagine in place of amino acid residue L552 also leads to further improved toxicity while reducing T cell responses. In a preferred embodiment of the invention with respect to the chimeric molecule, the substitution of one or more of amino acid residues F443, L477, R494, and L552 is a substitution of histidine in place of amino acid residue L477 and a substitution of glutamic acid or asparagine in place of amino acid residue L552. In an embodiment of the invention with respect to the chimeric molecule, the substitution of one or more of amino acid residues F443, L477, R494, and L552 is a substitution of alanine in place of amino acid residue F443; substitution of histidine in place of amino acid residue L477; a substitution of alanine in place of amino acid residue R494; and a substitution of glutamic acid or asparagine in place of amino acid residue L552.

[0262] In a preferred embodiment of the invention with respect to the chimeric molecule, the substitution of one or more of amino acid residues F443, L477, R494, and L552 is a substitution of alanine in place of amino acid residue F443; a substitution of histidine in place of amino acid residue L477; a substitution of alanine in place of amino acid residue R494; and a substitution of glutamic acid in place of amino acid residue L552, the PE has an arginine residue at position 458, and the further substitution of an amino acid within one or more B-cell epitopes is: (a) a substitution of alanine for amino acid residue R427 and (b) a substitution of alanine for amino acid residue R505 as defined by reference to SEQ ID NO: 1. In a preferred embodiment of the invention, the PE of the chimeric molecule comprises the amino acid sequence of SEQ ID NO: 289 (T18/T20).

[0263] In a preferred embodiment of the invention with respect to the chimeric molecule, the substitution of one or more of amino acid residues F443, L477, R494, and L552 is a substitution of alanine in place of amino acid residue F443; a substitution of histidine in place of amino acid residue L477; a substitution of alanine in place of amino acid residue R494; and a substitution of glutamic acid in place of amino acid residue L552, the PE has an arginine residue at position 458, and the further substitution of an amino acid within one or more B-cell epitopes is: (a) a substitution of alanine for amino acid residue R427; (b) a substitution of alanine for amino acid residue R456; (c) a substitution of alanine for amino acid residue R463; (d) a substitution of alanine for amino acid residue R467; (e) a substitution of alanine for amino acid residue R490; (f) a substitution of alanine for amino acid residue R505; and (g) a substitution of alanine for

amino acid residue R538; as defined by reference to SEQ ID NO: 1. In a preferred embodiment, the PE of the chimeric molecule comprises the amino acid sequence of SEQ ID NO: 285 (T14-L010R+456A).

[0264] In a preferred embodiment of the invention with respect to the chimeric molecule, the substitution of one or more of amino acid residues F443, L477, R494, and L552 is a substitution of alanine in place of amino acid residue F443; a substitution of histidine in place of amino acid residue L477; a substitution of alanine in place of amino acid residue R494; and a substitution of asparagine in place of amino acid residue L552, the PE has an arginine residue at position 458, and the further substitution of an amino acid within one or more B-cell epitopes is: (a) a substitution of alanine for amino acid residue R427; (b) a substitution of alanine for amino acid residue R456; (c) a substitution of alanine for amino acid residue R463; (d) a substitution of alanine for amino acid residue R467; (e) a substitution of alanine for amino acid residue R490; (f) a substitution of alanine for amino acid residue R505; and (g) a substitution of alanine for amino acid residue R538; as defined by reference to SEQ ID NO: 1. In a preferred embodiment, the PE of the chimeric molecule comprises the amino acid sequence of SEQ ID NO: 286 (T15-L010R+456A).

[0265] In a preferred embodiment of the invention with respect to the chimeric molecule, the substitution of one or more of amino acid residues F443, L477, R494, and L552 is a substitution of alanine in place of amino acid residue F443; a substitution of histidine in place of amino acid residue L477; a substitution of alanine in place of amino acid residue R494; and a substitution of glutamic acid in place of amino acid residue L552, the PE has an arginine residue at position 458, and the further substitution of an amino acid within one or more B-cell epitopes is: (a) a substitution of alanine for amino acid residue R427; (b) a substitution of alanine for amino acid residue R463; (c) a substitution of alanine for amino acid residue R467; (d) a substitution of alanine for amino acid residue R490; (e) a substitution of alanine for amino acid residue R505; and (f) a substitution of alanine for amino acid residue R538; as defined by reference to SEQ ID NO: 1. In a preferred embodiment, the PE of the chimeric molecule comprises the amino acid sequence of SEQ ID NO: 287 (T14-L010R).

[0266] In a preferred embodiment of the invention within the chimeric molecule, the substitution of one or more of amino acid residues F443, L477, R494, and L552 is a substitution of alanine in place of amino acid residue F443; a substitution of histidine in place of amino acid residue L477; a substitution of alanine in place of amino acid residue R494; and a substitution of asparagine in place of amino acid residue L552, the PE has an arginine residue at position 458, and the further substitution of an amino acid within one or more B-cell epitopes is: (a) a substitution of alanine for amino acid residue R427; (b) a substitution of alanine for amino acid residue R463; (c) a substitution of alanine for amino acid residue R467; (d) a substitution of alanine for amino acid residue R490; (e) a substitution of alanine for amino acid residue R505; and (f) a substitution of alanine for amino acid residue R538; as defined by reference to SEQ ID NO: 1. In a preferred embodiment, the PE of the chimeric molecule comprises the amino acid sequence of SEQ ID NO: 288 (T15-L010R).

[0267] In a preferred embodiment with respect to the chimeric molecule, the FCS=furin cleavage sequence (FCS) cor-

responding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGWEQL (SEQ ID NO: 8)).

[0268] In a preferred embodiment with respect to the chimeric molecule,

[0269] $n=1$ for R^1 and R^2 ,

[0270] R^1 =a linker of the amino acid sequence of SEQ ID NO: 282 (DKTHKASGG),

[0271] R^2 =a linker of the amino acid sequence of SEQ ID NO: 284 (GGGGGS), and

[0272] FCS=furin cleavage sequence (FCS) corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGWEQL (SEQ ID NO: 8)). In an especially preferred embodiment, n is 0 for R^3 .

[0273] In a preferred embodiment with respect to the chimeric molecule, R^1 -FCS- R^2 =a linker of the amino acid sequence of SEQ ID NO: 36 and the targeting moiety comprises the Fab fragment of an antibody.

[0274] In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-mesothelin antibody, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 285 (T14-L010R+456A). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-mesothelin antibody comprising the variable heavy chain domain VH of SEQ ID NO: 45 and the variable light chain domain of SEQ ID NO: 46.

[0275] In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-mesothelin antibody, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 286 (T15-L010R+456A). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-mesothelin antibody comprising the variable heavy chain domain VH of SEQ ID NO: 45 and the variable light chain domain of SEQ ID NO: 46.

[0276] In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-mesothelin antibody, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 287 (T14-L010R). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-mesothelin antibody comprising the variable heavy chain domain VH of SEQ ID NO: 45 and the variable light chain domain of SEQ ID NO: 46.

[0277] In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-mesothelin antibody, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 288 (T15-L010R). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-mesothelin antibody comprising the variable heavy chain domain VH of SEQ ID NO: 45 and the variable light chain domain of SEQ ID NO: 46.

[0278] In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-glypican-3 antibody, a furin cleavage sequence (FCS) corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGWEQL (SEQ ID NO: 8)) and a PE comprising SEQ ID NO: 289 (T18/T20). In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-glypican-3 antibody, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 289 (T18/T20). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-glypican-3 antibody

[0295] In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-CAIX antibody, a furin cleavage sequence (FCS) corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGW-WEQL (SEQ ID NO: 8)) and a PE comprising SEQ ID NO: 288 (T15-L010R). In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-CAIX antibody, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 288 (T15-L010R). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-CAIX antibody comprising the CDR1, CDR2 and CDR3 of the variable heavy chain domain VH of SEQ ID NO: 125 (SEQ ID NOS: 129, 133, and 137, respectively) and the CDR1, CDR2 and CDR3 of the variable light chain domain of SEQ ID NO: 126 (SEQ ID NOS: 130, 134, and 138, respectively). In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-L1CAM antibody, a furin cleavage sequence (FCS) corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGW-WEQL (SEQ ID NO: 8)) and a PE comprising SEQ ID NO: 289 (T18/T20). In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-L1CAM antibody, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising. In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-L1CAM antibody comprising the CDR1, CDR2 and CDR3 of the variable heavy chain domain VH of SEQ ID NO: 141 (SEQ ID NOS: 145, 149, and 153, respectively) and the CDR1, CDR2 and CDR3 of the variable light chain domain of SEQ ID NO: 142 (SEQ ID NOS: 146, 150, and 154, respectively). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-L1CAM antibody comprising the variable heavy chain domain VH of SEQ ID NO: 173 and the variable light chain domain of SEQ ID NO: 174.

antibody, a furin cleavage sequence (FCS) corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGWEQL (SEQ ID NO: 8)) and a PE comprising SEQ ID NO: 285 (T14-LO10R+456A). In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-L1CAM antibody, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 285 (T14-LO10R+456A). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-L1CAM antibody comprising the CDR1, CDR2 and CDR3 of the variable heavy chain domain VH of SEQ ID NO: 141 (SEQ ID NOs: 145, 149, and 153, respectively) and the CDR1, CDR2 and CDR3 of the variable light chain domain of SEQ ID NO: 142 (SEQ ID NOs: 146, 150, and 154, respectively). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-L1CAM antibody comprising the variable heavy chain domain VH of SEQ ID NO: 157 and the variable light chain domain of SEQ ID NO: 158. In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-L1CAM antibody comprising the variable heavy chain domain VH of SEQ ID NO: 173 and the variable light chain domain of SEQ ID NO: 174.

[0297] In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-L1CAM antibody, a furin cleavage sequence (FCS) corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGWEQL (SEQ ID NO: 8)) and a PE comprising SEQ ID NO: 286 (T15-L010R+456A). In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-L1CAM antibody, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 286 (T15-L010R+456A). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-L1CAM antibody comprising the CDR1, CDR2 and CDR3 of the variable heavy chain domain VH of SEQ ID NO: 141 (SEQ ID NOs: 145, 149, and 153, respectively) and the CDR1, CDR2 and CDR3 of the variable light chain domain of SEQ ID NO: 142 (SEQ ID NOs: 146, 150, and 154, respectively). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-L1CAM antibody comprising the variable heavy chain domain VH of SEQ ID NO: 157 and the variable light chain domain of SEQ ID NO: 158. In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-L1CAM antibody comprising the variable heavy chain domain VH of SEQ ID NO: 173 and the variable light chain domain of SEQ ID NO: 174.

[0298] In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-L1CAM antibody, a furin cleavage sequence (FCS) corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGWEQL (SEQ ID NO: 8)) and a PE comprising SEQ ID NO: 287 (T14-LO10R). In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-L1CAM antibody, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 287 (T14-LO10R). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-L1CAM antibody comprising the CDR1, CDR2 and CDR3 of the variable heavy chain domain VH of SEQ ID NO: 141 (SEQ ID NOs: 145, 149, and 153, respectively) and the CDR1, CDR2 and CDR3 of the variable light chain domain of SEQ ID NO: 142 (SEQ ID NOs: 146, 150, and 154, respectively). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-L1CAM antibody comprising the

variable heavy chain domain VH of SEQ ID NO: 157 and the variable light chain domain of SEQ ID NO: 158. In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-L1CAM antibody comprising the variable heavy chain domain VH of SEQ ID NO: 173 and the variable light chain domain of SEQ ID NO: 174.

[0299] In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-L1CAM antibody, a furin cleavage sequence (FCS) corresponding to amino acid residues 274-284 of SEQ ID NO: 1 (RHRQPRGWEQL (SEQ ID NO: 8)) and a PE comprising SEQ ID NO: 288 (T15-LO10R). In a preferred embodiment, the chimeric molecule comprises the antigen binding portion of an anti-L1CAM antibody, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 288 (T15-LO10R). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-L1CAM antibody comprising the CDR1, CDR2 and CDR3 of the variable heavy chain domain VH of SEQ ID NO: 141 (SEQ ID NOs: 145, 149, and 153, respectively) and the CDR1, CDR2 and CDR3 of the variable light chain domain of SEQ ID NO: 142 (SEQ ID NOs: 146, 150, and 154, respectively). In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-L1CAM antibody comprising the variable heavy chain domain VH of SEQ ID NO: 157 and the variable light chain domain of SEQ ID NO: 158. In a preferred embodiment, the antigen binding portion is the Fab fragment of an anti-L1CAM antibody comprising the variable heavy chain domain VH of SEQ ID NO: 173 and the variable light chain domain of SEQ ID NO: 174. Included in the scope of the invention are functional portions of the inventive PEs and chimeric molecules described herein. The term “functional portion” when used in reference to a PE or chimeric molecule refers to any part or fragment of the PE or chimeric molecule of the invention, which part or fragment retains the biological activity of the PE or chimeric molecule of which it is a part (the parent PE or chimeric molecule). Functional portions encompass, for example, those parts of a PE or chimeric molecule that retain the ability to specifically bind to and destroy or inhibit the growth of target cells or treat or prevent cancer, to a similar extent, the same extent, or to a higher extent, as the parent PE or chimeric molecule. In reference to the parent PE or chimeric molecule, the functional portion can comprise, for instance, about 10% or more, about 25% or more, about 30% or more, about 50% or more, about 68% or more, about 80% or more, about 90% or more, or about 95% or more, of the parent PE or chimeric molecule.

[0300] The functional portion can comprise additional amino acids at the amino or carboxy terminus of the portion, or at both termini, which additional amino acids are not found in the amino acid sequence of the parent PE or chimeric molecule. Desirably, the additional amino acids do not interfere with the biological function of the functional portion, e.g., specifically binding to and destroying or inhibiting the growth of target cells, having the ability to treat or prevent cancer, etc. More desirably, the additional amino acids enhance the biological activity, as compared to the biological activity of the parent PE or chimeric molecule.

[0301] Included in the scope of the invention are functional variants of the inventive PEs and chimeric molecules described herein. The term “functional variant” as used herein refers to a PE or chimeric molecule having substantial or significant sequence identity or similarity to a parent PE or chimeric molecule, which functional variant retains the bio-

logical activity of the PE or chimeric molecule of which it is a variant. Functional variants encompass, for example, those variants of the PE or chimeric molecule described herein (the parent PE or chimeric molecule) that retain the ability to specifically bind to and destroy or inhibit the growth of target cells to a similar extent, the same extent, or to a higher extent, as the parent PE or chimeric molecule. In reference to the parent PE or chimeric molecule, the functional variant can, for instance, be about 30% or more, about 50% or more, about 75% or more, about 80% or more, about 90% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, or about 99% or more identical in amino acid sequence to the parent PE or chimeric molecule.

[0302] The functional variant can, for example, comprise the amino acid sequence of the parent PE or chimeric molecule with at least one conservative amino acid substitution. Conservative amino acid substitutions are known in the art and include amino acid substitutions in which one amino acid having certain chemical and/or physical properties is exchanged for another amino acid that has the same chemical or physical properties. For instance, the conservative amino acid substitution can be an acidic amino acid substituted for another acidic amino acid (e.g., Asp or Glu), an amino acid with a nonpolar side chain substituted for another amino acid with a nonpolar side chain (e.g., Ala, Gly, Val, Ile, Leu, Met, Phe, Pro, Trp, Val, etc.), a basic amino acid substituted for another basic amino acid (Lys, Arg, etc.), an amino acid with a polar side chain substituted for another amino acid with a polar side chain (Asn, Cys, Gln, Ser, Thr, Tyr, etc.), etc.

[0303] Alternatively or additionally, the functional variants can comprise the amino acid sequence of the parent PE or chimeric molecule with at least one non-conservative amino acid substitution. In this case, it is preferable for the non-conservative amino acid substitution to not interfere with or inhibit the biological activity of the functional variant. Preferably, the non-conservative amino acid substitution enhances the biological activity of the functional variant, such that the biological activity of the functional variant is increased as compared to the parent PE or chimeric molecule.

[0304] The PE or chimeric molecule of the invention can consist essentially of the specified amino acid sequence or sequences described herein, such that other components of the functional variant, e.g., other amino acids, do not materially change the biological activity of the functional variant.

[0305] The PE or chimeric molecule of the invention (including functional portions and functional variants) of the invention can comprise synthetic amino acids in place of one or more naturally-occurring amino acids. Such synthetic amino acids are known in the art and include, for example, aminocyclohexane carboxylic acid, norleucine, α -amino n-decanoic acid, homoserine, S-acetylaminomethyl-cysteine, trans-3- and trans-4-hydroxyproline, 4-aminophenylalanine, 4-nitrophenylalanine, 4-chlorophenylalanine, 4-carboxyphenylalanine, β -phenylserine, β -hydroxyphenylalanine, phenylglycine, α -naphthylalanine, cyclohexylalanine, cyclohexylglycine, indoline-2-carboxylic acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, aminomalonic acid, aminomalonic acid monoamide, N'-benzyl-N'-methyl-lysine, N',N'-dibenzyl-lysine, 6-hydroxyl-lysine, ornithine, α -aminocyclopentane carboxylic acid, α -aminocyclohexane carboxylic acid, α -aminocycloheptane carboxylic acid, α -(2-amino-2-norbornane)-carboxylic acid, α,γ -diaminobutyric acid, α,β -diaminopropionic acid, homophenylalanine, and α -tert-butylglycine.

[0306] The PE or chimeric molecule of the invention (including functional portions and functional variants) can be glycosylated, amidated, carboxylated, phosphorylated, esterified, N-acylated, cyclized via, e.g., a disulfide bridge, or converted into an acid addition salt and/or optionally dimerized or polymerized, or conjugated.

[0307] An embodiment of the invention provides a method of producing the inventive PE comprising (a) recombinantly expressing the PE and (b) purifying the PE. The PEs and chimeric molecules of the invention (including functional portions and functional variants) can be obtained by methods of producing proteins and polypeptides known in the art. Suitable methods of de novo synthesizing polypeptides and proteins are described in references, such as Chan et al., *Fmoc Solid Phase Peptide Synthesis*, Oxford University Press, Oxford, United Kingdom, 2005; *Peptide and Protein Drug Analysis*, ed. Reid, R., Marcel Dekker, Inc., 2000; *Epitope Mapping*, ed. Westwood et al., Oxford University Press, Oxford, United Kingdom, 2000; and U.S. Pat. No. 5,449,752. Also, the PEs and chimeric molecules of the invention can be recombinantly expressed using the nucleic acids described herein using standard recombinant methods. See, for instance, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 3rd ed., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. 2001; and Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing Associates and John Wiley & Sons, NY, 1994.

[0308] The method further comprises purifying the PE. Once expressed, the inventive PEs may be purified in accordance with purification techniques known in the art. Exemplary purification techniques include, but are not limited to, ammonium sulfate precipitation, affinity columns, and column chromatography, or by procedures described in, e.g., R. Scopes, *Protein Purification*, Springer-Verlag, NY (1982).

[0309] Another embodiment of the invention provides a method of producing the inventive chimeric molecule comprising (a) recombinantly expressing the chimeric molecule and (b) purifying the chimeric molecule. The chimeric molecule may be recombinantly expressed and purified as described herein with respect to other aspects of the invention. In an embodiment of the invention, recombinantly expressing the chimeric molecule comprises inserting a nucleotide sequence encoding a targeting moiety and a nucleotide sequence encoding a PE into a vector. The method may comprise inserting the nucleotide sequence encoding the targeting moiety and the nucleotide sequence encoding the PE in frame so that it encodes one continuous polypeptide including a functional targeting moiety region and a functional PE region. In an embodiment of the invention, the method comprises ligating a nucleotide sequence encoding the PE to a nucleotide sequence encoding a targeting moiety so that, upon expression, the PE is located at the carboxyl terminus of the targeting moiety. In an alternative embodiment, the method comprises ligating a nucleotide sequence encoding the PE to a nucleotide sequence encoding a targeting moiety so that, upon expression, the PE is located at the amino terminus of the targeting moiety.

[0310] Still another embodiment of the invention provides a method of producing the inventive chimeric molecule comprising (a) recombinantly expressing the inventive PE, (b) purifying the PE, and (c) covalently linking a targeting moiety to the purified PE. The inventive PE may be recombinantly expressed as described herein with respect to other aspects of the invention. The method further comprises covalently link-

ing a targeting moiety to the purified PE. The method of attaching a PE to a targeting moiety may vary according to the chemical structure of the targeting moiety. For example, the method may comprise reacting any one or more of a variety of functional groups e.g., carboxylic acid (COOH), free amine ($-\text{NH}_2$), or sulfhydryl ($-\text{SH}$) groups present on the PE with a suitable functional group on the targeting moiety, thereby forming a covalent bond between the PE and the targeting moiety. Alternatively or additionally, the method may comprise derivatizing the targeting moiety or PE to expose or to attach additional reactive functional groups. Derivatizing may also include attaching one or more linkers to the targeting moiety or PE.

[0311] In another embodiment of the invention, the inventive PEs and chimeric molecules may be produced using non-recombinant methods. For example, the inventive PEs and chimeric molecules described herein (including functional portions and functional variants) can be commercially synthesized by companies, such as Synpep (Dublin, Calif.), Peptide Technologies Corp. (Gaithersburg, Md.), and Multiple Peptide Systems (San Diego, Calif.). In this respect, the inventive PEs and chimeric molecules can be synthetic, recombinant, isolated, and/or purified.

[0312] It may be desirable, in some circumstances, to free the PE from the targeting moiety when the chimeric molecule has reached one or more target cells. In this regard, the inventive chimeric molecules may comprise a cleavable linker. The linker may be cleavable by any suitable means, e.g., enzymatically. For example, when the target cell is a cancer (e.g., tumor) cell, the chimeric molecule may include a linker cleavable under conditions present at the tumor site (e.g., when exposed to tumor-associated enzymes or acidic pH).

[0313] An embodiment of the invention provides a nucleic acid comprising a nucleotide sequence encoding any of the inventive PEs or the inventive chimeric molecules described herein. The term "nucleic acid," as used herein, includes "polynucleotide," "oligonucleotide," and "nucleic acid molecule," and generally means a polymer of DNA or RNA, which can be single-stranded or double-stranded, which can be synthesized or obtained (e.g., isolated and/or purified) from natural sources, which can contain natural, non-natural, or altered nucleotides, and which can contain a natural, non-natural, or altered internucleotide linkage, such as a phosphoramidate linkage or a phosphorothioate linkage, instead of the phosphodiester found between the nucleotides of an unmodified oligonucleotide. It is generally preferred that the nucleic acid does not comprise any insertions, deletions, inversions, and/or substitutions. However, it may be suitable in some instances, as discussed herein, for the nucleic acid to comprise one or more insertions, deletions, inversions, and/or substitutions.

[0314] Preferably, the nucleic acids of the invention are recombinant. As used herein, the term "recombinant" refers to (i) molecules that are constructed outside living cells by joining natural or synthetic nucleic acid segments, or (ii) molecules that result from the replication of those described in (i) above. For purposes herein, the replication can be in vitro replication or in vivo replication.

[0315] The nucleic acids can be constructed based on chemical synthesis and/or enzymatic ligation reactions using procedures known in the art. See, for example, Sambrook et al., *supra*, and Ausubel et al., *supra*. For example, a nucleic acid can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to

increase the biological stability of the molecules or to increase the physical stability of the duplex formed upon hybridization (e.g., phosphorothioate derivatives and acridine substituted nucleotides). Examples of modified nucleotides that can be used to generate the nucleic acids include, but are not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N⁶-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N⁶-substituted adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N⁶-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, 3-(3-amino-3-N-2-carboxypropyl) uracil, and 2,6-diaminopurine. Alternatively, one or more of the nucleic acids of the invention can be purchased from companies, such as Macromolecular Resources (Fort Collins, Colo.) and Synthesgen (Houston, Tex.).

[0316] The invention also provides a nucleic acid comprising a nucleotide sequence which is complementary to the nucleotide sequence of any of the nucleic acids described herein or a nucleotide sequence which hybridizes under stringent conditions to the nucleotide sequence of any of the nucleic acids described herein.

[0317] The nucleotide sequence which hybridizes under stringent conditions preferably hybridizes under high stringency conditions. By "high stringency conditions" is meant that the nucleotide sequence specifically hybridizes to a target sequence (the nucleotide sequence of any of the nucleic acids described herein) in an amount that is detectably stronger than non-specific hybridization. High stringency conditions include conditions which would distinguish a polynucleotide with an exact complementary sequence, or one containing only a few scattered mismatches, from a random sequence that happened to have only a few small regions (e.g., 3-10 bases) that matched the nucleotide sequence. Such small regions of complementarity are more easily melted than a full-length complement of 14-17 or more bases, and high stringency hybridization makes them easily distinguishable. Relatively high stringency conditions would include, for example, low salt and/or high temperature conditions, such as provided by about 0.02-0.1 M NaCl or the equivalent, at temperatures of about 50-70° C. Such high stringency conditions tolerate little, if any, mismatch between the nucleotide sequence and the template or target strand, and are particularly suitable for detecting expression of any of the inventive PEs or chimeric molecules. It is generally appreciated that conditions can be rendered more stringent by the addition of increasing amounts of formamide.

[0318] The invention also provides a nucleic acid comprising a nucleotide sequence that is about 70% or more, e.g., about 80% or more, about 90% or more, about 91% or more, about 92% or more, about 93% or more, about 94% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, or about 99% or more identical to any of the nucleic acids described herein.

[0319] The nucleic acids of the invention can be incorporated into a recombinant expression vector. In this regard, the invention provides recombinant expression vectors comprising any of the nucleic acids of the invention. For purposes herein, the term "recombinant expression vector" means a genetically-modified oligonucleotide or polynucleotide construct that permits the expression of an mRNA, protein, polypeptide, or peptide by a host cell, when the construct comprises a nucleotide sequence encoding the mRNA, protein, polypeptide, or peptide, and the vector is contacted with the cell under conditions sufficient to have the mRNA, protein, polypeptide, or peptide expressed within the cell. The vectors of the invention are not naturally-occurring as a whole. However, parts of the vectors can be naturally-occurring. The inventive recombinant expression vectors can comprise any type of nucleotides, including, but not limited to DNA and RNA, which can be single-stranded or double-stranded, which can be synthesized or obtained in part from natural sources, and which can contain natural, non-natural or altered nucleotides. The recombinant expression vectors can comprise naturally-occurring, non-naturally-occurring internucleotide linkages, or both types of linkages. Preferably, the non-naturally occurring or altered nucleotides or internucleotide linkages does not hinder the transcription or replication of the vector.

[0320] The recombinant expression vector of the invention can be any suitable recombinant expression vector, and can be used to transform or transfect any suitable host cell. Suitable vectors include those designed for propagation and expansion or for expression or for both, such as plasmids and viruses. The vector can be selected from the group consisting of the pUC series (Fermentas Life Sciences), the pBluescript series (Stratagene, LaJolla, Calif.), the pET series (Novagen, Madison, Wis.), the pGEX series (Pharmacia Biotech, Uppsala, Sweden), and the pEX series (Clontech, Palo Alto, Calif.). Bacteriophage vectors, such as λ GT10, λ GT11, λ ZapII (Stratagene), λ EMBL4, and λ NM1149, also can be used. Examples of plant expression vectors include pBI01, pBI101.2, pBI101.3, pBI121 and pBIN19 (Clontech). Examples of animal expression vectors include pEUK-Cl, pMAM, and pMAMneo (Clontech). Preferably, the recombinant expression vector is a viral vector, e.g., a retroviral vector.

[0321] The recombinant expression vectors of the invention can be prepared using standard recombinant DNA techniques described in, for example, Sambrook et al., *supra*, and Ausubel et al., *supra*. Constructs of expression vectors, which are circular or linear, can be prepared to contain a replication system functional in a prokaryotic or eukaryotic host cell. Replication systems can be derived, e.g., from ColEI, 2 μ plasmid, SV40, bovine papilloma virus, and the like.

[0322] Desirably, the recombinant expression vector comprises regulatory sequences, such as transcription and translation initiation and termination codons, which are specific to the type of host (e.g., bacterium, fungus, plant, or animal) into which the vector is to be introduced, as appropriate and taking into consideration whether the vector is DNA- or RNA-based.

[0323] The recombinant expression vector can include one or more marker genes, which allow for selection of transformed or transfected hosts. Marker genes include biocide resistance, e.g., resistance to antibiotics, heavy metals, etc., complementation in an auxotrophic host to provide prototrophy, and the like. Suitable marker genes for the inventive expression vectors include, for instance, neomycin/G418

resistance genes, hygromycin resistance genes, histidinol resistance genes, tetracycline resistance genes, and ampicillin resistance genes.

[0324] The recombinant expression vector can comprise a native or nonnative promoter operably linked to the nucleotide sequence encoding the inventive PE or chimeric molecule (including functional portions and functional variants), or to the nucleotide sequence which is complementary to or which hybridizes to the nucleotide sequence encoding the PE or chimeric molecule. The selection of promoters, e.g., strong, weak, inducible, tissue-specific, and developmental-specific, is within the ordinary skill of the artisan. Similarly, the combining of a nucleotide sequence with a promoter is also within the ordinary skill of the artisan. The promoter can be a non-viral promoter or a viral promoter, e.g., a cytomegalovirus (CMV) promoter, an SV40 promoter, an RSV promoter, or a promoter found in the long-terminal repeat of the murine stem cell virus.

[0325] The inventive recombinant expression vectors can be designed for either transient expression, for stable expression, or for both. Also, the recombinant expression vectors can be made for constitutive expression or for inducible expression.

[0326] Another embodiment of the invention further provides a host cell comprising any of the recombinant expression vectors described herein. As used herein, the term “host cell” refers to any type of cell that can contain the inventive recombinant expression vector. The host cell can be a eukaryotic cell, e.g., plant, animal, fungi, or algae, or can be a prokaryotic cell, e.g., bacteria or protozoa. The host cell can be a cultured cell, an adherent cell or a suspended cell, i.e., a cell that grows in suspension. For purposes of producing a recombinant inventive PE or chimeric molecule, the host cell is preferably a prokaryotic cell, e.g., an *E. coli* cell.

[0327] Also provided by the invention is a population of cells comprising at least one host cell described herein. The population of cells can be a heterogeneous population comprising the host cell comprising any of the recombinant expression vectors described, in addition to at least one other cell, e.g., a host cell which does not comprise any of the recombinant expression vectors. Alternatively, the population of cells can be a substantially homogeneous population, in which the population comprises mainly (e.g., consisting essentially of) host cells comprising the recombinant expression vector. The population also can be a clonal population of cells, in which all cells of the population are clones of a single host cell comprising a recombinant expression vector, such that all cells of the population comprise the recombinant expression vector. In one embodiment of the invention, the population of cells is a clonal population of host cells comprising a recombinant expression vector as described herein.

[0328] The inventive PEs, chimeric molecules (including functional portions and functional variants), nucleic acids, recombinant expression vectors, host cells (including populations thereof), and populations of cells can be isolated and/or purified. The term “isolated” as used herein means having been removed from its natural environment. The term “purified” as used herein means having been increased in purity, wherein “purity” is a relative term, and not to be necessarily construed as absolute purity. For example, the purity can be about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, or about 100%. The

purity preferably is about 90% or more (e.g., about 90% to about 95%) and more preferably about 98% or more (e.g., about 98% to about 99%).

[0329] The inventive PEs, chimeric molecules (including functional portions and functional variants), nucleic acids, recombinant expression vectors, host cells (including populations thereof), and populations of cells, all of which are collectively referred to as “inventive PE materials” hereinafter, can be formulated into a composition, such as a pharmaceutical composition. In this regard, the invention provides a pharmaceutical composition comprising any of the PEs, chimeric molecules (including functional portions and functional variants), nucleic acids, recombinant expression vectors, host cells (including populations thereof), and populations of cells, and a pharmaceutically acceptable carrier. The inventive pharmaceutical composition containing any of the inventive PE materials can comprise more than one inventive PE material, e.g., a polypeptide and a nucleic acid, or two or more different PEs. Alternatively, the pharmaceutical composition can comprise an inventive PE material in combination with one or more other pharmaceutically active agents or drugs, such as a chemotherapeutic agents, e.g., asparaginase, busulfan, carboplatin, cisplatin, daunorubicin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea, methotrexate, paclitaxel, rituximab, vinblastine, vincristine, etc.

[0330] Preferably, the carrier is a pharmaceutically acceptable carrier. With respect to pharmaceutical compositions, the carrier can be any of those conventionally used and is limited only by chemico-physical considerations, such as solubility and lack of reactivity with the active compound(s), and by the route of administration. The pharmaceutically acceptable carriers described herein, for example, vehicles, adjuvants, excipients, and diluents, are well-known to those skilled in the art and are readily available to the public. It is preferred that the pharmaceutically acceptable carrier be one which is chemically inert to the active agent(s) and one which has no detrimental side effects or toxicity under the conditions of use.

[0331] The choice of carrier will be determined in part by the particular inventive PE material, as well as by the particular method used to administer the inventive PE material. Accordingly, there are a variety of suitable formulations of the pharmaceutical composition of the invention. The following formulations for parenteral (e.g., subcutaneous, intravenous, intraarterial, intramuscular, intradermal, interperitoneal, and intrathecal), oral, and aerosol administration are exemplary and are in no way limiting. More than one route can be used to administer the inventive PE materials, and in certain instances, a particular route can provide a more immediate and more effective response than another route.

[0332] Topical formulations are well-known to those of skill in the art. Such formulations are particularly suitable in the context of the invention for application to the skin.

[0333] Formulations suitable for oral administration can include (a) liquid solutions, such as an effective amount of the inventive PE material dissolved in diluents, such as water, saline, or orange juice; (b) capsules, sachets, tablets, lozenges, and troches, each containing a predetermined amount of the active ingredient, as solids or granules; (c) powders; (d) suspensions in an appropriate liquid; and (e) suitable emulsions. Liquid formulations may include diluents, such as water and alcohols, for example, ethanol, benzyl alcohol, and the polyethylene alcohols, either with or without the addition of a pharmaceutically acceptable surfactant. Capsule forms

can be of the ordinary hard- or soft-shelled gelatin type containing, for example, surfactants, lubricants, and inert fillers, such as lactose, sucrose, calcium phosphate, and corn starch. Tablet forms can include one or more of lactose, sucrose, mannitol, corn starch, potato starch, alginic acid, microcrystalline cellulose, acacia, gelatin, guar gum, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, calcium stearate, zinc stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, disintegrating agents, moistening agents, preservatives, flavoring agents, and other pharmacologically compatible excipients. Lozenge forms can comprise the inventive PE material in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the inventive PE material in an inert base, such as gelatin and glycerin, or sucrose and acacia, emulsions, gels, and the like additionally containing such excipients as are known in the art.

[0334] The inventive PE material, alone or in combination with other suitable components, can be made into aerosol formulations to be administered via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like. The aerosol formulations also may be formulated as pharmaceuticals for non-pressured preparations, such as in a nebulizer or an atomizer. Such spray formulations also may be used to spray mucosa.

[0335] Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. The inventive PE material can be administered in a physiologically acceptable diluent in a pharmaceutical carrier, such as a sterile liquid or mixture of liquids, including water, saline, aqueous dextrose and related sugar solutions, an alcohol, such as ethanol or hexadecyl alcohol, a glycol, such as propylene glycol or polyethylene glycol, dimethylsulfoxide, glycerol, ketals such as 2,2-dimethyl-1,3-dioxolane-4-methanol, ethers, poly(ethyleneglycol) 400, oils, fatty acids, fatty acid esters or glycerides, or acetylated fatty acid glycerides with or without the addition of a pharmaceutically acceptable surfactant, such as a soap or a detergent, suspending agent, such as pectin, carbomers, methylcellulose, hydroxypropylmethylcellulose, or carboxymethylcellulose, or emulsifying agents and other pharmaceutical adjuvants.

[0336] Oils, which can be used in parenteral formulations include petroleum, animal, vegetable, or synthetic oils. Specific examples of oils include peanut, soybean, sesame, cottonseed, corn, olive, petrolatum, and mineral. Suitable fatty acids for use in parenteral formulations include oleic acid, stearic acid, and isostearic acid. Ethyl oleate and isopropyl myristate are examples of suitable fatty acid esters.

[0337] Suitable soaps for use in parenteral formulations include fatty alkali metal, ammonium, and triethanolamine salts, and suitable detergents include (a) cationic detergents such as, for example, dimethyl dialkyl ammonium halides, and alkyl pyridinium halides, (b) anionic detergents such as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin, ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionic detergents such as, for example, fatty amine oxides, fatty acid alkanolamides, and polyoxyethylenepolypropylene copolymers, (d) amphoteric detergents such as, for example,

alkyl- β -aminopropionates, and 2-alkyl-imidazoline quaternary ammonium salts, and (e) mixtures thereof.

[0338] The parenteral formulations will typically contain from about 0.5% to about 25% by weight of the inventive PE material in solution. Preservatives and buffers may be used. In order to minimize or eliminate irritation at the site of injection, such compositions may contain one or more nonionic surfactants having a hydrophile-lipophile balance (HLB) of from about 12 to about 17. The quantity of surfactant in such formulations will typically range from about 5% to about 15% by weight. Suitable surfactants include polyethylene glycol sorbitan fatty acid esters, such as sorbitan monooleate and the high molecular weight adducts of ethylene oxide with a hydrophobic base, formed by the condensation of propylene oxide with propylene glycol. The parenteral formulations can be presented in unit-dose or multi-dose sealed containers, such as ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid excipient, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described. The requirements for effective pharmaceutical carriers for parenteral compositions are well-known to those of ordinary skill in the art (see, e.g., *Pharmaceutics and Pharmacy Practice*, J.B. Lippincott Company, Philadelphia, Pa., Banker and Chalmers, eds., pages 238-250 (1982), and *ASHP Handbook on Injectable Drugs*, Toissel, 4th ed., pages 622-630 (1986)).

[0339] It will be appreciated by one of skill in the art that, in addition to the above-described pharmaceutical compositions, the inventive PE materials of the invention can be formulated as inclusion complexes, such as cyclodextrin inclusion complexes, or liposomes.

[0340] For purposes of the invention, the amount or dose of the inventive PE material administered should be sufficient to effect a desired response, e.g., a therapeutic or prophylactic response, in the mammal over a reasonable time frame. For example, the dose of the inventive PE material should be sufficient to inhibit growth of a target cell or treat or prevent cancer in a period of from about 2 hours or longer, e.g., 12 to 24 or more hours, from the time of administration. In certain embodiments, the time period could be even longer. The dose will be determined by the efficacy of the particular inventive PE material and the condition of the mammal (e.g., human), as well as the body weight of the mammal (e.g., human) to be treated.

[0341] Many assays for determining an administered dose are known in the art. An administered dose may be determined in vitro (e.g., cell cultures) or in vivo (e.g., animal studies). For example, an administered dose may be determined by determining the IC_{50} (the dose that achieves a half-maximal inhibition of symptoms), LD_{50} (the dose lethal to 50% of the population), the ED_{50} (the dose therapeutically effective in 50% of the population), and the therapeutic index in cell culture and/or animal studies. The therapeutic index is the ratio of LD_{50} to ED_{50} (i.e., LD_{50}/ED_{50}).

[0342] The dose of the inventive PE material also will be determined by the existence, nature, and extent of any adverse side effects that might accompany the administration of a particular inventive PE material. Typically, the attending physician will decide the dosage of the inventive PE material with which to treat each individual patient, taking into consideration a variety of factors, such as age, body weight, general health, diet, sex, inventive PE material to be administered,

route of administration, and the severity of the condition being treated. By way of example and not intending to limit the invention, the dose of the inventive PE material can be about 0.001 to about 1000 mg/kg body weight of the subject being treated/day, from about 0.01 to about 10 mg/kg body weight/day, about 0.01 mg to about 1 mg/kg body weight/day, from about 1 to about 1000 mg/kg body weight/day, from about 5 to about 500 mg/kg body weight/day, from about 10 to about 250 mg/kg body weight/day, about 25 to about 150 mg/kg body weight/day, or about 10 mg/kg body weight/day.

[0343] Alternatively, the inventive PE materials can be modified into a depot form, such that the manner in which the inventive PE material is released into the body to which it is administered is controlled with respect to time and location within the body (see, for example, U.S. Pat. No. 4,450,150). Depot foams of inventive PE materials can be, for example, an implantable composition comprising the inventive PE materials and a porous or non-porous material, such as a polymer, wherein the inventive PE materials is encapsulated by or diffused throughout the material and/or degradation of the non-porous material. The depot is then implanted into the desired location within the body and the inventive PE materials are released from the implant at a predetermined rate.

[0344] The inventive PE materials may be assayed for cytotoxicity by assays known in the art. Examples of cytotoxicity assays include a WST assay, which measures cell proliferation using the tetrazolium salt WST-1 (reagents and kits available from Roche Applied Sciences), as described in International Patent Application Publication WO 2011/032022.

[0345] It is contemplated that the inventive pharmaceutical compositions, PEs, chimeric molecules, nucleic acids, recombinant expression vectors, host cells, or populations of cells can be used in methods of treating or preventing cancer. Without being bound by a particular theory or mechanism, it is believed that the inventive PEs destroy or inhibit the growth of cells through the inhibition of protein synthesis in eukaryotic cells, e.g., by the inactivation of the ADP-ribosylation of elongation factor 2 (EF-2). Without being bound to a particular theory or mechanism, the inventive chimeric molecules recognize and specifically bind to cell surface markers, thereby delivering the cytotoxic PE to the population of cells expressing the cell surface marker with minimal or no cross-reactivity with cells that do not express the cell surface marker. In this way, the cytotoxicity of PE can be targeted to destroy or inhibit the growth of a particular population of cells, e.g., cancer cells. In this regard, the invention provides a method of treating or preventing cancer in a mammal comprising administering to the mammal any of the PEs, chimeric molecules, nucleic acids, recombinant expression vectors, host cell, population of cells, or pharmaceutical compositions described herein, in an amount effective to treat or prevent cancer in the mammal.

[0346] The terms “treat” and “prevent” as well as words stemming therefrom, as used herein, do not necessarily imply 100% or complete treatment or prevention. Rather, there are varying degrees of treatment or prevention of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect. In this respect, the inventive methods can provide any amount of any level of treatment or prevention of cancer in a mammal. Furthermore, the treatment or prevention provided by the inventive method can include treatment or prevention of one or more conditions or

symptoms of the disease, e.g., cancer, being treated or prevented. Also, for purposes herein, “prevention” can encompass delaying the onset of the disease, or a symptom or condition thereof

[0347] For purposes of the inventive methods, wherein host cells or populations of cells are administered, the cells can be cells that are allogeneic or autologous to the host. Preferably, the cells are autologous to the host.

[0348] With respect to the inventive methods, the cancer can be any cancer, including any of adrenal gland cancer, sarcomas (e.g., synovial sarcoma, osteogenic sarcoma, leiomyosarcoma uteri, angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma, myxoma, rhabdomyoma, fibroma, lipoma, and teratoma), lymphomas (e.g., small lymphocytic lymphoma, Hodgkin lymphoma, and non-Hodgkin lymphoma), hepatocellular carcinoma, glioma, head cancers (e.g., squamous cell carcinoma), neck cancers (e.g., squamous cell carcinoma), acute lymphocytic cancer, leukemias (e.g., hairy cell leukemia, myeloid leukemia (acute and chronic), lymphatic leukemia (acute and chronic), prolymphocytic leukemia (PLL), myelomonocytic leukemia (acute and chronic), and lymphocytic leukemia (acute and chronic)), bone cancer (osteogenic sarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma)), multiple myeloma, malignant giant cell tumor, chordoma, osteochondroma (osteochondilagenous exostoses), benign chondroma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, and giant cell tumors), brain cancer (astrocytoma, medulloblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma multiforme, oligodendroglioma, schwannoma, and retinoblastoma), fallopian tube cancer, breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the oral cavity, cancer of the vulva (e.g., squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, and fibrosarcoma), myeloproliferative disorders (e.g., chronic myeloid cancer), colon cancers (e.g., colon carcinoma), esophageal cancer (e.g., squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, and lymphoma), cervical cancer (cervical carcinoma and pre-invasive cervical dysplasia), gastric cancer, gastrointestinal carcinoid tumor, hypopharynx cancer, larynx cancer, liver cancers (e.g., hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma), lung cancers (e.g., bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, and adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, chondromatous hamartoma, small cell lung cancer, non-small cell lung cancer, and lung adenocarcinoma), mesothelioma, skin cancer (e.g., melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, nevi, dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids), multiple myeloma, nasopharynx cancer, ovarian cancer (e.g., ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, endometrioid carcinoma, and clear cell adenocarcinoma), granulosa-theca cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, and malignant teratoma), pancreatic cancer (e.g., ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, and VIPoma), peritoneum, omentum, mesentery cancer, pharynx cancer, prostate cancer (e.g., adenocarcinoma and sarcoma), rectal

cancer, kidney cancer (e.g., adenocarcinoma, Wilms tumor (nephroblastoma), and renal cell carcinoma), small intestine cancer (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, and fibroma), soft tissue cancer, stomach cancer (e.g., carcinoma, lymphoma, and leiomyosarcoma), testicular cancer (e.g., seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, Leydig cell tumor, fibroma, fibroadenoma, adenomatoid tumors, and lipoma), cancer of the uterus (e.g., endometrial carcinoma), thyroid cancer, and urothelial cancers (e.g., squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma, ureter cancer, and urinary bladder cancer).

[0349] As used herein, the term "mammal" refers to any mammal, including, but not limited to, mammals of the order Rodentia, such as mice and hamsters, and mammals of the order Logomorpha, such as rabbits. It is preferred that the mammals are from the order Carnivora, including Felines (cats) and Canines (dogs). It is more preferred that the mammals are from the order Artiodactyla, including Bovines (cows) and Swines (pigs) or of the order Perssodactyla, including Equines (horses). It is most preferred that the mammals are of the order Primates, Ceboidea, or Simioida (monkeys) or of the order Anthropoidea (humans and apes). An especially preferred mammal is the human.

[0350] Also provided is a method of inhibiting the growth of a target cell comprising contacting the cell with the PE of any of the PEs, chimeric molecules, nucleic acids, recombinant expression vectors, host cell, population of cells, or pharmaceutical compositions described herein, in an amount effective to inhibit growth of the target cell. The growth of the target cell may be inhibited by any amount, e.g., by about 10% or more, about 15% or more, about 20% or more, about 25% or more, about 30% or more, about 35% or more, about 40% or more, about 45% or more, about 50% or more, about 55% or more, about 60% or more, about 65% or more, about 70% or more, about 75% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more, or about 100%. The target cell may be provided in a biological sample. A biological sample may be obtained from a mammal in any suitable manner and from any suitable source. The biological sample may, for example, be obtained by a blood draw, leukapheresis, and/or tumor biopsy or necropsy. The contacting can take place in vitro or in vivo with respect to the mammal. Preferably, the contacting is in vitro.

[0351] In an embodiment of the invention, the target cell is a cancer cell. The target cell may be a cancer cell of any of the cancers described herein. In an embodiment of the invention, the target may express a cell surface marker. The cell surface marker may be any cell surface marker described herein with respect to other aspects of the invention. The cell surface marker may be, for example, selected from the group consisting of CD19, CD21, CD22, CD25, CD30, CD33, CD79b, transferrin receptor, EGF receptor, mesothelin, cadherin, and Lewis Y.

[0352] The following examples further illustrate the invention but, of course, should not be construed as in any way limiting its scope.

Example 1

[0353] This example demonstrates the identification of T cell epitopes in domain III of PE38.

[0354] To identify the T cell epitopes in PE38, peripheral blood mononuclear cells (PBMCs) were first incubated with

a recombinant immunotoxin (RIT) for 14 days to allow the RIT to be processed by donor APCs to relevant peptides to be presented to T cells. The enriched PBMCs were subsequently exposed to a peptide library composed of 111 partially overlapping peptides spanning the sequence of PE38 and T cell activation was measured using an ELISpot assay for interleukin-2 (IL-2).

[0355] Samples from 50 normal donors with no recorded previous exposure to PE38 and with a broad distribution of human leukocyte antigen (HLA) alleles were analyzed. The cells of this population contained naïve T cell epitope. Samples from nine mesothelioma and seven hairy cell leukemia (HCL) patients that were previously treated with PE-based RIT and who had developed high levels of neutralizing antibodies were also analyzed. The cells of this population contained memory T cell epitopes. The responses of the naïve donors and the previously treated patients are shown in a heat map format in FIGS. 1A-1B.

[0356] FIG. 1A presents the positive and negative responses of the 50 naïve donors. The responses are shown as a percentage of responsive spots for each donor. The strongest positive response is shown as >20%, medium responses are shown as 10%-20%, weak responses are shown as 3%-10%, and the absence of a response (negative) is shown as <3%. The results included a total of 258 positive responses, and 201 of those were weak (3-10%), 44 were medium (10-20%), and 13 were strong (>20%), leaving a total of 5292 negative responses (<3%). There were 122 responses in domain II (peptides 1-38) including 11 strong, 24 medium, and 87 weak responses. There were 136 responses in domain III (peptides 39-111) including two strong, 20 medium and 114 weak responses.

[0357] Peptides 15 and 14 (in pool 3) provided the strongest and most frequent responses in the study with 21 and 18 positive responses, respectively. A total of 36 peptides did not provide any response. Sixteen of the 50 naïve donors had a single epitope giving a response, as indicated by one, two, or three responses in overlapping consecutive peptides. Fifteen donors had two separate epitopes, 14 had three epitopes, and five had four epitopes. On 22 occasions, a fine screen of a positive pool did not provide a specific peptide response or was not done, resulting in five consecutive positive responses in the heat map.

[0358] FIG. 1B illustrates the positive and negative responses of the nine mesothelioma and the seven HCL patients. It was found that the mesothelioma patients provided 919 negative responses and 80 responses, including two strong responses (>20%), four medium responses (10-20%), and 74 weak responses (3-10%). The two strong responses were in peptides 13 and 14, and the medium responses were in peptides 15, 35, 57 and 74. Thirty-five of the responses were in domain II (peptides 1-38) and 45 in domain III (peptides 38-111). The hot spot pattern created in the map is similar to the hot spot pattern in the naïve donors map. The responsiveness (meaning how many epitopes were found for each patient) was higher than the donor's pattern with one patient having two epitopes, four patients having three epitopes, two patients having four epitopes and two more patients having five epitopes.

[0359] Moreover, it was found that the seven HCL patients provided three strong responses (>20%), nine medium responses (10-20%), 37 weak responses (3-10%), and 728 negative responses (<3%). The strong responses were all in the consecutive peptides 75, 76 and 77. Twenty-two of the

responses were in domain II and 37 responses were in domain III. Interestingly, the immunodominant epitope in peptides 14 and 15 that was identified in more than 40% of the naïve donors and 55% of the mesothelioma patients (five out of nine samples) did not have a single response in the HCL patients. One patient responded to peptides 12 and 13 that have amino acids in common with peptides 14 and 15. However, no responses were found directly to peptides 14 and 15. This may be attributed to the biased HLA distribution of those patients' samples or to the nature of the disease.

[0360] Overall, eight major epitopes were identified in PE38 that account for 93% of the responses. Because all T cell epitopes in domain II could be eliminated using the LR deletion, the five epitopes remaining in domain III were the focus of subsequent study. Table 1A summarizes the epitopes' locations, sequences, response rates, and the mutation that diminishes each with minimal disturbance to cytotoxic activity. The epitope ranking was composed of a number of factors, including the number of naïve donors responding to the epitope, the relative strength of the response, the number of mesothelioma patients that responded, and, to a lesser extent, the HCL patients' responses. The epitopes from HCL patients were evaluated to a lesser extent in this analysis because of the HLA bias of the patient cohort and in the HCL patient population, in which HCL patients have an enrichment of BRB1_11 (Annino et al., *Leuk. Lymphoma*, 14 (Suppl.) 1:63-5 (1994)). Epitope 2 spans five peptides. To simplify analysis, it was divided into two sub-epitopes: peptides 77-78 (2A) and peptides 75-76 (2B). Some donors responded to both 2A and 2B epitopes, while others responded to only one. Epitope 6 (peptides 93-96) and epitope 8 (peptides 56-59) were also divided into two sub-epitopes.

[0361] To compare the results from naïve donors to immunotoxin-treated patients, two patient cohorts that made neutralizing antibodies against the RIT were studied. The patients' DRB1 HLA alleles are shown in Table 1B. The same epitopes identified in the donor cohort were also present in the patient cohorts. One cohort was from mesothelioma patients treated with SS1P (anti-mesothelin Fv fused to P38) (Chowdhury et al., *Nat. Biotechnol.*, 17: 568-572 (1999)); the other from leukemia patients treated with moxetumomab pasudotox (MP), a RIT including PE38 fused to an anti-CD22 Fv (Kreitman et al., *Clin. Cancer Res.*, 17: 6398-6405 (2011)). The naïve donor epitope responses ranged from 1-4 epitopes per donor, with an average of 2.1, and the patient responses ranged from 1-7 per patient, with a higher average of 3.4 ($P < 0.001$ in Student T test). This suggests that some responses in the naïve population were too weak to be detected by this method, and were amplified after exposure to immunotoxin. The patient samples did not identify any major epitopes that were not identified using the donor cohort.

TABLE 1B

Donor	Diagnosis	HLA haplotype DRB1
71509WBp	HCL	04, 11
102609aph	HCL	1103, 1303
112309aph	HCL	0404, 0701
121809aph	HCL	07, 11
050710aph	HCL	01, 07
021012baph	HCL	04, 07
071912aph	HCL	07, 11

TABLE 1A

Epitope ranking	Peptide #	Sequence	Responses			Relative cytotoxicity*
			Donors (n = 50)	Mesothelioma (n = 9)	HCL (n = 7)	
1	13-15	LVALYLAARLSWNQV SEQ ID NO: 189	21	6	1	Domain II deletion 100%
2	A 77-78	GALLRVYVPRSSLPG SEQ ID NO: 190	14 ^a	3 ^a	6 ^a	R505A 100%
	B 74-76	IRNGALLRVYVPRSS SEQ ID NO: 191	10 ^a	6 ^a	5 ^a	R494A 21-36%
3	8-9	RQPRGWLEQCGYP SEQ ID NO: 192	9	3	3	Domain II deletion 100%
4	5-6	LPLETFTRHRQPRGW SEQ ID NO: 193	10	2	0	Domain II deletion 100%
5	67-68	WRGFYIAGDPALAYG SEQ ID NO: 194	8	2	2	L477H 100%
6A + B	93-96	GPEEEGGRLETILGWPLA SEQ ID NO: 195	8	1	2	L552E 100%
7	51-52	TVERLLQAHRLQLEER SEQ ID NO: 196	5	1	0	R427A 100%
8A + B	56-59	FVGYHGTFLAAQSIVFG SEQ ID NO: 197	5	5	4	F443A >100%

*Activity for a single point mutation in HA22 RIT and evaluated in CA46 cell line.

^aDonors and patients that responded to epitope 2A overlap with the patients and donors that responded to 2B.

TABLE 1B-continued

Donor	Diagnosis	HLA haplotype DRB1
120909aph	Mesothelioma	0410, 1501
011410aph	Mesothelioma	0101, 0801
012810aph	Mesothelioma	0301, 1501
050510aph	Mesothelioma	0401, 1302
091510aph	Mesothelioma	07, 15
022811aph	Mesothelioma	1301, 1302
100711aph	Mesothelioma	0103, 03
021012aph	Mesothelioma	0101, 0101
031612aph	Mesothelioma	0401, 12

Example 2

[0362] This example demonstrates the elimination of T cell epitopes in domain III.

[0363] For each one of the epitopes in domain III that are described in Table 1, alanine scanning mutagenesis was performed. The alanine mutant was incorporated into the RIT according to the following 11 steps: (1) a list was made of all alanine peptide variants for each epitope; (2) in silico prediction was performed to rule out alanine variants that had increased binding to at least six HLA alleles using an HLA binding algorithm (Immune Epitope Database, IEDB) (Wang et al., *PLoS Comput. Biol.*, 4:e1000048 (2008)) that measured

their ability to bind to 13 major HLA groups; (3) alanine variants were assayed using 8-15 donors and patient samples with in vitro expansion and ELISpot; (4) an alanine mutation with diminished T cell activation was identified; (5) the alanine mutation was cloned into the HA22-LR plasmid, and a RIT was constructed with a single point mutation; (6) activity was studied using the WST8 assay.

[0364] If the protein was aggregated or has low cytotoxic activity, (7) in silico prediction and crystal structure was used to identify alternative amino acids to alanine and (8) the new mutation was cloned into an HA22-LR plasmid, and a RIT was constructed with a single point mutation and activity was studied. If the protein was aggregated or had low cytotoxic activity, then the next best alanine mutant was identified as in step 4 and step 5 was carried out. If the protein was active, step 10 was carried out.

[0365] If the protein was active, (10) validation was carried out to determine whether the epitope was diminished and that no new epitopes were created due to the mutation; and (11) the successful point mutations were combined into a single RIT.

[0366] The results for all epitopes are shown in Tables 2-7. In Tables 2-7, underlined values represent <10%, D=Donor, Pt=patient, "Meso"=mesothelioma, the position where the amino acid was replaced with alanine is underlined, and the average values are bolded. Alanine variants were assayed using 8-15 donor and patient samples with in vitro expansion and ELISpot.

TABLE 2

CD4+ T cell response to alanine variant peptides and WT76.												
donor/ patient		HCL Pt	Meso Pt	HCL Pt	Meso Pt	Meso Pt	D1	D2	D3	D4	D5	Mean n = 16
No peptide		3%	0%	0%	1%	0%	0%	9%	0%	17%	1%	0%
WT76	IRNGALLRVYVPR SS SEQ ID NO: 198	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
I493A	ARNGALLRVYVPR SS SEQ ID NO: 199	<u>2%</u>	13%	<u>0%</u>	36%	52%	<u>6%</u>	20%	110%	71%	76%	25%
R494A	IANGALLRVYVPR SS SEQ ID NO: 200	<u>1%</u>	<u>0%</u>	<u>2%</u>	<u>2%</u>	<u>0%</u>	12%	26%	111%	88%	94%	24%
N495A	IRAGALLRVYVPR SS SEQ ID NO: 201	95%	25%	<u>2%</u>	31%	12%	35%	40%	102%	72%	72%	34%
G496A	IRNAALLRVYVPR SS SEQ ID NO: 202	107%	58%	18%	63%	34%	18%	37%	96%	44%	99%	42%
L498A	IRNGAALLRVYVPR SS SEQ ID NO: 203	<u>4%</u>	<u>4%</u>	<u>0%</u>	<u>4%</u>	27%	<u>0%</u>	80%	<u>6%</u>	16%	31%	<u>5%</u>
L499A	IRNGALARRVYVPR SS SEQ ID NO: 204	<u>7%</u>	<u>0%</u>	<u>0%</u>	<u>1%</u>	<u>2%</u>	<u>6%</u>	31%	30%	15%	57%	<u>3%</u>
R500A	IRNGALLAVYVPR SS SEQ ID NO: 205	<u>5%</u>	<u>4%</u>	24%	<u>2%</u>	<u>0%</u>	24%	26%	<u>1%</u>	20%	<u>6%</u>	<u>4%</u>

TABLE 2-continued

CD4+ T cell response to alanine variant peptides and WT76.												
donor/ patient		HCL Pt	Meso Pt	HCL Pt	Meso Pt	Meso Pt	D1	D2	D3	D4	D5	Mean n = 16
V501A	IRNGALLRAYVPR SS SEQ ID NO: 206	5%	0%	7%	13%	29%	0%	46%	25%	27%	48%	11%
Y502A	IRNGALLRVAVPR SS SEQ ID NO: 207	29%	4%	18%	23%	70%	12%	23%	5%	20%	0%	19%
V503A	IRNGALLRVYAPR SS SEQ ID NO: 208	54%	58%	47%	68%	30%	41%	63%	35%	27%	43%	41%
P504A	IRNGALLRVYVAR SS SEQ ID NO: 209	91%	125%	49%	122%	117%	206%	60%	35%	26%	18%	74%
R505A	IRNGALLRVYVPA SS SEQ ID NO: 210	95%	83%	87%	127%	133%	147%	131%	36%	23%	30%	87%
S506A	IRNGALLRVYVPR AS SEQ ID NO: 211	92%	138%	44%	107%	100%	312%	214%	101%	55%	82%	106%
S507A	IRNGALLRVYVPR SA SEQ ID NO: 212	99%	96%	51%	69%	106%	235%	137%	71%	83%	84%	94%

TABLE 3

T cell response to alanine variant peptides and WT77.										
D/ Pt		HCL Pt 1	HCL Pt 2	HCL Pt 3	HCL Pt 4	Meso Pt 1	D1	D2	D3	Mean (n = 8)
No peptide		0%	0%	0%	12%	1%	18%	9%	7%	6%
wt 77	GALLRVYVPRSSLPG SEQ ID NO: 213	100%	100%	100%	100%	100%	100%	100%	100%	100%
G496A	AALLRVYVPRSSLPG SEQ ID NO: 214	29%	51%	126%	151%	37%	58%	112%	123%	86%
A497G	GGLLRVYVPRSSLPG SEQ ID NO: 215	103%	68%	102%	167%	71%	108%	129%	126%	109%
L498A	GAALRVYVPRSSLPG SEQ ID NO: 216	61%	38%	7%	166%	43%	20%	13%	140%	61%
L499A	GALARVYVPRSSLPG SEQ ID NO: 217	46%	24%	33%	162%	1%	26%	73%	61%	53%
R500A	GALLAVYVPRSSLPG SEQ ID NO: 218	59%	31%	1%	189%	6%	16%	1%	124%	53%
V501A	GALLRAYVPRSSLPG SEQ ID NO: 219	7%	18%	18%	84%	15%	26%	49%	28%	31%
Y502A	GALLRVAVPRSSLPG SEQ ID NO: 220	14%	1%	4%	10%	0%	25%	8%	9%	9%
V503A	GALLRVYAPRSSLPG SEQ ID NO: 221	17%	1%	15%	18%	1%	39%	49%	9%	19%
P504A	GALLRVYVARSSLPG SEQ ID NO: 222	46%	32%	38%	127%	36%	43%	12%	41%	47%

TABLE 3-continued

T cell response to alanine variant peptides and WT77.										
D/ Pt		HCL Pt 1	HCL Pt 2	HCL Pt 3	HCL Pt 4	Meso Pt 1	D1	D2	D3	Mean (n = 8)
R505A	GALLRVYVP <u>P</u> ASSLPG SEQ ID NO: 223	<u>7%</u>	<u>1%</u>	28%	15%	<u>2%</u>	24%	39%	22%	17%
S506A	GALLRVYVPR <u>A</u> SLPG SEQ ID NO: 224	68%	42%	107%	128%	48%	93%	122%	50%	82%
S507A	GALLRVYVPR <u>S</u> ALPG SEQ ID NO: 225	35%	37%	86%	164%	60%	106%	96%	224%	101%
L508A	GALLRVYVPR <u>S</u> APG SEQ ID NO: 226	<u>8%</u>	<u>0%</u>	73%	12%	46%	99%	88%	15%	43%
P509A	GALLRVYVPR <u>S</u> LAG SEQ ID NO: 227	10%	<u>4%</u>	87%	57%	72%	101%	119%	16%	58%

TABLE 4

T cell response to alanine variant peptides and WT 67												
% from WT		HCL Pt 1	HCL Pa 2	HCL Pt 3	Meso Pt 1	Meso Pt 2	D1	D2	D3	D4	D5	Mean (n = 14)
No peptide		6%	3%	3%	13%	1%	1%	13%	0%	0%	0%	13%
WT 67	WRGFYIAGD PALAYG SEQ ID NO: 228	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
F469A	WRG <u>A</u> YIAGD PALAYG SEQ ID NO: 229	80%	68%	93%	11%	81%	104%	35%	97%	88%	60%	69%
Y470A	WRGF <u>A</u> IAGD PALAYG SEQ ID NO: 230	61%	<u>6%</u>	61%	<u>6%</u>	68%	48%	67%	29%	16%	92%	43%
I471A	WRGFY <u>A</u> AGD PALAYG SEQ ID NO: 231	17%	36%	22%	<u>7%</u>	35%	20%	20%	22%	12%	55%	24%
A4720	WRGFYI <u>G</u> GD PALAYG SEQ ID NO: 232	37%	81%	38%	20%	60%	84%	75%	46%	19%	76%	48%
P475A	WRGFYIAGD <u>A</u> ALAYG SEQ ID NO: 233	72%	18%	46%	73%	38%	34%	57%	15%	16%	70%	43%
A476G	WRGFYIAGD PGLAYG SEQ ID NO: 234	75%	49%	40%	110%	32%	207%	26%	67%	35%	115%	70%
L477A	WRGFYIAGD P <u>A</u> AAYG SEQ ID NO: 235	54%	32%	54%	92%	52%	25%	42%	26%	16%	71%	44%
A478G	WRGFYIAGD PAL <u>G</u> YG SEQ ID NO: 236	80%	81%	62%	96%	58%	134%	24%	63%	98%	66%	72%

TABLE 4-continued

T cell response to alanine variant peptides and WT 67												
% from WT		HCL	HCL	HCL	Meso	Meso	D1	D2	D3	D4	D5	Mean
		Pt 1	Pa 2	Pt 3	Pt 1	Pt 2						(n = 14)
Y479A	WRGFYIAGD	114%	106%	76%	250%	138%	108%	117%	71%	21%	94%	104%
	PALAA <u>G</u>											
	SEQ ID NO:											
	237											

TABLE 5

Alanine scanning for peptides 93-94 GPEEEGGRLETILGWPLA (SEQ ID NO: 238)													
Responder groups		HCL	D1	D2	HCL	Meso	Meso	Meso	D3	D4	D5	Mean	
		Pt1			Pt 2	Pt 1	Pt 2	Pt 3				n = 10	
No peptide		93	93	93	94	94	94	94	94	94	94		
		3%	9%	2%	7%	4%	3%	15%	35%	25%	12%	11%	
WT 93-94	GPEEEGGRLETILGWPLA	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	
	SEQ ID NO: 238												
E547A	GPE <u>A</u> EGGRLETILGWPLA	73%	18%	254%	85%	120%	122%	136%	73%	106%	90%	108%	
	SEQ ID NO: 239												
E548A	GPE <u>E</u> AEGGRLETILGWPLA	58%	24%	170%	112%	98%	86%	137%	102%	207%	87%	108%	
	SEQ ID NO: 240												
R551A	GPEEEGGA <u>L</u> ETILGWPLA	62%	<u>6%</u>	2%	95%	70%	42%	54%	40%	67%	49%	49%	
	SEQ ID NO: 241												
L552A	GPEEEGGR <u>A</u> ETILGWPLA	54%	44%	<u>10%</u>	91%	35%	11%	14%	85%	51%	46%	44%	
	SEQ ID NO: 242												
T554A	GPEEEGGRLE <u>A</u> ILGWPLA	77%	<u>9%</u>	<u>5%</u>	94%	133%	130%	129%	110%	95%	112%	89%	
	SEQ ID NO: 243												
I555A	GPEEEGGRLE <u>T</u> ALGWPLA	111%	176%	119%	67%	25%	15%	36%	63%	36%	36%	69%	
	SEQ ID NO: 244												
L556A	GPEEEGGRLE <u>T</u> IAGWPLA	24%	235%	<u>3%</u>	40%	10%	13%	43%	35%	83%	29%	51%	
	SEQ ID NO: 245												
W558A	GPEEEGGRLETILG <u>A</u> PLA	20%	200%	13%	13%	26%	<u>7%</u>	26%	46%	54%	31%	44%	
	SEQ ID NO: 246												
P559A	GPEEEGGRLETILGW <u>A</u> LA	24%	197%	208%	95%	69%	37%	74%	65%	121%	46%	94%	
	SEQ ID NO: 247												
L560A	GPEEEGGRLETILGW <u>P</u> AA	81%	321%	162%	89%	132%	117%	75%	46%	138%	95%	126%	
	SEQ ID NO: 248												

TABLE 6

Alanine scanning for peptide TVERLLQAHRLQLEER (SEQ ID NO: 249)									
		HCL	Meso	Meso	Meso	D1	D2	D3	Mean
		Pt 1	Pt 1	Pt 2	Pt 3				n = 7
No peptide		0%	1%	0%	1%	13%	14%	7%	5%
WT51	TVERLLQAHRLQLEER	100%	100%	100%	100%	100%	100%	100%	100%
	SEQ ID NO: 249								
R421A	TVEALLQAHRLQLEER	23%	87%	<u>2%</u>	<u>5%</u>	22%	12%	26%	25%
	SEQ ID NO: 250								

TABLE 6-continued

Alanine scanning for peptide TVERLLQAHRQLEER (SEQ ID NO: 249)										
		HCL	Meso	Meso	Meso					Mean
		Pt 1	Pt 1	Pt 2	Pt 3	D1	D2	D3		n =7
L422A	TVER <u>A</u> LQAHRQLEER SEQ ID NO: 251	29%	18%	0%	1%	31%	10%	16%	17%	
L423A	TVERL <u>A</u> QAHRQLEER SEQ ID NO: 252	47%	21%	11%	3%	8%	10%	6%	14%	
A425G	TVERLLQ <u>G</u> HRQLEER SEQ ID NO: 253	105%	51%	4%	6%	57%	16%	68%	52%	
R427A	TVERLLQA <u>H</u> AQLEER SEQ ID NO: 254	78%	81%	1%	2%	37%	10%	35%	37%	
L429A	TVERLLQAHRQ <u>A</u> LEER SEQ ID NO: 255	63%	64%	38%	36%	28%	19%	124%	67%	
E430A	TVERLLQAHRQ <u>L</u> AER SEQ ID NO: 256	100%	100%	242%	73%	112%	26%	99%	108%	
R432A	TVERLLQAHRQLE <u>E</u> A SEQ ID NO: 257	105%	92%	87%	69%	65%	57%	142%	106%	

TABLE 7

Alanine scanning for 18 mer peptide FVG YHGTFL EAAQ SIVFG (57-58) (SEQ ID NO: 258)													
		HCL	Meso	Meso		HCL	HCL	Meso	Meso				
		Pt 1	Pt 1	Pt 2	D1	Pt 2	Pt 3	Pt 3	Pt 4	D2	D3	Avg	
Responder groups		57	57	57	57	58	58	58	58	58	58		
No peptide		0%	0%	0%	4%	0%	1%	1%	0%	10%	9%	4%	
WT 57-58	FVG YHGTFL EAAQ SIVFG SEQ ID NO: 258	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	
F436A	<u>A</u> VGYHGTFL EAAQ SIVFG SEQ ID NO: 259	57%	98%	159%	7%	103%	103%	89%	45%	41%	123%	83%	
V437A	F <u>A</u> GYHGTFL EAAQ SIVFG SEQ ID NO: 260	84%	78%	130%	81%	97%	95%	96%	85%	102%	148%	99%	
G438A	FV <u>A</u> YHGTFL EAAQ SIVFG SEQ ID NO: 261	67%	52%	78%	79%	71%	88%	118%	91%	98%	68%	83%	
Y439A	FVG <u>A</u> HGTFL EAAQ SIVFG SEQ ID NO: 262	22%	96%	21%	17%	79%	97%	125%	147%	110%	154%	91%	
H440A	FVG Y <u>A</u> GTFL EAAQ SIVFG SEQ ID NO: 263	11%	12%	95%	6%	46%	113%	108%	120%	90%	102%	75%	
T442A	FVG YH <u>G</u> AFLEAAQ SIVFG SEQ ID NO: 264	77%	84%	151%	31%	48%	102%	93%	50%	59%	127%	82%	
F443A	FVG YHGT <u>A</u> LEAAQ SIVFG SEQ ID NO: 265	2%	0%	40%	7%	5%	2%	1%	1%	20%	7%	10%	
L444A	FVG YHGT <u>F</u> ALEAAQ SIVFG SEQ ID NO: 266	69%	54%	74%	140%	9%	4%	55%	8%	14%	0%	37%	
A446G	FVG YHGTFL E <u>G</u> AQ SIVFG SEQ ID NO: 267	80%	40%	47%	119%	80%	37%	107%	125%	69%	16%	78%	
A447G	FVG YHGTFL E <u>A</u> GQ SIVFG SEQ ID NO: 268	65%	104%	57%	103%	19%	28%	118%	87%	43%	7%	67%	
S449A	FVG YHGTFL EAAQ <u>S</u> IVFG SEQ ID NO: 269	98%	126%	93%	104%	23%	65%	128%	123%	163%	200%	110%	

TABLE 7-continued

Alanine scanning for 18 mer peptide FVG YHGTFLEAAQSIVFG (57-58) (SEQ ID NO: 258)												
		HCL	Meso	Meso		HCL	HCL	Meso	Meso			
		Pt 1	Pt 1	Pt 2	D1	Pt 2	Pt 3	Pt 3	Pt 4	D2	D3	Avg
I450A	FVG YHGTFLEAAQSIVFG	138%	159%	130%	124%	2%	66%	108%	104%	31%	11%	78%
	SEQ ID NO: 270											
V451A	FVG YHGTFLEAAQSIVFG	119%	127%	162%	121%	82%	117%	142%	118%	137%	50%	116%
	SEQ ID NO: 271											
F452A	FVG YHGTFLEAAQSIVFG	119%	126%	154%	156%	99%	104%	103%	151%	104%	123%	127%
	SEQ ID NO: 272											

[0367] Epitopes 2A and 2B were scanned separately to cover the 9 mer core of all five peptides that gave responses. Y502A diminished the responses of both epitopes (Tables 2 and 3). For epitopes 5 and 7, alanine mutants were compared to peptide 67 and 51, respectively, and I471A and L423A had the lowest T cell response (Tables 4 and 6). To cover all 9 mer cores in epitopes 6 and 8 that contained four positive peptides, 18 mer WT and alanine variants were synthesized. It was found that L552A was the most effective in lowering the response in epitope 6 (Table 5) and F443A was best for epitope 8 (Table 7).

Example 3

[0368] This example demonstrates the cytotoxic activity of point mutation proteins in HA22-LR.

[0369] Step 4 of Example 2 was carried out. The best variants identified in the alanine scan or using further in silico prediction are described in Table 1A.

[0370] Forty mutant RITs were constructed. The cytotoxic activity of point mutation proteins in HA22-LR was evaluated with respect to CA46, Raji, and Daudi cells. Yields of purified protein, calculated accessible surface areas (Lee et al., *J. Mol. Biol.*, 55:379-400 (1971); Roscoe et al., *Infect. Immunity*, 62:5055-5065 (1994)) of WT amino acids residues and cytotoxic activity of each RIT are shown in Table 8.

TABLE 8

Peptide	Mutation	ASA (Å ²)*	Protein yield (mg)	Protein activity Mean relative activity (%) ± SD		
				CA46	Raji	Daudi
76	R500A	0	A			
76	L498A	4	A			
76	L499A	0.1	A			
76	R494A	35	2.0	21 ± 3	33 ± 10	36 ± 8
76	R494D	35	3.23			11
77	R505A	150	4	78 ± 13	185 ± 106	
76/77	Y502A	0	A			
76/77	Y502H	0	A			
76/77	Y502F	0	A			
76/77	Y502K	0	A			
67	I471A	4	1.6			24
67	I471V	4	4	83		108
67	I471M	4	3	3		
67	I471H	4	A			
67	I471G	4	A			
67	I471S	4	1.3	2		
67	I471D	4	A			
67	Y470A	98	2.3	<1	<1	
67	L477A	7	1.4	54 ± 21	47 ± 13	

TABLE 8-continued

Peptide	Mutation	ASA (Å ²)*	Protein yield (mg)	Protein activity Mean relative activity (%) ± SD		
				CA46	Raji	Daudi
67	A476G	38	5	67 ± 4	84	
67	L477G	7	4	14 ± 6	14 ± 6	
67	L477T	7	2.5	<1	<1	
67	L477H	7	3	101 ± 22	95 ± 13	
51	L422A	0	2	<1		
51	L423A	22	4	30		
51	L423N	22	3	5		
51	L423T	22	3.2	50		76
51	L423S	22	5	65		
51	R421A	16	1	<10		
51	R427A	142	0.71	185 ± 85	150 ± 61	150 ± 4
93	R551A	100	4	208		188 ± 464
94	W558A	40	1	<1		>2
94	W558D	40	1	<1		
94	W558N	40	0.7	<1		
94	L556A	0	1.2	2	0	2 ± 0.4
94	L556V	0	4.2	95 ± 32	77	
94	L552N	82	2.4	200		
94	L552E	82	2.1	110		
57/58	F443A	12	3.6	174 ± 110	113 ± 60	
57/58	F443V	12	2.26	95		

A—aggregated

*Accessible Surface Areas (ASA) were calculated for the wild type residue.

Example 4

[0371] This example demonstrates that the substitutions in PE domain III diminish the epitope and do not create new epitopes due to the mutation.

[0372] The response of three donor samples and one patient sample to 22 peptide pools after stimulation with either HA22 (wt) or LR-R494A was measured. "LR" denotes the deletion of all of domain II except the furin cleavage sequence. The results are shown in FIGS. 2A-2D. As shown in FIGS. 2A-2D, the epitope in peptide 76 was diminished by the R494A mutation.

[0373] The response of two donor samples and one patient sample to 22 peptide pools after stimulation with either HA22 (wt) or LR-R505A was measured. The results are shown in FIGS. 3A-3C. As shown in FIGS. 3A-3C, the epitope in peptide 77 was diminished by the R505A mutation.

[0374] The response of two donors to 22 peptide pools after stimulation with either HA22-LR (WT) or HA22-R551A and restimulation with the appropriate peptides was also mea-

sured. The results are shown in FIGS. 4A-4B. As shown in FIGS. 4A and 4B, the mutation R551A diminished the epitope in peptide 93.

[0375] The response of cells from two donors and two patients after stimulation with RIT and restimulation with peptides 93, 94 with either the WT amino acid sequence, L552E or L552N was measured. The results are shown in FIGS. 5A-5D. As shown in FIGS. 5A-5D, the epitope in peptides 93 and 94 was diminished by the L552N and L552E mutations.

[0376] The response of three donors to 22 peptide pools after stimulation with either HA22-LR (WT) or LR-R427A and restimulation with the appropriate peptides was also measured. The results are shown in FIGS. 6A-6C. As shown in FIGS. 6A-6C, the epitope in peptide 51 was diminished by the R427A mutation.

[0377] The response of two patients and one donor to pools 8-22 after stimulation with either HA22-LR (WT) or LR-F443A and restimulation with the appropriate peptides was measured. The results are shown in FIGS. 7A-7C. As shown in FIGS. 7A-7C, the epitope in pools 11 and 12 was diminished by the F443A mutation.

[0378] Four donor samples were stimulated with RIT and restimulated with peptide 67 containing a valine or alanine mutation at position I471. The response is shown in FIGS. 9A-9D in Spot Forming Cells (SFC)/ 10^6 cells. As shown in FIGS. 9A-9D, mutation I471V did not diminish the epitope in peptide 67.

[0379] T cell activation as a response to stimulation with peptide 67 or 68 that contained an alanine or histidine mutation at position L477 or no mutation (WT) was also measured. The results (SFC/ 10^6 cells) are shown in Table 9 and FIGS. 10A-10D. As shown in FIGS. 10A-10D and Table 9, the mutation L477H diminished the epitope in peptide 67 and 68.

TABLE 9

	11410	41311	102909	hel 021012	meso 031612	Mean
WT 67	100	100	100	100	100	100
67 L477A	81	21	24	133	39	60
67 L477H	0	30	123	65	23	48
WT 68	100	100	100	100	100	100
68 L477A	69	19	31	62	38	44
68 L477H	2	34	46	32	48	32

[0380] Cells from two patients were stimulated with RIT and restimulated with peptide 93, 94 or 95 with either the WT

amino acid sequence or L556V. The results are shown in FIGS. 11A and B. Mutation L477V did not diminish the epitope in peptide 94.

Example 5

[0381] This example demonstrates the activity of combinations of mutations in HA22-LR.

[0382] To combine the point mutations that were effective in diminishing the T cell epitopes and maintain good cytotoxic activity, genes were designed that contain different combinations of point mutations. The genes were cloned into the HA22-LR RIT plasmid. Table 10 shows the seven RITs that were constructed and also HA22-LR WT. Table 10 also shows the cytotoxic activity in two cell lines and the calculated remaining T cell response. The calculated remaining response is the sum of the responses shown in the epitope heat map for each of the epitopes, assuming that the mutation will eliminate the responses in the epitope completely. This calculation does not take into account the strength of the response.

[0383] As shown in Table 10, out of the 258 responses identified in the donor screen of PE38, 136 responses were in domain III and are present in HA22-LR. Elimination of the epitopes in peptide (77-78), (51-52) and (57-58) with mutations R505A, R427A and F443A (HA22-LR-T2) reduced the calculated responses to 82 responses and maintained a very active protein with 280% and 135% relative activity in CA46 and Raji cells, respectively, compared to WT. HA22-LR-T3 contains four mutations: R505A, R427A, F443A and R494A and had diminished activity of 55% and 50%. HA22-LR-T7 also has four mutations, (R505A, R427A, F443A and R551A) and had good cytotoxic activity with 113% and 100% relative activity in CA46 and Raji cells. For the construction of HA22-LR-T5, five mutations, R505A, R494A, L427A, R551A and F443A, were inserted which reduced the calculated remaining response to 39 responses. However, the protein's cytotoxic activity was severely reduced to 24% and 19% relative activity with $EC_{50} > 1$ ng/ml. HA22-LR-T9 also had five point mutations (R505A, R427A, F443A, R494A and L477A). T9 had 46 calculated remaining responses; all 46 remaining responses were weak or medium). It maintained cytotoxic activity with $EC_{50} < 1$ ng/ml with relative activity of 36% and 26% in CA46 and Raji cells, respectively. HA22-LR-T11 substitutes L477A in T9 with L477H which improved that activity to 0.2 ng/ml with 85% relative activity in CA46. Lastly, T18 (also referred to as "LMB-T18") was the first RIT that contains six mutations and diminished all the major epitopes that were identified. It had good relative activity with $IC_{50} < 0.3$ ng/ml and relative activity of 63% and 104% compared to HA22-LR in CA46 and Raji cells. To improve cytotoxic activity, a Gly-Gly-Ser peptide linker was inserted after the furin cleavage site.

TABLE 10

		HA22-LR	T2-HA	T3-HA	T5-HA	T7-HA	T9-HA	T11-HA	T18
RIT backbone		HA22-LR	HA22-LR	HA22-LR	HA22-LR	HA22-LR	HA22-LR	HA22-LR	HA22-LR
R505A	77-78		+	+	+	+	+	+	+
R494A	75-76			+	+		+	+	+
L477A	67-68						+		
L477H	67-68							+	+
R427A	51-52		+	+	+	+	+	+	+
R551A	93-94				+	+			
L552E									+
F443A	57-58		+	+	+	+	+	+	+

TABLE 10-continued

	HA22-LR	T2-HA	T3-HA	T5-HA	T7-HA	T9-HA	T11-HA	T18
Cytotoxic Activity								
CA46 IC ₅₀ * (ng/ml)	0.17	0.06	0.31	0.71	0.15	0.48	0.2	0.27
CA46 Relative activity	100%	280%	55%	24%	113%	36%	85%	63%
Raji IC ₅₀ * (ng/ml)	0.23	0.17	0.46	1.18	0.23	0.88		0.24
Raji Relative activity	100%	135%	50%	19%	100%	26%		104%
Calculated Responses	136/258	82/258	62/258	39/258	59/258	46/258	46/258	19/258

*IC₅₀ values are an average of 2-9 assays, depending on the protein.

[0384] To characterize the cytotoxic activity properties of T3 and T18, WST-8 assays were performed in four cell lines that express CD22: ca46, Raji, Daudi and HAL-01. Each assay was performed three times. Table 11A shows the average EC₅₀ values for each cell line. Both HA22-LR-T3 and HA22-LR-T18 were very cytotoxic, although somewhat less than the parent molecule HA22-LR-GGS. Compared with HA22-LR-GGS, HA22-LR-T18 showed relative activity that ranged between 28%-55% with IC₅₀<1 ng/ml in the four cell lines. HA22-LR-T3 was also very active, however, less active than T18.

TABLE 11A

Summary of EC ₅₀ and relative activity of HA22-LR-T3 and HA22-LR-T18 RITs				
Cell Line		HA22-LR-GGS	HA22-LR-T3	HA22-LR-T18
CA46	EC ₅₀ ± (ng/mL)	0.1	0.4	0.3
	SD	±0.003	±0.08	±0.01
	Relative activity (%)	100	18	28
Raji	EC ₅₀ ± (ng/mL)	0.1	0.3	0.2
	SD	±0.04	0.15	±0.07
	Relative activity (%)	100	34	55
Daudi	EC ₅₀ ± (ng/mL)	0.1	0.4	0.3
	SD	±0.04	0.08	±0.17
	Relative activity (%)	100	31	38
HAL-01	EC ₅₀ ± (ng/mL)	0.3	1.5	0.7
	SD	±0.05	±0.47	±0.16
	Relative activity (%)	100	20	42

[0385] Cytotoxicity assays of LMB-T18 were performed on four CD22 expressing cell lines and compared with the cytotoxic activity of MP (FIG. 27A, Table 11B). LMB-T18 was very potent with an EC₅₀<10 pM in all cell lines. Compared to MP, LMB-T18 had a small increase of 53% in activity in CA46 cells, 54% in Daudi cells and >200% in HAL-01 cells (p=0.2, 0.06 and 0.01 respectively in Student T test); however, in Raji cells LMB-T18 had a 52% activity decrease (p=0.3 in Student T test). Without being bound by a particular theory or mechanism, it is believed that the decrease in activity in Raji cells was probably due to the domain II deletion (Weldon et al., *Blood*, 113: 3792-3800 (2009)). The stability of LMB-T18 was compared with MP by heating samples for

15 minutes at various temperatures and, after cooling, measuring residual cytotoxic activities (FIG. 27B) on Raji cells. MP lost 50% of its activity after 15 minutes incubation at 56° C. Unexpectedly, LMB-T18 was more heat-resistant (p<0.05 in Student T test); it only lost 50% of its activity after a 15-minute incubation at 70° C. Cells from seven HCL and six chronic lymphocytic leukemia (CLL) patients were used to determine activity on patient cells. FIGS. 27C-D show that LMB-T18 is more active than MP on CLL cells though this difference is not seen with HCL cells.

TABLE 11B

Cell line	EC ₅₀ ± SD (pM)		Relative activity	
	MP	LMB-T18	(%)	P value
CA46 (n = 4)	3.4 ± 1.7	2.2 ± 0.4	153	0.2
Raji (n = 4)	1.1 ± 0.3	2.3 ± 0.6	48	0.3
Daudi (n = 4)	3.7 ± 1.6	2.4 ± 0.8	154	0.06
HAL-01 (n = 4)	25.7 ± 3	8.1 ± 1	318	0.01

Example 6

[0386] This example demonstrates the relative activity of B and T cell epitope modified RIT.

[0387] B cell epitopes in PE38 were previously identified and the bulky surface residues were mutated with alanine or serine to reduce antigenicity (Liu et al., *Protein Eng. Dec. Sel.*, (25)(1): 1-6 (2012)). The previously identified mutant RIT with low antigenicity was named SS1LO10R and it contained the following mutations: R505A, R427A, R490A, R463A, R467A, R538A.

[0388] To make a minimally immunogenic RIT targeting mesothelin, the LO10 modifications were incorporated into SS1P and then the T cell epitope-point mutations were incorporated one by one. Cytotoxic activity was tested for each one of the variants using mesothelin expressing cell lines (A9/431 and HAY). Two mutations R505A and R427A were found to be effective in diminishing both B and T cell epitopes.

[0389] Table 12 summarizes the cytotoxic activity of the mutated PE in two cell lines and the calculated remaining response of the combination RIT that were constructed. Combination of SS1-LO10 with a single point mutation F443A (SS1-LO10-T2) had high (100%-115%) relative activity that corresponded to the activity of these point mutations in HA22-LR. Combination of R494A and R551A in SS1-

LO10-T1 gave a very low activity indicating that the combination of R551A and R494A diminished protein activity in both HA22 and SS1-LO10.

TABLE 12

Relative activity of B and T cell epitope modified RIT											
RIT Backbone	R505A 77-78	R494A 75-76	L477H 67-68	R477H	R427A 51-52	R551A 93-94	L552E	L552N	F443A 57-58	R456A	
SS1											
LO10R											
SS1 SS1	+	+			+	+					
LO10R- LO10R											
T1											
SS1 SS1	+				+				+		
LO10R- LO10R											
T2											
SS1 SS1	+	+			+				+		
LO10R- LO10R											
T3											
SS1 SS1	+	+			+				+	+	
LO10R- LO10R											
T4											
SS1 SS1	+				+	+			+		
LO10R- LO10R											
T7											
SS1 SS1	+				+	+			+	+	
LO10R- LO10R											
T8											
SS1 SS1	+	+	+		+				+		
LO10R- LO10R											
T9											
SS1 SS1	+	+		+	+				+		
LO10R- LO10R											
T11											
SS1 SS1	+	+		+	+		+		+		
LO10R- LO10R											
T14											
SS1 SS1	+	+		+	+			+	+		
LO10R- LO10R											
T15											

Cytotoxic activity					
A431/H9		HAY		Calculated responses	
IC50* (ng/m)	Relative activity	IC50* (ng/m)	Relative activity		
SS1	0.3		0.5		136/258
LO10R					
SS1	1.6	19%	50	10%	52/258
LO10R- T1					
SS1	0.17	176%	0.5	100%	82/258
LO10R- T2					
SS1	0.29	103%	0.6	83%	62/258
LO10R- T3					
SS1	2	15%	nd		62/258
LO10R- T4					
SS1	0.6	50%	2	50%	59/258
LO10R- T7					
SS1	0.9	33%	2.5	20%	59/258
LO10R- T8					
SS1	1.1	27%	6.9	7%	46/258
LO10R- T9					
SS1	0.42	71%	7	7%	46/258
LO10R- T11					

TABLE 12-continued

Relative activity of B and T cell epitope modified RIT						
SS1 LO10R- T14	0.23	130%	1.5	33%	19/258	
SS1 LO10R- T15	0.27	111%	1.9	26%	19/258	

*IC50 values are an average of 1-9 assays, depending on the protein;
nd—not done

[0390] SS1 LO10R-T11, which contained R505A, R427A, R494A, F443A and L477H, had 71% activity in H9 cells but only 7% in HAY cells (assay in HAY was done once). T14 and T15, which contained R505A, R427A, R494A, F443A and L477H, with an additional mutation (L552E and L552N, respectively) had >100% relative activity in H9 cells and IC50>1 ng/ml. These two mutants represent the maximal T cell deimmunization done in this project thus far.

[0391] Mutant T14 was selected as the best candidate for clinical development because it includes the removal of B cell and many T cell epitopes, yet provides good cytotoxic activity on mesothelin expressing cell lines.

Example 7

[0392] This example demonstrates the anti-tumor activity of T14.

[0393] Anti-tumor experiments were carried out by injecting saline (control) or T14 into nude mice with A431/H9 xenografts. Tumor size was measured every other day and reported in mm. Animals were weighed at the same time and the weight was reported in grams. The results are shown in Table 13 below. In Table 13, the arrows show the day immunotoxin was injected. As shown in Table 13, doses up to 7 mg/kgx3 were well tolerated with no signs of toxicity in the mice. In addition, major tumor regressions were seen at all dose levels of T14.

TABLE 13

		Days								
Group	Mouse #	Day 5 ↓		7 ↓		9 ↓		12 ↓	14 ↓	
A	1	108	23 g	114	22 g	74	23 g	46	36	
T14	2	100	22 g	100	22 g	56	22 g	40	64	
5 mg mg/kgx5	3	97	20 g	92	20 g	31	20 g	0	10	
iv QOD	4	101	19 g	94	19 g	60	20 g	52	74	
(100 ug/mouse)	5	97	22 g	83	22 g	57	22 g	41	70	
	6	103	21 g	95	21 g	58	21 g	37	58	
	Mean	101		96		56		36	52	
B	1	100	22 g	91	20 g	81	20 g	86	78	
T 14	2	96	23 g	103	23 g	50	23 g	14	66	
6 mg/kgx3	3	100	21 g	112	21 g	91	22 g	54	88	
iv QOD	4	103	24 g	117	24 g	53	24 g	55	98	
(120 ug/mouse)	5	102	21 g	121	20 g	62	20 g	82	125	
	Mean	100		109		67		58	91	
C	1	100	21 g	98	21 g	36	22 g	53	22 g	69
7 mg/kgx3	2	101	20 g	126	19 g	44	20 g	65	21 g	103
iv GOD	Mean	101		112		40		59		86
(140 ug/mouse)										
D	1	100		239		440		816		
Control	2	95		133		234		612		
saline	3	104		252		463		813		
	4	92		138		251		543		
	5	100		152		231		589		
	Mean	98		183		324		675		Over 800

Example 8

[0394] This example demonstrates the thermal stability of T18.

[0395] The stability of T18 was investigated by heating the RIT for 15 minutes at various temperatures. Cytotoxic assays were subsequently performed. EC50 of the different heated proteins were calculated. The results are shown in FIG. 8. The fold increase in EC50 is shown. As shown in FIG. 8, it was found that T18 maintained cytotoxic activity in 60° C. and lost 50% of its activity at 68° C. Leaver et al., *Methods in Enzymology*, 487: 545-74 (2011).

Example 9.1

[0396] This example demonstrates the construction, expression, and purification of anti-mesothelin deimmunized PE chimeric molecules with an elongated linker between the anti-mesothelin-Fab fragment heavy chain and the PE 24 domain and the removal of predicted T cell epitopes in the linker.

[0397] The linker sequence used in WO 2012/154530 and Weldon et al., *Mol. Cancer Ther.*, 12: 48-57 (2013) to fuse the dsFv fragment (via the C-terminus of VH domain) to the deimmunized PE was also used to fuse a Fab fragment (via the C-terminus of CH1 domain) to the deimmunized PE. The resulting peptide region, including parts of the CH1 domain,

the linker, and part of the the deimmunized PE (SEQ ID NO: 273) was examined by TEPITOPE analysis (Bian et al., *Methods*, 34: 468-475 (2004)). Potential T cell epitopes relevant for European (EU) and United States populations were identified within the region between the CH1 domain and the linker and the region between the linker and the PE24 domain. Potential T cell epitopes were characterized by a confidence number of 3 or lower. The results are shown in Table 14. As shown in Table 14, the linker region without the specific elongations (SEQ ID NO: 273) showed seven potential T-cell epitopes. One potential T-cell epitope was located in the transition region WEQLGGSPT (SEQ ID NO: 274), and the other six T-cell epitopes were located in the transition region VEPKSCAS (SEQ ID NO: 275). Both of these regions are relevant mainly for European (EU) and Asian populations. [0398] The potential T cell epitopes were destroyed by inserting an amino acid sequence (insert) in each of the tran-

sition regions, thereby providing an insert on each of both sides of the furin cleavage site. The sequence DKTH (SEQ ID NO: 276) was inserted into the linker at a location not directly adjacent to the furin cleavage sequence (FCS), and the sequence GGG (SEQ ID NO: 277) was inserted into the linker at a location directly adjacent to the FCS without potential T-cell epitopes. The resulting elongated peptide region, including a) parts of the CH1 domain, b) the linker elongated at the Fab fusion area and elongated at the PE fusion area, and c) part of the of the the deimmunized PE comprised amino acid SEQ ID NO: 278. The elongated peptide region was studied using TEPITOPE analysis, and the results are shown in Table 15A. As shown in Table 15A, the elongated linker did not generate an alert in the TEPITOPE analysis (confidence numbers of 6 or higher) and, at the same time, provided improved stability (see Example 9.2 below).

TABLE 14

Start Pos	Sequence	Score	Confi- dence	Profile	Inhi- Anchor	Inhi- bitors	Allele	Pivot	Pep- tide	f (EU)	f (US)	f (NE Asia)	f (SE Asia)	f (SW Asia)	max (f (all))
26	WEQLGGSPT (SEQ ID NO: 274)	0.3	3	*****	0	0	HLA-DRB1*0101	1	0	8.0%	0.6%	5.7%	0.1%	4.1%	8.0%
8	VEPKSCAS (SEQ ID NO: 275)	1.6	2	***A*****	1	0	HLA-DRB1*0802	1	0	0.1%	12.0%	2.6%	0.1%	0.8%	12.0%
8	VEPKSCAS (SEQ ID NO: 275)	2.6	2	***A*****	1	0	HLA-DRB1*0804	1	0	0.1%	0.1%	0.6%	0.0%	0.0%	0.6%
8	VEPKSCAS (SEQ ID NO: 275)	2.6	3	***A*****	1	0	HLA-DRB1*0806	1	0	0.1%	0.0%	0.1%	0.0%	0.0%	0.1%
8	VEPKSCAS (SEQ ID NO: 275)	1.9	3	*****	0	0	HLA-DRB1*1102	1	0	0.2%	0.0%	0.0%	0.0%	1.0%	1.0%
8	VEPKSCAS (SEQ ID NO: 275)	1.9	3	*****	0	0	HLA-DRB1*1121	1	0	N.A.	N.A.	N.A.	N.A.	N.A.	0.0%
8	VEPKSCAS (SEQ ID NO: 275)	1.9	3	*****	0	0	HLA-DRB1*1322	1	0	N.A.	N.A.	N.A.	N.A.	N.A.	0.0%

all Alerts listed < = 3

TABLE 15A

Start Pos	Sequence	Score	Confi- dence	Profile	Anchor	Inhi- bitors	Allele	Pep- tide	f (EU)	f (US)	f (NE Asia)	f (SE Asia)	f (SW Asia)	
30	WEQLGGGGG (SEQ ID NO: 279)	-1.2	9	*****I**	0	1	HLA-DRB1*0101	1	0	8.0%	0.6%	5.7%	0.1%	4.1%
33	LGGGGGSPT (SEQ ID NO: 280)	-0.7	9	*****	0	0	HLA-DRB1*0102	1	0	0.6%	0.1%	0.0%	0.0%	0.7%
30	WEQLGGGGG (SEQ ID NO: 279)	-1	9	***A****I	1	1	HLA-DRB1*1307	1	0	0.0%	0.0%	0.0%	0.0%	0.0%
30	WEQLGGGGG (SEQ ID NO: 279)	1.4	6	*****	0	0	HLA-DRB5*0101	1	0	N.A.	N.A.	N.A.	N.A.	N.A.

TABLE 15A-continued

Start Pos	Sequence	Score	Confi- dence	Profile	Inhi- bitors	Allele	Pep- Pivot	f tide	f (EU)	f (US)	f(NE Asia)	f(SE Asia)	f(SW Asia)
30	WEQLGGGGG (SEQ ID NO: 279)	1.4	6	*****	0	0	HLA-DRB5*0105	1	0	N.A.	N.A.	N.A.	N.A.

no Alert < = 3

Example 9.2

[0399] This example demonstrates the stability of the deimmunized PE fusion proteins and conjugates having the elongated linker of SEQ ID NO: 36.

[0400] Six Fab-Linker-PE24 variants were produced and compared with respect to their thermal stability and propensity for aggregation. The six variants all contained the same humanized Fab variant H1/L1 of the SS1 antibody, but differed with respect to the linker and the PE24 mutant. For the linker, either the linker described in International Patent Application Publication WO 2012/154530 (kasggrhrqprgweqlggs (SEQ ID NO: 281)) or the elongated linker with the additional amino acids ("long linker"; SEQ ID NO: 36 (dkthkasggrhrqprgweqlggggs))) was used. As PE24 variants, LRO10R, LRO10R-456A (SEQ ID NO: 37) or LRO10R-456A-551A were employed in the constructs.

[0401] FIGS. 12-13 show the level of aggregation of the two constructs with the PE24 variant LRO10R-456A that was measured in terms of the area under the aggregate peak by size exclusion chromatography (SEC) after incubation at 33° C. The two constructs in FIGS. 12-13 differed only with respect to the linker employed. The short linker SEQ ID NO: 281 was used in construct cFP-0170 and the elongated linker SEQ ID NO: 36 was used in construct cFP-0171.

[0402] FIGS. 14-16 show the thermal stability of constructs as measured by dynamic light scattering (DLS). For dynamic light scattering, samples were prepared at a concentration of 1 mg/mL in 20 mM histidine/histidine chloride, 140 mM NaCl, pH 6.0, transferred into an optical 384-well plate by centrifugation through a 0.4 µm filter plate and covered with paraffin oil. The hydrodynamic radius was measured in a WYATT DYNAPRO Plate Reader II repeatedly by dynamic light scattering while the samples were heated at a rate of 0.05° C./min from 25° C. to 80° C. The aggregation onset temperature was defined as the temperature at which the hydrodynamic radius starts to increase. The results are shown in FIGS. 14-16. The DLS curves for the six constructs showed higher aggregation temperatures for the elongated linker compared to the short published linker, with a strong shift to a higher aggregation temperature for the LRO10R variant (FIGS. 14-16).

[0403] Table 15B shows the thermal stability of constructs cFP-0170 and cFP-0171 as measured by differential scanning calorimetry (DSC). Differential scanning calorimetry was performed using a MicroCal DSC system (GE Healthcare). The samples were adjusted to a protein concentration of approximately 1 mg/ml in 20 mM histidine/HCl, 140 mM sodium chloride, pH 6.0. The reference cell was filled with a buffer corresponding to the sample buffer. The samples were placed in the sample cell and heated from 4° C. to 110° C. at a heating rate of 60° C./hour. The pre-scan was 15 minutes, the filtering period was 10 seconds, and the feedback mode/gain was set to passive. The midpoint of a thermal transition

temperature (T_m, or thermal transition temperature) was obtained by analyzing the data using MicroCal DSC analysis software.

TABLE 15B

Construct	T-max of the Fab fragment part	T-max of the PE24 part
Humanized SS1 Fab long linker-LRO10R, LRO10R- 456A	73.6	41.2
Humanized SS1 Fab long linker-LRO10R, LRO10R	73.7	43.2

[0404] As shown in FIGS. 12-16 and Table 15B, all chimeric Fab-PE molecules with the elongated linker provided a decreased tendency toward aggregation and a higher aggregation temperature as compared to chimeric Fab-PE molecules with a short linker that was not elongated.

Example 10

[0405] This example demonstrates the ability of deimmunized PE fusion proteins with an extended linker to kill tumor cells and inhibit cellular protein synthesis. This example also demonstrates the antigenicity of the deimmunized PE fusion proteins with an extended linker.

[0406] The potency of different Fab-PE24 variants with respect to the ability to inhibit protein synthesis was compared. A clone of the pancreatic cancer cell line ASPC-1 (ASPC-1 Luc) that was stably transfected with luciferase was used. The luciferase protein in these cells undergoes a high turnover so that the measurable activity drops markedly within 24 hours of inhibition of its resynthesis. Briefly, cells were seeded on 96 well plates. After overnight culture, different concentrations of the cFP variants were added to the medium, and cells were incubated for another 72 hours. At the end of the incubation period, the cells were lysed, and luciferase activity was determined with the STEADY-GLOW assay according to the manufacturer's instructions. In a typical experiment, an 80-90% reduction of luciferase activity was observed in lysates from treated cells as compared to lysates from untreated control cells. EC₅₀ values, i.e., the concentrations that achieve half maximal effects, were determined based on a free four parameter fit. Table 16 compares the relative potencies in a representative experiment by setting the IC₅₀ of huFabLRO10R to 1.

[0407] Untargeted PE24 (variant LR8M) only inhibited at concentrations >3.5 µg/ml, while the previously described LRO10 variant fused to a humanized SS1 Fab fragment was ~500 fold more potent on a molar basis. The LRO10R back-mutation increased potency 10 to 20 fold (EC₅₀ values 1-2 ng/ml versus 18 ng/ml). The 456A mutation had no adverse effect on potency, while the 551A mutation did reduce activity to the level of LRO10 (EC₅₀ 10-23 ng/ml). The new

extended linker also had no negative impact on the cellular potency of the molecules in a comparison of any of the three pairs of constructs with the extended linker versus those with the previously described shorter linker.

[0408] Using cell viability assessed by CELLTITER-GLOW assays, the cytotoxic potency of different Fab-PE24 variants using the same humanized SS1 targeting variant on two different tumor cell lines (A431 H9 and H596) was compared. Briefly, cells were seeded on 96 well plates. After overnight culture, different concentrations of the cFPs were added to the medium, and cells were incubated for 72 hours. At the end of the incubation period, cell viability was determined using a CELLTITERGLOW assay. Table 16 compares the relative potencies by setting the IC50 of huFabLRO10R to 1.

TABLE 16

Viability assay results Luciferase assay results cFP variant	A431 H9	H596	AsPC-1 Luc
	Fold potency reduction relative to huFabLRO10R		
huFabLRO10 LR8M	1.8	2.5	17.5
huFabLRO10R	400	450	9452
huFabLRO10R-long linker	1	1	1
huFabLRO10R-456A	1.2	1	2.3
huFabLRO10R-456A-longlinker	0.8	1	2.1
huFabLRO10R-456A-551A	0.9	1.2	3
huFabLRO10R-456A-551A-longlinker	2.1	3.3	22.5
huFabLRO10R-456A-551A-longlinker	2.1	4.5	9.8

[0409] Results similar to those in Table 16 were also obtained using a cell viability assay with an 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT)-based read-out in different cell lines (Table 17).

TABLE 17

IC 50s in ng/ml (did not correct for MW differences)						
	Hu-1	Hu2	Hu3	HAY	AGS	L55
SS1P	2	0.3	2.9	1.0	0.3	3.0
SS1-LR-GGS	0.25	0.01	0.7	—	—	1.0
SS1-LR-GGS-010R	—	0.01	—	0.3	1.0	2.0
Fab-LR-GGS-010R Short	0.25	0.08	0.4	2.5	0.6	3.5
Fab-LR-GGS-010R 456A Short	0.25	0.05	0.6	2.5	0.6	3.0
Fab-LR-GGS-010R long	0.35	0.04	1.8	2.5	0.9	5.0
Fab-LR-GGS-010R 456A long	0.25	0.04	2.0	1.4	1.1	5.0
Fab-LR-GGS-010R 456A 551A Short	0.7	0.18	4.2	4.0	6.0	20.0
Fab-LR-GGS-010R 456A 551A long	Also low	Also low	Also low	Also low	Also low	Also low

Example 11

[0410] This example demonstrates the removal of B-cell epitopes by 456A mutations in PE.

[0411] A phagemid containing the scFv 9H3 in the vector pCANTAB as described by Liu et al., *PNAS*, 109: 11782-

11787 (2012) was prepared by standard methods as described in Sambrook, J. et al., *Molecular cloning: A laboratory manual*; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989. The molecular biological reagents were used according to the manufacturer's instructions. The phagemid was transformed into electrocompetent TG1 cells. From single colonies, precultures were grown overnight and used to inoculate 4 ml cultures of 2×YT/1% glucose supplemented with the appropriate selective antibiotic ampicillin. At an OD₆₀₀ of 0.3-0.8, 10¹⁰ cfu VCSM 13 helper phage and IPTG was added to a final concentration of 1 mM. After incubation for 15 minutes at 37° C., the culture was grown at 37° C. overnight. Two hours after helper phage addition, kanamycin was added to final concentration of 30 µg/ml. The phage-containing supernatant was harvested from the overnight culture by centrifugation, and the scFv displaying phage were precipitated from the supernatant by addition of 1/5 v/v 20% PEG-6000/2.5 M NaCl and isolated by centrifugation. The phage pellet was dissolved in 0.5 ml PBS/1% BSA, and the phage solution was cleared by centrifugation and sterile filtration. The titer of the phage solution was determined by standard methods as described in Barbas, C. et al., *Phage Display—A laboratory manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2001.

[0412] 96 well MaxiSorp microtiter plates were coated with 100 µg/ml Fab-PE24 variants. After blocking with PBS buffer supplemented with 2% BSA, 10⁷ and 10⁸ scFv-displaying phage were captured on the plate for one hour. As specific negative controls, scFv-displaying phages were pre-incubated with 50 µg/m of the Fab-PE24 variants for 1 hour at room temperature (RT) before capturing them on the plate. Plates were washed with PBST buffer (PBS+0.5% Tween 20). Binding of scFv-displaying phage was detected with POD conjugated anti-m13 antibody (Progen). After a final wash, the plates were incubated with POD substrate. Absorbance was measured at 405 nm. Results are shown in FIG. 17, where it can be seen that the B-cell epitope contained in the phagemid containing the scFv 9H3 was not removed in LRO10R (with 458R backmutation) while it was eliminated by both mutations 458A and 456A with a slightly stronger effect for the 456A mutation.

[0413] Antigenicity testing was done as described in Weldon et al., *Mol. Cancer Ther.*, 12: 48-57 (2013). As shown in FIGS. 18A and 18B, compared to SS1P (T1), the de-immunized variant LRO10R (T2) had a 100-10,000 fold reduced reactivity with most sera from patients that have been previously exposed to a PE-based therapeutic fusion protein both with the murine dsFv fusion format and the humanized Fab fusion format. Also the introduction of the 456A mutation (T3 and T5) or the new extended linker (T5 and T6) showed a 100-10,000 fold reduced reactivity with most sera from patients that have been previously exposed to a PE-based therapeutic fusion protein.

Example 12

[0414] This example demonstrates the construction, expression and purification of deimmunized PE variants and Fab fusions thereof as well as dsFv fusions for comparison.

Example 12.1

Cloning of Anti-Mesothelin Deimmunized PE
Chimeric Molecules cFP-0077 (SEQ ID NOs: 41 and 42) and cFP-0078 (SEQ ID NOs: 43 and 44)

[0415] For the expression of cFP-0077 and cFP-0078, the *E. coli* host/vector system, which enables an antibiotic-free

plasmid selection by complementation of an *E. coli* auxotrophy (PyrF), was employed (European Patent Application Publication 0 972 838 and U.S. Pat. No. 6,291,245). Standard methods were used to manipulate DNA as described in Sambrook, J. et al., supra. The molecular biological reagents were used according to the manufacturer's instructions. Desired gene segments were made by commercial gene synthesis. The synthesized gene fragments were cloned into a specified expression vector. The DNA sequences of the subcloned gene fragments were confirmed by DNA sequencing.

[0416] The expression plasmids for the production of the light chain and the heavy chain, respectively, were prepared as follows: The light chain (LC) plasmids 15478 (based on the amino acid sequences of cFP-0077 and encoding SEQ ID NO: 41) and 15479 (based on the amino acid sequences of cFP-0078 and encoding SEQ ID NO: 43) are expression plasmids for the expression of an antibody light chain fragment in *E. coli*. They were generated by ligating the antibody VL domain fragment into the vector using the XhoI/BsiWI restriction sites for 15478, and XhoI/BlpI for 15479.

[0417] The light chain *E. coli* expression plasmids comprise the following elements:

[0418] the origin of replication from the vector pBR322 for replication in *E. coli* (corresponding to positions 2517-3160 according to Sutcliffe et al., *Quant. Biol.*, 43: 77-90 (1979),

[0419] the URA3 gene of *Saccharomyces cerevisiae* coding for orotidine 5'-phosphate decarboxylase (Rose et al., *Gene*, 29: 113-124 (1984) which allows plasmid selection by complementation of *E. coli* pyrF mutant strains (uracil auxotrophy),

[0420] the antibody light chain expression cassette comprising:

[0421] the T5 hybrid promoter (T5-PN25/03/04 hybrid promoter according to Bujard et al., *Methods. Enzymol.*, 155: 416-433 (1987) and Stueber, et al., *Immunol. Methods IV*, 121-152 (1990) including a synthetic ribosomal binding site according to Stueber et al. (supra),

[0422] the antibody light chain variable domain comprising the CDRs of SS1, and

[0423] the human Ck domain for 15478 but not for 15479,

[0424] two bacteriophage-derived transcription terminators, the λ -T0 terminator (Schwarz et al., *Nature*, 272: 410-414 (1978) and the fd-terminator (Beck et al., *Gene*, 1-3: 35-58 (1981), and

[0425] the lad repressor gene from *E. coli* (Farabaugh, *Nature*, 274: 765-769 (1978).

[0426] The heavy chain (HC) plasmids 15476 (based on the amino acid sequences of cFP-0077 and encoding SEQ ID NO: 42) and 15477 (based on the amino acid sequences of cFP-0078 and encoding SEQ ID NO: 44) are expression plasmids for the expression of a fusion protein including an antibody heavy chain fragment, a linker containing a furin cleavage site, and a mutant of domain III of *Pseudomonas aeruginosa* Exotoxin A (PE), in *E. coli*. It was generated by ligation of the VH domain fragment into the vector using the XhoI/BsrGI restriction sites for 15476, and XhoI/HindIII restriction sites for 15477.

[0427] The cytolytic fusion protein heavy chain *E. coli* expression plasmids comprise the following elements:

[0428] the origin of replication from the vector pBR322 for replication in *E. coli* (corresponding to positions 2517-3160 according to Sutcliffe et al., *Quant. Biol.*, 43: 77-90 (1979),

[0429] the URA3 gene of *Saccharomyces cerevisiae* coding for orotidine 5'-phosphate decarboxylase (Rose et al., *Gene*, 29: 113-124 (1984) which allows plasmid selection by complementation of *E. coli* pyrF mutant strains (uracil auxotrophy),

[0430] the heavy chain-PE domain III fusion protein expression cassette comprising

[0431] the T5 hybrid promoter (T5-PN25/03/04 hybrid promoter according to Bujard et al., *Methods. Enzymol.*, 155: 416-433 (1987) and Stueber et al., *Immunol. Methods IV*, (1990) 121-152) including a synthetic ribosomal binding site according to Stueber et al. (supra),

[0432] the antibody heavy chain variable domain comprising the CDRs of SS1,

[0433] the human CH1 domain for 15476 but not for 15477,

[0434] the linker comprising a furin cleavage site

[0435] the mutant variant of *Pseudomonas aeruginosa* Exotoxin A domain III

[0436] two bacteriophage-derived transcription terminators, the λ -T0 terminator (Schwarz et al., *Nature*, 272: 410-414 (1978) and the fd-terminator (Beck et al., *Gene*, 1-3: 35-58 (1981), and

[0437] the lad repressor gene from *E. coli* (Farabaugh, *Nature*, 274: 765-769 (1978).

Example 12.2

Expression of Anti-Mesothelin Deimmunized PE
Chimeric Molecules cFP-0077 and cFP-0078 in *E. coli*

[0438] All polypeptide chains were expressed separately in the *E. coli* strain CSPZ-6.

[0439] The *E. coli* K12 strain CSPZ-6 (thi-1, Δ pyrF) was transformed by electroporation with the expression plasmids 15476, 15477, 15478 and 15479, respectively, resulting in the 4 strains cFP-0019 (based on plasmid 15476), cFP-0020 (based on plasmid 15477), cFP-0040 (based on plasmid 15478) and cFP-0041 (based on plasmid 15479). For each of the four strains, the transformed *E. coli* cells were first grown at 37° C. on agar plates. A colony picked from this plate was transferred to a 3 mL roller culture and grown at 37° C. to an optical density of 1-2 (measured at 578 nm). Then 1000 μ l of culture was mixed with 1000 μ l sterile 86%-glycerol and immediately frozen at -80° C. for long time storage. The correct product expression of this clone was first verified in small scale shake flask experiments and analyzed with SDS-Page prior to the transfer to the 10 L fermenter.

Pre Cultivation:

[0440] For pre-fermentation, a chemically defined medium (CD-PCMv2.20) was used: NH_4Cl 1.0 g/l, $\text{K}_2\text{HPO}_4 \cdot 3\text{H}_2\text{O}$ 18.3 g/l, citrate 1.6 g/l, Glycine 0.78 g/l, L-Alanine 0.29 g/l, L-Arginine 0.41 g/l, L-Asparagine $\cdot \text{H}_2\text{O}$ 0.37 g/l, L-Aspartate 0.05 g/l, L-Cysteine $\cdot \text{HCl} \cdot \text{H}_2\text{O}$ 0.05 g/l, L-Histidine 0.05 g/l, L-Isoleucine 0.31 g/l, L-Leucine 0.38 g/l, L-Lysine $\cdot \text{HCl}$ 0.40 g/l, L-Methionine 0.27 g/l, L-Phenylalanine 0.43 g/l,

L-Proline 0.36 g/l, L-Serine 0.15 g/l, L-Threonine 0.40 g/l, L-Tryptophan 0.07 g/l, L-Valine 0.33 g/l, L-Tyrosine 0.51 g/l, L-Glutamine 0.12 g/l, Na-L-Glutamate*H₂O 0.82 g/l, Glucose*H₂O 6.0 g/l, trace elements solution 0.5 ml/l, MgSO₄*7H₂O 0.86 g/l, and Thiamin*HCl 17.5 mg/l. The trace elements solution contained FeSO₄*7H₂O 10.0 g/l, ZnSO₄*7H₂O 2.25 g/l, MnSO₄*H₂O 2.13 g/l, H₃BO₃ 0.50 g/l, (NH₄)₆Mo₇O₂₄*4H₂O 0.3 g/l, CoCl₂*6H₂O 0.42 g/l, and CuSO₄*5H₂O 1.0 g/l dissolved in 0.5M HCl.

[0441] For pre-fermentation, 220 ml of CD-PCMV2.20 medium in a 1000 ml Erlenmeyer-flask with four baffles was inoculated with 1.0 ml out of a research seed bank ampoule. The cultivation was performed on a rotary shaker for 8 hours at 32° C. and 170 rpm until an optical density (578 nm) of 2.9 was obtained. 100 ml of the pre cultivation was used to inoculate the batch medium of the 10 L bioreactor.

Fermentation of cFP-0019 and cFP-0020:

[0442] For fermentation in a 10 l Biostat C, DCU3 fermenter (Sartorius, Melsungen, Germany) the following chemically defined batch medium was used: KH₂PO₄ 1.59 g/l, (NH₄)₂HPO₄ 7.45 g/l, K₂HPO₄*3H₂O 13.32 g/l, citrate 2.07 g/l, L-methionine 1.22 g/l, NaHCO₃ 0.82 g/l, trace elements solution 7.3 ml/l, MgSO₄*7 H₂O 0.99 g/l, thiamine*HCl 20.9 mg/l, glucose*H₂O 29.3 g/l, biotin 0.2 mg/l, and 1.2 ml/l Synperonic 10% anti foam agent. The trace elements solution contained FeSO₄*7H₂O 10 g/l, ZnSO₄*7H₂O 2.25 g/l, MnSO₄*H₂O 2.13 g/l, CuSO₄*5H₂O 1.0 g/l, CoCl₂*6H₂O 0.42 g/l, (NH₄)₆Mo₇O₂₄*4H₂O 0.3 g/l, and H₃BO₃ 0.50 g/l solubilized in 0.5M HCl solution.

[0443] The feed 1 solution contained 700 g/l glucose*H₂O, 7.4 g/l MgSO₄*7 H₂O and 0.1 g/l FeSO₄*7H₂O. Feed 2 comprises KH₂PO₄ 52.7 g/l, K₂HPO₄*3H₂O 139.9 g/l and (NH₄)₂HPO₄ 66.0 g/l. All components were dissolved in deionized water. The alkaline solution for pH regulation was an aqueous 12.5% (w/v) NH₃ solution supplemented with 11.25 g/l L-methionine.

[0444] Starting with 4.2 l sterile batch medium plus 100 ml inoculum from the pre-cultivation, the batch fermentation was performed at 31° C., pH 6.9±0.2, 800 mbar back pressure and an initial aeration rate of 10 l/min. The relative value of dissolved oxygen (pO₂) was kept at 50% throughout the fermentation by increasing the stirrer speed up to 1500 rpm. After the initially supplemented glucose was depleted, indicated by a steep increase in dissolved oxygen values, the temperature was shifted to 25° C., and 15 minutes later the fermentation entered the fed-batch mode with the start of both feeds (60 and 14 g/h respectively). The rate of feed of 2 was kept constant, while the rate of feed 1 was increased stepwise with a predefined feeding profile from 60 to finally 160 g/h within 7 hours. When carbon dioxide off gas concentration leveled above 2%, the aeration rate was constantly increased from 10 to 20 l/min within 5 hours. The expression of recombinant protein was induced by the addition of 2.4 g IPTG at an optical density of approx. 120. The target protein was expressed as inclusion bodies within the cytoplasm.

[0445] After 24 hours of cultivation, an optical density of 209 was achieved, and the whole broth was cooled down to 4-8° C. The bacteria were harvested via centrifugation with a flow-through centrifuge (13,000 rpm, 13 l/h) and the obtained biomass was stored at -20° C. until further processing (cell disruption).

Fermentation of cFP-0040 and cFP-0041:

[0446] For fermentation in a 10 l Biostat C, DCU3 fermenter (Sartorius, Melsungen, Germany) the following com-

plex batch medium was used: Bacto-Trypton 20 g/l, yeast extract 15 g/l, KH₂PO₄ 1.5 g/l, K₂HPO₄*3H₂O 6.6 g/l, NaCl 1.0 g/l, MgSO₄*7 H₂O 0.74 g/l, glucose*H₂O 3.0 g/l, and 0.2 ml/l Synperonic 10% anti foam agent.

[0447] The feed 1 solution contained Bacto-Trypton 250 g/l and yeast extract 175 g/l. pH was controlled using a 75% glucose*H₂O. All components were dissolved in deionized water.

[0448] Starting with 7.6 l sterile batch medium plus 100 ml inoculum from the pre cultivation, the batch fermentation was performed at 37° C., pH 7.0±0.3, 500 mbar back pressure and an initial aeration rate of 10 l/min. The relative value of dissolved oxygen (pO₂) was kept at 50% throughout the fermentation by increasing the stirrer speed up to 1500 rpm. The feeding of feed 1 was started after the culture reached an optical density of 15. When carbon dioxide off gas concentration leveled above 2%, the aeration rate was constantly increased from 10 to 20 l/min within 5 hours. The expression of recombinant protein was induced by the addition of 2.4 g IPTG at an optical density of approx. 20. The target protein was expressed insoluble to inclusion bodies within the cytoplasm.

[0449] After 13 hours of cultivation, an optical density of 100-115 was achieved and the whole broth was cooled down to 4-8° C. The bacteria were harvested via centrifugation with a flow-through centrifuge (13,000 rpm, 13 l/h) and the obtained biomass was stored at -20° C. until further processing (cell disruption and inclusion body preparation).

Analysis of Product Formation (for cFP-0019, -0020-0040 and -0041):

[0450] Samples were drawn from the fermenter, one prior to induction and the others at dedicated time points after induction of protein expression, were analyzed with SDS-polyacrylamide gel electrophoresis. From every sample, the same amount of cells (OD_{target}=10) were suspended in 5 mL PBS buffer and disrupted via sonication on ice. Then 100 µL of each suspension were centrifuged (15,000 rpm, 5 minutes), and each supernatant was withdrawn and transferred to a separate vial. This was to discriminate between soluble and insoluble expressed target protein. To each supernatant (=soluble protein fraction) 100 µL and to each pellet (=insoluble protein fraction) 200 µL of SDS sample buffer (Laemmli, *Nature*, 227: 680-685 (1970)) were added. Samples were heated for 15 minutes at 95° C. under intense mixing to solubilize and reduce all proteins in the samples. After cooling to room temperature, 5 µL of each sample were transferred to a 4-20% TGX Criterion Stain Free polyacrylamide gel (Bio-Rad). Additionally, 5 µL molecular weight standard (Precision Plus Protein Standard, Bio-Rad) were applied.

[0451] The electrophoresis was run for 60 minutes at 200 V and thereafter the gel was transferred the GELDOC EZ Imager (Bio-Rad) and processed for 5 minutes with UV radiation. Gel images were analyzed using IMAGE LAB analysis software (Bio-Rad). Relative quantification of protein expression was done by comparing the volume of the product bands to the volume of the 25 kDa band of the molecular weight standard.

Inclusion Body Preparation:

[0452] The inclusion body preparations (IBP) of the 10 L fermentations were started directly after the harvest of the bacteria with the re-suspension of the harvested bacteria cells in buffer 1 (12.1 g/l Tris, 0.246 g/l MgSO₄*7H₂O, 12 ml/l 25%-HCl). The buffer volume was calculated in dependence

of the dry matter content of the biomass. Lysozyme (100 kU/mg, 0.12 mg/g DCW) and a small amount of benzonase (5 U/g DCW) were added. Then the suspension was homogenized at 900 bar (APV Rannie 5, 1 pass) to disrupt the bacteria cells followed by the addition of further benzonase (30 U/g DCW) and an incubation for 30 minutes at 30-37° C. Then the first wash buffer (60 g/l Brij, 87.6 g/l NaCl, 22.5 g/l EDTA, 6 ml/l 10N NaOH) was added, and again the suspension was incubated for 30 minutes. The following centrifugation step (BP 12, Sorvall) led to the inclusion body slurry, which was re-suspended in the second wash buffer (12.1 g/l Tris, 7.4 g/l EDTA, 11 ml/l 25%-HCl) and incubated for 20 minutes. A further separation step harvested the inclusion bodies, which were stored frozen at -20° C. or immediately solubilized for refolding and purification.

Example 12.3

Refolding and Purification of Anti-Mesothelin Deimmunized PE Chimeric Molecules cFP-0077 and cFP-0078

[0453] cFP-0077 and cFP-0078 were both obtained by refolding and purification.

[0454] Renaturation and Purification of Fab-PE24 (cFP-0077):

[0455] Inclusion bodies of HC-PE24 and LC were solubilized separately in 8 M Guanidinium-Hydrochloride, 100 mM Tris/HCl, 1 mM EDTA, pH 8.0+100 mM Dithiothreitol (DTT) overnight at RT (1 g IB in 5 mL). Solubilizates were adjusted to pH 3 and centrifuged, and the pellet was discarded. After extensive dialysis against 8 M Guanidinium-HCl, 10 mM EDTA, pH 3.0 to remove DTT, the total protein concentration was determined using the Biuret method. The purity of HC and LC content was estimated via SDS-PAGE.

[0456] Solubilizates were diluted at a 1:1 molar ratio in renaturation buffer containing 0.5 M arginine, 2 mM EDTA, pH 10+0.9 mM GSH/GSSG, respectively, at 2-10° C. The target protein concentration was increased in two steps to 0.22 g/L, with an incubation time of 4 h between the two doses. Afterwards, the renaturation solution was kept at 2-10° C. overnight.

[0457] The renaturate was diluted with H₂O to <3 mS/cm and pumped onto an anion exchange column (AIEX) equilibrated in 20 mM Tris/HCl, pH 7.4. After washing the column with equilibration buffer, the protein was eluted with a gradient up to 20 mM Tris/HCl, 400 mM NaCl, pH 7.4. Peak fractions containing Fab-PE24 were pooled, concentrated and applied onto a preparative Size Exclusion Column (SEC) in 20 mM Tris, 150 mM NaCl, pH 7.4 to remove aggregates, fragments and *E. coli* proteins. The final protein pool was adjusted to the required protein concentration and analyzed via SDS-PAGE, analytical SEC and UV₂₈₀, and identity was confirmed by mass spectrometry.

[0458] Renaturation and Purification of dsFv-PE24 (cFP-0078):

[0459] Inclusion bodies of HC-PE24 and LC were solubilized separately 8 M Guanidinium-Hydrochloride, 100 mM Tris/HCl, 1 mM EDTA, pH 8.5+100 mM DTT overnight at RT (1 g IB in 5 mL). Solubilizates were adjusted to pH 3 and centrifuged, and the pellet was discarded. After extensive dialysis against 7.2 M Guanidinium-HCl, 10 mM EDTA, pH 3.0 to remove DTT, the total protein concentration was determined using the Biuret method, and the purity of HC and LC content was estimated via SDS-PAGE.

[0460] Solubilizates were diluted 1:100 in renaturation buffer containing 0.5 M arginine, 2 mM EDTA, pH 10+0.9 mM GSH/GSSG, respectively, at a 1:1 molar ratio and kept overnight at 2-10° C.

[0461] The renaturate was diluted with H₂O to <3 mS/cm and pumped onto an anion exchange column (AIEX) equilibrated in 20 mM Tris/HCl, 1 mM EDTA, pH 7.4. After washing the column with equilibration buffer, the protein was eluted with a gradient up to 20 mM Tris/HCl, 1 mM EDTA, 400 mM NaCl, pH 7.4. Peak fractions containing dsFv-PE24 were pooled, concentrated and applied onto a preparative Size Exclusion Column (SEC) in 20 mM Tris/HCl, 150 mM NaCl, pH 7.4 to remove aggregates, fragments and *E. coli* proteins. The final protein pool was adjusted to the required protein concentration and analyzed via CE-SDS, analytical SEC and UV₂₈₀. Identity was confirmed by mass spectrometry.

Example 12.4

Protein Analysis of cFP-0077 and cFP-0078

[0462] Samples were analyzed by OD 280 nm using a UV spectrophotometer to determine the protein concentration in solution. The extinction coefficient required for this was calculated from the amino acid sequence according to Pace et al., *Protein Science*, 4: 2411-2423 (1995). Size-exclusion chromatography (SE-HPLC) was performed on TSK-Ge1300SWXL or Superdex 200 columns with a 0.2 M potassium phosphate buffer, comprising 0.25 M KCl, pH 7.0 as mobile phase in order to determine the content of monomeric, aggregated and degraded species in the samples. Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (reducing and non-reducing) was performed to determine the purity of the complex preparations with regard to product-related degradation products and unrelated impurities (for details, see below). Electrospray ionisation mass spectrometry (ESI-MS) was performed with reduced (TCEP) samples to confirm the correct mass/identity of each chain and detect chemical modifications. ESI-MS of the non-reduced samples was carried out to analyze the nature and quality of the fully assembled protein and detect potential product-related side products.

Method for SDS-PAGE and Coomassie Staining

Device: Invitrogen XCELL SURE LOCK Mini-Cell

Gel: 4-20% Tris-Glycine Gel, Invitrogen EC6025BOX

Buffer: Tris-Glycine SDS Running Buffer (10×), Invitrogen LC2675-5

[0463] Sample buffer: Tris-Glycine SDS Sample Buffer (2×), Invitrogen LC2676

Reducing buffer: NuPAGE Sample Reducing Agent (10×), Invitrogen NP0004

Molecular Weight Marker: Mark 12, MW Standard, Invitrogen LC5677

[0464] The sample was adjusted to a protein concentration of 1 mg/ml with buffer. For sample reduction, the following procedure was carried out: A reduction buffer including 4 ml Sample buffer (2×) and 1 ml reducing buffer (10×) was pre-

pared. The sample was diluted 1:1 with reduction buffer and incubated for 5 minutes at 70° C.

[0465] The gel electrophoresis was carried out at 125 V for 90 minutes. The gels were stained with SIMPLY BLUE Safe Stain (Invitrogen, Cat. No. LC6065).

Example 12.5

Comparison of Fab vs dsFv Fusion Protein-Cytotoxic Properties

[0466] The cytotoxic potency of a dsFv-PE24 fusion protein format and a Fab-PE24 format was compared using the same humanized SS1 targeting moiety on three different tumor cell lines (MKN45, H596, and A431H9). Briefly, cells were seeded, on 96 well plates. After overnight culture, different concentrations of the cFPs were added to the medium and cells were incubated for 72 h. At the end of incubation period, cell viability was determined using a CELLTITER-GLOW assay.

[0467] In each case, the dose-response curves and IC50 values for inhibition of cell viability were similar for the dsFv-PE24 and the Fab-PE24 format. The molar ratio of the IC50 values is listed in Table 18. Depending on the cell line tested, the targeted PE24 fusion proteins were several hundred to one thousand fold more potent than untargeted PE24.

TABLE 18

Cell line	Ratio of the molar IC50 values dsFv-PE24/Fab-PE24
A431H9	0.37
MKN45	2.3
H596	0.38

Example 12.6

Comparison of Fab Versus dsFv Fusion Protein-Serum Kinetics

[0468] The serum kinetics of the following three *Pseudomonas* exotoxin A (PE)-based anti-mesothelin immunotoxins in SCID beige mice was compared: SS1dsFv-PE38 (MW: 62.5 kDa), SS1dsFv-PE24 (MW: 49.9 kDa) and SS1Fab-PE24 (MW: 72.2 kDa). The murine SS1 antibody moiety was used for all constructs. The kinetics were compared at doses equimolar to 0.2 mg/kg (3.2 nmol/kg) SS1P) corresponding to 0.231 mg/kg SS1Fab-PE24, and 0.160 mg/kg for SS1dsFv-PE24.

[0469] The constructs were administered as a single intravenous dose, and their serum levels were analyzed at 0.08, 0.5, 1, 1.5, 2, 3, 4, 5, and 7 hours after dosing. Nine mice per group were administered the study medication, and blood was collected in a staggered manner at three times per animal by retro-orbital puncture, resulting in nine time points with n=3 samples. Serum samples were analyzed by an ELISA that detects only intact test compounds having the antibody fragment plus the PE part. In this assay format, the cFP is captured on a MSLN-coated surface and the PE moiety is detected with a rabbit polyclonal anti-PE antibody and biotinylated anti-rabbit secondary antibody.

[0470] For each time point, average serum values from three animals were plotted for the treatment groups together with historical data from CD2F1 mice. The SS1dsFv-PE24 construct was very rapidly cleared with a serum half-life of

only ~12 minutes. In agreement with the historical data, clearance of SS1P was much slower, resulting in a serum half life of between 35 and 44 minutes (values derived from measured and historical data, respectively). The pharmacokinetic properties of the SS1Fab-PE24 construct were very similar to SS1dsFv-PE38 with a serum half life of 43 minutes and similar values were also obtained for clearance rate, volume of distribution, c_{max} and area under the curve (Table 19 and FIG. 19).

TABLE 19

Comparison Fab versus dsFv fusion protein- Serum kinetics				
Parameter	Unit	SS1P	SS1-Fab-PE24	SS1-dsFv-PE24
C_L	mL/(min · kg)	2.24	1.53	7.06
V_C	mL/kg	84.3	75.4	146
V_{SS}	mL/kg	92	80.5	103
$T_{1/2}$	h	0.574	0.716	0.201
C_{max}	ng/mL	1990	2730	837
AUC (0-inf)	ng · h/mL	1490	2520	378

Example 13

[0471] This example demonstrates the humanization of the anti-mesothelin antibody SS1.

Example 13.1

Design of Humanized Heavy and Light Chain Variable Regions

[0472] The structures of the VH and the VL domain of the SS1 antibody were modeled in silico, and the model was compared to a structural database of human VH and VL domains. A panel of the most structurally similar V domains were chosen for grafting the CDRs of SS1 onto the human VH and VL domains. In addition, similarities in the primary sequence were taken into account to narrow down the choice of the human V domains by aligning the primary sequence of the VH and VL domain of SS1 to the human V domain repertoire. Backmutations within the human framework regions to mouse parent residues were introduced in some humanization variants. Similarly, mutations in the CDRs were introduced in some variants, where appropriate, to potentially increase the affinity to the antigen or to maintain the CDR tertiary structure.

[0473] The designed V domain variants were cloned into heavy chain and light chain vectors 6318 and 6319 via unique cloning sites to generate human IgG light and heavy chains. The heavy and light chain vectors were co-transfected into HEK293 suspension cells in microtiter culture plates in a matrix manner to obtain cell cultures expressing full size IgG having all possible light/heavy chain combinations. After 5 days, cultivation at 37° C., the supernatants were harvested and purified by Protein A affinity chromatography in the microtiter scale.

Example 13.2

Cloning of Humanized Heavy and Light Chain Variable Regions

[0474] Standard methods were used to manipulate DNA as described in Sambrook, J. et al., supra. The molecular biological reagents were used according to the manufacturer's

instructions. Desired gene segments were prepared by commercial gene synthesis. The synthesized gene fragments were cloned into a specified expression vector. The DNA sequence of the subcloned gene fragments were confirmed by DNA sequencing.

[0475] Expression Vector for the Antibody Heavy Chains:

[0476] The gene segments of the designed humanized antibody heavy chain variable domains were cloned into the specified expression vector via the unique restriction sites HindIII and XhoI. The expression vector was designed to express the antibody heavy chain variable domain in fusion with the human antibody domains CH1, hinge, CH2 and CH3 in HEK293 cells, resulting in a conventional antibody heavy chain. All domains were separated by introns. Besides the expression cassette for the antibody heavy chain, the vector contained:

[0477] an origin of replication from the vector pUC18 which allows replication of this plasmid in *E. coli*,

[0478] a β -lactamase gene which confers ampicillin resistance in *E. coli*,

[0479] an SV40 promoter and origin for expression of the DHFR selection marker,

[0480] Murine dihydrofolate reductase (DHFR) as selection marker for antibody expression, and

[0481] SV40' early polyadenylation ("early poly A") signal sequence.

[0482] The transcription unit of the antibody heavy chain is composed of the following elements:

[0483] the immediate early enhancer and promoter from the human cytomegalovirus,

[0484] a 5'-untranslated region of a human antibody germline gene,

[0485] a murine immunoglobulin heavy chain signal sequence including a signal sequence intron (signal sequence 1, intron, signal sequence 2 [L1-intron-L2]),

[0486] the VH sequence followed by an intron,

[0487] human CH1, hinge, CH2, CH3 domains separated by introns,

[0488] the bovine growth hormone (bGH) polyadenylation ("poly A") signal sequence, and

[0489] the human gastrin transcription terminator (HGT).

[0490] Expression Vector for the Antibody Light Chains:

[0491] The gene segments of the designed humanized antibody light chain variable domains were cloned into a specified expression vector via the unique restriction sites BsmI and ClaI. The expression vector was designed to place the antibody light chain variable domain in fusion with the human antibody domain Ck in HEK293 cells. Both domains were separated by an intron. Besides the expression cassette for the antibody light chain, the vector contains:

[0492] an origin of replication from the vector pUC18 which allows replication of this plasmid in *E. coli*, and

[0493] a β -lactamase gene which confers ampicillin resistance in *E. coli*.

[0494] The transcription unit of the antibody light chain is composed of the following elements:

[0495] the immediate early enhancer and promoter from the human cytomegalovirus,

[0496] a 5'-untranslated region of the human cytomegalovirus,

[0497] an Intron A sequence of the human cytomegalovirus,

[0498] a 5'-untranslated region of a human antibody germline gene,

[0499] a murine immunoglobulin heavy chain signal sequence including a signal sequence intron (signal sequence 1, intron, signal sequence 2 [L1-intron-L2]) and the unique restriction site BsmI at the 3' end of L2,

[0500] a VL domain followed by an intron,

[0501] human Ck domain,

[0502] the bovine growth hormone (bGH) polyadenylation ("poly A") signal sequence, and

[0503] Human gastrin transcription termination factor (HGT).

Example 13.3

Expression of Humanized Antibodies

[0504] Transient Transfection of Humanized Antibody Light and Heavy Chains:

[0505] Recombinant humanized antibody variants were generated by transient transfection of HEK293-Freestyle cells (human embryonic kidney cell line 293, Invitrogen) grown in suspension. The transfected cells were cultivated in F17 medium (Gibco) or Freestyle 293 medium (Invitrogen), either one supplemented with 6 mM glutamine, either ultraglutamine (Biowhitake/Lonza) or L-glutamine (Sigma), with 8% CO₂ at 37° C. in shake flasks in the scale of 2 ml medium in 48-deep-well plates to 1 L medium in shake flasks. 293-Free transfection reagent (Novagen/Merck) was used in a ratio of reagent (μ l) to DNA (μ g) of 4:3. Light and heavy chains were expressed from two different plasmids using a molar ratio of light chain to heavy chain encoding plasmid ranging from 1:2 to 2:1, respectively. Humanized antibody containing cell culture supernatants were harvested at day 6 to 8 after transfection. General information regarding the recombinant expression of human immunoglobulins in, e.g., HEK293 cells, is given in: Meissner et al., *Biotechnol. Bioeng.*, 75: 197-203 (2001). The supernatants were purified by affinity chromatography on MabSelect Sure (GE, Protein A) equilibrated in PBS. After application of the filtrated supernatants, the antibodies were eluted with 50 mM sodium acetate, pH 3.2. The pH of the eluates was adjusted immediately to pH >6 with 2 M Tris/HCl, pH 9.0 followed by dialysis into 20 mM histidine, 140 mM NaCl, pH 6.0. Antibodies were analyzed by UV₂₈₀, SDS-PAGE and analytical SEC. The sequence was confirmed by mass spectrometry.

Example 13.4

Characterization of Humanized SS1 Variants

[0506] ELISA Screening of Humanized SS1 Variants:

[0507] All SS1 humanization variants in the IgG format were screened for affinity by ELISA. 384 well MaxiSorp microtiter plates were coated with 0.5 μ g/ml anti-His antibody (Novagen). After blocking with PBS buffer supplemented with 2% BSA, 0.1% Tween 20, and 0.2 μ g/ml human/cynomolgus/murine mesothelin (in house/R&D Systems), all proteins with a His-tag were captured on the plate for one hour. The plates were washed with PBST Buffer (PBS+0.1% Tween 20) and dilutions of humanized anti-mesothelin antibodies in PBS were incubated for 1 hour at room temperature. Binding of antibodies was detected with HRP conjugated anti human Fc antibody (GE Healthcare). After a final wash, the plates were incubated with HRP substrate. Absorbance was measured at 370 nm on an ENVISION plate reader. EC50

curve fit analysis was performed using XLfit4 analysis plug-in for EXCEL software (model 205).

[0508] To normalize the obtained values to the IgG titer, quantitation of human IgG was performed by sandwich ELISA using streptavidin coated plates. Streptavidin-coated 384 well microtiter plates (Microcoat) were incubated with a mixture of 0.25 µg/ml biotinylated anti-human IgG antibody (Jackson Imm. Res.), 0.05 µg/ml anti-human IgG-HRP conjugate (Jackson Imm. Res.), and dilutions of the humanized ant-mesothelin antibodies. After 1.5 hours incubation at room temperature (RT), plates were washed with PBS buffer supplemented with 0.1% Tween 20. HRP substrate was added, and the absorbance was measured at 370 nm on an ENVISION plate reader. The calculation of data was performed using a human IgG reference as a standard (in house) for calibration and XLfit4 analysis plug-in for EXCEL software (model 205) for curve fit analysis.

[0509] In Tables 20-21 below, the ELISA data of all humanization variants are shown. ELISA/BIACORE binding to huMesothelin (EC50 ng/ml) was measured, and the results are shown in Table 20 (in house) and Table 21 (R&D). Normalized to IgG titer, this primary screen identified the variant VL001/VH001 as one of the combinations with the best EC50 value.

[0510] BiaCore Screening of Humanized SS1 Variants:

[0511] The best variants containing CDRs most similar to SS1 were chosen for kinetics analysis by surface plasmon resonance (SPR). An SPR based assay has been used to determine the kinetic parameters of the binding between several MSLN PE cFP humanization variants and human mesothelin. Therefore, Protein A was immobilized by amine coupling to the surface of the CM5 biosensor chip. The samples were then captured, and human mesothelin was injected. The sensor chip surface was regenerated between each analysis cycle. The equilibrium constant K_D , as well as the rate constants k_a and k_d , were finally gained by fitting the data to a 1:1 langmuir interaction model. About 175 response units (RU) of Protein A (10 µg/ml) were coupled onto the CM5 sensor chip at pH 4.0 by using an amine coupling kit supplied by GE Healthcare (10 minutes activation). The sample and system buffer was HBS-P+ (0.01 M HEPES, 0.15 M NaCl, 0.005% surfactant P20 sterile-filtered, pH 7.4). The flow cell temperature was set to 25° C., and the sample compartment temperature was set to 12° C. The system was primed with running buffer. The protein A binding sites were saturated with IgGs (about 0.03 µg/mL) to generate similar capture levels for each sample, by injecting them for 40 seconds at a flow rate of 10 µl/min. Afterwards, a single 50 nM human mesothelin solution was injected for 120 seconds at a flow rate of 30 µl/min, followed by a 180 second dissociation phase. Thereby a relative KD determination allowed a ranking of different MSLN binders. Each cycle was regenerated with two injections of glycine-HCl pH 1.5 (30 seconds, 30 µl/min).

[0512] Table 22 below lists the BiaCore data of 12 selected humanization variants. The final humanization variant VL01/VH01 shows one of the lowest Kd values among all humanization variants. Table 22 shows the Biacore results for cFP. 15438-15457 and cFP.15438-15459, all comprising humanized VH1. cFP.15438, which comprises the amino acid sequence of SEQ ID NO: 45, displays the highest affinity of the humanized variants of SS1 antibody. Thus, the VH of cFP.15438 provides advantageous binding properties.

[0513] The five best variants were cloned into the Fab-Linker-PE format containing the published linker and LRO10

as the PE24 variant, expressed, refolded and purified. Cloning, expression, refolding and purification were carried out as described below for cFP-0205. The five humanization variants in the cytolytic fusion format were analyzed for stability at 37° C. for 7 days by the method of dynamic light scattering described in Example 9.2, size exclusion chromatography, SDS-PAGE, and mass spectrometry at distinct time points.

[0514] Size-exclusion chromatography (SE-HPLC) was performed on TSK-Gel300SWXL or Superdex 200 columns with a 0.2 M potassium phosphate buffer comprising 0.25 M KCl (pH 7.0) as the mobile phase in order to determine the content of monomeric, aggregated, and degraded species in the samples. Sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (reducing and non-reducing) was performed to analyze the purity of the complex preparations with regard to product-related degradation products and unrelated impurities (for details, see below). Electrospray ionisation mass spectrometry (ESI-MS) was performed with reduced (TCEP) samples to confirm the correct mass/identity of each chain and to detect chemical modifications. ESI-MS of the non-reduced samples was carried out to analyze the nature and quality of the fully assembled protein and to detect potential product-related side products.

[0515] The active concentration of the Fab fragments within the cytolytic fusion format after temperature stress at 37° C. for 7 days was monitored by surface plasmon resonance (SPR). Mesothelin was immobilized onto the surface of a SPR biosensor. By injecting the sample into the flow cells of the SPR spectrometer, it formed a complex with the immobilized mesothelin, resulting in an increased mass on the sensor chip surface and, therefore, a higher response (as 1 RU is defined as 1 pg/mm²). Afterwards, the sensor chip is regenerated by dissolving the sample-mesothelin-complex. The gained responses are then evaluated relative to the response displayed by the reference standard (which is assumed to be 100% active). First, around 50 resonance units (RU) of human MSLN (0.75 µg/ml) were coupled on a C1 chip (GE Healthcare) at pH 4.5 by using the amine coupling kit of GE Healthcare. The sample and system buffer was HBS-P+ (0.01 M HEPES, 0.15 M NaCl, 0.005% surfactant P20 sterile-filtered, pH 7.4). The flow cell temperature was set to 25° C., and the sample compartment temperature was set to 12° C. The system was primed with running buffer. Then, a 5 nM solution of the MSLN PE cFP construct was injected for 60 seconds at a flow rate of 30 µl/min, followed by a 60 second dissociation phase. Then, the sensor chip surface was regenerated by two 20 second long injections of the regeneration solution (0.31M KSCN, 1.22M MgCl₂, 0.61M urea, 1.22M Gua-HCl, 6.7 mM EDTA) at a flow rate of 30 µl/min, followed by an extra wash step with buffer and a 5 second stabilization period.

[0516] Stability data were obtained by incubating the 5 best humanized variants in the Fab-linker-PE24LRO10 format at 37° C. for 7 days. The results are shown in Table 23. As shown in Table 23, the variant VH01/VL01 was the only variant that showed no fragmentation after temperature stress. The VL01 promoted recovery as all VL01 combinations formed only aggregates after temperature stress but did not precipitate. Negative results of affinity measurements after temperature stress were due to these aggregates. Accordingly, the humanization variant VH1/VL1 (SEQ ID NO: 45)/(SEQ ID NO: 46) was chosen for further development. VH1 (SEQ ID NO: 45) provided favorable functionality and binding properties. The combination of VH1 (SEQ ID NO: 45)/VL1 (SEQ ID NO: 46) provided favorable developability.

TABLE 20

			z	a	b VL	c	d
			000/ 15456 mouse mVL	001/ 15457 (SEQ ID NO: 46)	002/ 15458 humanized	003/ 15459	004/ 15460
VH			Past (C99Q)	IMGT_ hVK_1_39	IMGT_ hVK_3_11	IMGT_ hVK_1_39	Hercept.
Mouse	0	000/15437 mVH Past (C44Q)	20.10	17.80	13.36	20.80	32.72
Humanized	1	001/15438 (SEQ ID NO: 45)	32.04	20.27	15.57	22.44	28.95
	2	002/15439 VBase_VH1_1	88.85	204.74	32.01	48.39	38.63
	3	003/15440 VBase_VH1_1	37.76	100.18	31.58	39.86	63.66
	4	004/15441 VBase_VH1_1	39.46	46.18	20.21	52.31	112.42
	5	005/15442 Herceptin	71.84	432.87	39.39	70.55	94.99
	6	006/15443 IMGT_hVH_5_51	196.59	287.08	41.11	144.51	466.56
	7	007/15444 IMGT_hVH_5_51	155.21	67.47	137.39	71.03	>500.0
	8	008/15445 IMGT_hVH_5_51	431.47	44.39	42.37	17.40	143.88
	9	009/15446 IMGT_hVH_1_8	118.32	62.23	71.58	31.00	230.84
	10	010/15447 IGHV4-34-05	41.35	93.85	35.06	33.49	135.83
	11	011/15448 IMGT_hVH_3_21	44.04	52.11	24.52	41.68	54.65
	12	012/15449 VBase_VH1_1	30.19	37.51	7.86	47.87	36.40
	13	013/15450 VBase_VH1_1	70.85	>500.0	58.84	129.80	111.42
	14	014/15451 VBase_VH1_1	#N/A	#N/A	#N/A	#N/A	#N/A
M1	MSAb-1/ 15452	Morphotek	25.65	19.12	13.24	18.82	33.79
M2	MSAb-2/ 15453	Morphotek	23.42	15.51	33.37	18.46	30.84
M3	MSAb-3/ 15454	Morphotek	34.70	62.58	17.71	15.82	64.02
SS1	HC_SS1/ 15436	Pastan	47.15	38.16	26.40	28.85	60.38
			e	m1	m2 VL	m3	ss1
			005/ 15461	MSAb-1/ 15462	MSAb-2/ 15463 humanized	MSAb-3/ 15464	LC_SS1/ 15455
			IMGT_ hVK_1_39	Morphotek PAT	Morphotek PAT	Morphotek PAT	Pastan PAT
Mouse	0		20.15	16.89	26.38	13.89	17.42
Humanized	1		30.31	33.50	21.78	21.23	27.22
	2		103.46	181.39	81.92	47.73	271.77
	3		70.03	26.60	108.18	39.95	230.87
	4		68.93	73.53	71.82	89.99	270.06
	5		119.52	26.06	326.88	60.33	>500.0
	6		163.55	>500.0	83.61	78.58	52.29
	7		69.42	210.52	89.05	182.10	181.13
	8		25.90	20.03	16.34	37.09	87.91
	9		68.65	103.29	97.08	80.73	44.37
	10		95.84	66.42	65.63	26.84	235.42
	11		62.08	15.60	124.88	35.08	47.05
	12		61.27	30.13	35.53	20.68	86.50
	13		132.05	16.51	204.88	33.20	>500.0
	14		#N/A	#N/A	#N/A	#N/A	#N/A
M1			21.71	26.82	13.24	17.05	7.37
M2			30.16	39.31	23.75	35.77	30.54
M3			53.63	117.75	19.86	42.60	45.23
SS1			37.42	29.65	29.79	14.77	41.13

TABLE 21

			z	a	b VL	c	d
			000/ 15456 mouse mVL 001/ 15457 (SEQ ID NO: 46) humanized 002/ 15458 humanized 003/ 15459 humanized 004/ 15460 humanized				
VH			Past (C99Q)	IMGT_ hVK_1_39	IMGT_ hVK_3_11	IMGT_ hVK_1_39	Hercept
Mouse	0	000/15437 mVH Past (C44Q)	24.93	18.25	14.91	16.97	28.24
Humanized	1	001/15438 IMGT_hVH_1_46 (SEQ ID NO: 45)	22.81	15.55	16.22	21.03	14.77
	2	002/15439 VBase_VH1_1	20.80	30.71	9.67	22.61	18.10
	3	003/15440 VBase_VH1_1	11.17	64.84	21.95	24.52	27.66
	4	004/15441 VBase_VH1_1	13.30	18.79	11.38	20.34	20.71
	5	005/15442 Herceptin	57.64	75.30	21.79	26.38	22.71
	6	006/15443 IMGT_hVH_5_51	37.98	68.72	17.00	31.68	96.41
	7	007/15444 IMGT_hVH_5_51	30.92	32.33	50.56	47.93	97.81
	8	008/15445 IMGT_hVH_5_51	27.84	32.16	13.63	17.70	36.39
	9	009/15446 IMGT_hVH_1_8	37.15	20.48	23.00	9.24	99.49
	10	010/15447 IGHV4-34-05	17.19	36.94	18.55	3.79	33.67
	11	011/15448 IMGT_hVH_3_21	17.85	19.31	12.09	26.23	19.38
	12	012/15449 VBase_VH1_1	26.50	18.36	4.84	25.45	32.87
	13	013/15450 VBase_VH1_1	17.11	48.46	26.21	32.81	17.97
	14	014/15451 VBase_VH1_1	#N/A	#N/A	#N/A	#N/A	#N/A
M1	MSAb-1/ 15452	Morphotek	16.76	26.05	10.85	15.40	27.67
M2	MSAb-2/ 15453	Morphotek	18.94	13.24	25.61	18.06	18.24
M3	MSAb-3/ 15454	Morphotek	43.79	80.00	24.10	20.13	57.15
SS1	HC_SS1/ 15436	Pastan	34.77	37.48	30.64	28.76	50.76
			e	m1	m2 VL	m3	ss1
			005/ 15461 humanized MSAb-1/ 15462 humanized MSAb-2/ 15463 humanized MSAb-3/ 15464 humanized LC SS1/ 15455 humanized				
			IMGT_ hVK_1_39	Morph PAT	Morph PAT	Morph PAT	Pastan PAT
	Mouse	0	19.65	13.30	20.08	16.62	21.59
	Humanized	1	21.75	33.91	21.69	18.48	20.27
		2	23.88	26.61	30.97	26.83	23.16
		3	46.86	11.40	33.78	23.40	43.11
		4	23.06	18.22	20.33	19.35	35.09
		5	32.75	7.46	78.60	41.55	51.40
		6	77.48	59.94	13.32	37.23	9.70
		7	21.06	35.60	49.19	35.21	26.52
		8	14.14	8.96	12.58	15.26	14.19
		9	45.65	13.29	16.81	20.11	11.92
		10	29.20	15.63	19.91	14.16	58.47
		11	25.78	6.71	42.47	25.88	26.04
		12	32.83	22.30	16.38	21.03	30.01
		13	55.13	18.76	40.91	16.60	70.42
		14	#N/A	#N/A	#N/A	#N/A	#N/A
	M1	15.26	18.45	10.07	14.15	10.22	
	M2	32.68	49.52	33.94	33.72	31.20	
	M3	51.29	76.89	21.74	57.13	43.21	
	SS1	48.23	24.34	31.68	17.66	46.14	

TABLE 22

Antibody	Antigen	Curve	Temp (° C.)	Fit	ka	kd	KD	KD [nM]
cFP-0004-0002	Mesothelin	Fc = 4-3	25	1:1 Binding	7.88E+05	2.39E-04	3.04E-10	0.30
cFP-0006-0002	Mesothelin	Fc = 4-3	25	1:1 Binding	9.29E+05	2.62E-04	2.83E-10	0.28
cFP.15438-15457	Mesothelin	Fc = 4-3	25	1:1 Binding	8.39E+05	2.20E-04	2.63E-10	0.26
cFP.15438-15459	Mesothelin	Fc = 4-3	25	1:1 Binding	7.13E+05	1.97E-04	2.77E-10	0.28
cFP.15438-15460	Mesothelin	Fc = 4-3	25	1:1 Binding	4.92E+05	1.63E-04	3.31E-10	0.33
cFP.15442-15457	Mesothelin	Fc = 4-3	25	1:1 Binding	2.15E+05	0.001387	6.45E-09	6.45
cFP.15442-15459	Mesothelin	Fc = 4-3	25	1:1 Binding	2.25E+05	0.002445	1.09E-08	10.89
cFP.15442-15460	Mesothelin	Fc = 4-3	25	1:1 Binding	1.42E+05	0.002221	1.57E-08	15.70
cFP.15447-15457	Mesothelin	Fc = 4-3	25	1:1 Binding	6.31E+05	9.76E-04	1.55E-09	1.55
cFP.15447-15459	Mesothelin	Fc = 4-3	25	1:1 Binding	5.14E+05	0.001916	3.73E-09	3.73
cFP.15447-15460	Mesothelin	Fc = 4-3	25	1:1 Binding	3.55E+05	0.002069	5.82E-09	5.82
cFP.15448-15457	Mesothelin	Fc = 4-3	25	1:1 Binding	1.77E+05	0.001729	9.79E-09	9.79
cFP.15448-15459	Mesothelin	Fc = 4-3	25	1:1 Binding	1.73E+05	0.001909	1.11E-08	11.05
cFP.15448-15460	Mesothelin	Fc = 4-3	25	1:1 Binding	1.12E+05	0.00216	1.93E-08	19.32

TABLE 23

VL	VH	T _{aggregation} [° C.]	Recovery	SEC	SDS-PAGE	ESI-MS d	ESI-MS d&r	Target binding	Stress effect on binding
VL01	VH10	40	+	HMW	Fragmentation	Fragmentation.	Fragmentation.	+/-	HMW
VL03	VH01	~35	-	LMW	Fragmentation.	Fragmentation.	Fragmentation.	+	+/-
VL01	VH01	37	+	HMWs	No fragmentation	No fragmentation	No fragmentation	+	HMW
VL03	VH10	37	-	HMW	+/-	Fragmentation.	Fragmentation.	+/-	+/-
VL04	VH01	34	-	LMW	+/-	No fragmentation	No fragmentation	+	+

Example 14

[0517] This example demonstrates the cloning, expression, refolding, and purification of chimeric deimmunized PE LOR10-456A as a Fab fusion with humanized anti-mesothelin SS1 (cFP-0205).

[0518] The chimeric PE anti-mesothelin molecule cFP-0205 was obtained after cloning, expression, refolding, and purification. cFP-0205 (also referred to as R205 or RG7787) comprises amino acid sequences SEQ ID NO: 39 and 40.

[0519] Cloning of cFP-0205:

[0520] For the expression of cFP-0205, the *E. coli* host/vector system which enables an antibiotic-free plasmid selection by complementation of an *E. coli* auxotrophy (PyrF) was employed (EP 0 972 838 and U.S. Pat. No. 6,291,245). Standard methods were used to manipulate DNA as described in Sambrook, J. et al., supra. The molecular biological reagents were used according to the manufacturer's instructions. Desired gene segments were made by commercial gene synthesis. The synthesized gene fragments were cloned into a specified expression vector. The DNA sequences of the sub-cloned gene fragments were confirmed by DNA sequencing.

[0521] The expression plasmids for the production of the light chain (LC) and the heavy chain (HC), respectively, were prepared as follows: The LC Plasmid 15496 is an expression plasmid for the expression of an antibody light chain in *E. coli*. It was generated by ligating the antibody VL domain fragment into the vector using the NdeI/BsiWI restriction sites.

[0522] The light chain *E. coli* expression plasmid comprises the following elements:

[0523] the origin of replication from the vector pBR322 for replication in *E. coli* (corresponding to positions 2517-3160 according to Sutcliffe et al., *Quant. Biol.*, 43: 77-90 (1979),

[0524] the URA3 gene of *Saccharomyces cerevisiae* coding for orotidine 5'-phosphate decarboxylase (Rose et al., *Gene*, 29: 113-124 (1984), which allows plasmid selection by complementation of *E. coli* pyrF mutant strains (uracil auxotrophy),

[0525] the antibody light chain expression cassette, comprising

[0526] the T5 hybrid promoter (T5-PN25/03/04 hybrid promoter according to Bujard et al., *Methods. Enzymol.*, 155: 416-433 (1987) and Stueber et al., *Immunol. Methods IV*, 121-152 (1990) including a synthetic ribosomal binding site according to Stueber et al. (supra),

[0527] the antibody light chain variable domain comprising the CDRs of SS1,

[0528] the human Ck domain,

[0529] two bacteriophage-derived transcription terminators, the λ -T0 terminator (Schwarz et al., *Nature*, 272: 410-414 (1978) and the fd-terminator (Beck et al., *Gene*, 1-3: 35-58 (1981), and

[0530] the lac repressor gene from *E. coli* (Farabaugh, P. J., *Nature*, 274 (1978) 765-769).

[0531] The HC Plasmid 18023 is an expression plasmid for the expression of a fusion protein including an antibody heavy chain, a linker containing a furin cleavage site, and a mutant of domain III of *Pseudomonas* Exotoxin A, in *E. coli*. It was generated by ligation of the VH domain fragment into the vector using the NdeI/BsrGI restriction sites. The specific PE variant fragment was exchanged using the BsrGI/BsiWI restriction sites.

[0532] The cytolytic fusion protein heavy chain *E. coli* expression plasmid comprises the following elements:

[0533] the origin of replication from the vector pBR322 for replication in *E. coli* (corresponding to positions 2517-3160 according to Sutcliffe et al., *Quant. Biol.*, 43: 77-90 (1979),

[0534] the URA3 gene of *Saccharomyces cerevisiae* coding for orotidine 5'-phosphate decarboxylase (Rose et al., *Gene*, 29: 113-124 (1984), which allows plasmid selection by complementation of *E. coli* pyrF mutant strains (uracil auxotrophy),

[0535] the heavy chain-PE domain III fusion protein expression cassette, comprising:

[0536] the T5 hybrid promoter (T5-PN25/03/04 hybrid promoter according to Bujard et al., *Methods. Enzymol.*, 155: 416-433 (1987) and Stueber et al., *Immunol. Methods IV*, 121-152 (1990), including a synthetic ribosomal binding site according to Stueber et al. (supra),

[0537] the antibody heavy chain variable domain comprising the CDRs of SS1,

[0538] the human CH1 domain,

[0539] the linker comprising a furin cleavage site,

[0540] the mutant variant of *Pseudomonas* Exotoxin A domain III,

[0541] two bacteriophage-derived transcription terminators, the λ -T0 terminator (Schwarz et al., *Nature*, 272: 410-414 (1978) and the fd-terminator (Beck et al., *Gene*, 1-3: 35-58 (1981), and

[0542] the lac repressor gene from *E. coli* (Farabaugh, *Nature*, 274: 765-769 (1978).

[0543] Expression of cFP-0205 in *E. coli*:

[0544] The *E. coli* K12 strains CSPZ-6 (thi-1, Δ pyrF) and CSPZ-13 (thi-1, Δ ompT, Δ pyrF) were transformed by electroporation with the expression plasmid nos. 15496 and 18023, respectively. The transformed *E. coli* cells were first grown at 37° C. on agar plates. For each transformation, a colony picked from this plate was transferred to a 3 mL roller culture and grown at 37° C. to an optical density of 1-2 (measured at 578 nm). Then 1000 μ l of culture were mixed with 1000 μ l sterile 86%-glycerol and immediately frozen at -80° C. for long term storage. The correct product expression of these clones was first verified by small scale shake flask experiments and analyzed with SDS-Page prior to the transfer to the 10 L fermenter.

Pre Cultivation:

[0545] For pre-fermentation, a chemically defined medium (CD-PCMV2.60) was used: NH_4Cl 1.25 g/l, $\text{K}_2\text{HPO}_4 \cdot 3\text{H}_2\text{O}$ 18.3 g/l, citrate 1.6 g/l, L-Methionine 0.20 g/l, Glucose $\cdot \text{H}_2\text{O}$ 8.0 g/l, trace elements solution 0.5 ml/l, $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ 0.86 g/l, and Thiamin $\cdot \text{HCl}$ 17.5 mg/l. The trace elements solution contained $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ 10.0 g/l, $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ 2.25 g/l, $\text{MnSO}_4 \cdot \text{H}_2\text{O}$ 2.13 g/l, H_3BO_3 0.50 g/l, $(\text{NH}_4)_6\text{Mo}_7\text{O}_{24} \cdot 4\text{H}_2\text{O}$ 0.3 g/l, $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$ 0.42 g/l, $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ 1.0 g/l dissolved in 0.5M HCl.

[0546] For pre-fermentation, five 1000 mL shake-flasks with four baffles filled with 220 mL of medium were inoculated with 1.0 mL each out of a primary seed bank ampoule. The cultivation was performed on a rotary shaker for 11-12 hours at 37° C. and 170 rpm until an optical density (578 nm) of 7 to 9 was obtained. The shake flasks were pooled, and the optical density was determined. The inoculum volume was calculated with $\text{Vinoc.} = 1000 \text{ mL} \cdot 5 / \text{OD}_{\text{PC}}$ and is dependent

on the optical density of the pre cultivation to inoculate the batch medium of each 100 L bioreactor run with an equal amount of cells.

100 L Scale Fermentation:

[0547] For fermentation in a 100 L fermenter (Sartorius, Melsungen, Germany), the following chemically defined batch medium was used: KH_2PO_4 1.59 g/l, $(\text{NH}_4)_2\text{HPO}_4$ 7.45 g/l, $\text{K}_2\text{HPO}_4 \cdot 3\text{H}_2\text{O}$ 13.32 g/l, citrate 2.07 g/l, L-methionine 1.22 g/l, NaHCO_3 0.82 g/l, trace elements solution 7.3 ml/l, $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ 0.99 g/l, thiamine $\cdot \text{HCl}$ 20.9 mg/l, glucose $\cdot \text{H}_2\text{O}$ 29.3 g/l, biotin 0.2 mg/l, 1.2 ml/l Synperonic 10% anti foam agent. The trace elements solution contained $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$ 10 g/l, $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ 2.25 g/l, $\text{MnSO}_4 \cdot \text{H}_2\text{O}$ 2.13 g/l, $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ 1.0 g/l, $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$ 0.42 g/l, $(\text{NH}_4)_6\text{Mo}_7\text{O}_{24} \cdot 4\text{H}_2\text{O}$ 0.3 g/l, H_3BO_3 0.50 g/l solubilized in a 0.5M HCl solution.

[0548] The feed 1 solution contained 700 g/l glucose $\cdot \text{H}_2\text{O}$, 7.4 g/l $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ and 0.1 g/l $\text{FeSO}_4 \cdot 7\text{H}_2\text{O}$. Feed 2 comprised KH_2PO_4 52.7 g/l, $\text{K}_2\text{HPO}_4 \cdot 3\text{H}_2\text{O}$ 139.9 g/l and $(\text{NH}_4)_2\text{HPO}_4$ 66.0 g/l. All components were dissolved in deionized water. The alkaline solution for pH regulation was an aqueous 12.5% (w/v) NH_3 solution supplemented with 11.25 g/l L-methionine.

[0549] Starting with 42 L of sterile batch medium plus the calculated inoculum of the pre cultivation the batch, fermentation was performed at 31° C., pH 6.9 $\pm$ 0.2, 800 mbar back pressure and an initial aeration rate of 50 l/min. The relative value of dissolved oxygen (pO_2) was kept at 50% throughout the fermentation by increasing the stirrer speed up to 1000 rpm. After the initially supplemented glucose was depleted, indicated by a steep increase in dissolved oxygen values, the temperature was shifted to 37° C. when producing the light chain or kept constant when producing the heavy chain construct and 15 minutes later, the fermentation entered the fed-batch mode with the start of both feeds (600 and 140 g/h respectively). The rate of feed 2 was kept constant, while the rate of feed 1 was increased stepwise with a predefined feeding profile from 600 to finally 1400 g/h when producing the light chain or 1600 g/h when producing the heavy chain construct within 6-7 hours. When carbon dioxide off gas concentration leveled above 2%, the aeration rate was stepwise increased by 10 L/min from 50 to 100 l/min within 5 hours. The expression of recombinant target proteins as insoluble inclusion bodies located in the cytoplasm was induced by the addition of 24 g IPTG at an optical density of approx. 40 for the variable light Fab-chain and 120 for the variable heavy Fab-chain.

[0550] After 24 hours of cultivation, the whole broth was cooled down to 4-8° C. and stored overnight in the fermenter vessel. The bacteria were harvested via centrifugation with a flow-through centrifuge (13,000 rpm, 13 l/h) or a separator and the obtained biomass was stored at -20° C. until further processing (cell disruption) or immediately processed for inclusion body isolation.

Analysis of Product Formation:

[0551] Samples were drawn from the fermenter, one prior to induction and the others at dedicated time points after induction of protein expression. The samples were analyzed by SDS-Polyacrylamide gel electrophoresis. For every sample, the same amount of cells ($\text{OD}_{\text{target}} = 10$) was suspended in 5 mL PBS buffer and disrupted via sonication on

ice. Then, 100 μ L of each suspension were centrifuged (15,000 rpm, 5 minutes) and each supernatant was withdrawn and transferred to a separate vial. This was to discriminate between soluble and insoluble expressed target protein. To each supernatant (=soluble protein fraction) 100 μ L and to each pellet (=insoluble protein fraction) 200 μ L of SDS sample buffer (Laemmli, *Nature*, 227: 680-685 (1970) were added. Samples were heated for 15 minutes at 95° C. under intense mixing to solubilize and reduce all proteins in the samples. After cooling to room temperature, 5 μ L of each sample were transferred to a 4-20% TGX Criterion Stain Free polyacrylamide gel (Bio-Rad). Additionally, 5 μ L molecular weight standard (Precision Plus Protein Standard, Bio-Rad) and 3 amounts (0.3 μ L, 0.6 μ L and 0.9 μ L) quantification standard with known target protein concentration (0.1 μ g/ μ L) were applied.

[0552] The electrophoresis was run for 60 Minutes at 200V and, thereafter, the gel was transferred the GELDOC EZ Imager (Bio-Rad) and processed for 5 minutes with UV radiation. Gel images were analyzed using Image Lab analysis software (Bio-Rad). With the three standards, a linear regression curve was calculated with a coefficient of >0.99 and the concentrations of target protein in the original sample were calculated. The yield was up to 3-4 g/L of the Fab-light chain and 10-12 g/L for the Fab-heavy chain PE fusion.

Inclusion Body Preparation:

[0553] The inclusion body preparations (IBP) of the 100 L fermentations were started directly after the harvest of the bacteria with the re-suspension of the harvested bacteria cells in buffer 1 (12.1 g/L Tris, 0.246 g/L $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, 12 mL/L 25%-HCl). The buffer volume was calculated in dependence of the dry matter content of the biomass. Lysozyme (100 kU/mg, 0.12 mg/g DCW) and a small amount of benzonase (5 U/g DCW) were added. Then, the suspension was homogenized at 900 bar (APV Rannie 5, 1 pass) to disrupt the bacteria cells followed by the addition further benzonase (30 U/g DCW) and an incubation for 30 minutes at 30-37° C. Then, the first wash buffer (60 g/L Brij, 87.6 g/L NaCl, 22.5 g/L EDTA, 6 mL/L 10N NaOH) was added and again the suspension was incubated for 30 minutes. The following separation step (CSCE, Westfalia) led to an inclusion body slurry which was re-suspended in the second wash buffer (12.1 g/L Tris, 7.4 g/L EDTA, 11 mL/L 25%-HCl) and incubated for 20 minutes. A further separation step harvested the inclusion bodies to a single use, sterile, plastic bag, which was immediately transferred to the DSP department.

Results:

[0554] The fermentations of the light chain yielded an optical density measured at 578 nm of 170-190 and a final product yield of 10-12 g/L. The fermentations of the heavy chain toxin fusion yielded an optical density measured at 578 nm of 210-230 and a final product yield of 3-4.5 g/L.

[0555] Refolding and Purification of cFP-0205:

[0556] Inclusion bodies of HC-PE24 and LC were solubilized separately in 8 M guanidinium-hydrochloride, 100 mM Tris/HCl, 1 mM EDTA, pH 8.0+100 mM dithiothreitol (DTT) overnight at RT (1 g IB in 5 mL). Solubilizates were adjusted to pH 3 and centrifuged, and the pellet was discarded. After extensive dialysis against 8 M guanidinium-HCl, 10 mM EDTA, pH 3.0 to remove DTT, the total protein concentration

was determined using the Biuret method. The purity of the HC and LC content was estimated via SDS-PAGE.

[0557] Solubilizates were diluted at a 1:1 molar ratio in renaturation buffer containing 0.5 M arginine, 2 mM EDTA, pH 10+1 mM GSH/GSSG, respectively, at 2-10° C. The target protein concentration was increased stepwise from 0.1 g/L up to 0.5 g/L, with an incubation time of 2 hours between each dose. After up to 5 pulses, the renaturation solution was kept at 2-10° C. overnight.

[0558] The renatrate was diluted with H_2O to <3 mS/cm and pumped onto an anion exchange column (AIEX) equilibrated in 20 mM Tris/HCl, pH 7.4. After washing the column with equilibration buffer, the protein was eluted with a gradient up to 20 mM Tris/HCl, 400 mM NaCl, pH 7.4. Peak fractions containing Fab-PE24 were pooled, concentrated and applied onto a preparative Size Exclusion Column (SEC) in 20 mM His, 140 mM NaCl, pH 5.5 or 6.0 to remove aggregates, fragments, and *E. coli* proteins. The final protein pool was adjusted to the required protein concentration and analyzed via SDS-PAGE or CE-SDS, analytical SEC and UV₂₈₀. Identity was confirmed by mass spectrometry.

[0559] Protein Analysis of cFP-0205:

[0560] Sample analysis was carried out as described above. Characterization of Final Deimmunized PE Variant as Fab Fusion with Humanized Anti-Mesothelin SS1 (cFP0205).

[0561] Cytotoxicity and In Vitro Tumor Cell Killing:

[0562] The cytotoxic potency of cFP0205 was compared to that of SS1P in cell viability assays with different cancer cell lines and primary mesothelioma cells. The results are shown in Table 24. As shown in Table 24, for many cancer cell lines, SS1P and cFP0205 had comparable potencies (difference in IC_{50} values ≤ 3). However, some cell lines (e.g., Hu-1 and Hu-2) and also the primary mesothelioma cells (RH19, RH21) were significantly more sensitive to cFP0205 than to SS1P (6-10 fold lower IC_{50} values).

TABLE 24

Cell line	SS1P (IC_{50} in ng/ml)	cFP0205 (IC_{50} in ng/ml)
Hu-1	2	0.25
Hu-2	0.3	0.04
Hu-3	2.9	2
HAY	1	1.4
AG5	0.3	1.1
L55	3	5
MKN-28	0.5	2
ASPC-1-luc	1.3	2.4
H596	4.6	15.7
RH19	3.7	1.2
RH21	2.3	0.35

Characterization of Final Deimmunized PE Variant as Fab Fusion with Humanized Anti-Mesothelin SS1 (cFP0205).

[0563] Serum Half Life:

[0564] A pilot study was performed in cynomolgus monkeys (1 male and 1 female) with cFP0205 in order to assess the pharmacokinetics of single doses. The animals were intravenously dosed with 0.3 mg/kg of cFP0205. For pharmacokinetics, blood samples were taken predose, 0.083 (5 minutes, end of infusion), 1, 2, 3, 5, 8, 24, 48 and 168 hours postdose. Levels of free drug (dashed line) as well as total drug (black squares and solid line) were determined by different ELISA formats (FIG. 20). For determining total drug levels, a one-step acid dissociation was performed before the capturing step on mesothelin coated plates. The free and total

drug levels were plotted over time. For comparison, historical data with SS1P were also inserted into FIG. 20 (black circles and solid line). These historical data were generated with a cytotoxic activity assay as a read-out for serum levels of SS1P. The cytotoxicity assay detects free drug, but also detects, at least in part, drug bound to soluble mesothelin which might contribute to the observed activity. The measured free drug levels for cFP0205 were similar to the first phase of the historical data with SS1P. The measured total drug levels for cFP0205 were comparable to the second phase of the kinetic observed for SS1P. In summary, not only in mice, but also in cynomolgus monkey, the serum level kinetics of SS1P and cFP0205 were very comparable.

Characterization of Final Deimmunized PE Variant as Fab Fusion with Humanized Anti Mesothelin SS1 (cFP0205)

[0565] Reduced Off-Target Toxicity:

[0566] SCID beige mice with small subcutaneous tumors of H596 lung cancer cells (average tumor volume 100 mm³) were dosed with 0.5, 1, 2, and 3 mg/kg cFP0205 3x/w qod and body weight loss was monitored over one month. The results are shown in FIG. 21.

[0567] As shown in FIG. 21, the maximally tolerated dose of SS1P in mice given intravenously 3x/w qod was 0.4 mg/kg. cFP0205 given with this same regimen was tolerated in SCID beige mice at doses up to 3 mg/kg. Some body weight loss was observed in all treatment groups. However, the effect of the 0.5 mg/kg dose of cFP0205 was indiscriminable from the vehicle control. Dose-dependently, an increasing loss of body weight occurred with 1, 2, and 3 mg/kg. In the 3 mg/kg group, the maximum weight loss was 15% and this was observed 4 days after the last application of cFP0205. In the 2 and 3 mg/kg treatment groups, no further decline in body weight was observed after the last application. All animals started to recover body weight from day 5 after the last treatment onwards. Initial body weight recovery was most pronounced in the 3 mg/kg group. In summary, despite similar pharmacokinetic properties of both molecules in mice, cFP0205 was tolerated at an almost 10 fold higher dose compared to SS1P.

[0568] A single intravenous dose (short infusion) toxicology study was done in 8 week old female Wistar Furth rats (150-175 g body weight) in order to evaluate and compare the off-target toxicity of SS1P and cFP0205. In particular, the risk of inducing vascular leak (edema) in the lung caused by the test item was investigated. Three animals per group received the active substance or vehicle by an intravenous short infusion at an infusion rate of 0.3 ml/min. Animals were necropsied 24 hours after dosing. Lung with mainstem bronchi and liver were macroscopically evaluated, fluid collection in the lung was assessed, and clinical chemistry assays were performed on blood samples. The results are shown in Table 25.

TABLE 25

	SS1P	cFP0205
Dose (i.v.), n = 3	2 mg/kg	10 mg/kg
In-life (clinical signs, bw)	rales (lung), rolling gait, hunched posture, piloerection and slight bw loss	none
Necropsy	tan-stained thoracic fluid in 2 rats; brown discoloration of liver in all 3 rats	none
Fluid Smear	mesothelial cells and eosinophils	none
Evaluation		
Clinical	Liver: ↑↑↑ in ALT (30x), AST (40x), γGT, GLDH, SDH;	Liver: marginal
Chemistry	VLS: ↓ Protein, ↓ albumin (serum protein loss)	SDH ↑

TABLE 25-continued

SS1P	cFP0205
Hemolysis ? : ↑ bilirubin (but no hematology indication)	
↑ BUN: poor physical condition (↑ protein catabolism)	

The serum half life of SS1P and cFP0205 is expected to be very similar in rats as shown for mice.

[0569] As shown in Table 25, two out of three rats that were dosed intravenously with 2 mg/kg of SS1P showed fluid accumulation in the lungs. All animals in this group showed clear clinical signs of toxicity and, for all animals, clinical chemistry values were indicative of severe liver damage. In contrast to this, all three animals treated with 10 mg/kg of cFP0205 showed no signs of toxicity. Only in one animal was the value for one of the liver enzymes slightly elevated. These findings demonstrate that the cFP0205 molecule causes much less hepatotoxicity and vascular leak syndrome than the SS1P classical immunotoxin format.

[0570] A pilot toxicology study was performed in cynomolgus monkeys (1 male and 1 female) with cFP0205 in order to determine the tolerability of repeated daily doses of the test item following intravenous administration and to check for potential late onset toxicity (up to 72 hrs after last repeat-dose). Postdosing observations of the animals were performed immediately, 0.25, 0.5, 1, 2, and 4 hours after end of dosing. During the dosing phase, the general behavior and appearance of the animals was observed twice daily, while body weight, food consumption and feces were analysed daily.

[0571] Dosing cFP0205 at 1 mg/kg daily for 5 consecutive days was well tolerated by both animals. No hemorrhaging, acute inflammation, or ulceration at the injection site were observed. That the animals showed no clinical signs of toxicity or non-tolerability firmly established 1 mg/kg/d 5x as the non-severely toxic dose, while the classical immunotoxin format represented by SS1P had previously been shown to be non-tolerated at a dose of 0.3 mg/kg/d 5x with animals showing persistent clinical signs of toxicity like hunched posture with tremors, hypoactivity, and poor appetite. In summary, cFP0205 is much better tolerated than SS1P not only in mice, but also in cynomolgus monkeys, a fully cross-reactive species for the targeting moieties of these immunoconjugates.

Characterization of Final Deimmunized PE Variant as Fab Fusion with Humanized SS1 (cFP0205)

[0572] cFP0205 and SS1P were labeled with Cy5 on free amino groups. Outstaged SCID beige mice with subcutaneous H596 tumors were intravenously injected (4 mice/group) at a dose of 2 mg/kg with the 2 fluorescent-labeled molecules. After 6 hours, the animals were sacrificed. The lung, liver, and spleen were formalin-fixed, embedded and sectioned. Fluorescence images of representative sections of these organs were taken at different magnification. The results are shown in FIGS. 22A-22L.

[0573] As shown in FIGS. 22A-22L, SS1P treatment led to pronounced fluorescence staining of lung and spleen tissue and massively stained what appeared to be the reticuloendothelial system in the liver. In contrast to this, there was no staining of lung tissue observed upon cFP0205 application. Also, staining of the spleen was much less pronounced and the staining pattern was different from that of SS1P treated animals. Also in the liver, the staining with cFP0205 was

drastically reduced compared to SS1P. Only isolated single cells that appear to be Kupffer cells were fluorescently stained. This suggests that the lower off-target toxicity of a Fab-PE24 compared to a dsFv-PE38 is due to differences in normal tissue distribution.

Example 15

[0574] This example demonstrates the production of anti-glypican 3-PE variant chimeric molecules.

[0575] An anti-glypican 3-PE variant chimeric molecule comprising a linker comprising the amino acid sequence of SEQ ID NO: 36, a PE comprising SEQ ID NO: 37 (L010R-456A), the variable heavy chain domain VH of SEQ ID NO: 61, and the variable light chain domain of SEQ ID NO: 62 (GPC3-PE24-LR-LO10R-456A-long-linker) was prepared by a method analogous to the method of preparing the anti-mesothelin PE variant chimeric molecule cFP-077 described in Example 12 (from cloning to purification).

[0576] An anti-glypican 3-PE variant chimeric molecule comprising a linker comprising the amino acid sequence of SEQ ID NO: 36, a PE comprising SEQ ID NO: 37 (L010R-456A), the variable heavy chain domain VH of SEQ ID NO: 77, and the variable light chain domain of SEQ ID NO: 78 was also prepared by a method analogous to the method of preparing the anti-mesothelin PE variant chimeric molecule cFP-077 described in Example 12 (from cloning to purification).

Example 16

[0577] This example demonstrates the cytotoxic properties of the anti-glypican 3-PE variant chimeric molecule GPC3-

PE24”) or mistargeted PE24 (“CD33-Fab-PE”; HepG2 cells do not express CD33) did not show any significant reduction of cell viability at concentrations <30 μ M. In summary, the more completely de-immunized GPC3-targeted LR-LO10R-456A-long-linker variant had the same or even slightly better cytotoxic potency as compared to the GPC3-targeted LR-LO1 OR variant with the shorter linker. Due to the additional 456A mutation within the PE, all B-cell epitopes were removed.

TABLE 26

Fusion protein	IC50 in CELLTITERGLOW assay with HepG2 (expressing glypican-3)
GPC3-PE24-LR-LO10R-short-linker	0.68 nM
GPC3-PE24-LR-LO10R-456A-long-linker	0.54 nM
Non-targeted PE24	>>30 μ M
CD33-PE24-LR-LO10R-short-linker	no effect up to 30 μ M

Example 17

[0580] This example demonstrates the cytotoxicity of deimmunized PE fusion proteins having a A458R mutation.

[0581] The cytotoxicity of SS1P, SS1-LR-GGS, SS1-LR-GGS-LO10, SS1-LR-GGS-LO10-A458R, and SS1-LR-GGS-LO10-A458-456A was measured using the WST method. The results are shown in Table 27.

TABLE 27

	A431/H9	HAY	M30	Hu-Meso	AGS
SS1P	0.05 (N = 14)	1.49 (N = 6)	0.28 (N = 5)	0.48 (N = 5)	0.36 (N = 5)
SS1-LR-GGS	0.16 (N = 2)	ND	ND	ND	0.3
SS1-LR-GGS-LO10	0.17 (N = 5)	0.68	3.99	0.11	11 (N = 2)
SS1-LR-GGS-LO10-A458R	0.13 (N = 18)	0.39 (N = 11)	0.57 (N = 3)	0.03 (N = 4)	1.05 (N = 9)
SS1-LR-GGS-LO10-A458R-456A	0.07 (N = 4)	0.1 (N = 2)	0.58 (N = 3)	ND	0.5

PE24-LR-LO10R-456A-long-linker as compared to GPC3-PE24-LR-LO10R.

[0578] The cytotoxic potency of GPC3-PE24-LR-LO1 OR was compared to that of GPC3-PE24-LR-LO10R-456A-long-linker on the glypican 3-positive liver cancer cell line HepG2. Briefly, HepG2 cells were seeded at a density of 6000 cells/well on 96 well plates. After overnight culture, different concentrations of the cFPs were added to the medium, and the cells were incubated for 72 hours. At the end of incubation period, cell viability was determined using a CELLTITER-GLOW assay. The results are shown in Table 26.

[0579] As shown in Table 26, comparable dose-response curves for the inhibition of cell viability were observed on HepG2 cells for both molecules. The IC₅₀ value of the more completely de-immunized PE variant with the 456A mutation and the longer linker was even slightly lower than that of the LR-LO10R variant with the short linker. Non-targeted (“free

[0582] As shown in Table 27, the A458R mutation increased the activity of SS1-LR-GGS-LO10 on several cell lines. The addition of the 456A mutation further increased activity on several cell lines. A431/H9 is an epidermoid carcinoma expressing mesothelin, and Hay is a mesothelioma line. M30 is also a mesothelioma cell line, and AGS is a stomach cancer cell line. Hu-Meso are cells from a mesothelioma patient that were placed in culture for a few months.

Example 18

[0583] This example demonstrates the treatment of HCC70 tumors using RG7787.

[0584] Female nude mice were inoculated into the intramammary fat pad with HCC70 cells at time 0. HCC70 is a breast cancer cell line. Intravenous treatment with RG7787 (2.5 mg/kg IV) or vehicle was begun on day 6 and continued every other day for a total of 5 doses (arrows). The size of the tumor was measured. The results are shown in FIG. 24.

[0585] As shown in FIG. 24, the tumor size of mice treated with RG7787 was decreased as compared to that of control mice (vehicle). There is a statistically significant difference between the 2 groups beginning at day 10, with $p < 0.00001$ by day 14.

Example 19

[0586] This example demonstrates the treatment of KLM1 tumors in mice using a combination of paclitaxel and RG7787.

[0587] Four week, four day old mice were injected with 4×10^6 KLM1 cells. KLM1 is a pancreatic cancer cell line that expresses mesothelin. Thirteen days later, mice were untreated or treated with paclitaxel (50 mg/kg), RG7787 (2.5 mg/kg), or a combination of RG7787 (2.5 mg/kg) and paclitaxel (50 mg/kg). Tumor size was measured for up to 89 days after treatment. The results are shown in FIG. 23.

[0588] As shown in FIG. 23, the tumor size of mice treated with the combination of paclitaxel and RG7787 was decreased as compared to that of control mice (untreated) or that of the mice treated with paclitaxel alone or RG7787 alone.

Example 20

[0589] This example demonstrates the treatment of HCC70 tumors in mice using a combination of paclitaxel and RG7787.

[0590] Female athymic nude mice were inoculated with HCC70 cells at time 0. Animals were treated with vehicle, RG7787 with IP vehicle injection, paclitaxel with IV vehicle injection, or paclitaxel and RG7787 combination. Paclitaxel (50 mg/kg) was administered by IP injection on days marked with long arrows. RG7787 (2.5 mg/kg) was administered IV on days indicated by short arrows. Mean tumor volumes for $n=5$ vehicle and $n=6$ mice treated with RG7787, paclitaxel or the combination are indicated by the markers. The results are shown in FIG. 25.

[0591] As shown in FIG. 25, the tumor size of mice treated with the combination of paclitaxel and RG7787 was decreased as compared to that of control mice (vehicle) or that of the mice treated with paclitaxel alone or RG7787 alone.

Example 21

[0592] This example demonstrates the treatment of MKN-28 tumors in mice using a combination of paclitaxel and R205.

[0593] Athymic nude mice were inoculated with MKN-28 cells at time 0. MKN-28 is a gastric cancer cell line which expresses mesothelin. Animals were untreated (UT) or treated with Roche 205 (R205 or 205) alone, paclitaxel (taxol) alone, or a combination of R205 and paclitaxel. Tumor size was measured. The results are shown in FIG. 26.

As shown in FIG. 26, the tumor size of mice treated with the combination of paclitaxel and R205 was decreased as compared to that of control mice (untreated) or that of the mice treated with paclitaxel alone or R205 alone.

Example 22

[0594] This example demonstrates the in vivo antitumor activity of LMB-T18. Severe combined immunodeficient (SCID) mice were implanted with CA46 cells. Seven days later, when tumors reached over 100 mm^3 in size, the mice were treated with PBS (control) or LMB-T18 (5 mg/kg $\times$ 4 or

7.5 mg/kg $\times$ 3) intravenously. Mice receiving 5.0 mg/kg were treated four times, on days 7, 9, 11 and 16, and the higher dose group was treated with 7.5 mg/kg three times on days 7, 9 and 11. Marked tumor regressions were observed in all mice (FIG. 27E) with only minor weight loss (average of 6%). 5/7 mice treated with 5.0 mg/kg maintained complete tumor regression on day 33, and 3/7 maintained complete tumor regression in the 7.5 mg/kg group. To assess the nonspecific toxicity of LMB-T18, six tumor bearing mice were treated intravenously with two doses of 10 mg/kg QOD. One mouse showed severe weight loss and was euthanized.

Example 23

[0595] This example demonstrates that LMB-T18 has greatly diminished T cell activation.

[0596] To determine if LMB-T18 had a decrease in T cell stimulation or if new T cell epitopes were created by the mutations, PBMCs were stimulated from the highest responder donors ($n=13$) and HCL and mesothelioma patients ($n=7$) with MP or LMB-T18. Cells were re-stimulated with the 39 novel peptides representing the differences between MP and LMB-T18. A decrease of 90% in donor T cell activation ($p < 0.0001$ in Student T test) was observed. Even in patients with activated T cells, there was an 83% decrease. ($p < 0.0001$ in Student T test). Furthermore, no new epitopes were created by the mutations.

Example 24

[0597] This example demonstrates that LMB-T18 has reduced binding to anti-sera from patients.

[0598] The antigenicity of LMB-T18 was evaluated by comparing the reactivity of MP, HA22-LR and LMB-T18 with serum from patients with neutralizing antibodies to MP. Binding was measured using ICC-ELISA with serum from 13 MP treated patients and is shown in FIG. 27F. It was found that like HA22-LR, LMB-T18 had a significantly reduced binding to serum compared to MP ($p < 0.001$ one-way ANOVA). It was also found that LMB-T18 had significantly lower binding compared to HA22-LR ($p < 0.001$ one-way ANOVA), indicating that the mutations in LMB-T18 reduced the binding to anti-sera.

Example 25

[0599] This example demonstrates the production of anti-FAP-PE variant chimeric molecules.

[0600] Three anti-FAP-PE variant chimeric molecules comprising:

[0601] (a) a linker comprising the amino acid sequence of SEQ ID NO: 36, a PE comprising SEQ ID NO: 37 (L010R-456A), the variable heavy chain domain VH of SEQ ID NO: 93, and the variable light chain domain of SEQ ID NO: 94 (iFAP-PE24-LR-L010R-456A-long-linker)

[0602] (b) a linker comprising the amino acid sequence of SEQ ID NO: 36, a PE comprising SEQ ID NO: 37 ((L010R-456A)), the variable heavy chain domain VH of SEQ ID NO: 93, and the variable light chain domain of SEQ ID NO: 294 (LCL4-PE24-LR-L010R-456A-long-linker) (including the VL variant of SEQ ID NO: 290), and

[0603] (c) a linker comprising the amino acid sequence of SEQ ID NO: 36, a PE comprising SEQ ID NO: 37

(T-20), the variable heavy chain domain VH of SEQ ID NO: 93, and the variable light chain domain of SEQ ID NO: 290 (LCL4-T20);

were prepared by a method analogous to the method of preparing the anti-mesothelin PE variant chimeric molecule cFP-077 described in Example 12 (from cloning to purification), except as described below.

[0604] The anti-FAP-PE variant chimeric molecules (b) and (c) included a modified variable light chain domain (VL) in which the methionine at position 4 of the original VL sequence of SEQ ID NO: 94 was substituted with leucine to provide a modified VL sequence of SEQ ID NO: 290 ("LCL4"). The modified variable light chain domain SEQ ID NO: 290 was found to reduce the production of impurities related to N-terminal modifications. These N-terminal modifications provided a mixture of variants with different light chain lengths due to the initiation of expression of the unmodified sequence at either the N-terminal methionine or the methionine at position 4 of SEQ ID NO: 94.

Pre-Cultivation:

[0605] For pre-fermentation, the same chemically defined medium (CD-PCMV2.20) was used as described in Example 12.

[0606] The cultivation was performed on a rotary shaker for 8 hours at 37° C. and 170 rpm until an optical density (578 nm) of 13.3 or 14.4 was obtained. 150 ml of the pre-cultivation was used to inoculate the batch medium of the 10 L bioreactor.

Fermentation:

[0607] For fermentation in a 101 Biostat C, DCU3 fermenter (Sartorius, Melsungen, Germany), the same chemically-defined batch medium as described in Example 12 was used.

[0608] One feed solution that was used contained 700 g/l glucose*H₂O, 7.4 g/l MgSO₄*7 H₂O and 0.1 g/l FeSO₄*7H₂O. All components were dissolved in deionized water. The alkaline solution for pH regulation was an aqueous 12.5% (w/v) NH₃ solution supplemented with 11.25 g/l L-methionine and 10 g/L Leucine and 10 g/L Threonine.

[0609] Starting with 6.24 L sterile batch medium plus 150 mL inoculum from the pre-cultivation, the batch fermentation was performed at 32° C., pH 6.9±0.2, 800 mbar back pressure and an initial aeration rate of 10 l/min. The relative value of dissolved oxygen (pO₂) was kept at 50% throughout the fermentation by increasing the stirrer speed up to 1500 rpm. After the initially supplemented glucose was depleted, indicated by a steep increase in dissolved oxygen values, the temperature was shifted to 32° C. or 37° C., and 15 minutes later, the fermentation entered the fed-batch mode with the start of both the feeds (60 and 14 g/h respectively). The rate of the feed was increased stepwise with a predefined feeding profile from 90 to finally 210 or 240 g/h within 5.5 or 6.5 hours. When carbon dioxide off gas concentration leveled above 2%, the aeration rate was constantly increased from 10 to 20 l/min within 5 hours. The expression of recombinant protein was induced by the addition of 3.6 g IPTG at an optical density of approx. 40 or 120. The target protein was expressed as inclusion bodies within the cytoplasm.

[0610] After 24 hours of cultivation, an optical density of 179 or 171 was achieved, and the whole broth was cooled down to 4-8° C. The bacteria were harvested via centrifuga-

tion with lab centrifuge (4500 rpm, cooling at 4° C., for 1 h) and the obtained biomass was stored at -20° C. until further processing (cell disruption).

Analysis of Product Formation:

[0611] The specific differences in comparison to the method of Example 12 are described below:

[0612] The same amount of cells (OD_{target}=10) from every sample were suspended in 5 mL PBS buffer and disrupted via sonication on ice. Then 100 µL of each suspension were centrifuged (8,000 rpm, 5 minutes) and each supernatant was withdrawn and transferred to a separate vial.

[0613] After adding Laemmli buffer, the samples were heated for 45 minutes 40° C. under intense mixing to solubilize and reduce all proteins in the samples.

Inclusion Body Preparation:

[0614] The inclusion body preparations (IBP) of the 10 L fermentations were processed in a manner analogous to the method described in Example 12, with the exception that after disruption of the bacteria cells, further benzoase (30 U/g DCW) was added and incubated for 60 minutes at 25° C.

[0615] Solubilization, renaturation and purification were performed in a manner similar to that described in Example 12. The following sequences were used:

[0616] Sequence of iFAP-PE24-LR-LO10R-456A-long-linker and LCL4-PE24-LR-LO10R-456A-long-linker chimeric full length heavy chain comprising the variable domain VH of SEQ ID NO: 93, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 37 (SEQ ID NO: 291);

[0617] Sequence LCL4-T20 chimeric heavy chain construct comprising the full length heavy chain comprising the variable domain VH of SEQ ID NO: 93, a linker comprising the amino acid sequence of SEQ ID NO: 36 and a PE comprising SEQ ID NO: 289 (T18/T20) (SEQ ID NO: 292);

[0618] Sequence of full length iFAP light chain (SEQ ID NO: 293) comprising the variable light chain domain of SEQ ID NO: 94 and constant region;

[0619] Sequence of full length LCL4 light chain (SEQ ID NO: 294) comprising the variable light chain domain of SEQ ID NO: 290 and constant region; and

[0620] Sequence of the variable light chain domain of SEQ ID NO: 290 (with mutation M4L at position 4 (compared to SEQ ID NO: 94).

Example 26

[0621] This example demonstrates the cytotoxicity of the anti-FAP-PE variant chimeric molecules iFAP-PE24-LR-LO10R-456A-long-linker, LCL4-PE24-LR-LO10R-456A-long-linker, and LCL4-T20.

[0622] The cytotoxicity of iFAP-PE24-LR-LO10R-456A-long-linker was compared to that of LCL4-PE24-LR-LO10R-456A-long-linker and LCL4-T20 ("cFPs") with respect to the FAP-positive fibroblast cell line MRC-5, the FAP-positive desmoplastic melanoma cell line LOX-IMVI, and the FAP-positive sarcoma cell line OsA-CL. Briefly, cells were seeded at a density of 10,000 cells/well on 96-well plates. After overnight culture, different concentrations of the cFPs were added to the medium, and the cells were incubated for 72 hours. At the end of incubation period, cell viability

was determined using a CELLTITER GLO assay. The results are shown in Table 28 and Table 29.

[0623] As shown in Table 28, comparable IC₅₀ values for the inhibition of cell viability were observed on all 3 tested cell lines for iFAP-PE24-LR-LO10R-456A-long-linker (3 different batches) and for LCL4-PE24-LR-LO10R-456A-long-linker. As shown in Table 29, LCL4-T20 also showed potent inhibition of cell viability. In summary, iFAP-PE24-LR-LO10R-456A-long-linker, LCL4-PE24-LR-LO10R-456A-long-linker, and LCL4-T20 showed potent cytotoxic effects on FAP-positive tumor cell lines and fibroblasts.

TABLE 28

Fusion protein	IC50 in CELLTITER GLO assay with cell lines expressing FAP(ng/ml)			
	MRC-5 (experiment 1)	MRC-5 (experiment 2)	LOX-IMVI	OsA-CL
iFAP- PE24-LR-LO10R-456A-long-linker (Batch 1)	14.3	8.5	6.6	98.3
iFAP- PE24-LR-LO10R-456A-long-linker (Batch 2)	14.4	9.3	9.1	46.3
iFAP- PE24-LR-LO10R-456A-long-linker (Batch 3)	10.0	5.5	5.7	55.3
LCL4- PE24-LR-LO10R-456A-long-linker	13.9	9.8	9.7	103.1

TABLE 29

Fusion protein	IC50 in CELLTITER GLO assay with cell lines expressing FAP(nM)		
	MRC-5	LOX-IMVI	OsA-CL
LCL4- PE24-LR-LO10R-456A-long-linker	0.15 nM	0.33 nM	0.23 nM
LCL4-T20	0.98 nM	8.99 nM	0.50 nM

Example 27

[0624] This example demonstrates the production of anti-CAIX-PE variant chimeric molecules.

[0625] Two anti-CAIX-PE variant chimeric molecules comprising:

[0626] (a) a linker comprising the amino acid sequence of SEQ ID NO: 36, a PE comprising SEQ ID NO: 37 (L010R-456A), the variable heavy chain domain VH of SEQ ID NO: 125, and the variable light chain domain of SEQ ID NO: 126; or

[0627] (b) a linker comprising the amino acid sequence of SEQ ID NO: 36, a PE comprising SEQ ID NO: 289 (T-20), the variable heavy chain domain VH of SEQ ID NO: 125, and the variable light chain domain of SEQ ID NO: 126;

[0628] were prepared by a method analogous to that described for the anti-mesothelin PE variant chimeric

molecule cFP-077 of Example 12 (from cloning to purification), except as described below.

[0629] Samples were analyzed by OD 280 nm using a UV spectrophotometer to determine the protein concentration in solution. The materials for the SDS-PAGE and Coomassie Staining Device are set forth in Table 30 below.

TABLE 30

Invitrogen XCell Sure Lock Mini-Cell	
Gel:	4-12% Bis-Tris Gel, Invitrogen NP0321
Buffer:	MES SDS Running Buffer (10×), Invitrogen NP0002
Sample buffer:	Tris-Glycine SDS Sample Buffer (2×), Invitrogen LC2676
Reducing buffer:	NUPAGE Sample Reducing Agent (10×), Invitrogen NP0004
Molecular Weight Marker:	Precision Plus KALEIDOSCOPE Standard 161-0375

[0630] After adding Laemmli buffer, the samples were heated for 45 minutes at 40° C. under intense mixing to solubilize and reduce all proteins in the samples.

[0631] The sample was adjusted to a protein concentration of 1 mg/ml with buffer. Sample reduction used a reduction buffer comprising 4 ml of sample buffer (2×) and 1 ml of reducing buffer (10×). The samples were reduced by diluting the sample 1:1 with reduction buffer and incubating the sample for 10 minutes at 70° C.

[0632] The gel electrophoresis was carried out at 200 V for 40 minutes. The gels were stained with SIMPLY BLUE Safe Stain (Invitrogen, Cat. No. LC6065).

Inclusion Body Preparation:

[0633] The inclusion body preparations (IBP) of the 10 L fermentations were processed in a manner analogous to that described in Example 12, with the exception that after disruption of the bacteria cells, further benzoase (30 U/g DCW) was added and incubated for 60 minutes at 25° C.

[0634] Solubilization, renaturation and purification were performed in a manner similar to that described in Example 12.

[0635] The following sequences were used:

[0636] Sequence of CAIX-PE24-LR-LO10R-456A-long-linker chimeric heavy chain construct (SEQ ID NO: 295): comprising the variable heavy chain domain VH of SEQ ID NO: 125, a linker comprising the amino acid sequence of SEQ ID NO: 36, and a PE comprising SEQ ID NO: 37;

[0637] Sequence of CAIX-T20 chimeric heavy chain construct (SEQ ID NO: 296) comprising the variable heavy chain domain VH of SEQ ID NO: 125, a linker comprising the amino acid sequence of SEQ ID NO: 36 and a PE comprising SEQ ID NO: 289 (T18/T20); and

[0638] Sequence of full length light chain (SEQ ID NO: 297) comprising the variable light chain domain of SEQ ID NO: 126) and constant region.

Example 28

[0639] This example demonstrates the cytotoxicity (in vitro tumor cell killing) of the anti-CAIX-PE variant chimeric molecules CAIX-PE24-LR-LO10R-456A-long-linker and CAIX-T20.

[0640] The cytotoxicity of CAIX-PE24-LR-LO10R-456A-long-linker and CAIX-T20 (“cFPs”) was compared in cell viability assays using CAIX-expressing RCC-MF cells. Briefly, cells were seeded at a density of 7,500 cells/well on 96 well plates. After overnight culture, different concentrations of the cFPs were added to the medium, and the cells were incubated for 72 hours. At the end of incubation period, cell viability was determined using a CELLTITER GLO assay. The results are shown in Table 31.

[0641] In summary, CAIX-PE24-LR-LO10R-456A-long-linker and CAIX-T20 showed potent cytotoxic effects on CAIX-positive tumor cell lines.

TABLE 31

Fusion protein	IC50 in CELLTITER GLO assay with cell lines expressing CAIX (nM) RCC-MF cells
CAIX-PE24-LR-LO10R-456A-long-linker	0.02 nM
CAIX-T20	0.048 nM

[0642] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

[0643] The use of the terms “a” and “an” and “the” and “at least one” and similar referents in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contra-

dicted by context. The use of the term “at least one” followed by a list of one or more items (for example, “at least one of A and B”) is to be construed to mean one item selected from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (i.e., meaning “including, but not limited to,”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

[0644] Preferred embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Variations of those preferred embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 297

<210> SEQ ID NO 1

<211> LENGTH: 613

<212> TYPE: PRT

<213> ORGANISM: *Pseudomonas aeruginosa*

<400> SEQUENCE: 1

Ala Glu Glu Ala Phe Asp Leu Trp Asn Glu Cys Ala Lys Ala Cys Val
1 5 10 15

Leu Asp Leu Lys Asp Gly Val Arg Ser Ser Arg Met Ser Val Asp Pro
20 25 30

Ala Ile Ala Asp Thr Asn Gly Gln Gly Val Leu His Tyr Ser Met Val
35 40 45

Leu Glu Gly Gly Asn Asp Ala Leu Lys Leu Ala Ile Asp Asn Ala Leu
50 55 60

Ser Ile Thr Ser Asp Gly Leu Thr Ile Arg Leu Glu Gly Gly Val Glu
65 70 75 80

Pro Asn Lys Pro Val Arg Tyr Ser Tyr Thr Arg Gln Ala Arg Gly Ser
85 90 95

-continued

Trp	Ser	Leu	Asn	Trp	Leu	Val	Pro	Ile	Gly	His	Glu	Lys	Pro	Ser	Asn	
			100					105					110			
Ile	Lys	Val	Phe	Ile	His	Glu	Leu	Asn	Ala	Gly	Asn	Gln	Leu	Ser	His	
		115					120				125					
Met	Ser	Pro	Ile	Tyr	Thr	Ile	Glu	Met	Gly	Asp	Glu	Leu	Leu	Ala	Lys	
	130					135					140					
Leu	Ala	Arg	Asp	Ala	Thr	Phe	Phe	Val	Arg	Ala	His	Glu	Ser	Asn	Glu	
145					150					155					160	
Met	Gln	Pro	Thr	Leu	Ala	Ile	Ser	His	Ala	Gly	Val	Ser	Val	Val	Met	
			165						170					175		
Ala	Gln	Thr	Gln	Pro	Arg	Arg	Glu	Lys	Arg	Trp	Ser	Glu	Trp	Ala	Ser	
			180					185					190			
Gly	Lys	Val	Leu	Cys	Leu	Leu	Asp	Pro	Leu	Asp	Gly	Val	Tyr	Asn	Tyr	
	195						200					205				
Leu	Ala	Gln	Gln	Arg	Cys	Asn	Leu	Asp	Asp	Thr	Trp	Glu	Gly	Lys	Ile	
	210					215					220					
Tyr	Arg	Val	Leu	Ala	Gly	Asn	Pro	Ala	Lys	His	Asp	Leu	Asp	Ile	Lys	
225					230					235					240	
Pro	Thr	Val	Ile	Ser	His	Arg	Leu	His	Phe	Pro	Glu	Gly	Gly	Ser	Leu	
			245						250					255		
Ala	Ala	Leu	Thr	Ala	His	Gln	Ala	Cys	His	Leu	Pro	Leu	Glu	Thr	Phe	
		260						265					270			
Thr	Arg	His	Arg	Gln	Pro	Arg	Gly	Trp	Glu	Gln	Leu	Glu	Gln	Cys	Gly	
	275						280					285				
Tyr	Pro	Val	Gln	Arg	Leu	Val	Ala	Leu	Tyr	Leu	Ala	Ala	Arg	Leu	Ser	
	290					295					300					
Trp	Asn	Gln	Val	Asp	Gln	Val	Ile	Arg	Asn	Ala	Leu	Ala	Ser	Pro	Gly	
305					310				315						320	
Ser	Gly	Gly	Asp	Leu	Gly	Glu	Ala	Ile	Arg	Glu	Gln	Pro	Glu	Gln	Ala	
			325						330					335		
Arg	Leu	Ala	Leu	Thr	Leu	Ala	Ala	Ala	Glu	Ser	Glu	Arg	Phe	Val	Arg	
		340						345					350			
Gln	Gly	Thr	Gly	Asn	Asp	Glu	Ala	Gly	Ala	Ala	Asn	Ala	Asp	Val	Val	
		355					360					365				
Ser	Leu	Thr	Cys	Pro	Val	Ala	Ala	Gly	Glu	Cys	Ala	Gly	Pro	Ala	Asp	
	370					375					380					
Ser	Gly	Asp	Ala	Leu	Leu	Glu	Arg	Asn	Tyr	Pro	Thr	Gly	Ala	Glu	Phe	
385					390					395					400	
Leu	Gly	Asp	Gly	Gly	Asp	Val	Ser	Phe	Ser	Thr	Arg	Gly	Thr	Gln	Asn	
			405						410					415		
Trp	Thr	Val	Glu	Arg	Leu	Leu	Gln	Ala	His	Arg	Gln	Leu	Glu	Glu	Arg	
		420						425					430			
Gly	Tyr	Val	Phe	Val	Gly	Tyr	His	Gly	Thr	Phe	Leu	Glu	Ala	Ala	Gln	
	435						440					445				
Ser	Ile	Val	Phe	Gly	Gly	Val	Arg	Ala	Arg	Ser	Gln	Asp	Leu	Asp	Ala	
	450					455					460					
Ile	Trp	Arg	Gly	Phe	Tyr	Ile	Ala	Gly	Asp	Pro	Ala	Leu	Ala	Tyr	Gly	
465					470				475						480	
Tyr	Ala	Gln	Asp	Gln	Glu	Pro	Asp	Ala	Arg	Gly	Arg	Ile	Arg	Asn	Gly	
			485					490						495		
Ala	Leu	Leu	Arg	Val	Tyr	Val	Pro	Arg	Ser	Ser	Leu	Pro	Gly	Phe	Tyr	

-continued

500	505	510
Arg Thr Ser Leu Thr Leu Ala Ala Pro Glu Ala Ala Gly Glu Val Glu		
515	520	525
Arg Leu Ile Gly His Pro Leu Pro Leu Arg Leu Asp Ala Ile Thr Gly		
530	535	540
Pro Glu Glu Glu Gly Gly Arg Leu Glu Thr Ile Leu Gly Trp Pro Leu		
545	550	555
Ala Glu Arg Thr Val Val Ile Pro Ser Ala Ile Pro Thr Asp Pro Arg		
565	570	575
Asn Val Gly Gly Asp Leu Asp Pro Ser Ser Ile Pro Asp Lys Glu Gln		
580	585	590
Ala Ile Ser Ala Leu Pro Asp Tyr Ala Ser Gln Pro Gly Lys Pro Pro		
595	600	605
Arg Glu Asp Leu Lys		
610		

<210> SEQ ID NO 2
 <211> LENGTH: 12
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic
 <220> FEATURE:
 <221> NAME/KEY: MISC_FEATURE
 <222> LOCATION: (1)..(1)
 <223> OTHER INFORMATION: Xaa at position 1 is Leu or Ala
 <220> FEATURE:
 <221> NAME/KEY: MISC_FEATURE
 <222> LOCATION: (4)..(4)
 <223> OTHER INFORMATION: Xaa at position 4 is Leu or Ala
 <220> FEATURE:
 <221> NAME/KEY: MISC_FEATURE
 <222> LOCATION: (5)..(5)
 <223> OTHER INFORMATION: Xaa at position 5 is Tyr or Ala
 <220> FEATURE:
 <221> NAME/KEY: MISC_FEATURE
 <222> LOCATION: (6)..(6)
 <223> OTHER INFORMATION: Xaa at position 6 is Leu or Ala
 <220> FEATURE:
 <221> NAME/KEY: MISC_FEATURE
 <222> LOCATION: (9)..(9)
 <223> OTHER INFORMATION: Xaa at position 9 is Arg or Ala

<400> SEQUENCE: 2

Xaa Val Ala Xaa Xaa Xaa Ala Ala Xaa Leu Ser Trp
1 5 10

<210> SEQ ID NO 3
 <211> LENGTH: 12
 <212> TYPE: PRT
 <213> ORGANISM: *Pseudomonas aeruginosa*

<400> SEQUENCE: 3

Leu Val Ala Leu Tyr Leu Ala Ala Arg Leu Ser Trp
1 5 10

<210> SEQ ID NO 4
 <211> LENGTH: 4
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic
 <220> FEATURE:
 <221> NAME/KEY: MISC_FEATURE

-continued

<222> LOCATION: (2)..(2)
<223> OTHER INFORMATION: Xaa at position 2 is any amino acid
<220> FEATURE:
<221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (3)..(3)
<223> OTHER INFORMATION: Xaa at position 3 is Arg or Lys

<400> SEQUENCE: 4

Arg Xaa Xaa Arg
1

<210> SEQ ID NO 5
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 5

Lys Asp Glu Leu
1

<210> SEQ ID NO 6
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas aeruginosa

<400> SEQUENCE: 6

Arg Glu Asp Leu Lys
1 5

<210> SEQ ID NO 7
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas aeruginosa

<400> SEQUENCE: 7

Arg Glu Asp Leu
1

<210> SEQ ID NO 8
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Pseudomonas aeruginosa

<400> SEQUENCE: 8

Arg His Arg Gln Pro Arg Gly Trp Glu Gln Leu
1 5 10

<210> SEQ ID NO 9
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (2)..(3)
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid

<400> SEQUENCE: 9

Arg Xaa Xaa Arg
1

-continued

<210> SEQ ID NO 10
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 10

Arg Lys Lys Arg
1

<210> SEQ ID NO 11
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 11

Arg Arg Arg Arg
1

<210> SEQ ID NO 12
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 12

Arg Lys Ala Arg
1

<210> SEQ ID NO 13
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 13

Ser Arg Val Ala Arg Ser
1 5

<210> SEQ ID NO 14
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 14

Thr Ser Ser Arg Lys Arg Arg Phe Trp
1 5

<210> SEQ ID NO 15
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 15

Ala Ser Arg Arg Lys Ala Arg Ser Trp
1 5

-continued

<210> SEQ ID NO 16
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 16

Arg Arg Val Lys Lys Arg Phe Trp
1 5

<210> SEQ ID NO 17
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 17

Arg Asn Val Val Arg Arg Asp Trp
1 5

<210> SEQ ID NO 18
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 18

Thr Arg Ala Val Arg Arg Arg Ser Trp
1 5

<210> SEQ ID NO 19
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 19

Arg Gln Pro Arg
1

<210> SEQ ID NO 20
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 20

Arg His Arg Gln Pro Arg Gly Trp
1 5

<210> SEQ ID NO 21
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 21

-continued

Arg His Arg Gln Pro Arg Gly Trp Glu
1 5

<210> SEQ ID NO 22
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 22

His Arg Gln Pro Arg Gly Trp Glu Gln
1 5

<210> SEQ ID NO 23
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 23

Arg Gln Pro Arg Gly Trp Glu
1 5

<210> SEQ ID NO 24
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 24

Arg His Arg Ser Lys Arg Gly Trp Glu Gln Leu
1 5 10

<210> SEQ ID NO 25
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 25

Arg Ser Lys Arg
1

<210> SEQ ID NO 26
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 26

Arg His Arg Ser Lys Arg Gly Trp
1 5

<210> SEQ ID NO 27
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

-continued

<400> SEQUENCE: 27

His Arg Ser Lys Arg Gly Trp Glu
1 5

<210> SEQ ID NO 28
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 28

Arg Ser Lys Arg Gly Trp Glu Gln Leu
1 5

<210> SEQ ID NO 29
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 29

His Arg Ser Lys Arg Gly Trp Glu Gln Leu
1 5 10

<210> SEQ ID NO 30
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 30

Arg His Arg Ser Lys Arg
1 5

<210> SEQ ID NO 31
<211> LENGTH: 106
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 31

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30

His Trp Tyr Gln Gln Lys Ser Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45

Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu
65 70 75 80

Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Lys His Pro Leu Thr
85 90 95

Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105

-continued

<210> SEQ ID NO 32
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 32

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
1 5 10 15
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
20 25 30
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
35 40 45
Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
50 55 60
Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
65 70 75 80
Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
85 90 95
Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105

<210> SEQ ID NO 33
<211> LENGTH: 214
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 33

Met Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val
1 5 10 15
Gly Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr
20 25 30
Met His Trp Tyr Gln Gln Lys Ser Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Lys His Pro Leu
85 90 95
Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190

-continued

Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205

Phe Asn Arg Gly Glu Cys
210

<210> SEQ ID NO 34
<211> LENGTH: 119
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 34

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
20 25 30
Thr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Leu Ile Thr Pro Tyr Asn Gly Ala Ser Ser Tyr Asn Gln Lys Phe
50 55 60
Arg Gly Lys Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Tyr Asp Gly Arg Gly Phe Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115

<210> SEQ ID NO 35
<211> LENGTH: 103
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 35

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95
Lys Val Glu Pro Lys Ser Cys
100

<210> SEQ ID NO 36
<211> LENGTH: 26
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 36

Asp Lys Thr His Lys Ala Ser Gly Gly Arg His Arg Gln Pro Arg Gly
1 5 10 15

Trp Glu Gln Leu Gly Gly Gly Gly Ser
20 25

<210> SEQ ID NO 37

<211> LENGTH: 219

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 37

Pro Thr Gly Ala Glu Phe Leu Gly Asp Gly Gly Asp Val Ser Phe Ser
1 5 10 15

Thr Arg Gly Thr Gln Asn Trp Thr Val Glu Arg Leu Leu Gln Ala His
20 25 30

Ala Gln Leu Glu Glu Arg Gly Tyr Val Phe Val Gly Tyr His Gly Thr
35 40 45

Phe Leu Glu Ala Ala Gln Ser Ile Val Phe Gly Gly Val Ala Ala Arg
50 55 60

Ser Gln Asp Leu Ala Ala Ile Trp Ala Gly Phe Tyr Ile Ala Gly Asp
65 70 75 80

Pro Ala Leu Ala Tyr Gly Tyr Ala Gln Asp Gln Glu Pro Asp Ala Ala
85 90 95

Gly Arg Ile Arg Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Ala Ser
100 105 110

Ser Leu Pro Gly Phe Tyr Arg Thr Ser Leu Thr Leu Ala Ala Pro Glu
115 120 125

Ala Ala Gly Glu Val Glu Arg Leu Ile Gly His Pro Leu Pro Leu Ala
130 135 140

Leu Asp Ala Ile Thr Gly Pro Glu Glu Glu Gly Gly Arg Leu Glu Thr
145 150 155 160

Ile Leu Gly Trp Pro Leu Ala Glu Arg Thr Val Val Ile Pro Ser Ala
165 170 175

Ile Pro Thr Asp Pro Arg Asn Val Gly Gly Asp Leu Asp Pro Ser Ser
180 185 190

Ile Pro Asp Lys Glu Gln Ala Ile Ser Ala Leu Pro Asp Tyr Ala Ser
195 200 205

Gln Pro Gly Lys Pro Pro Arg Glu Asp Leu Lys
210 215

<210> SEQ ID NO 38

<211> LENGTH: 223

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 38

Met Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly
1 5 10 15

```
<210> SEQ ID NO 39
<211> LENGTH: 214
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 39
```

Met	Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val
1				5					10					15	
Gly	Asp	Arg	Val	Thr	Ile	Thr	Cys	Ser	Ala	Ser	Ser	Ser	Val	Ser	Tyr
			20					25					30		
Met	His	Trp	Tyr	Gln	Gln	Lys	Ser	Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile
		35					40					45			
Tyr	Asp	Thr	Ser	Lys	Leu	Ala	Ser	Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly
	50					55					60				
Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro
65					70					75					80
Glu	Asp	Phe	Ala	Thr	Tyr	Tyr	Cys	Gln	Gln	Trp	Ser	Lys	His	Pro	Leu
				85					90					95	
Thr	Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg	Thr	Val	Ala	Ala
			100					105					110		
Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser	Gly
		115					120					125			
Thr	Ala	Ser	Val	Val	Cys	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu	Ala	
	130					135				140					

-continued

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
 145 150 155 160
 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
 165 170 175
 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
 180 185 190
 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 195 200 205
 Phe Asn Arg Gly Glu Cys
 210

<210> SEQ ID NO 40
 <211> LENGTH: 468
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 40

Met Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly
 1 5 10 15
 Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly
 20 25 30
 Tyr Thr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp
 35 40 45
 Met Gly Leu Ile Thr Pro Tyr Asn Gly Ala Ser Ser Tyr Asn Gln Lys
 50 55 60
 Phe Arg Gly Lys Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Val
 65 70 75 80
 Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr
 85 90 95
 Cys Ala Arg Gly Gly Tyr Asp Gly Arg Gly Phe Asp Tyr Trp Gly Gln
 100 105 110
 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
 115 120 125
 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
 130 135 140
 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
 145 150 155 160
 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
 165 170 175
 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
 180 185 190
 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
 195 200 205
 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp
 210 215 220
 Lys Thr His Lys Ala Ser Gly Gly Arg His Arg Gln Pro Arg Gly Trp
 225 230 235 240
 Glu Gln Leu Gly Gly Gly Gly Ser Pro Thr Gly Ala Glu Phe Leu
 245 250 255
 Gly Asp Gly Gly Asp Val Ser Phe Ser Thr Arg Gly Thr Gln Asn Trp
 260 265 270

-continued

Thr Val Glu Arg Leu Leu Gln Ala His Ala Gln Leu Glu Glu Arg Gly
 275 280 285
 Tyr Val Phe Val Gly Tyr His Gly Thr Phe Leu Glu Ala Ala Gln Ser
 290 295 300
 Ile Val Phe Gly Gly Val Ala Ala Arg Ser Gln Asp Leu Ala Ala Ile
 305 310 315 320
 Trp Ala Gly Phe Tyr Ile Ala Gly Asp Pro Ala Leu Ala Tyr Gly Tyr
 325 330 335
 Ala Gln Asp Gln Glu Pro Asp Ala Ala Gly Arg Ile Arg Asn Gly Ala
 340 345 350
 Leu Leu Arg Val Tyr Val Pro Ala Ser Ser Leu Pro Gly Phe Tyr Arg
 355 360 365
 Thr Ser Leu Thr Leu Ala Ala Pro Glu Ala Ala Gly Glu Val Glu Arg
 370 375 380
 Leu Ile Gly His Pro Leu Pro Leu Ala Leu Asp Ala Ile Thr Gly Pro
 385 390 395 400
 Glu Glu Glu Gly Gly Arg Leu Glu Thr Ile Leu Gly Trp Pro Leu Ala
 405 410 415
 Glu Arg Thr Val Val Ile Pro Ser Ala Ile Pro Thr Asp Pro Arg Asn
 420 425 430
 Val Gly Gly Asp Leu Asp Pro Ser Ser Ile Pro Asp Lys Glu Gln Ala
 435 440 445
 Ile Ser Ala Leu Pro Asp Tyr Ala Ser Gln Pro Gly Lys Pro Pro Arg
 450 455 460
 Glu Asp Leu Lys
 465

<210> SEQ ID NO 41
 <211> LENGTH: 214
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 41

Met Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro
 1 5 10 15
 Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr
 20 25 30
 Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile
 35 40 45
 Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Gly Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Asn Ser Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala
 65 70 75 80
 Glu Asp Asp Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Lys His Pro Leu
 85 90 95
 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala
 100 105 110
 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
 115 120 125
 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
 130 135 140

-continued

Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
 145 150 155 160
 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
 165 170 175
 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
 180 185 190
 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
 195 200 205
 Phe Asn Arg Gly Glu Cys
 210

<210> SEQ ID NO 42
 <211> LENGTH: 461
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 42

Met Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Glu Lys Pro Gly
 1 5 10 15
 Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly
 20 25 30
 Tyr Thr Met Asn Trp Val Lys Gln Ser His Gly Lys Gly Leu Glu Trp
 35 40 45
 Ile Gly Leu Ile Thr Pro Tyr Asn Gly Ala Ser Ser Tyr Asn Gln Lys
 50 55 60
 Phe Arg Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala
 65 70 75 80
 Tyr Met Asp Leu Leu Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe
 85 90 95
 Cys Ala Arg Gly Gly Tyr Asp Gly Arg Gly Phe Asp Tyr Trp Gly Gln
 100 105 110
 Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
 115 120 125
 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
 130 135 140
 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
 145 150 155 160
 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
 165 170 175
 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
 180 185 190
 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
 195 200 205
 Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Lys
 210 215 220
 Ala Ser Gly Gly Arg His Arg Gln Pro Arg Gly Trp Glu Gln Leu Gly
 225 230 235 240
 Gly Ser Pro Thr Gly Ala Glu Phe Leu Gly Asp Gly Gly Asp Val Ser
 245 250 255
 Phe Ser Thr Arg Gly Thr Gln Asn Trp Thr Val Glu Arg Leu Leu Gln
 260 265 270

-continued

Ala His Ala Gln Leu Glu Glu Arg Gly Tyr Val Phe Val Gly Tyr His
 275 280 285

Gly Thr Phe Leu Glu Ala Ala Gln Ser Ile Val Phe Gly Gly Val Arg
 290 295 300

Ala Ala Ser Gln Asp Leu Ala Ala Ile Trp Ala Gly Phe Tyr Ile Ala
 305 310 315 320

Gly Asp Pro Ala Leu Ala Tyr Gly Tyr Ala Gln Asp Gln Glu Pro Asp
 325 330 335

Ala Ala Gly Arg Ile Arg Asn Gly Ala Leu Leu Arg Val Tyr Val Pro
 340 345 350

Ala Ser Ser Leu Pro Gly Phe Tyr Arg Thr Ser Leu Thr Leu Ala Ala
 355 360 365

Pro Glu Ala Ala Gly Glu Val Glu Arg Leu Ile Gly His Pro Leu Pro
 370 375 380

Leu Ala Leu Asp Ala Ile Thr Gly Pro Glu Glu Glu Gly Gly Arg Leu
 385 390 395 400

Glu Thr Ile Leu Gly Trp Pro Leu Ala Glu Arg Thr Val Val Ile Pro
 405 410 415

Ser Ala Ile Pro Thr Asp Pro Arg Asn Val Gly Gly Asp Leu Asp Pro
 420 425 430

Ser Ser Ile Pro Asp Lys Glu Gln Ala Ile Ser Ala Leu Pro Asp Tyr
 435 440 445

Ala Ser Gln Pro Gly Lys Pro Pro Arg Glu Asp Leu Lys
 450 455 460

<210> SEQ ID NO 43
 <211> LENGTH: 107
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 43

Met Asp Ile Glu Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro
 1 5 10 15

Gly Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr
 20 25 30

Met His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile
 35 40 45

Tyr Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Gly Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Asn Ser Tyr Ser Leu Thr Ile Ser Ser Val Glu Ala
 65 70 75 80

Glu Asp Asp Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Lys His Pro Leu
 85 90 95

Thr Phe Gly Cys Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> SEQ ID NO 44
 <211> LENGTH: 358
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 44

-continued

```

Met Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Glu Lys Pro Gly
 1          5          10          15
Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly
 20          25          30
Tyr Thr Met Asn Trp Val Lys Gln Ser His Gly Lys Cys Leu Glu Trp
 35          40          45
Ile Gly Leu Ile Thr Pro Tyr Asn Gly Ala Ser Ser Tyr Asn Gln Lys
 50          55          60
Phe Arg Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala
 65          70          75          80
Tyr Met Asp Leu Leu Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe
 85          90          95
Cys Ala Arg Gly Gly Tyr Asp Gly Arg Gly Phe Asp Tyr Trp Gly Gln
100          105          110
Gly Thr Thr Val Thr Val Ser Ser Lys Ala Ser Gly Gly Arg His Arg
115          120          125
Gln Pro Arg Gly Trp Glu Gln Leu Gly Gly Ser Pro Thr Gly Ala Glu
130          135          140
Phe Leu Gly Asp Gly Gly Asp Val Ser Phe Ser Thr Arg Gly Thr Gln
145          150          155          160
Asn Trp Thr Val Glu Arg Leu Leu Gln Ala His Ala Gln Leu Glu Glu
165          170          175
Arg Gly Tyr Val Phe Val Gly Tyr His Gly Thr Phe Leu Glu Ala Ala
180          185          190
Gln Ser Ile Val Phe Gly Gly Val Arg Ala Ala Ser Gln Asp Leu Ala
195          200          205
Ala Ile Trp Ala Gly Phe Tyr Ile Ala Gly Asp Pro Ala Leu Ala Tyr
210          215          220
Gly Tyr Ala Gln Asp Gln Glu Pro Asp Ala Ala Gly Arg Ile Arg Asn
225          230          235          240
Gly Ala Leu Leu Arg Val Tyr Val Pro Ala Ser Ser Leu Pro Gly Phe
245          250          255
Tyr Arg Thr Ser Leu Thr Leu Ala Ala Pro Glu Ala Ala Gly Glu Val
260          265          270
Glu Arg Leu Ile Gly His Pro Leu Pro Leu Ala Leu Asp Ala Ile Thr
275          280          285
Gly Pro Glu Glu Glu Gly Gly Arg Leu Glu Thr Ile Leu Gly Trp Pro
290          295          300
Leu Ala Glu Arg Thr Val Val Ile Pro Ser Ala Ile Pro Thr Asp Pro
305          310          315          320
Arg Asn Val Gly Gly Asp Leu Asp Pro Ser Ser Ile Pro Asp Lys Glu
325          330          335
Gln Ala Ile Ser Ala Leu Pro Asp Tyr Ala Ser Gln Pro Gly Lys Pro
340          345          350
Pro Arg Glu Asp Leu Lys
355

```

<210> SEQ ID NO 45

<211> LENGTH: 119

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

-continued

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 45

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Gly Tyr
20 25 30
Thr Met Asn Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Leu Ile Thr Pro Tyr Asn Gly Ala Ser Ser Tyr Asn Gln Lys Phe
50 55 60
Arg Gly Lys Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Val Tyr
65 70 75 80
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Gly Gly Tyr Asp Gly Arg Gly Phe Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Leu Val Thr Val Ser Ser
115

<210> SEQ ID NO 46

<211> LENGTH: 106

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 46

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met
20 25 30
His Trp Tyr Gln Gln Lys Ser Gly Lys Ala Pro Lys Leu Leu Ile Tyr
35 40 45
Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu
65 70 75 80
Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Lys His Pro Leu Thr
85 90 95
Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105

<210> SEQ ID NO 47

<211> LENGTH: 30

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 47

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr
20 25 30

-continued

<210> SEQ ID NO 48
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 48

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys
20

<210> SEQ ID NO 49
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 49

Gly Tyr Thr Met Asn
1 5

<210> SEQ ID NO 50
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 50

Ser Ala Ser Ser Ser Val Ser Tyr Met His
1 5 10

<210> SEQ ID NO 51
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 51

Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly
1 5 10

<210> SEQ ID NO 52
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 52

Trp Tyr Gln Gln Lys Ser Gly Lys Ala Pro Lys Leu Leu Ile Tyr
1 5 10 15

<210> SEQ ID NO 53
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 53

-continued

Leu Ile Thr Pro Tyr Asn Gly Ala Ser Ser Tyr Asn Gln Lys Phe Arg
1 5 10 15

Gly

<210> SEQ ID NO 54
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 54

Asp Thr Ser Lys Leu Ala Ser
1 5

<210> SEQ ID NO 55
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 55

Lys Ala Thr Met Thr Val Asp Thr Ser Thr Ser Thr Val Tyr Met Glu
1 5 10 15

Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> SEQ ID NO 56
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 56

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys
20 25 30

<210> SEQ ID NO 57
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 57

Gly Gly Tyr Asp Gly Arg Gly Phe Asp Tyr
1 5 10

<210> SEQ ID NO 58
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 58

Gln Gln Trp Ser Lys His Pro Leu Thr
1 5

-continued

<210> SEQ ID NO 59
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 59

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
1 5 10

<210> SEQ ID NO 60
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 60

Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
1 5 10

<210> SEQ ID NO 61
<211> LENGTH: 115
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 61

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30

Glu Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45

Gly Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe
50 55 60

Lys Gly Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Thr Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr
100 105 110

Val Ser Ser
115

<210> SEQ ID NO 62
<211> LENGTH: 112
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 62

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Ser Leu Val His Ser
20 25 30

-continued

Asn Arg Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
35 40 45
Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
50 55 60
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65 70 75 80
Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn
85 90 95
Thr His Val Pro Pro Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
100 105 110

<210> SEQ ID NO 63
<211> LENGTH: 30
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 63

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
20 25 30

<210> SEQ ID NO 64
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 64

Asp Val Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
1 5 10 15
Glu Pro Ala Ser Ile Ser Cys
20

<210> SEQ ID NO 65
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 65

Asp Tyr Glu Met His
1 5

<210> SEQ ID NO 66
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 66

Arg Ser Ser Gln Ser Leu Val His Ser Asn Arg Asn Thr Tyr Leu His
1 5 10 15

<210> SEQ ID NO 67

-continued

<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 67

Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met Gly
1 5 10

<210> SEQ ID NO 68
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 68

Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr
1 5 10 15

<210> SEQ ID NO 69
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 69

Ala Leu Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Gln Lys Phe Lys
1 5 10 15

Gly

<210> SEQ ID NO 70
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 70

Lys Val Ser Asn Arg Phe Ser
1 5

<210> SEQ ID NO 71
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 71

Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu
1 5 10 15

Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg
20 25 30

<210> SEQ ID NO 72
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

-continued

<400> SEQUENCE: 72

Gly	Val	Pro	Asp	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr
1			5					10					15		
Leu	Lys	Ile	Ser	Arg	Val	Glu	Ala	Glu	Asp	Val	Gly	Val	Tyr	Tyr	Cys
			20					25					30		

<210> SEQ ID NO 73

<211> LENGTH: 6

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 73

Phe	Tyr	Ser	Tyr	Thr	Tyr
1			5		

<210> SEQ ID NO 74

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 74

Ser	Gln	Asn	Thr	His	Val	Pro	Pro	Thr
1				5				

<210> SEQ ID NO 75

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 75

Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser
1			5						10	

<210> SEQ ID NO 76

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 76

Phe	Gly	Gln	Gly	Thr	Lys	Leu	Glu	Ile	Lys
1				5					10

<210> SEQ ID NO 77

<211> LENGTH: 115

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 77

Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala
1				5					10					15	
Ser	Val	Thr	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr	Asp	Tyr
				20				25						30	

-continued

Glu Met His Trp Ile Arg Gln Pro Pro Gly Glu Gly Leu Glu Trp Ile
 35 40 45

Gly Ala Ile Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Glu Ser Phe
 50 55 60

Gln Asp Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr
 65 70 75 80

Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Thr Arg Phe Tyr Ser Tyr Thr Tyr Trp Gly Gln Gly Thr Leu Val Thr
 100 105 110

Val Ser Ser
 115

<210> SEQ ID NO 78
 <211> LENGTH: 112
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 78

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly
 1 5 10 15

Glu Pro Ala Ser Ile Ser Cys Gln Ala Ser Glu Ser Leu Val His Ser
 20 25 30

Asn Arg Asn Thr Tyr Leu His Trp Tyr Leu Gln Lys Pro Gly Gln Ser
 35 40 45

Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro
 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Ser Gln Asn
 85 90 95

Thr His Val Pro Pro Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Glu
 100 105 110

<210> SEQ ID NO 79
 <211> LENGTH: 30
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 79

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

Ser Val Thr Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
 20 25 30

<210> SEQ ID NO 80
 <211> LENGTH: 23
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 80

Asp Ile Val Met Thr Gln Ser Pro Leu Ser Leu Pro Val Thr Pro Gly

-continued

1	5	10	15
---	---	----	----

Glu Pro Ala Ser Ile Ser Cys
20

<210> SEQ ID NO 81
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 81

Asp Tyr Glu Met His
1 5

<210> SEQ ID NO 82
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 82

Gln Ala Ser Glu Ser Leu Val His Ser Asn Arg Asn Thr Tyr Leu His
1 5 10 15

<210> SEQ ID NO 83
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 83

Trp Ile Arg Gln Pro Pro Gly Glu Gly Leu Glu Trp Ile Gly
1 5 10

<210> SEQ ID NO 84
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 84

Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr
1 5 10 15

<210> SEQ ID NO 85
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 85

Ala Ile Asp Pro Lys Thr Gly Asp Thr Ala Tyr Ser Glu Ser Phe Gln
1 5 10 15

Asp

<210> SEQ ID NO 86
<211> LENGTH: 7
<212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 86

Lys Val Ser Asn Arg Phe Ser
1 5

<210> SEQ ID NO 87
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 87

Arg Val Thr Leu Thr Ala Asp Lys Ser Thr Ser Thr Ala Tyr Met Glu
1 5 10 15

Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys Thr Arg
20 25 30

<210> SEQ ID NO 88
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 88

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
1 5 10 15

Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys
20 25 30

<210> SEQ ID NO 89
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 89

Phe Tyr Ser Tyr Thr Tyr
1 5

<210> SEQ ID NO 90
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 90

Ser Gln Asn Thr His Val Pro Pro Thr
1 5

<210> SEQ ID NO 91
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 91

-continued

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
1 5 10

<210> SEQ ID NO 92
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 92

Phe Gly Gln Gly Thr Lys Val Glu Ile Glu
1 5 10

<210> SEQ ID NO 93
<211> LENGTH: 124
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 93

Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Ser Val Lys Val Ser Cys Lys Thr Ser Arg Tyr Thr Phe Thr Glu Tyr
20 25 30

Thr Ile His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile
35 40 45

Gly Gly Ile Asn Pro Asn Asn Gly Ile Pro Asn Tyr Asn Gln Lys Phe
50 55 60

Lys Gly Arg Val Thr Ile Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Arg Arg Ile Ala Tyr Gly Tyr Asp Glu Gly His Ala Met Asp
100 105 110

Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> SEQ ID NO 94
<211> LENGTH: 113
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 94

Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1 5 10 15

Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20 25 30

Arg Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45

Pro Pro Lys Leu Leu Ile Phe Trp Ala Ser Thr Arg Glu Ser Gly Val
50 55 60

Pro Asp Arg Phe Ser Gly Ser Gly Phe Gly Thr Asp Phe Thr Leu Thr
65 70 75 80

-continued

Ile	Ser	Ser	Leu	Gln	Ala	Glu	Asp	Val	Ala	Val	Tyr	Tyr	Cys	Gln	Gln
			85						90					95	

Tyr	Phe	Ser	Tyr	Pro	Leu	Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile
			100					105					110		

Lys

<210> SEQ ID NO 95
<211> LENGTH: 30
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 95

Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	Ala
1			5						10					15	

Ser	Val	Lys	Val	Ser	Cys	Lys	Thr	Ser	Arg	Tyr	Thr	Phe	Thr
			20				25						30

<210> SEQ ID NO 96
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 96

Asp	Ile	Val	Met	Thr	Gln	Ser	Pro	Asp	Ser	Leu	Ala	Val	Ser	Leu	Gly
1			5						10					15	

Glu	Arg	Ala	Thr	Ile	Asn	Cys
			20			

<210> SEQ ID NO 97
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 97

Glu	Tyr	Thr	Ile	His
1			5	

<210> SEQ ID NO 98
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 98

Lys	Ser	Ser	Gln	Ser	Leu	Leu	Tyr	Ser	Arg	Asn	Gln	Lys	Asn	Tyr	Leu
1			5						10					15	

Ala

<210> SEQ ID NO 99
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

-continued

<400> SEQUENCE: 99

Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp Ile Gly
1 5 10

<210> SEQ ID NO 100

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 100

Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Phe
1 5 10 15

<210> SEQ ID NO 101

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 101

Gly Ile Asn Pro Asn Asn Gly Ile Pro Asn Tyr Asn Gln Lys Phe Lys
1 5 10 15

Gly

<210> SEQ ID NO 102

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 102

Trp Ala Ser Thr Arg Glu Ser
1 5

<210> SEQ ID NO 103

<211> LENGTH: 32

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 103

Arg Val Thr Ile Thr Val Asp Thr Ser Ala Ser Thr Ala Tyr Met Glu
1 5 10 15

Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
20 25 30

<210> SEQ ID NO 104

<211> LENGTH: 32

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 104

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Phe Gly Thr Asp Phe Thr
1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys

-continued

20	25	30
----	----	----

<210> SEQ ID NO 105
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 105

Arg Arg Ile Ala Tyr Gly Tyr Asp Glu Gly His Ala Met Asp Tyr
1 5 10 15

<210> SEQ ID NO 106
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 106

Gln Gln Tyr Phe Ser Tyr Pro Leu Thr
1 5

<210> SEQ ID NO 107
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 107

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
1 5 10

<210> SEQ ID NO 108
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 108

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
1 5 10

<210> SEQ ID NO 109
<211> LENGTH: 115
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 109

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Thr
1 5 10 15

Ser Val Arg Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr
20 25 30

Thr Ile His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
35 40 45

Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe
50 55 60

-continued

Glu Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95
Ala Ala Gly Trp Asn Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr
100 105 110
Val Ser Ser
115

<210> SEQ ID NO 110
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 110

Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
1 5 10 15
Asp Arg Val Ser Ile Ile Cys Lys Ala Ser Gln Asp Val Gly Thr Ala
20 25 30
Val Asp Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
35 40 45
Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Asn Val Gln Ser
65 70 75 80
Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu
85 90 95
Thr Phe Gly Ala Gly Thr Met Leu Asp Leu Lys
100 105

<210> SEQ ID NO 111
<211> LENGTH: 30
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 111

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Thr
1 5 10 15
Ser Val Arg Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr
20 25 30

<210> SEQ ID NO 112
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 112

Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
1 5 10 15
Asp Arg Val Ser Ile Ile Cys
20

-continued

<210> SEQ ID NO 113
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 113

Glu Tyr Thr Ile His
1 5

<210> SEQ ID NO 114
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 114

Lys Ala Ser Gln Asp Val Gly Thr Ala Val Asp
1 5 10

<210> SEQ ID NO 115
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 115

Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly
1 5 10

<210> SEQ ID NO 116
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 116

Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr
1 5 10 15

<210> SEQ ID NO 117
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 117

Asn Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe Glu
1 5 10 15

Asp

<210> SEQ ID NO 118
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 118

-continued

Trp Ala Ser Thr Arg His Thr
1 5

<210> SEQ ID NO 119
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 119

Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu
1 5 10 15
Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Ala
20 25 30

<210> SEQ ID NO 120
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 120

Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr
1 5 10 15
Leu Thr Ile Thr Asn Val Gln Ser Glu Asp Leu Ala Asp Tyr Phe Cys
20 25 30

<210> SEQ ID NO 121
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 121

Gly Trp Asn Phe Asp Tyr
1 5

<210> SEQ ID NO 122
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 122

Gln Gln Tyr Asn Ser Tyr Pro Leu Thr
1 5

<210> SEQ ID NO 123
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 123

Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
1 5 10

<210> SEQ ID NO 124

-continued

<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 124

Phe Gly Ala Gly Thr Met Leu Asp Leu Lys
1 5 10

<210> SEQ ID NO 125
<211> LENGTH: 119
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 125

Asp Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Leu Gly Gly
1 5 10 15
Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30
Tyr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Leu Val
35 40 45
Ala Ala Ile Asn Ser Asp Gly Gly Ile Thr Tyr Tyr Leu Asp Thr Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu Phe Tyr Cys
85 90 95
Ala Arg His Arg Ser Gly Tyr Phe Ser Met Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Ser Val Thr Val Ser Ser
115

<210> SEQ ID NO 126
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 126

Asp Ile Val Met Thr Gln Ser Gln Arg Phe Met Ser Thr Thr Val Gly
1 5 10 15
Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Val Ser Ala
20 25 30
Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
35 40 45
Tyr Ser Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Met Gln Ser
65 70 75 80
Glu Asp Leu Ala Asp Phe Phe Cys Gln Gln Tyr Ser Asn Tyr Pro Trp
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105

-continued

<210> SEQ ID NO 127
<211> LENGTH: 30
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 127

Asp Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Leu Gly Gly
1 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser
 20 25 30

<210> SEQ ID NO 128
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 128

Asp Ile Val Met Thr Gln Ser Gln Arg Phe Met Ser Thr Thr Val Gly
1 5 10 15

Asp Arg Val Ser Ile Thr Cys
 20

<210> SEQ ID NO 129
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 129

Asn Tyr Tyr Met Ser
1 5

<210> SEQ ID NO 130
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 130

Lys Ala Ser Gln Asn Val Val Ser Ala Val Ala
1 5 10

<210> SEQ ID NO 131
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 131

Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Leu Val Ala
1 5 10

<210> SEQ ID NO 132
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 132

Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile Tyr
1 5 10 15

<210> SEQ ID NO 133
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 133

Ala Ile Asn Ser Asp Gly Gly Ile Thr Tyr Tyr Leu Asp Thr Val Lys
1 5 10 15

Gly

<210> SEQ ID NO 134
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 134

Ser Ala Ser Asn Arg Tyr Thr
1 5

<210> SEQ ID NO 135
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 135

Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu Gln
1 5 10 15

Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu Phe Tyr Cys Ala Arg
20 25 30

<210> SEQ ID NO 136
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 136

Gly Val Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr
1 5 10 15

Leu Thr Ile Ser Asn Met Gln Ser Glu Asp Leu Ala Asp Phe Phe Cys
20 25 30

<210> SEQ ID NO 137
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

-continued

<400> SEQUENCE: 137

His Arg Ser Gly Tyr Phe Ser Met Asp Tyr
1 5 10

<210> SEQ ID NO 138
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 138

Gln Gln Tyr Ser Asn Tyr Pro Trp Thr
1 5

<210> SEQ ID NO 139
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 139

Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
1 5 10

<210> SEQ ID NO 140
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 140

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
1 5 10

<210> SEQ ID NO 141
<211> LENGTH: 117
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 141

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Ser Gly Ala
1 5 10 15

Ser Val Asn Leu Ser Cys Arg Ala Ser Gly Tyr Thr Phe Thr Arg Tyr
20 25 30

Trp Met Leu Trp Val Arg Gln Arg Pro Gly His Gly Leu Glu Trp Val
35 40 45

Gly Glu Ile Asn Pro Arg Asn Asp Arg Thr Asn Tyr Asn Glu Lys Phe
50 55 60

Lys Thr Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Thr Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
85 90 95

Ala Leu Gly Gly Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser
100 105 110

Val Thr Val Ser Ser

-continued

115

<210> SEQ ID NO 142
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 142

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Phe Leu Gly
1 5 10 15
Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile
35 40 45
Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln
65 70 75 80
Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105

<210> SEQ ID NO 143
<211> LENGTH: 30
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 143

Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Ser Gly Ala
1 5 10 15
Ser Val Asn Leu Ser Cys Arg Ala Ser Gly Tyr Thr Phe Thr
20 25 30

<210> SEQ ID NO 144
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 144

Asp Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Phe Leu Gly
1 5 10 15
Asp Arg Val Thr Ile Ser Cys
20

<210> SEQ ID NO 145
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 145

Arg Tyr Trp Met Leu

-continued

1 5

<210> SEQ ID NO 146
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 146

Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn
1 5 10

<210> SEQ ID NO 147
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 147

Trp Val Arg Gln Arg Pro Gly His Gly Leu Glu Trp Val Gly
1 5 10

<210> SEQ ID NO 148
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 148

Trp Tyr Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr
1 5 10 15

<210> SEQ ID NO 149
<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 149

Glu Ile Asn Pro Arg Asn Asp Arg Thr Asn Tyr Asn Glu Lys Phe Lys
1 5 10 15

Thr

<210> SEQ ID NO 150
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 150

Tyr Thr Ser Arg Leu His Ser
1 5

<210> SEQ ID NO 151
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

-continued

<400> SEQUENCE: 151

Lys Ala Thr Leu Thr Val Asp Arg Ser Ser Ser Thr Ala Tyr Met Gln
1 5 10 15

Leu Thr Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Leu
20 25 30

<210> SEQ ID NO 152

<211> LENGTH: 32

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 152

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Ser
1 5 10 15

Leu Thr Ile Ser Asn Leu Glu Gln Glu Asp Phe Ala Thr Tyr Phe Cys
20 25 30

<210> SEQ ID NO 153

<211> LENGTH: 8

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 153

Gly Gly Gly Tyr Ala Met Asp Tyr
1 5

<210> SEQ ID NO 154

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 154

Gln Gln Gly Asn Thr Leu Pro Trp Thr
1 5

<210> SEQ ID NO 155

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 155

Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser
1 5 10

<210> SEQ ID NO 156

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 156

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
1 5 10

-continued

<210> SEQ ID NO 157
<211> LENGTH: 117
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 157

Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Arg Ala Ser Gly Tyr Thr Phe Thr Arg Tyr
 20 25 30

Trp Met Leu Trp Val Arg Gln Arg Pro Gly His Gly Leu Glu Trp Val
 35 40 45

Gly Glu Ile Asn Pro Arg Asn Asp Arg Thr Asn Tyr Asn Glu Lys Phe
 50 55 60

Lys Thr Arg Phe Thr Ile Ser Val Asp Arg Ser Lys Ser Thr Ala Tyr
65 70 75 80

Leu Gln Met Asp Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys
 85 90 95

Ala Leu Gly Gly Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu
 100 105 110

Val Thr Val Ser Ser
 115

<210> SEQ ID NO 158
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 158

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
 20 25 30

Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
 35 40 45

Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp
 85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

<210> SEQ ID NO 159
<211> LENGTH: 30
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Syntheti

<400> SEQUENCE: 159

-continued

Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Arg Ala Ser Gly Tyr Thr Phe Thr
20 25 30

<210> SEQ ID NO 160
<211> LENGTH: 23
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Syntheti

<400> SEQUENCE: 160

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys
20

<210> SEQ ID NO 161
<211> LENGTH: 5
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 161

Arg Tyr Trp Met Leu
1 5

<210> SEQ ID NO 162
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 162

Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn
1 5 10

<210> SEQ ID NO 163
<211> LENGTH: 14
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 163

Trp Val Arg Gln Arg Pro Gly His Gly Leu Glu Trp Val Gly
1 5 10

<210> SEQ ID NO 164
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 164

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
1 5 10 15

<210> SEQ ID NO 165

-continued

<211> LENGTH: 17
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 165

Glu Ile Asn Pro Arg Asn Asp Arg Thr Asn Tyr Asn Glu Lys Phe Lys
1 5 10 15

Thr

<210> SEQ ID NO 166
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 166

Tyr Thr Ser Arg Leu His Ser
1 5

<210> SEQ ID NO 167
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 167

Arg Phe Thr Ile Ser Val Asp Arg Ser Lys Ser Thr Ala Tyr Leu Gln
1 5 10 15

Met Asp Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys Ala Leu
20 25 30

<210> SEQ ID NO 168
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 168

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys
20 25 30

<210> SEQ ID NO 169
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 169

Gly Gly Gly Tyr Ala Met Asp Tyr
1 5

<210> SEQ ID NO 170
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 170

Gln Gln Gly Asn Thr Leu Pro Trp Thr
1 5

<210> SEQ ID NO 171
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 171

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
1 5 10

<210> SEQ ID NO 172
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 172

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
1 5 10

<210> SEQ ID NO 173
<211> LENGTH: 117
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 173

Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Arg Ala Ser Gly Tyr Thr Phe Thr Arg Tyr
20 25 30

Trp Met Leu Trp Val Arg Gln Arg Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Glu Ile Asn Pro Arg Asn Asp Arg Thr Asn Tyr Asn Glu Lys Phe
50 55 60

Lys Thr Arg Phe Thr Ile Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asp Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys
85 90 95

Ala Leu Gly Gly Gly Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110

Val Thr Val Ser Ser
115

<210> SEQ ID NO 174
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

-continued

<400> SEQUENCE: 174

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr
20 25 30
Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile
35 40 45
Tyr Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80
Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100 105

<210> SEQ ID NO 175

<211> LENGTH: 30

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 175

Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Ser Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Arg Ala Ser Gly Tyr Thr Phe Thr
20 25 30

<210> SEQ ID NO 176

<211> LENGTH: 23

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 176

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Asp Arg Val Thr Ile Thr Cys
20

<210> SEQ ID NO 177

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 177

Arg Tyr Trp Met Leu
1 5

<210> SEQ ID NO 178

<211> LENGTH: 11

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

-continued

<400> SEQUENCE: 178

Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn
1 5 10

<210> SEQ ID NO 179

<211> LENGTH: 14

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 179

Trp Val Arg Gln Arg Pro Gly Lys Gly Leu Glu Trp Val Ala
1 5 10

<210> SEQ ID NO 180

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 180

Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr
1 5 10 15

<210> SEQ ID NO 181

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 181

Glu Ile Asn Pro Arg Asn Asp Arg Thr Asn Tyr Asn Glu Lys Phe Lys
1 5 10 15

Thr

<210> SEQ ID NO 182

<211> LENGTH: 7

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 182

Tyr Thr Ser Arg Leu His Ser
1 5

<210> SEQ ID NO 183

<211> LENGTH: 32

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 183

Arg Phe Thr Ile Ser Val Asp Arg Ser Lys Asn Thr Leu Tyr Leu Gln
1 5 10 15

Met Asp Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys Ala Leu
20 25 30

-continued

<210> SEQ ID NO 184
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 184

Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr
1 5 10 15

Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys
20 25 30

<210> SEQ ID NO 185
<211> LENGTH: 8
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 185

Gly Gly Gly Tyr Ala Met Asp Tyr
1 5

<210> SEQ ID NO 186
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 186

Gln Gln Gly Asn Thr Leu Pro Trp Thr
1 5

<210> SEQ ID NO 187
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 187

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
1 5 10

<210> SEQ ID NO 188
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 188

Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
1 5 10

<210> SEQ ID NO 189
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 189

-continued

Leu Val Ala Leu Tyr Leu Ala Ala Arg Leu Ser Trp Asn Gln Val
1 5 10 15

<210> SEQ ID NO 190
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 190

Gly Ala Leu Leu Arg Val Tyr Val Pro Arg Ser Ser Leu Pro Gly
1 5 10 15

<210> SEQ ID NO 191
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 191

Ile Arg Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Arg Ser Ser
1 5 10 15

<210> SEQ ID NO 192
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 192

Arg Gln Pro Arg Gly Trp Glu Gln Leu Glu Gln Cys Gly Tyr Pro
1 5 10 15

<210> SEQ ID NO 193
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 193

Leu Pro Leu Glu Thr Phe Thr Arg His Arg Gln Pro Arg Gly Trp
1 5 10 15

<210> SEQ ID NO 194
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 194

Trp Arg Gly Phe Tyr Ile Ala Gly Asp Pro Ala Leu Ala Tyr Gly
1 5 10 15

<210> SEQ ID NO 195
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

-continued

<400> SEQUENCE: 195

Gly Pro Glu Glu Glu Gly Gly Arg Leu Glu Thr Ile Leu Gly Trp Pro
1 5 10 15

Leu Ala

<210> SEQ ID NO 196

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 196

Thr Val Glu Arg Leu Leu Gln Ala His Arg Gln Leu Glu Glu Arg
1 5 10 15

<210> SEQ ID NO 197

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 197

Phe Val Gly Tyr His Gly Thr Phe Leu Glu Ala Ala Gln Ser Ile Val
1 5 10 15

Phe Gly

<210> SEQ ID NO 198

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 198

Ile Arg Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Arg Ser Ser
1 5 10 15

<210> SEQ ID NO 199

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 199

Ala Arg Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Arg Ser Ser
1 5 10 15

<210> SEQ ID NO 200

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 200

Ile Ala Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Arg Ser Ser
1 5 10 15

-continued

<210> SEQ ID NO 201
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 201

Ile	Arg	Ala	Gly	Ala	Leu	Leu	Arg	Val	Tyr	Val	Pro	Arg	Ser	Ser
1				5					10				15	

<210> SEQ ID NO 202
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 202

Ile	Arg	Asn	Ala	Ala	Leu	Leu	Arg	Val	Tyr	Val	Pro	Arg	Ser	Ser
1				5					10				15	

<210> SEQ ID NO 203
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 203

Ile	Arg	Asn	Gly	Ala	Ala	Leu	Arg	Val	Tyr	Val	Pro	Arg	Ser	Ser
1				5					10				15	

<210> SEQ ID NO 204
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 204

Ile	Arg	Asn	Gly	Ala	Leu	Ala	Arg	Val	Tyr	Val	Pro	Arg	Ser	Ser
1				5					10				15	

<210> SEQ ID NO 205
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 205

Ile	Arg	Asn	Gly	Ala	Leu	Leu	Ala	Val	Tyr	Val	Pro	Arg	Ser	Ser
1				5					10				15	

<210> SEQ ID NO 206
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 206

Ile	Arg	Asn	Gly	Ala	Leu	Leu	Arg	Ala	Tyr	Val	Pro	Arg	Ser	Ser
1				5					10				15	

-continued

<210> SEQ ID NO 207
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 207

Ile Arg Asn Gly Ala Leu Leu Arg Val Ala Val Pro Arg Ser Ser
1 5 10 15

<210> SEQ ID NO 208
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 208

Ile Arg Asn Gly Ala Leu Leu Arg Val Tyr Ala Pro Arg Ser Ser
1 5 10 15

<210> SEQ ID NO 209
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 209

Ile Arg Asn Gly Ala Leu Leu Arg Val Tyr Val Ala Arg Ser Ser
1 5 10 15

<210> SEQ ID NO 210
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 210

Ile Arg Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Ala Ser Ser
1 5 10 15

<210> SEQ ID NO 211
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 211

Ile Arg Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Arg Ala Ser
1 5 10 15

<210> SEQ ID NO 212
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 212

-continued

Ile	Arg	Asn	Gly	Ala	Leu	Leu	Arg	Val	Tyr	Val	Pro	Arg	Ser	Ala
1			5						10				15	

<210> SEQ ID NO 213
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 213

Gly	Ala	Leu	Leu	Arg	Val	Tyr	Val	Pro	Arg	Ser	Ser	Leu	Pro	Gly
1			5						10				15	

<210> SEQ ID NO 214
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 214

Ala	Ala	Leu	Leu	Arg	Val	Tyr	Val	Pro	Arg	Ser	Ser	Leu	Pro	Gly
1			5						10				15	

<210> SEQ ID NO 215
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 215

Gly	Gly	Leu	Leu	Arg	Val	Tyr	Val	Pro	Arg	Ser	Ser	Leu	Pro	Gly
1			5						10				15	

<210> SEQ ID NO 216
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 216

Gly	Ala	Ala	Leu	Arg	Val	Tyr	Val	Pro	Arg	Ser	Ser	Leu	Pro	Gly
1			5						10				15	

<210> SEQ ID NO 217
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 217

Gly	Ala	Leu	Ala	Arg	Val	Tyr	Val	Pro	Arg	Ser	Ser	Leu	Pro	Gly
1			5						10				15	

<210> SEQ ID NO 218
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

-continued

<400> SEQUENCE: 218

Gly Ala Leu Leu Ala Val Tyr Val Pro Arg Ser Ser Leu Pro Gly
1 5 10 15

<210> SEQ ID NO 219

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 219

Gly Ala Leu Leu Arg Ala Tyr Val Pro Arg Ser Ser Leu Pro Gly
1 5 10 15

<210> SEQ ID NO 220

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 220

Gly Ala Leu Leu Arg Val Ala Val Pro Arg Ser Ser Leu Pro Gly
1 5 10 15

<210> SEQ ID NO 221

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 221

Gly Ala Leu Leu Arg Val Tyr Ala Pro Arg Ser Ser Leu Pro Gly
1 5 10 15

<210> SEQ ID NO 222

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 222

Gly Ala Leu Leu Arg Val Tyr Val Ala Arg Ser Ser Leu Pro Gly
1 5 10 15

<210> SEQ ID NO 223

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 223

Gly Ala Leu Leu Arg Val Tyr Val Pro Ala Ser Ser Leu Pro Gly
1 5 10 15

<210> SEQ ID NO 224

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

-continued

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 224

Gly Ala Leu Leu Arg Val Tyr Val Pro Arg Ala Ser Leu Pro Gly
1 5 10 15

<210> SEQ ID NO 225

<211> LENGTH: 12

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 225

Gly Ala Leu Leu Arg Val Tyr Val Pro Arg Ser Ala
1 5 10

<210> SEQ ID NO 226

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 226

Gly Ala Leu Leu Arg Val Tyr Val Pro Arg Ser Ser Ala Pro Gly
1 5 10 15

<210> SEQ ID NO 227

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 227

Gly Ala Leu Leu Arg Val Tyr Val Pro Arg Ser Ser Leu Ala Gly
1 5 10 15

<210> SEQ ID NO 228

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 228

Trp Arg Gly Phe Tyr Ile Ala Gly Asp Pro Ala Leu Ala Tyr Gly
1 5 10 15

<210> SEQ ID NO 229

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 229

Trp Arg Gly Ala Tyr Ile Ala Gly Asp Pro Ala Leu Ala Tyr Gly
1 5 10 15

<210> SEQ ID NO 230

<211> LENGTH: 15

<212> TYPE: PRT

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 230

Trp Arg Gly Phe Ala Ile Ala Gly Asp Pro Ala Leu Ala Tyr Gly
1 5 10 15

<210> SEQ ID NO 231
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 231

Trp Arg Gly Phe Tyr Ala Ala Gly Asp Pro Ala Leu Ala Tyr Gly
1 5 10 15

<210> SEQ ID NO 232
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 232

Trp Arg Gly Phe Tyr Ile Gly Gly Asp Pro Ala Leu Ala Tyr Gly
1 5 10 15

<210> SEQ ID NO 233
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 233

Trp Arg Gly Phe Tyr Ile Ala Gly Asp Ala Ala Leu Ala Tyr Gly
1 5 10 15

<210> SEQ ID NO 234
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 234

Trp Arg Gly Phe Tyr Ile Ala Gly Asp Pro Gly Leu Ala Tyr Gly
1 5 10 15

<210> SEQ ID NO 235
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 235

Trp Arg Gly Phe Tyr Ile Ala Gly Asp Pro Ala Ala Ala Tyr Gly
1 5 10 15

<210> SEQ ID NO 236

-continued

<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 236

Trp Arg Gly Phe Tyr Ile Ala Gly Asp Pro Ala Leu Gly Tyr Gly
1 5 10 15

<210> SEQ ID NO 237
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 237

Trp Arg Gly Phe Tyr Ile Ala Gly Asp Pro Ala Leu Ala Ala Gly
1 5 10 15

<210> SEQ ID NO 238
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 238

Gly Pro Glu Glu Glu Gly Gly Arg Leu Glu Thr Ile Leu Gly Trp Pro
1 5 10 15

Leu Ala

<210> SEQ ID NO 239
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 239

Gly Pro Glu Ala Glu Gly Gly Arg Leu Glu Thr Ile Leu Gly Trp Pro
1 5 10 15

Leu Ala

<210> SEQ ID NO 240
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 240

Gly Pro Glu Glu Ala Gly Gly Arg Leu Glu Thr Ile Leu Gly Trp Pro
1 5 10 15

Leu Ala

<210> SEQ ID NO 241
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

-continued

<400> SEQUENCE: 241

Gly Pro Glu Glu Glu Gly Gly Ala Leu Glu Thr Ile Leu Gly Trp Pro
1 5 10 15

Leu Ala

<210> SEQ ID NO 242

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 242

Gly Pro Glu Glu Glu Gly Gly Arg Ala Glu Thr Ile Leu Gly Trp Pro
1 5 10 15

Leu Ala

<210> SEQ ID NO 243

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 243

Gly Pro Glu Glu Glu Gly Gly Arg Leu Glu Ala Ile Leu Gly Trp Pro
1 5 10 15

Leu Ala

<210> SEQ ID NO 244

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 244

Gly Pro Glu Glu Glu Gly Gly Arg Leu Glu Thr Ala Leu Gly Trp Pro
1 5 10 15

Leu Ala

<210> SEQ ID NO 245

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 245

Gly Pro Glu Glu Glu Gly Gly Arg Leu Glu Thr Ile Ala Gly Trp Pro
1 5 10 15

Leu Ala

<210> SEQ ID NO 246

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

-continued

<400> SEQUENCE: 246

Gly Pro Glu Glu Glu Gly Gly Arg Leu Glu Thr Ile Leu Gly Ala Pro
1 5 10 15

Leu Ala

<210> SEQ ID NO 247

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 247

Gly Pro Glu Glu Glu Gly Gly Arg Leu Glu Thr Ile Leu Gly Trp Ala
1 5 10 15

Leu Ala

<210> SEQ ID NO 248

<211> LENGTH: 18

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 248

Gly Pro Glu Glu Glu Gly Gly Arg Leu Glu Thr Ile Leu Gly Trp Pro
1 5 10 15

Ala Ala

<210> SEQ ID NO 249

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 249

Thr Val Glu Arg Leu Leu Gln Ala His Arg Gln Leu Glu Glu Arg
1 5 10 15

<210> SEQ ID NO 250

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 250

Thr Val Glu Ala Leu Leu Gln Ala His Arg Gln Leu Glu Glu Arg
1 5 10 15

<210> SEQ ID NO 251

<211> LENGTH: 15

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 251

Thr Val Glu Arg Ala Leu Gln Ala His Arg Gln Leu Glu Glu Arg
1 5 10 15

-continued

<210> SEQ ID NO 252
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 252

Thr	Val	Glu	Arg	Leu	Ala	Gln	Ala	His	Arg	Gln	Leu	Glu	Glu	Arg
1				5					10				15	

<210> SEQ ID NO 253
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 253

Thr	Val	Glu	Arg	Leu	Leu	Gln	Gly	His	Arg	Gln	Leu	Glu	Glu	Arg
1				5					10				15	

<210> SEQ ID NO 254
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 254

Thr	Val	Glu	Arg	Leu	Leu	Gln	Ala	His	Ala	Gln	Leu	Glu	Glu	Arg
1				5					10				15	

<210> SEQ ID NO 255
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 255

Thr	Val	Glu	Arg	Leu	Leu	Gln	Ala	His	Arg	Gln	Ala	Glu	Glu	Arg
1				5					10				15	

<210> SEQ ID NO 256
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 256

Thr	Val	Glu	Arg	Leu	Leu	Gln	Ala	His	Arg	Gln	Leu	Ala	Glu	Arg
1				5					10				15	

<210> SEQ ID NO 257
<211> LENGTH: 15
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 257

Thr	Val	Glu	Arg	Leu	Leu	Gln	Ala	His	Arg	Gln	Leu	Glu	Glu	Ala
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

-continued

1	5	10	15
---	---	----	----

<210> SEQ ID NO 258
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 258

Phe Val Gly Tyr His Gly Thr Phe Leu Glu Ala Ala Gln Ser Ile Val
1 5 10 15

Phe Gly

<210> SEQ ID NO 259
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 259

Ala Val Gly Tyr His Gly Thr Phe Leu Glu Ala Ala Gln Ser Ile Val
1 5 10 15

Phe Gly

<210> SEQ ID NO 260
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 260

Phe Ala Gly Tyr His Gly Thr Phe Leu Glu Ala Ala Gln Ser Ile Val
1 5 10 15

Phe Gly

<210> SEQ ID NO 261
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 261

Phe Val Ala Tyr His Gly Thr Phe Leu Glu Ala Ala Gln Ser Ile Val
1 5 10 15

Phe Gly

<210> SEQ ID NO 262
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 262

Phe Val Gly Ala His Gly Thr Phe Leu Glu Ala Ala Gln Ser Ile Val
1 5 10 15

Phe Gly

-continued

<210> SEQ ID NO 263
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 263

Phe Val Gly Tyr Ala Gly Thr Phe Leu Glu Ala Ala Gln Ser Ile Val
1 5 10 15

Phe Gly

<210> SEQ ID NO 264
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 264

Phe Val Gly Tyr His Gly Ala Phe Leu Glu Ala Ala Gln Ser Ile Val
1 5 10 15

Phe Gly

<210> SEQ ID NO 265
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 265

Phe Val Gly Tyr His Gly Thr Ala Leu Glu Ala Ala Gln Ser Ile Val
1 5 10 15

Phe Gly

<210> SEQ ID NO 266
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 266

Phe Val Gly Tyr His Gly Thr Phe Ala Glu Ala Ala Gln Ser Ile Val
1 5 10 15

Phe Gly

<210> SEQ ID NO 267
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 267

Phe Val Gly Tyr His Gly Thr Phe Leu Glu Gly Ala Gln Ser Ile Val
1 5 10 15

Phe Gly

-continued

<210> SEQ ID NO 268
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 268

Phe Val Gly Tyr His Gly Thr Phe Leu Glu Ala Gly Gln Ser Ile Val
1 5 10 15

Phe Gly

<210> SEQ ID NO 269
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 269

Phe Val Gly Tyr His Gly Thr Phe Leu Glu Ala Ala Gln Ala Ile Val
1 5 10 15

Phe Gly

<210> SEQ ID NO 270
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 270

Phe Val Gly Tyr His Gly Thr Phe Leu Glu Ala Ala Gln Ser Ala Val
1 5 10 15

Phe Gly

<210> SEQ ID NO 271
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 271

Phe Val Gly Tyr His Gly Thr Phe Leu Glu Ala Ala Gln Ser Ile Ala
1 5 10 15

Phe Gly

<210> SEQ ID NO 272
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 272

Phe Val Gly Tyr His Gly Thr Phe Leu Glu Ala Ala Gln Ser Ile Val
1 5 10 15

Ala Gly

-continued

<210> SEQ ID NO 273
<211> LENGTH: 42
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 273

Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Lys Ala Ser
1 5 10 15

Gly Gly Arg His Arg Gln Pro Arg Gly Trp Glu Gln Leu Gly Gly Ser
20 25 30

Pro Thr Gly Ala Glu Phe Leu Gly Asp Gly
35 40

<210> SEQ ID NO 274
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 274

Trp Glu Gln Leu Gly Gly Ser Pro Thr
1 5

<210> SEQ ID NO 275
<211> LENGTH: 9
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 275

Val Glu Pro Lys Ser Cys Lys Ala Ser
1 5

<210> SEQ ID NO 276
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 276

Asp Lys Thr His
1

<210> SEQ ID NO 277
<211> LENGTH: 3
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 277

Gly Gly Gly
1

<210> SEQ ID NO 278
<211> LENGTH: 49
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 278

Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr
1 5 10 15

His Lys Ala Ser Gly Gly Arg His Arg Gln Pro Arg Gly Trp Glu Gln
20 25 30

Leu Gly Gly Gly Gly Gly Ser Pro Thr Gly Ala Glu Phe Leu Gly Asp
35 40 45

Gly

<210> SEQ ID NO 279

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 279

Trp Glu Gln Leu Gly Gly Gly Gly Gly
1 5

<210> SEQ ID NO 280

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 280

Leu Gly Gly Gly Gly Gly Ser Pro Thr
1 5

<210> SEQ ID NO 281

<211> LENGTH: 19

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 281

Lys Ala Ser Gly Gly Arg His Arg Gln Pro Arg Gly Trp Glu Gln Leu
1 5 10 15

Gly Gly Ser

<210> SEQ ID NO 282

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 282

Asp Lys Thr His Lys Ala Ser Gly Gly
1 5

<210> SEQ ID NO 283

<211> LENGTH: 3

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

-continued

<400> SEQUENCE: 283

Gly Gly Ser
1

<210> SEQ ID NO 284

<211> LENGTH: 6

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 284

Gly Gly Gly Gly Gly Ser
1 5

<210> SEQ ID NO 285

<211> LENGTH: 219

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 285

Pro Thr Gly Ala Glu Phe Leu Gly Asp Gly Gly Asp Val Ser Phe Ser
1 5 10 15Thr Arg Gly Thr Gln Asn Trp Thr Val Glu Arg Leu Leu Gln Ala His
20 25 30Ala Gln Leu Glu Glu Arg Gly Tyr Val Phe Val Gly Tyr His Gly Thr
35 40 45Ala Leu Glu Ala Ala Gln Ser Ile Val Phe Gly Gly Val Ala Ala Arg
50 55 60Ser Gln Asp Leu Ala Ala Ile Trp Ala Gly Phe Tyr Ile Ala Gly Asp
65 70 75 80Pro Ala His Ala Tyr Gly Tyr Ala Gln Asp Gln Glu Pro Asp Ala Ala
85 90 95Gly Arg Ile Ala Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Ala Ser
100 105 110Ser Leu Pro Gly Phe Tyr Arg Thr Ser Leu Thr Leu Ala Ala Pro Glu
115 120 125Ala Ala Gly Glu Val Glu Arg Leu Ile Gly His Pro Leu Pro Leu Ala
130 135 140Leu Asp Ala Ile Thr Gly Pro Glu Glu Glu Gly Gly Arg Glu Glu Thr
145 150 155 160Ile Leu Gly Trp Pro Leu Ala Glu Arg Thr Val Val Ile Pro Ser Ala
165 170 175Ile Pro Thr Asp Pro Arg Asn Val Gly Gly Asp Leu Asp Pro Ser Ser
180 185 190Ile Pro Asp Lys Glu Gln Ala Ile Ser Ala Leu Pro Asp Tyr Ala Ser
195 200 205Gln Pro Gly Lys Pro Pro Arg Glu Asp Leu Lys
210 215

<210> SEQ ID NO 286

<211> LENGTH: 219

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 286

```
Pro Thr Gly Ala Glu Phe Leu Gly Asp Gly Gly Asp Val Ser Phe Ser
1           5           10          15
Thr Arg Gly Thr Gln Asn Trp Thr Val Glu Arg Leu Leu Gln Ala His
          20          25          30
Ala Gln Leu Glu Glu Arg Gly Tyr Val Phe Val Gly Tyr His Gly Thr
          35          40          45
Ala Leu Glu Ala Ala Gln Ser Ile Val Phe Gly Gly Val Ala Ala Arg
          50          55          60
Ser Gln Asp Leu Ala Ala Ile Trp Ala Gly Phe Tyr Ile Ala Gly Asp
65          70          75          80
Pro Ala His Ala Tyr Gly Tyr Ala Gln Asp Gln Glu Pro Asp Ala Ala
          85          90          95
Gly Arg Ile Ala Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Ala Ser
          100         105         110
Ser Leu Pro Gly Phe Tyr Arg Thr Ser Leu Thr Leu Ala Ala Pro Glu
          115         120         125
Ala Ala Gly Glu Val Glu Arg Leu Ile Gly His Pro Leu Pro Leu Ala
          130         135         140
Leu Asp Ala Ile Thr Gly Pro Glu Glu Glu Gly Gly Arg Asn Glu Thr
145         150         155         160
Ile Leu Gly Trp Pro Leu Ala Glu Arg Thr Val Val Ile Pro Ser Ala
          165         170         175
Ile Pro Thr Asp Pro Arg Asn Val Gly Gly Asp Leu Asp Pro Ser Ser
          180         185         190
Ile Pro Asp Lys Glu Gln Ala Ile Ser Ala Leu Pro Asp Tyr Ala Ser
          195         200         205
Gln Pro Gly Lys Pro Pro Arg Glu Asp Leu Lys
          210         215
```

<210> SEQ ID NO 287

<211> LENGTH: 219

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 287

```
Pro Thr Gly Ala Glu Phe Leu Gly Asp Gly Gly Asp Val Ser Phe Ser
1           5           10          15
Thr Arg Gly Thr Gln Asn Trp Thr Val Glu Arg Leu Leu Gln Ala His
          20          25          30
Ala Gln Leu Glu Glu Arg Gly Tyr Val Phe Val Gly Tyr His Gly Thr
          35          40          45
Ala Leu Glu Ala Ala Gln Ser Ile Val Phe Gly Gly Val Arg Ala Arg
          50          55          60
Ser Gln Asp Leu Ala Ala Ile Trp Ala Gly Phe Tyr Ile Ala Gly Asp
65          70          75          80
Pro Ala His Ala Tyr Gly Tyr Ala Gln Asp Gln Glu Pro Asp Ala Ala
          85          90          95
Gly Arg Ile Ala Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Ala Ser
```

<400> SEQUENCE: 288

Pro 1	Thr	Gly	Ala	Glu 5	Phe	Leu	Gly	Asp 10	Gly	Asp	Val	Ser	Phe 15	Ser
Thr	Arg	Gly	Thr 20	Gln	Asn	Trp	Thr	Val 25	Glu	Arg	Leu	Leu 30	Gln	Ala His
Ala	Gln	Leu	Glu 35	Glu	Arg	Gly	Tyr 40	Val	Phe	Val	Gly	Tyr 45	His	Gly Thr
Ala	Leu 50	Glu	Ala	Ala	Gln	Ser 55	Ile	Val	Phe	Gly	Gly 60	Val	Arg	Ala Arg
Ser 65	Gln	Asp	Leu	Ala	Ala 70	Ile	Trp	Ala	Gly	Phe	Tyr 75	Ile	Ala	Gly Asp 80
Pro	Ala	His	Ala	Tyr 85	Gly	Tyr	Ala	Gln	Asp 90	Gln	Glu	Pro	Asp	Ala Ala 95
Gly	Arg	Ile	Ala 100	Asn	Gly	Ala	Leu	Leu 105	Arg	Val	Tyr	Val	Pro 110	Ala Ser
Ser	Leu	Pro	Gly 115	Phe	Tyr	Arg	Thr 120	Ser	Leu	Thr	Leu	Ala 125	Ala	Pro Glu
Ala 130	Ala	Gly	Glu	Val	Glu	Arg 135	Leu	Ile	Gly	His	Pro 140	Leu	Pro	Leu Ala
Leu 145	Asp	Ala	Ile	Thr	Gly 150	Pro	Glu	Glu	Glu	Gly 155	Gly	Arg	Asn	Glu Thr 160
Ile	Leu	Gly	Trp 165	Pro	Leu	Ala	Glu	Arg	Thr 170	Val	Val	Ile	Pro	Ser Ala 175
Ile	Pro	Thr 180	Asp	Pro	Arg	Asn	Val	Gly 185	Gly	Asp	Leu	Asp 190	Pro	Ser Ser
Ile	Pro	Asp 195	Lys	Glu	Gln	Ala	Ile 200	Ser	Ala	Leu	Pro	Asp 205	Tyr	Ala Ser
Gln 210	Pro	Gly	Lys	Pro	Pro	Arg 215	Glu	Asp	Leu	Lys				

-continued

```

<210> SEQ ID NO 289
<211> LENGTH: 219
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 289

Pro Thr Gly Ala Glu Phe Leu Gly Asp Gly Gly Asp Val Ser Phe Ser
1          5          10
Thr Arg Gly Thr Gln Asn Trp Thr Val Glu Arg Leu Leu Gln Ala His
20        25        30
Ala Gln Leu Glu Glu Arg Gly Tyr Val Phe Val Gly Tyr His Gly Thr
35        40        45
Ala Leu Glu Ala Ala Gln Ser Ile Val Phe Gly Gly Val Arg Ala Arg
50        55        60
Ser Gln Asp Leu Asp Ala Ile Trp Arg Gly Phe Tyr Ile Ala Gly Asp
65        70        75        80
Pro Ala His Ala Tyr Gly Tyr Ala Gln Asp Gln Glu Pro Asp Ala Arg
85        90        95
Gly Arg Ile Ala Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Ala Ser
100       105       110
Ser Leu Pro Gly Phe Tyr Arg Thr Ser Leu Thr Leu Ala Ala Pro Glu
115       120       125
Ala Ala Gly Glu Val Glu Arg Leu Ile Gly His Pro Leu Pro Leu Arg
130       135       140
Leu Asp Ala Ile Thr Gly Pro Glu Glu Glu Gly Gly Arg Glu Glu Thr
145       150       155       160
Ile Leu Gly Trp Pro Leu Ala Glu Arg Thr Val Val Ile Pro Ser Ala
165       170       175
Ile Pro Thr Asp Pro Arg Asn Val Gly Gly Asp Leu Asp Pro Ser Ser
180       185       190
Ile Pro Asp Lys Glu Gln Ala Ile Ser Ala Leu Pro Asp Tyr Ala Ser
195       200       205
Gln Pro Gly Lys Pro Pro Arg Glu Asp Leu Lys
210       215

```

```

<210> SEQ ID NO 290
<211> LENGTH: 113
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 290

Asp Ile Val Leu Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly
1          5          10        15
Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Leu Leu Tyr Ser
20        25        30
Arg Asn Gln Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35        40        45
Pro Pro Lys Leu Leu Ile Phe Trp Ala Ser Thr Arg Glu Ser Gly Val
50        55        60
Pro Asp Arg Phe Ser Gly Ser Gly Phe Gly Thr Asp Phe Thr Leu Thr
65        70        75        80

```

-continued

```

Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln
      85                               90                               95

Tyr Phe Ser Tyr Pro Leu Thr Phe Gly Gln Gly Thr Lys Val Glu Ile
      100                        105                        110

```

Lys

```

<210> SEQ ID NO 291
<211> LENGTH: 473
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic

```

<400> SEQUENCE: 291

```

Met Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly
1      5      10      15

Ala Ser Val Lys Val Ser Cys Lys Thr Ser Arg Tyr Thr Phe Thr Glu
      20      25      30

Tyr Thr Ile His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp
      35      40      45

Ile Gly Gly Ile Asn Pro Asn Asn Gly Ile Pro Asn Tyr Asn Gln Lys
      50      55      60

Phe Lys Gly Arg Val Thr Ile Thr Val Asp Thr Ser Ala Ser Thr Ala
      65      70      75      80

Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr
      85      90      95

Cys Ala Arg Arg Arg Ile Ala Tyr Gly Tyr Asp Glu Gly His Ala Met
      100      105      110

Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr
      115      120      125

Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser
      130      135      140

Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu
      145      150      155      160

Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His
      165      170      175

Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser
      180      185      190

Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys
      195      200      205

Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu
      210      215      220

Pro Lys Ser Cys Asp Lys Thr His Lys Ala Ser Gly Gly Arg His Arg
      225      230      235      240

Gln Pro Arg Gly Trp Glu Gln Leu Gly Gly Gly Gly Ser Pro Thr
      245      250      255

Gly Ala Glu Phe Leu Gly Asp Gly Gly Asp Val Ser Phe Ser Thr Arg
      260      265      270

Gly Thr Gln Asn Trp Thr Val Glu Arg Leu Leu Gln Ala His Ala Gln
      275      280      285

Leu Glu Glu Arg Gly Tyr Val Phe Val Gly Tyr His Gly Thr Phe Leu
      290      295      300

Glu Ala Ala Gln Ser Ile Val Phe Gly Gly Val Ala Ala Arg Ser Gln

```

-continued

305	310	315	320
Asp Leu Ala Ala Ile Trp Ala Gly Phe Tyr Ile Ala Gly Asp Pro Ala			
	325	330	335
Leu Ala Tyr Gly Tyr Ala Gln Asp Gln Glu Pro Asp Ala Ala Gly Arg			
	340	345	350
Ile Arg Asn Gly Ala Leu Leu Arg Val Tyr Val Pro Ala Ser Ser Leu			
	355	360	365
Pro Gly Phe Tyr Arg Thr Ser Leu Thr Leu Ala Ala Pro Glu Ala Ala			
	370	375	380
Gly Glu Val Glu Arg Leu Ile Gly His Pro Leu Pro Leu Ala Leu Asp			
	385	390	395
Ala Ile Thr Gly Pro Glu Glu Glu Gly Gly Arg Leu Glu Thr Ile Leu			
	405	410	415
Gly Trp Pro Leu Ala Glu Arg Thr Val Val Ile Pro Ser Ala Ile Pro			
	420	425	430
Thr Asp Pro Arg Asn Val Gly Gly Asp Leu Asp Pro Ser Ser Ile Pro			
	435	440	445
Asp Lys Glu Gln Ala Ile Ser Ala Leu Pro Asp Tyr Ala Ser Gln Pro			
	450	455	460
Gly Lys Pro Pro Arg Glu Asp Leu Lys			
	465	470	

<210> SEQ ID NO 292

<211> LENGTH: 473

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 292

Met Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly			
1	5	10	15
Ala Ser Val Lys Val Ser Cys Lys Thr Ser Arg Tyr Thr Phe Thr Glu			
	20	25	30
Tyr Thr Ile His Trp Val Arg Gln Ala Pro Gly Gln Arg Leu Glu Trp			
	35	40	45
Ile Gly Gly Ile Asn Pro Asn Asn Gly Ile Pro Asn Tyr Asn Gln Lys			
	50	55	60
Phe Lys Gly Arg Val Thr Ile Thr Val Asp Thr Ser Ala Ser Thr Ala			
	65	70	75
Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr			
	85	90	95
Cys Ala Arg Arg Arg Ile Ala Tyr Gly Tyr Asp Glu Gly His Ala Met			
	100	105	110
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr			
	115	120	125
Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser			
	130	135	140
Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu			
	145	150	155
Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His			
	165	170	175
Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser			

-continued

180					185					190					
Val	Val	Thr	Val	Pro	Ser	Ser	Ser	Leu	Gly	Thr	Gln	Thr	Tyr	Ile	Cys
	195						200					205			
Asn	Val	Asn	His	Lys	Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu
	210					215					220				
Pro	Lys	Ser	Cys	Asp	Lys	Thr	His	Lys	Ala	Ser	Gly	Gly	Arg	His	Arg
	225					230					235				240
Gln	Pro	Arg	Gly	Trp	Glu	Gln	Leu	Gly	Gly	Gly	Gly	Gly	Ser	Pro	Thr
			245						250					255	
Gly	Ala	Glu	Phe	Leu	Gly	Asp	Gly	Gly	Asp	Val	Ser	Phe	Ser	Thr	Arg
			260						265				270		
Gly	Thr	Gln	Asn	Trp	Thr	Val	Glu	Arg	Leu	Leu	Gln	Ala	His	Ala	Gln
			275					280					285		
Leu	Glu	Glu	Arg	Gly	Tyr	Val	Phe	Val	Gly	Tyr	His	Gly	Thr	Ala	Leu
	290					295					300				
Glu	Ala	Ala	Gln	Ser	Ile	Val	Phe	Gly	Gly	Val	Arg	Ala	Arg	Ser	Gln
	305					310					315				320
Asp	Leu	Asp	Ala	Ile	Trp	Arg	Gly	Phe	Tyr	Ile	Ala	Gly	Asp	Pro	Ala
			325						330					335	
His	Ala	Tyr	Gly	Tyr	Ala	Gln	Asp	Gln	Glu	Pro	Asp	Ala	Arg	Gly	Arg
			340					345					350		
Ile	Ala	Asn	Gly	Ala	Leu	Leu	Arg	Val	Tyr	Val	Pro	Ala	Ser	Ser	Leu
	355						360					365			
Pro	Gly	Phe	Tyr	Arg	Thr	Ser	Leu	Thr	Leu	Ala	Ala	Pro	Glu	Ala	Ala
	370					375					380				
Gly	Glu	Val	Glu	Arg	Leu	Ile	Gly	His	Pro	Leu	Pro	Leu	Arg	Leu	Asp
	385					390					395				400
Ala	Ile	Thr	Gly	Pro	Glu	Glu	Glu	Gly	Gly	Arg	Glu	Glu	Thr	Ile	Leu
			405						410					415	
Gly	Trp	Pro	Leu	Ala	Glu	Arg	Thr	Val	Val	Ile	Pro	Ser	Ala	Ile	Pro
			420					425					430		
Thr	Asp	Pro	Arg	Asn	Val	Gly	Gly	Asp	Leu	Asp	Pro	Ser	Ser	Ile	Pro
	435						440					445			
Asp	Lys	Glu	Gln	Ala	Ile	Ser	Ala	Leu	Pro	Asp	Tyr	Ala	Ser	Gln	Pro
	450					455					460				
Gly	Lys	Pro	Pro	Arg	Glu	Asp	Leu	Lys							
	465					470									

<210> SEQ ID NO 293

<211> LENGTH: 221

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 293

Met	Asp	Ile	Val	Met	Thr	Gln	Ser	Pro	Asp	Ser	Leu	Ala	Val	Ser	Leu
1				5					10					15	

Gly	Glu	Arg	Ala	Thr	Ile	Asn	Cys	Lys	Ser	Ser	Gln	Ser	Leu	Leu	Tyr
		20						25					30		

Ser	Arg	Asn	Gln	Lys	Asn	Tyr	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly
		35					40					45			

Gln	Pro	Pro	Lys	Leu	Leu	Ile	Phe	Trp	Ala	Ser	Thr	Arg	Glu	Ser	Gly
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

-continued

50	55	60
Val Pro Asp Arg Phe	Ser Gly Ser Gly Phe	Gly Thr Asp Phe Thr Leu
65	70	75 80
Thr Ile Ser Ser Leu	Gln Ala Glu Asp Val	Ala Val Tyr Tyr Cys Gln
	85	90 95
Gln Tyr Phe Ser Tyr	Pro Leu Thr Phe	Gly Gln Gly Thr Lys Val Glu
	100	105 110
Ile Lys Arg Thr Val	Ala Ala Pro Ser	Val Phe Ile Phe Pro Pro Ser
	115	120 125
Asp Glu Gln Leu Lys	Ser Gly Thr Ala	Ser Val Val Cys Leu Leu Asn
	130	135 140
Asn Phe Tyr Pro Arg	Glu Ala Lys Val	Gln Trp Lys Val Asp Asn Ala
	145	150 155 160
Leu Gln Ser Gly Asn	Ser Gln Glu Ser	Val Thr Glu Gln Asp Ser Lys
	165	170 175
Asp Ser Thr Tyr Ser	Leu Ser Ser Thr	Leu Thr Leu Ser Lys Ala Asp
	180	185 190
Tyr Glu Lys His Lys	Val Tyr Ala Cys	Glu Val Thr His Gln Gly Leu
	195	200 205
Ser Ser Pro Val Thr	Lys Ser Phe Asn	Arg Gly Glu Cys
	210	215 220

<210> SEQ ID NO 294

<211> LENGTH: 221

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 294

Met Asp Ile Val Leu	Thr Gln Ser Pro	Asp Ser Leu Ala	Val Ser Leu
1	5	10	15
Gly Glu Arg Ala Thr	Ile Asn Cys Lys	Ser Ser Gln Ser	Leu Leu Tyr
	20	25	30
Ser Arg Asn Gln Lys	Asn Tyr Leu Ala	Trp Tyr Gln Gln	Lys Pro Gly
	35	40	45
Gln Pro Pro Lys Leu	Leu Ile Phe Trp	Ala Ser Thr Arg	Glu Ser Gly
	50	55	60
Val Pro Asp Arg Phe	Ser Gly Ser Gly	Phe Gly Thr Asp	Phe Thr Leu
65	70	75	80
Thr Ile Ser Ser Leu	Gln Ala Glu Asp	Val Ala Val Tyr	Tyr Cys Gln
	85	90	95
Gln Tyr Phe Ser Tyr	Pro Leu Thr Phe	Gly Gln Gly Thr	Lys Val Glu
	100	105	110
Ile Lys Arg Thr Val	Ala Ala Pro Ser	Val Phe Ile Phe	Pro Pro Ser
	115	120	125
Asp Glu Gln Leu Lys	Ser Gly Thr Ala	Ser Val Val Cys	Leu Leu Asn
	130	135	140
Asn Phe Tyr Pro Arg	Glu Ala Lys Val	Gln Trp Lys Val	Asp Asn Ala
	145	150	155 160
Leu Gln Ser Gly Asn	Ser Gln Glu Ser	Val Thr Glu Gln	Asp Ser Lys
	165	170	175
Asp Ser Thr Tyr Ser	Leu Ser Ser Thr	Leu Thr Leu Ser	Lys Ala Asp

-continued

180	185	190
Tyr Glu Lys His Lys Val	Tyr Ala Cys Glu Val	Thr His Gln Gly Leu
195	200	205
Ser Ser Pro Val Thr Lys	Ser Phe Asn Arg Gly	Glu Cys
210	215	220
<210> SEQ ID NO 295		
<211> LENGTH: 464		
<212> TYPE: PRT		
<213> ORGANISM: Artificial Sequence		
<220> FEATURE:		
<223> OTHER INFORMATION: Synthetic		
<400> SEQUENCE: 295		
Met Asp Val Lys Leu Val	Glu Ser Gly Gly Gly	Leu Val Lys Leu Gly
1	5	10
Gly Ser Leu Lys Leu Ser	Cys Ala Ala Ser Gly	Phe Thr Phe Ser Asn
20	25	30
Tyr Tyr Met Ser Trp Val	Arg Gln Thr Pro Glu	Lys Arg Leu Glu Leu
35	40	45
Val Ala Ala Ile Asn Ser	Asp Gly Gly Ile Thr	Tyr Tyr Leu Asp Thr
50	55	60
Val Lys Gly Arg Phe Thr	Ile Ser Arg Asp Asn	Ala Lys Asn Thr Leu
65	70	75
Tyr Leu Gln Met Ser Ser	Leu Lys Ser Glu Asp	Thr Ala Leu Phe Tyr
85	90	95
Cys Ala Arg His Arg Ser	Gly Tyr Phe Ser Met	Asp Tyr Trp Gly Gln
100	105	110
Gly Thr Ser Val Thr Val	Ser Ser Ala Ser Thr	Lys Gly Pro Ser Val
115	120	125
Phe Pro Leu Ala Pro Ser	Ser Lys Ser Thr Ser	Gly Gly Thr Ala Ala
130	135	140
Leu Gly Cys Leu Val Lys	Asp Tyr Phe Pro Glu	Pro Val Thr Val Ser
145	150	155
Trp Asn Ser Gly Ala Leu	Thr Ser Gly Val His	Thr Phe Pro Ala Val
165	170	175
Leu Gln Ser Ser Gly Leu	Tyr Ser Leu Ser Ser	Val Val Thr Val Pro
180	185	190
Ser Ser Ser Leu Gly Thr	Gln Thr Tyr Ile Cys	Asn Val Asn His Lys
195	200	205
Pro Ser Asn Thr Lys Val	Asp Lys Lys Val Glu	Pro Lys Ser Cys Lys
210	215	220
Ala Ser Gly Gly Arg His	Arg Gln Pro Arg Gly	Trp Glu Gln Leu Gly
225	230	235
Gly Gly Gly Gly Ser Pro	Thr Gly Ala Glu Phe	Leu Gly Asp Gly Gly
245	250	255
Asp Val Ser Phe Ser Thr	Arg Gly Thr Gln Asn	Trp Thr Val Glu Arg
260	265	270
Leu Leu Gln Ala His Ala	Gln Leu Glu Glu Arg	Gly Tyr Val Phe Val
275	280	285
Gly Tyr His Gly Thr Phe	Leu Glu Ala Ala Gln	Ser Ile Val Phe Gly
290	295	300
Gly Val Ala Ala Arg Ser	Gln Asp Leu Ala Ala	Ile Trp Ala Gly Phe

-continued

305	310	315	320
Tyr Ile Ala Gly Asp	Pro Ala Leu Ala	Tyr Gly Tyr Ala Gln Asp Gln	
	325	330	335
Glu Pro Asp Ala Ala Gly Arg Ile Arg Asn Gly Ala Leu Leu Arg Val			
	340	345	350
Tyr Val Pro Ala Ser Ser Leu Pro Gly Phe Tyr Arg Thr Ser Leu Thr			
	355	360	365
Leu Ala Ala Pro Glu Ala Ala Gly Glu Val Glu Arg Leu Ile Gly His			
	370	375	380
Pro Leu Pro Leu Ala Leu Asp Ala Ile Thr Gly Pro Glu Glu Glu Gly			
385	390	395	400
Gly Arg Leu Glu Thr Ile Leu Gly Trp Pro Leu Ala Glu Arg Thr Val			
	405	410	415
Val Ile Pro Ser Ala Ile Pro Thr Asp Pro Arg Asn Val Gly Gly Asp			
	420	425	430
Leu Asp Pro Ser Ser Ile Pro Asp Lys Glu Gln Ala Ile Ser Ala Leu			
	435	440	445
Pro Asp Tyr Ala Ser Gln Pro Gly Lys Pro Pro Arg Glu Asp Leu Lys			
	450	455	460

<210> SEQ ID NO 296
 <211> LENGTH: 464
 <212> TYPE: PRT
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 296

Met Asp Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Leu Gly	
1	15
Gly Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn	
20	30
Tyr Tyr Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Leu	
35	45
Val Ala Ala Ile Asn Ser Asp Gly Gly Ile Thr Tyr Tyr Leu Asp Thr	
50	60
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu	
65	80
Tyr Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Leu Phe Tyr	
85	95
Cys Ala Arg His Arg Ser Gly Tyr Phe Ser Met Asp Tyr Trp Gly Gln	
100	110
Gly Thr Ser Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val	
115	125
Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala	
130	140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser	
145	160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val	
165	175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro	
180	190
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys	

-continued

195					200					205					
Pro	Ser	Asn	Thr	Lys	Val	Asp	Lys	Lys	Val	Glu	Pro	Lys	Ser	Cys	Lys
210						215					220				
Ala	Ser	Gly	Gly	Arg	His	Arg	Gln	Pro	Arg	Gly	Trp	Glu	Gln	Leu	Gly
225					230					235					240
Gly	Gly	Gly	Gly	Ser	Pro	Thr	Gly	Ala	Glu	Phe	Leu	Gly	Asp	Gly	Gly
				245					250					255	
Asp	Val	Ser	Phe	Ser	Thr	Arg	Gly	Thr	Gln	Asn	Trp	Thr	Val	Glu	Arg
			260					265					270		
Leu	Leu	Gln	Ala	His	Ala	Gln	Leu	Glu	Glu	Arg	Gly	Tyr	Val	Phe	Val
		275					280					285			
Gly	Tyr	His	Gly	Thr	Ala	Leu	Glu	Ala	Ala	Gln	Ser	Ile	Val	Phe	Gly
	290					295					300				
Gly	Val	Arg	Ala	Arg	Ser	Gln	Asp	Leu	Asp	Ala	Ile	Trp	Arg	Gly	Phe
305					310					315					320
Tyr	Ile	Ala	Gly	Asp	Pro	Ala	His	Ala	Tyr	Gly	Tyr	Ala	Gln	Asp	Gln
			325						330					335	
Glu	Pro	Asp	Ala	Arg	Gly	Arg	Ile	Ala	Asn	Gly	Ala	Leu	Leu	Arg	Val
			340					345					350		
Tyr	Val	Pro	Ala	Ser	Ser	Leu	Pro	Gly	Phe	Tyr	Arg	Thr	Ser	Leu	Thr
		355					360					365			
Leu	Ala	Ala	Pro	Glu	Ala	Ala	Gly	Glu	Val	Glu	Arg	Leu	Ile	Gly	His
	370					375					380				
Pro	Leu	Pro	Leu	Arg	Leu	Asp	Ala	Ile	Thr	Gly	Pro	Glu	Glu	Glu	Gly
385					390					395					400
Gly	Arg	Glu	Glu	Thr	Ile	Leu	Gly	Trp	Pro	Leu	Ala	Glu	Arg	Thr	Val
			405						410					415	
Val	Ile	Pro	Ser	Ala	Ile	Pro	Thr	Asp	Pro	Arg	Asn	Val	Gly	Gly	Asp
		420						425					430		
Leu	Asp	Pro	Ser	Ser	Ile	Pro	Asp	Lys	Glu	Gln	Ala	Ile	Ser	Ala	Leu
	435					440					445				
Pro	Asp	Tyr	Ala	Ser	Gln	Pro	Gly	Lys	Pro	Pro	Arg	Glu	Asp	Leu	Lys
	450					455					460				

<210> SEQ ID NO 297

<211> LENGTH: 215

<212> TYPE: PRT

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic

<400> SEQUENCE: 297

Met	Asp	Ile	Val	Met	Thr	Gln	Ser	Gln	Arg	Phe	Met	Ser	Thr	Thr	Val
1				5					10					15	
Gly	Asp	Arg	Val	Ser	Ile	Thr	Cys	Lys	Ala	Ser	Gln	Asn	Val	Val	Ser
		20						25					30		
Ala	Val	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Ser	Pro	Lys	Leu	Leu
		35					40					45			
Ile	Tyr	Ser	Ala	Ser	Asn	Arg	Tyr	Thr	Gly	Val	Pro	Asp	Arg	Phe	Thr
	50					55				60					
Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Asn	Met	Gln
65					70					75				80	
Ser	Glu	Asp	Leu	Ala	Asp	Phe	Phe	Cys	Gln	Gln	Tyr	Ser	Asn	Tyr	Pro


-continued

85								90					95				
Trp	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Leu	Glu	Ile	Lys	Arg	Thr	Val	Ala		
			100					105					110				
Ala	Pro	Ser	Val	Phe	Ile	Phe	Pro	Pro	Ser	Asp	Glu	Gln	Leu	Lys	Ser		
			115				120					125					
Gly	Thr	Ala	Ser	Val	Val	Cys	Leu	Leu	Asn	Asn	Phe	Tyr	Pro	Arg	Glu		
	130					135					140						
Ala	Lys	Val	Gln	Trp	Lys	Val	Asp	Asn	Ala	Leu	Gln	Ser	Gly	Asn	Ser		
145					150					155					160		
Gln	Glu	Ser	Val	Thr	Glu	Gln	Asp	Ser	Lys	Asp	Ser	Thr	Tyr	Ser	Leu		
				165					170					175			
Ser	Ser	Thr	Leu	Thr	Leu	Ser	Lys	Ala	Asp	Tyr	Glu	Lys	His	Lys	Val		
			180					185					190				
Tyr	Ala	Cys	Glu	Val	Thr	His	Gln	Gly	Leu	Ser	Ser	Pro	Val	Thr	Lys		
		195					200					205					
Ser	Phe	Asn	Arg	Gly	Glu	Cys											
	210					215											

1. A *Pseudomonas* exotoxin A (PE) comprising a PE amino acid sequence wherein one or more of amino acid residues F443, R456, L477, R494, and L552 as defined by reference to SEQ ID NO: 1 are, independently, substituted, wherein the PE optionally has:

- (i) a further substitution of one or more amino acid residues within one or more B cell epitopes, and the further substitution for an amino acid within one or more B-cell epitopes is a substitution of, independently, one or more of amino acid residues D403, D406, R412, R427, E431, R432, D461, R463, R467, R490, R505, R513, E522, R538, E548, R551, R576, Q592, and L597 as defined by reference to SEQ ID NO: 1,
- (ii) a further substitution of one or more amino acid residues within one or more T-cell epitopes,
- (iii) a deletion of one or more continuous amino acid residues of residues 1-273 and 285-394 as defined by SEQ ID NO: 1, or
- (iv) a combination of any one, two, or three of (i)-(iii).

2. An isolated, mutated *Pseudomonas* exotoxin A (PE), comprising a sequence of the following formula:



wherein:

n=0 or 1 independently for each of R¹, R² and R³,
R¹=1 to 10 amino acid residues

FCS=a furin cleavage sequence of amino acid residues, which sequence is cleavable by furin and has an amino end and a carboxyl end,

R²=1 to 10 amino acid residues;

R³=1 or more contiguous residues of residues 365-394 of SEQ ID NO: 1; and,

PE functional domain III=residues 395-613 of SEQ ID NO:1, wherein one or more of amino acid residues F443, R456, L477, R494, and L552 as defined by reference to SEQ ID NO: 1 are, independently, substituted, wherein the PE optionally has:

- (i) a further substitution of one or more amino acid residues within one or more B cell epitopes, and the further substitution for an amino acid within one or more B-cell

epitopes is a substitution of, independently, one or more of amino acid residues D403, D406, R412, R427, E431, R432, D461, R463, R467, R490, R505, R513, E522, R538, E548, R551, R576, Q592, and L597 as defined by reference to SEQ ID NO: 1,

- (ii) a further substitution of one or more amino acid residues within one or more T-cell epitopes, or

- (iii) both (i) and (ii).

3. The mutated PE of claim 2, further wherein the FCS is represented by the formula P4-P3-P2-P1, wherein P4 is an amino acid residue at the amino end, P1 is an amino acid residue at the carboxyl end, P1 is an arginine or a lysine residue, and the sequence is cleavable at the carboxyl end of P1 by furin.

4. The mutated PE of claim 3, further wherein the FCS (i) further comprises amino acid residues represented by P6-P5 at the amino end, (ii) further comprises amino acid residues represented by P1'-P2' at the carboxyl end, (iii) wherein if P1 is an arginine or a lysine residue, P2' is tryptophan, and P4 is arginine, valine or lysine, provided that if P4 is not arginine, then P6 and P2 are basic residues, and (iv) the sequence is cleavable at the carboxyl end of P1 by furin.

5. The mutated PE of any one of claims 2-4, further wherein the PE functional domain III consists of the sequence of residues 395 to 613 of SEQ ID NO: 1.

6. The mutated PE of any one of claims 2-5, wherein the mutated PE comprises one or more contiguous residues of residues 365-394 of SEQ ID NO: 1 between the FCS and the PE domain III.

7. The mutated PE of any one of claims 2-6, wherein n is 1 for R¹ and R².

8. The mutated PE of any one of claims 2-7, wherein the FCS is SEQ ID NO: 8.

9. The mutated PE of any one of claims 2-8, wherein R¹=a linker of the amino acid sequence of SEQ ID NO: 282, R²=a linker of the amino acid sequence SEQ ID NO: 284, and the FCS=SEQ ID NO: 8.

10. The mutated PE of any one of claims 2-9, wherein n is 0 for R³.

11. The mutated PE of any one of claims 2-10, wherein PE functional domain III comprises the amino acid sequence of SEQ ID NO: 37.

12. The mutated PE of any one of claims 2-11, wherein R^1_n -FCS- R^2_n =SEQ ID NO: 36.

13. The PE of any one of claims 1-12, wherein the substitution of one or more of amino acid residues F443, R456, L477, R494, and L552 is a substitution of, independently, alanine, glutamic acid, histidine, or asparagine in place of one or more of amino acid residues F443, R456, L477, R494, and L552.

14. The PE of any one of claims 1-13, wherein the substitution of L552 is a substitution of glutamic acid or asparagine in place of L552 and the substitution of L477 is a substitution of histidine in place of L477.

15. The PE of any one of claims 1-14, wherein the further substitution of an amino acid within one or more B-cell epitopes is a substitution of, independently, alanine, glycine, serine, or glutamine in place of one or more of amino acid residues E282, E285, P290, R313, N314, P319, D324, E327, E331, Q332, D403, D406, R412, R427, E431, R432, D461, R463, R467, R490, R505, R513, E522, R538, E548, R551, R576, K590, Q592, and L597, as defined by reference to SEQ ID NO: 1.

16. The PE of any one of claims 1-15, wherein the PE has the further substitution of an amino acid within one or more T-cell epitopes, and the further substitution of an amino acid within one or more T-cell epitopes is a substitution of independently, alanine, glycine, serine, or glutamine in place of one or more of amino acid residues R421, L422, L423, A425, R427, L429, Y439, H440, F443, L444, A446, A447, I450, 463-519, R551, L552, T554, I555, L556, and W558 as defined by reference to SEQ ID NO: 1.

17. The PE of any one of claims 1-16, wherein the substitution of one or more of amino acid residues F443, R456, L477, R494, and L552 is a substitution of alanine in place of amino acid residue F443; a substitution of alanine in place of amino acid residue R456; a substitution of histidine in place of amino acid residue L477; a substitution of alanine in place of amino acid residue R494; and a substitution of glutamic acid in place of amino acid residue L552, the PE has an arginine residue at position 458, and the further substitution of an amino acid within one or more B-cell epitopes is:

- (a) a substitution of alanine for amino acid residue R427;
- (b) a substitution of alanine for amino acid residue R463;
- (c) a substitution of alanine for amino acid residue R467;
- (d) a substitution of alanine for amino acid residue R490;
- (e) a substitution of alanine for amino acid residue R505; and
- (f) a substitution of alanine for amino acid residue R538; as defined by reference to SEQ ID NO: 1.

18. The PE of any one of claims 1-16, wherein the substitution of one or more of amino acid residues F443, R456, L477, R494, and L552 is a substitution of alanine in place of amino acid residue R456, the PE has an arginine residue at position 458, and the further substitution of an amino acid within one or more B-cell epitopes is:

- (a) a substitution of alanine for amino acid residue R427;
- (b) a substitution of alanine for amino acid residue R463;
- (c) a substitution of alanine for amino acid residue R467;
- (d) a substitution of alanine for amino acid residue R490;

(e) a substitution of alanine for amino acid residue R505; and

(f) a substitution of alanine for amino acid residue R538; as defined by reference to SEQ ID NO: 1.

19. The PE of any one of claims 1-16, wherein the substitution of one or more of amino acid residues F443, R456, L477, R494, and L552 is a substitution of alanine in place of amino acid residue F443; a substitution of alanine in place of amino acid residue R456; a substitution of histidine in place of amino acid residue L477; a substitution of alanine in place of amino acid residue R494; and a substitution of asparagine in place of amino acid residue L552, the PE has an arginine residue at position 458, and the further substitution of an amino acid within one or more B-cell epitopes is:

- (a) a substitution of alanine for amino acid residue R427;
- (b) a substitution of alanine for amino acid residue R463;
- (c) a substitution of alanine for amino acid residue R467;
- (d) a substitution of alanine for amino acid residue R490;
- (e) a substitution of alanine for amino acid residue R505; and

(f) a substitution of alanine for amino acid residue R538; as defined by reference to SEQ ID NO: 1.

20. The mutated PE of claim 2, wherein one or more of amino acid residues F443, L477, R494, and L552 as defined by reference to SEQ ID NO: 1 are, independently, substituted.

21. The mutated PE of claim 20, wherein the substitution of one or more of amino acid residues F443, L477, R494, and L552 is a substitution of alanine in place of amino acid residue F443, a substitution of histidine in place of amino acid residue L477, a substitution of alanine in place of amino acid residue R494, and a substitution of glutamic acid or asparagine in place of amino acid residue L552.

22. An isolated, mutated *Pseudomonas* exotoxin A (PE), comprising a sequence of the following formula:



wherein:

$n=0$ or 1 independently for each of R^1 , R^2 and R^3 ,

$R^1=1$ to 10 amino acid residues

FCS=a furin cleavage sequence of amino acid residues, which sequence is cleavable by furin and has an amino end and a carboxyl end,

$R^2=1$ to 10 amino acid residues;

$R^3=1$ or more contiguous residues of residues 365-394 of SEQ ID NO:1; and,

PE functional domain III=residues 395-613 of SEQ ID NO:1, wherein the PE includes an arginine at position 458, as defined by reference to SEQ ID NO: 1, and wherein the PE has:

- (a) a substitution of alanine for amino acid residue R427;
- (b) a substitution of alanine for amino acid residue R463;
- (c) a substitution of alanine for amino acid residue R467;
- (d) a substitution of alanine for amino acid residue R490;
- (e) a substitution of alanine for amino acid residue R505; and
- (f) a substitution of alanine for amino acid residue R538.

23. A chimeric molecule comprising (a) a targeting moiety conjugated or fused to (b) the PE of any one of claims 1-22.

24. The chimeric molecule of claim 23, wherein the targeting moiety is a monoclonal antibody or an antigen binding portion of the monoclonal antibody.

25. The chimeric molecule of claim 24, wherein the monoclonal antibody or antigen binding portion of the monoclonal antibody specifically binds to a cell surface marker selected

from the group consisting of CD19, CD21, CD22, CD25, CD30, CD79b, transferrin receptor, epidermal growth factor (EGF) receptor, mesothelin, cadherin, Lewis Y, glypican-3, FAP (fibroblast activation protein alpha), PSMA (prostate specific membrane antigen), CA9=CAIX (carbonic anhydrase IX), L1CAM (neural cell adhesion molecule L1), endosialin, HER3 (activated conformation of epidermal growth factor receptor family member 3), Alk1/BMP9 complex (anaplastic lymphoma kinase 1/bone morphogenetic protein 9), TPBG=5T4 (trophoblast glycoprotein), CD33 (sialic acid binding Ig-like lectin 3, myeloid cell surface antigen), CD123 (interleukin 3 receptor alpha), MUC1 (tumor-associated epithelial mucin), ROR1 (receptor tyrosine kinase-like surface antigen), HER1 (activated conformation of epidermal growth factor receptor), and CLL1 (C-type lectin domain family 12, member A).

26. The chimeric molecule of claim **23**, wherein the targeting moiety is selected from the group consisting of B3, RFB4, SS, SS1, MN, MB, HN1, HN2, HB21, MORAb-009, antigen binding portions thereof, and the antigen binding portion of HA22.

27. The chimeric molecule of claim **23**, wherein the targeting moiety is a humanized SS1 or an antigen binding portion of the humanized SS1.

28. The chimeric molecule of claim **23**, wherein the targeting moiety comprises:

- (a) SEQ ID NOs: 31 and 34;
- (b) SEQ ID NOs: 45 and 46;
- (c) SEQ ID NOs: 61 and 62;
- (d) SEQ ID NOs: 77 and 78;
- (e) SEQ ID NOs: 93 and 94;
- (f) SEQ ID NOs: 109 and 110;
- (g) SEQ ID NOs: 125 and 126;
- (h) SEQ ID NOs: 141 and 142;
- (i) SEQ ID NOs: 157 and 158;
- (j) SEQ ID NOs: 173 and 174;
- (k) SEQ ID NOs: 49, 50, 53, 54, 57, and 58;
- (l) SEQ ID NOs: 65, 66, 69, 70, 73, and 74;
- (m) SEQ ID NOs: 81, 82, 85, 86, 89, and 90;
- (n) SEQ ID NOs: 97, 98, 101, 102, 105, and 106;
- (o) SEQ ID NOs: 113, 114, 117, 118, 121, and 122;
- (p) SEQ ID NOs: 129, 130, 133, 134, 137, and 138;
- (q) SEQ ID NOs: 145, 146, 149, 150, 153, and 154;
- (r) SEQ ID NOs: 161, 162, 165, 166, 169, and 170;
- (s) SEQ ID NOs: 177, 178, 181, 182, 185, and 186;
- (t) SEQ ID NOs: 31-32 and 34-36;
- (u) SEQ ID NOs: 33 and 38; or
- (v) SEQ ID NOs: 93 and 290.

29. The chimeric molecule of any one of claims **23-28**, wherein the chimeric molecule comprises a linker comprising SEQ ID NO: 36.

30. The chimeric molecule of any one of claims **23-28**, comprising

- (a) SEQ ID NOs: 39 and 40;
- (b) SEQ ID NOs: 41 and 42;
- (c) SEQ ID NOs: 43 and 44;
- (d) SEQ ID NOs: 291 and 293;
- (e) SEQ ID NOs: 291 and 294;
- (f) SEQ ID NOs: 292 and 294;
- (g) SEQ ID NOs: 295 and 297; or
- (h) SEQ ID NOs: 296 and 297.

31. A nucleic acid comprising a nucleotide sequence encoding the PE of any one of claims **1-22** or the chimeric molecule of any one of claims **23-30**.

32. A recombinant expression vector comprising the nucleic acid of claim **31**.

33. A host cell comprising the recombinant expression vector of claim **32**.

34. A population of cells comprising at least one host cell of claim **33**.

35. A pharmaceutical composition comprising (a) the PE of any one of claims **1-22**, the chimeric molecule of any one of claims **23-30**, the nucleic acid of claim **31**, the recombinant expression vector of claim **32**, the host cell of claim **33**, or the population of cells of claim **34**, and (b) a pharmaceutically acceptable carrier.

36. The PE of any one of claims **1-22**, the chimeric molecule of any one of claims **23-30**, the nucleic acid of claim **31**, the recombinant expression vector of claim **32**, the host cell of claim **33**, the population of cells of claim **34**, or the pharmaceutical composition of claim **35**, for use in treating or preventing cancer in the mammal.

37. The PE of any one of claims **1-22**, the chimeric molecule of any one of claims **23-30**, the nucleic acid of claim **31**, the recombinant expression vector of claim **32**, the host cell of claim **33**, the population of cells of claim **34**, or the pharmaceutical composition of claim **35**, for use in inhibiting growth of a target cell.

38. The PE, chimeric molecule, nucleic acid, recombinant expression vector, host cell, population of cells, or pharmaceutical composition for the use of claim **37**, wherein the target cell is a cancer cell.

39. The PE, chimeric molecule, nucleic acid, recombinant expression vector, host cell, population of cells, or pharmaceutical composition for the use of claim **37**, wherein the target cell expresses a cell surface marker selected from the group consisting of CD19, CD21, CD22, CD25, CD30, CD79b, transferrin receptor, EGF receptor, mesothelin, cadherin, Lewis Y, glypican-3, FAP (fibroblast activation protein alpha), PSMA (prostate specific membrane antigen), CA9=CAIX (carbonic anhydrase IX), L1CAM (neural cell adhesion molecule L1), Endosialin, HER3 (activated conformation of epidermal growth factor receptor family member 3), Alk1/BMP9 complex (anaplastic lymphoma kinase 1/bone morphogenetic protein 9), TPBG=5T4 (trophoblast glycoprotein), CD33 (sialic acid binding Ig-like lectin 3, myeloid cell surface antigen), CD123 (interleukin 3 receptor alpha), MUC1 (tumor-associated epithelial mucin), ROR1 (receptor tyrosine kinase-like surface antigen), HER1 (activated conformation of epidermal growth factor receptor), and CLL1 (C-type lectin domain family 12, member A).

40. A method of producing the PE of any one of claims **1-22** comprising (a) recombinantly expressing the PE and (b) purifying the PE.

41. A method of producing the chimeric molecule of any one of claims **23-30** comprising (a) recombinantly expressing the chimeric molecule and (b) purifying the chimeric molecule.

42. A method of producing the chimeric molecule of any one of claims **23-30** comprising (a) recombinantly expressing the PE of any one of claims **1-22**, (b) purifying the PE, and (c) covalently linking a targeting moiety to the purified PE.

* * * * *